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ABSTRACT 
The primary aim of this thesis is to investigate the challenges in conducting economic 
evaluations for medical devices with evolving evidence bases. While economic evaluations 
for capital projects and medicines are well established in theory and practice, the same 
cannot be said for novel medical devices. New medical devices are often expensive and 
rely on scarce evidence for efficacy and cost. This increases uncertainty surrounding their 
clinical and cost effectiveness. In addition, as fewer formal procedures exist for evaluating 
devices relative to medicines, evidence bases are weak and health technology assessment 
agencies are reluctant to make rapid decisions. To address these issues a continuous 
iterative framework developed and proposed for economic evaluations of medical devices.  
In this thesis, using Transcatheter Aortic Valve Implantation (TAVI) as a case study, an 
iterative economic evaluation, employing Bayesian techniques, is developed to investigate 
how the challenges associated with medical devices can be overcome to produce an 
efficient and informative economic evaluation. This study is the first to investigate these 
challenges and identify solutions while conducting an economic evaluation early in a 
device’s life cycle, using the proposed continuous iterative framework. The consideration 
of Access with Evidence Development schemes to overcome these challenges and balance 
access with evidence generation for expensive and novel medical devices, with evolving 
evidence, is another important contribution of the thesis.  
Transcatheter Aortic Valve Implantation (TAVI) is a novel treatment for severe Aortic 
Stenosis for operable and inoperable patients. The iterative economic evaluation concludes 
that TAVI can be considered cost effective for inoperable patients compared to medical 
management. There is little value in commissioning new research for continued data 
collection for this group. However, the continued collection of evidence via the UK TAVI 
registry as indicated in the National Institute of Clinical Excellence (NICE) guidelines will 
ensure up to date evidence is available to inform future decisions regarding TAVI in this 
patient group. For operable patients, the iterative model could not conclude that TAVI was 
cost effective compared to Aortic Valve Replacement (AVR). However, additional 
evidence of improved outcomes from TAVI should enhance its cost effectiveness for these 
patients. The Bayesian value of information analysis indicates that further information on 
short and long term probability, resource and quality of life parameters is most valuable 
and the optimal research design for collecting such information is a registry. 
ii 
 
Using TAVI as a case study affords the opportunity to examine the challenges in 
undertaking a cost effectiveness analysis for complex medical device technologies in real 
time. These challenges were identified and overcome by employing flexible Bayesian 
techniques in the continuous iterative framework. This demonstrates that economic 
evaluations do not have to be static once-off activities. In fact, owing to the characteristics 
of medical devices (learning curve, incremental innovations etc.) economic evaluations of 
this kind should be continuous. Therefore, incorporating evolving evidence into the 
decision making process to re-estimate cost effectiveness on an iterative basis.  
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CHAPTER 1 INTRODUCTION 
 
1.1 INTRODUCTION 
This thesis develops a framework for conducting economic evaluations of expensive, novel 
medical device technologies with evolving evidence. While economic evaluation methods 
and guidelines are well established for capital projects and medicines, the characteristics of 
medical devices present unique challenges which need to be addressed in conducting 
evaluations. Using Transcatheter Aortic Valve Implantation (TAVI) as a case study, a 
framework for a continuous iterative economic evaluation, employing Bayesian 
techniques, is developed here to investigate how the challenges associated with medical 
devices can be overcome to produce an efficient and informative economic evaluation. 
While the challenges associated with economic evaluations of medical devices have been 
reported on retrospectively (i.e. after the evaluation) (Sorenson et al., 2011), this study is 
the first to investigate these challenges and identify solutions while conducting an 
economic evaluation early in a device’s life cycle. The consideration of Access with 
Evidence Development schemes to overcome these challenges and balance access with 
evidence generation for expensive and novel medical devices with evolving evidence, is 
another important contribution of the thesis. 
 
1.2 CONTEXT AND RATIONALE 
Health care systems are subject to many challenges: scarce resources, rising expenditures, 
increased pressures from stakeholders and advancing health technologies. These challenges 
present infinite demands on already limited resources necessitating choices between 
competing alternatives. Economic evaluations offer a means of informing these choices, by 
comparing the costs and benefits of alternative resource uses (Banta, 2003, Drummond et 
al., 2007), therefore addressing four issues:  does the technology work, for whom does it 
work, at what cost does it work and how does it compare with alternatives (HTA, 2012). It 
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is recognised that other issues, such as affordability, the budgetary impact of the 
technology, the financial and fiscal environment, patients’ needs and preferences and other 
matters pertaining to the political and health environment at that time, are considered 
alongside economic evaluations when decision makers consider technologies. The latter 
include,  the demographics of the population, incentives and motivation amongst 
clinicians; influence of partisan groups; political stability; emotional ambivalence 
associated with the condition/disease; availability of the health technology in neighbouring 
countries and public and industry pressures  (Europe, 2008, Scotland, 2012, Sorenson et 
al., 2008, Garrido et al., 2008, Robert et al., 2009, Gagnon et al., 2006, Gerhardus and 
Dintsios, 2005). However, this thesis focuses on economic evaluations and cost 
effectiveness, these other issues are considered to be outside the remit of this thesis.  
 
Employing the results of economic evaluations then, along with budgetary considers, 
preferences etc. mentioned above, health care decision makers are encouraged to consider 
two related decisions. These are the adoption and research priority decisions. The adoption 
decision is related to the granting of coverage for a technology, given current information. 
That is to say, should the technology be made available to patients and reimbursed or not.  
The research priority setting decision is concerned with determining if there is value in 
collecting additional information on that technology and how that additional information 
should be collected. 
Since the application of economic evaluations to health care, methods and policies 
surrounding adoption and evidence collection have developed (Glick, 2007). The 
employment of value of information (VOI) analysis for example, provide methods to 
determine if further information is required, after the adoption decision is made (Griffin et 
al., 2011). Incorporating VOI analysis into the decision making process provides formal 
recognition that data collection is not costless (Claxton et al., 2001). Also, decisions are 
often delayed owing to unsubstantiated needs for further evidence; such behaviour is 
deterred with VOI as the need for further evidence is formally quantified. Iterative 
frameworks for employing economic evaluations are also recommended, whereby the 
adoption and need for further research decisions are re-assessed on an iterative basis as the 
evidence base develops (Fenwick et al., 2000, Sculpher et al., 1997). 
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While economic evaluation methods and frameworks for capital projects and medicines are 
well established in theory and practice, the same cannot be said for novel medical device 
technologies (Drummond et al., 2008). New medical devices are often expensive, have 
scarce evidence and subsequently there may be high uncertainty surrounding their clinical 
and cost effectiveness. Also, as patients are becoming more health literate they, and other 
stakeholders, can put pressure on health care systems to be early adopters of technologies. 
In addition, fewer formal procedures exist for evaluating devices relative to medicines. As 
a result of these challenges, health technology assessment agencies are reluctant to make 
rapid, definitive decisions on reimbursement and further research of medical devices. 
When decision makers are reluctant to make speedy decisions patients are denied access to 
potentially promising technologies. Emerging policy strategies, such as Access with 
Evidence Development schemes, aim to overcome such issues while recognising persisting 
uncertainty surrounding effectiveness and the risk that a technology granted coverage may 
have to be removed if concerns about its effectiveness and/or cost effectiveness persist or 
are confirmed.  VOI analysis can be employed here also, facilitating an alternative to the 
conventional “yes/no” adoption decision. Here, by granting conditional coverage to 
specific sub-group(s) of patients, additional evidence can be collected while offering 
limited access (Pearson et al., 2006, Tunis and Chalkidou, 2007, Tunis and Pearson, 2006). 
This evidence can be used when the adoption decision is re-addressed on an iterative basis. 
 
1.2.1 Challenging Characteristics of Medical Device Technologies  
While drugs and medical devices are both health care technologies, the latter have unique 
characteristics which when combined can present challenges in performing economic 
evaluations. These characteristics are identified and explained below.  
Evidence Requirements / Licensing Procedures / Diffusion 
Unlike drug technologies, there are no formal requirements to undertake randomised 
control trials (RCTs) for market approval for medical devices. While RCTs are standard 
for drug approval, they are far beyond what is required for devices to obtain a CE Mark
1
. 
                                                 
1
 The Conformitè Europèene or CE Mark is the requirement for market authorisation in the 
European Union (Drummond et al. 2009).  
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Only the demonstration of performance and safety is necessary for market approval (for 
example, the CE Mark) and generally this is only performed at the point of market entry. 
As a result, there is rapid clinical uptake of these devices and they often become part of 
clinical practice as soon as they become available (Drummond et al., 2009).  
While this rapid approval process has advantages, in that it can improve competition, 
which may reduce prices and provide quicker access for patients, it can discourage further 
research. In fact, the current regulatory process provides incentives for manufacturers to be 
fast followers rather than inventors, so as to avoid high research costs (Sorenson et al., 
2011, Drummond et al., 2009).  
Learning Curve 
Unlike drugs, there is a learning curve with medical devices owing to the interaction 
between the operator/clinician and the medical device. This interaction increases the 
probability of errors and adverse events along a learning curve. This device-clinician 
learning curve raises issues in clinical trials where the new technology is being compared 
to standard practice. As clinicians have been performing the standard procedure routinely 
they are proficient in its delivery, so the probability of errors and procedure related events 
is significantly reduced. However, it takes time to reach this level of proficiency and 
competency with a new procedure. This means that in early trials it can be difficult to 
distinguish between the performance of the device and the clinician, owing to the 
interaction between them, and their experience with the old and inexperience with the new. 
Difficulties in isolating this learning curve effect mean the true potential of the device may 
not be realised in early trials when compared to the standard alternative (Drummond et al., 
2009, Sorenson et al., 2011, Taylor and Iglesias, 2009).  
Difficulties with Randomised Control Trials (RTCs) 
Small, non-randomised studies are common for medical devices, owing to the initial small 
patient population for devices relative to drug technologies (Sorenson et al., 2011). Also, 
randomisation can be difficult owing to the device-clinician learning curve. This is because 
inexperience with the new technology can influence uncertainty concerning the merits of 
the technologies in each arm of the trial, which impacts clinical equipoise.  Consequently, 
there may be no “gold standard” i.e. randomised evidence, available when conducting an 
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economic evaluation. In addition, studies with small sample sizes may not be able to detect 
mortality results as they are often not large enough to demonstrate statistically significant 
differences. The short term follow up in early studies also makes it difficult to fully realise 
the value of a new device relative to the standard model of care. This is because the 
incremental costs mainly represent the initial cost of the new device, whereas the benefits 
are found in long term efficiency. These benefits are not demonstrated in short term follow 
up studies. Not being able to detect important differences between standard and new 
technologies can increase uncertainty in the analysis (Sorenson et al., 2011, Zwanziger et 
al., 2006). 
There is also a tendency for these early studies to focus on higher risk patients, where most 
benefit can be demonstrated. Such data are used as “generic” and are “genericized” or 
applied to other patient groups. This practice makes it difficult to consider heterogeneity 
between sub-groups of patients and tends to ignore the relevance of the evidence for 
different patient groups (Drummond et al., 2009, Taylor and Iglesias, 2009). 
Incremental Innovation 
Unlike drugs, where phase III trials are undertaken when clinical results are robust, devices 
undergo frequent modifications which impact efficiency and end-points overtime. These 
evolutions are in response to clinical evidence and practice and may result in reduced 
procedure length, reduction in the number failures etc. Consequently, there is rarely a 
“steady-state” period where RCTs for devices could be undertaken without being obsolete 
upon reporting (Drummond et al., 2009, Taylor and Iglesias, 2009).   
Genericization and Class Affect 
Another challenging characteristic of medical devices is the lack of equalised clinical 
evidence for all products. With drugs, where assumptions about class effects are common, 
treating clinical evidence as generic may be suitable. With respect to devices however, 
while some clinical outcomes between brands are similar, their properties and modes can 
differ. Thus, assuming evidence is generic for medical devices can be flawed if the 
assumption is based on inadequate evidence of equivalence. Consequently, extrapolating 
evidence from one brand to another may be acceptable in the short run but assuming 
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devices are generic in the long run can be inaccurate and discourages research, which can 
impact patient safety (Drummond et al., 2009, Sorenson et al., 2011).  
Pricing 
Also, unlike drugs the price of medical devices can change frequently. This is due to new 
market entrants, incremental innovations in the device development and more flexible 
procurement systems for devices compared with drugs. This represents a further challenge 
as it affects the incremental cost effectiveness ratio (ICER) and subsequently impacts 
pricing and adoption decisions. Again, short term data collection efforts are insufficiently 
powered to detect such changes (Drummond et al., 2009, Sorenson et al., 2011).  
 
1.2.2 Case Study 
The regulation process, lack of randomised control trials, incremental innovations, the 
learning curve and other challenging characteristics of expensive medical device 
technologies (see Section 1.2.1) raises the question of how economic evaluations can be 
performed to inform adoption and research priority setting decisions in a timely and 
informative manner. To test the hypothesis that a continuous iterative framework 
(explained in Chapter 2) for economic evaluations is suitable for these technologies, a case 
study of an expensive novel technology with an immature evidence base for which demand 
is great is warranted. The case study chosen for this thesis is Transcatheter Aortic Valve 
Implantation (TAVI) for the treatment of severe, symptomatic patients with Aortic 
Stenosis (AS) in the United Kingdom (UK). 
AS is a degenerative heart valve disease. It refers to an age-related, progressive build-up of 
calcium in the aortic valve. Once symptoms develop progression is rapid and if left 
untreated survival estimates are low at 2-3 years (Legrand et al., 1991, Vahanian et al., 
2008). Therefore, managing AS effectively and efficiently is a priority. The traditional 
treatment for AS was aortic valve replacement (AVR) via open heart surgery. However, 
this procedure is often considered inappropriate for severe AS patients who have multiple 
co-morbidities, owing to increased complications post-surgery and mortality. 
Consequently, approximately one third of patients are considered inoperable and only 
receive medical management. The latter only offers transient relief. Transcatheter Aortic 
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Valve Implantation (TAVI) is a less invasive treatment for patients, whereby a bio 
prosthetic valve is inserted through a catheter and guided to the diseased aortic valve where 
it is implanted. The less invasive nature of TAVI suggests reduced complications and 
length of stay for operable patients compared with AVR and offers an alternative to 
medical management for inoperable patients. Despite its potential, uncertainty surrounding 
TAVI’s effectiveness persists, evidence is evolving and consequently access is limited 
(Vahanian et al., 2008).  
This thesis is the first iterative investigation of the cost effectiveness of TAVI for operable 
and inoperable patients. Also, as an economic evaluation for a novel expensive medical 
device technology, with an evolving evidence base, it identifies and addresses the key 
challenges with using economic evaluations to address coverage and research priority 
decisions for such technologies. Using TAVI as a case study, this thesis aims to contribute 
to the discussion about how health technology assessment agencies could deal with such 
medical technologies.  
 
1.3 AIMS AND OBJECTIVES OF THESIS 
The overall objective of this thesis is to investigate the challenges in applying economic 
evaluation methods, frameworks and policies to novel expensive medical technologies 
with evolving evidence. In doing so the cost effectiveness of TAVI in treating severe AS 
amongst operable and inoperable patients and value of collecting further information is 
investigated for the UK in an iterative manner. As outlined above, TAVI’s adoption has 
become a topical issue in the UK where demand for TAVI amongst patients and clinicians 
is great but access is restricted owing to scarce evidence. In this context the following 
research questions will be addressed: 
- How could uncertainty surrounding the cost effectiveness of a novel expensive 
medical device be incorporated into an economic evaluation? 
- Could a continuous iterative framework be used to reflect evolving evidence in 
investigating the cost effectiveness of a novel expensive medical device?   
- Can TAVI be considered cost effective for operable and/or inoperable patients with 
severe AS in the UK? 
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- Is there value in collecting additional evidence on TAVI? 
- How might Access with Evidence Development schemes be used for technologies 
like TAVI in collecting evidence and reducing uncertainties? 
- What are the challenges in determining the cost effectiveness of technologies like 
TAVI?  
- Can the lessons learnt in this economic evaluation of TAVI inform future analyses 
of similar technologies? 
 
Objective 1: Identify the challenges and recommendations for conducting 
economic evaluations of uncertain technologies with evolving evidence bases. 
This thesis employs TAVI as a case study to identify the challenges presented when 
attempting to investigate the cost effectiveness of novel technologies with evolving 
evidence. Recommendations to address these challenges are made. 
Objective 2: Investigate the cost effectiveness of TAVI. 
To investigate the cost effectiveness of TAVI a decision analytical model, reflecting 
current understanding of the disease and technology, is constructed in this thesis. This 
incorporates the uncertainty surrounding the technology from a variety of sources from the 
evolving evidence base. A probabilistic sensitivity analysis produces estimates of the mean 
costs and quality adjusted life years (QALYs) to determine the cost effectiveness of TAVI 
for operable and inoperable.  Employing a continuous iterative framework, this is re-
examined as the evidence base evolves.  
Objective 3:  Examine the value of collecting further evidence for TAVI 
This thesis examines the value of collecting further evidence on TAVI. To do so the results 
of the probabilistic sensitivity analysis are employed in a Bayesian Value of Information 
(VOI) analysis to investigate the following for TAVI: Is there value in collecting additional 
information? On which parameters is additional information most useful? How should the 
additional information be collected? These questions are re-examined in an iterative 
manner as the evidence base evolves. 
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Objective 4: Consider the Suitability of Access with Evidence Development 
Schemes  
Having determined the cost effectiveness and value of collecting further information for 
TAVI on an iterative basis, as the evidence evolves, attention in the thesis turns to where 
now with TAVI. This assessment includes examining the suitability of Access with 
Evidence Development schemes for novel medical technologies with evolving evidence.  
 
1.4 STRUCTURE OF THESIS  
Chapter 2 presents the conceptual framework, theories and methodologies employed to 
address the research questions and objectives of the thesis. This includes economic 
decision analytical modelling, VOI analysis and an overview of Performance Based Risk 
Sharing Agreements, including Access with Evidence Development schemes. A 
continuous iterative framework, incorporating these methods, to address the challenges 
associated with medical devices is proposed. 
In Chapter 3, the empirical case study is introduced and a detailed description of AS and 
the treatments for AS (including TAVI) are provided. This includes a review of the 
epidemiology of the disease and technology and the clinical and cost effectiveness 
evidence base, which existed at the time the case study commenced.  
In Chapter 4, a decision analytical model is described and the results from the cost 
effectiveness analysis of TAVI are presented. This Chapter includes a description of the 
model structure and mechanics, the model parameters and the evidence used to populate 
the model in the first instance. The model is employed for a cost effectiveness analysis and 
Bayesian VOI analysis of TAVI for operable and inoperable patients. 
Following the release of new evidence the cost effectiveness and VOI analyses for 
inoperable and operable patients are revised and presented in Chapters 5 and 6, 
respectively. Each chapter includes a detailed description as to why and how the new 
evidence was incorporated into the model and its effect on the adoption and research 
decisions. Also, the results from the re-analyses are compared to the original analyses from 
Chapter 4. This addresses objectives one, two and three.  
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Chapter 7 investigates what next for TAVI. The effect of further advances in the TAVI 
evidence base on the cost effectiveness and value of collecting further information on 
TAVI is considered for operable and inoperable patients. This includes considering the 
suitability of Access with Evidence Development schemes. This addresses objectives three 
and four. 
Finally, Chapter 8 summarises and discusses the main findings of the thesis, with respect to 
conducting economic evaluations of expensive novel medical devices with evolving 
evidence.  Here the challenges and recommendations for informing adoption and research 
priority decisions are discussed. The limitations of the thesis and the scope for future 
research are also presented. 
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CHAPTER 2 A METHODOLOGICAL FRAMEWORK 
FOR APPROACHING ECONOMIC EVALUATIONS 
 
2.1 INTRODUCTION  
Health systems globally face many challenges, the largest of which is rising health care 
expenditures  (Banta, 2003). In the United States (U.S.) for example, total health 
expenditure as a percentage of gross domestic product (GDP) increased from 7.4% in 1972 
(Glick, 2007) to 17.9% in 2009 (McKinsey, 2011). While in the United Kingdom (U.K.), 
health care expenditure increased from 4.6% of GDP in 1972 to 9.8% by 2009 (Qaiser, 
2011). Such rising health care expenditures are thought to reflect changes in population 
demographics and citizens’ health needs, increased availability of health technologies, 
wage and price inflation, changes in service intensity and the quantity of inputs per unit of 
health care demanded (Banta and Luce, 1993, Thorpe, 2005, Erixon, 2011). Linked to this 
is the rapid development and pace of change, of health technologies. Health technologies 
include pharmaceutical products, devices, interventions programmes etc. and refer to some 
form of applied knowledge which aims to contribute to a healthier population (Banta and 
Luce, 1993).  
These challenges put further pressure on already scarce resources in health care systems. 
The unlimited demands for scarce resources means choices have to be made between 
competing health technologies, leading to cost control efforts. To address this at the macro 
level, risk-sharing between interested parties (patients, payers, providers etc.) and reliance 
on market-orientated incentives are advocated (Glick, 2007). While at the micro level, 
choosing between competing health technologies is increasingly based on an assessment of 
value for money (Glick, 2007). Those assessments are termed economic evaluations and 
involve the comparison of alternative health technologies in terms of their costs and 
consequences (Drummond et al., 2007). They address whether the benefits accruable from 
the technology are worth the cost of implementing the technology (Banta and Luce, 1993). 
Such assessments are most appropriate when the efficacy, effectiveness and availability of 
the technology are also determined. Efficacy examines if the technology works and does 
more good than harm (Drummond et al., 2007). Therefore, determining the extent to which 
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a technology can bring about the intended effects in ideal circumstances, such as those 
provided by randomised control trials (Marley, 2000, Bégaud, 2000).  Effectiveness 
assesses if the technology works, its usefulness and considers the efficacy and acceptance 
of the technology amongst the target audience (Drummond et al., 2007). Thus, determining 
if a technology works in practice (Marley, 2000, Bégaud, 2000).  Availability determines if 
the technology is accessible to those who need it and who could benefit from it 
(Drummond et al., 2007).  
Economic evaluations provide a means of assessing the costs and benefits of competing 
health technologies under consideration. This allows for a comparison between them, 
following which the best (i.e. most cost effective) technology can be recommended for 
reimbursement (Drummond et al., 2007).  
 
2.1.1 Healthcare Decision Making 
In recent years, economic evaluation methods have advanced and are considered capable 
of informing technology adoption/reimbursement decisions and research and development 
prioritisation (Chalkidou et al., 2008, Sculpher et al., 2006).  
The first decision, the adoption decision, considers if the technology is cost effective 
compared to its’ alternative(s), given current evidence on costs and benefits.  This adoption 
decision is based on what is currently known about costs and benefits of a technology 
relative to its comparators. Consequently, there is a chance that the decision made may be 
the wrong decision, i.e. when further information becomes available the decision may 
change, and this has associated costs (i.e. opportunity costs) (Briggs et al., 2006). If a 
technology is falsely rejected, patients are denied access to cost effective technologies. 
Alternatively, if a technology is falsely accepted, patients are exposed to technologies 
which are not cost effective. Therefore, it is important that adoption decisions are re-
examined as evidence evolves, especially if there is uncertainty surrounding the original 
decision. The cost effectiveness analysis techniques for measuring decision uncertainty are 
described in this chapter.  
The second decision, the research decision, considers if it is worthwhile collecting further 
evidence. It is recommended that, irrespective of the adoption decision the value of 
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collecting further information should be considered. Where this research decision is 
positive, the additional evidence, once collected, can be used in re-considering the 
adoption and research priority setting decisions (Chalkidou et al., 2008, Sculpher et al., 
2006). However, generating additional evidence after a positive adoption decision can be 
difficult. Research (Griffin et al., 2011) has demonstrated that there is a negative 
relationship between further evidence generation and adoption; whereby once access to a 
technology is granted the likelihood of collecting further evidence decreases. An 
explanation for this lies in the recruitment difficulties and the ethical concerns surrounding 
randomisation of patients between technologies where the technology under review is 
widely available outside the study (Chalkidou et al., 2008). In addition, there may be 
difficulties sourcing finance for further research once a coverage decision has been made 
(Chalkidou et al., 2008). 
 
2.1.2 Chapter Structure 
This Chapter presents a methodological framework for approaching economic evaluations, 
to consider both the adoption and research priority setting decision. Before describing such 
a framework, the tools and techniques necessary for addressing the adoption and research 
priority setting decisions are explained and traditional frameworks are examined. While 
these techniques and analyses are performed routinely for consideration of medicines, 
capital projects etc., conducting economic evaluations for medical devices is relatively 
unexplored. This is owing to the distinctive characteristics (discussed in Section 1.2.1) and 
the lack of formal requirements for economic evaluations of medical devices, which 
present unique challenges in conducting evaluations. These challenges contribute to a lack 
of evidence on long term outcomes, incremental innovations and movements along the 
learning curve, which result in an evolving evidence base. Therefore, after examining 
existing frameworks, a methodological framework for novel expensive medical devices 
with evolving evidence is proposed. This framework incorporates decision analytical 
modelling, probabilistic sensitivity analyses, Bayesian value of information (VOI) 
techniques and Performance Based Risk Sharing Agreements (PBRSA) in a continuous 
iterative manner to address the challenges associated with medical devices.  
This chapter therefore is structured as follows: 
 Section 2.2 Tools And Techniques for the Adoption Decision 
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 Section 2.3 Tools And Techniques for the Research Priority Setting Decision 
 Section 2.4 Policies For Collecting Additional Information 
 Section 2.5 Traditional Frameworks for Conducting Economic Evaluations 
 Section 2.6 A Continuous Iterative Framework for Economic Evaluations 
 Section 2.7 Conclusion 
 
2.2 TOOLS AND TECHNIQUES FOR THE ADOPTION 
DECISION  
Economic evaluations inform decisions regarding the adoption of new technologies and 
whether further research should be undertaken using evidence of incremental costs and 
effects based on current information (Eckermann and Willan, 2008).  The process begins 
with the identification of the decision problem after which the tools and techniques used to 
address the adoption decision for a technology are explained in this section. This includes 
decision analytical modelling, probabilistic sensitivity analysis etc. The results of which 
can be used in presented the cost effectiveness (CE) plane, incremental cost effectiveness 
ratio (ICER), cost effectiveness acceptability curve (CEAC) and incremental net benefit 
(INB) to address the adoption decision in a cost effectiveness analysis. 
 
2.2.1 Definition of the Decision Problem 
To begin the process of an economic evaluation, a clear statement identifying the decision 
problem, the objective of the economic evaluation and its scope should be written (Roberts 
et al., 2012, Caro et al., 2012). This should be in line with the perspective taken and the 
policy context in which the decision is being considered. The statement should also include 
a detailed description of the technology, the condition under consideration and the target 
population and sub-population, including the stage of the disease, co-morbidities and 
location (Philips et al., 2006). Also, all expected outcomes, health and other, should be 
defined (Briggs et al., 2006, Caro et al., 2012, Roberts et al., 2012). The health outcomes 
can be measured as events, deaths, quality-adjusted life-years (QALYs), disability-adjusted 
life-years etc.  
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2.2.2 Decision Analytical Modelling 
In the last 20 years, the methodology for conducting economic evaluations has developed 
rapidly (Glick, 2007). For example, 20 years ago economic evaluations were informed by 
key findings from clinical trials; output parameters were point estimates of incremental 
costs and effects and uncertainty was only accounted for in a deterministic sensitivity 
analysis. Since the 1990’s however, evidence from clinical trials and various other sources 
need to be brought together and extrapolated into the future when considering the decision 
problem, so as to include all relevant comparators (Buxton et al., 1997). Subsequently, the 
use of decision analytical modelling as a complement to cost effectiveness analysis has 
evolved. It employs quantitative methods to systematically examine the clinical, 
epidemiological and economic evidence base of the technology under review. This 
generates a precise point estimate for a specific outcome, as well as reporting uncertainty 
surrounding this outcome and the decision under review, which can be used to inform 
medical decisions and health care resource allocation (Briggs et al., 2012). 
Decision analytical modelling is particularly useful when a technology is in the early 
stages of development, where data is sparse (Buxton et al., 1997).  This may be owing to 
the lack of clinical trials conducted or where the clinical trials did not gather economic 
data. Here, decision analytical models can be employed to extrapolate beyond the data 
observed in trial; link intermediate clinical endpoints to final outcomes; generalise 
outcomes to other settings and synthesise head-to-head comparisons where relevant trials 
are non-existent thereby offering a means to inform decisions in the absence of mature data 
(Buxton et al., 1997).  
Using mathematical relationships to describe a series of possible consequences which 
could occur, from a set of alternative technologies under consideration, decision analytical 
modelling provides a framework for making decisions under conditions of uncertainty  
(Briggs et al., 2006, Drummond et al., 2007). This framework provides a structure to 
represent the possible prognoses and treatment pathways arising from the technology. 
According to the ISPOR-SMDM Modelling Good Research Practices Task Force (Roberts 
et al., 2012, Caro et al., 2012), current understanding of theory and practice of the 
condition(s) and treatment pathways should be captured in decision analytical models. 
However, while the decision model aims to reflect reality in terms of the condition and 
treatment pathways they can be limited, owing to the constraints of the model type 
employed. Thus, it may not be possible to include all possible consequences and outcomes 
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from a disease or following a technology. Modellers therefore need to decide what options, 
outcomes or pathways will be formally captured in the model to best reflect current 
understanding (Briggs et al., 2006). 
It is also worth noting, that while the availability of data can impact on model boundaries 
and scope, the model structure itself should reflect the natural history of the disease and 
treatment pathways and should not be determined by the availability of data (Philips et al., 
2006). 
Decision analytical modelling can also handle uncertainty and variability across sub-
groups and individuals. Uncertainties arise owing to methodological variation between 
analysis; data requirements; sampling variation; where results need to extrapolated over 
time or from intermediate to final settings and where results from one study are generalised 
to another setting (Briggs et al., 2006, Drummond et al., 2007) (see 2.2.4 for full 
description). Economic evaluations should indicate how such uncertainties translate into 
decision uncertainty, i.e. indicate the probability that the decision made is the right one. 
Although, the use of decision analytical modelling in economic evaluations is not 
universally accepted it is endorsed and recommended by prominent decision makers such 
as the National Institute of Clinical Effectiveness (NICE) in the UK (Briggs et al., 2006). 
Some concern has been raised about the inappropriate use of decision analytical modelling 
and the transparency and validity associated with models generated (Buxton et al., 1997). 
These concerns centre around the inappropriate use of clinical data, biases from 
observation data and the resulting difficulties with extrapolating and verifying results 
(Buxton et al., 1997). However, despite the short-comings, decision analytical modelling is 
a useful tool in economic evaluations. While it is true that no amount of modelling can 
fully offset the gaps in available information, modelling can provide point estimates for 
cost effectiveness analysis (Buxton et al., 1997). In particular, modelling permits valid 
statistical analysis of data (Drummond et al., 2007), to inform economic evaluations.  
Types of Decision Models 
There are many types of decision models such as decision trees, state transition modelling, 
dynamic transition modelling and discrete event simulation  (Sonnenberg and Beck, 1993, 
Drummond et al., 2007).   
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Decision trees, the simplest and most common decision model, provide a means of 
graphically representing the prognosis of alternative interventions using pathways 
(Sonnenberg and Beck, 1993, Drummond et al., 2007). Their use is recommended for 
simple models, those with short time horizons or where there are complex value structures 
(Roberts et al., 2012). The key components of decision trees are the decision and chance 
nodes, pathways and probabilities. At the beginning of the decision tree there is a square 
decision node: this indicates a decision point between alternative options representing the 
decision problem. Circular chance nodes are used where two or more alternative events are 
possible from the decision node. These are depicted as branches growing out of the 
decision node. Pathways illustrate the mutually exclusive sequence of events possible, i.e. 
treatment effects. Finally, probabilities demonstrate the likelihood of a particular event 
occurring at a chance node. Expected costs and outcomes are derived from the pathway 
values weighted by the probability associated with that pathway (Briggs et al., 2006).  
There are however some limitations which hinder their use. These include the undefined 
nature of time within trees, the inability for repeat treatments or relapses and the cluttered 
appearance as the number of pathways and nodes increase. 
State transition models conceptualise decision problems in terms of a set of states and 
transitions between those states, for a particular condition. State transition models are 
useful where time-dependent parameters are required and if time to an event or repeated 
events are important (Siebert et al., 2012). Also, they are particularly useful for 
representing events whose rates vary over time or the effect of interventions that span long 
time frames (Roberts et al., 2012). A common type of state transition model is a Markov 
model (Siebert et al., 2012). These models represent random processes that occur over time 
using cycles (Briggs and Sculpher, 1998). Cycles are discrete time periods through which 
the probability of a patient occupying a given state is assessed. Each state presents a 
different prognosis associated with alternative health interventions and has an associated 
cost and outcome (Drummond et al., 2007). States are illustrated as ovals. Movement 
between states, including direction and speed, are defined by transition probabilities. These 
are represented by arrows. Probabilities are attached to the Markov model to facilitate the 
cost and health outcome estimations. Finally, the costs and outcomes are discounted to 
improve the representation of the model (Briggs and Sculpher, 1998). Markov models offer 
distinct advantages over decision trees in that they facilitate better handling of disease 
complexities. Also, they can simultaneously manage costs and outcomes straightforwardly 
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over the long term, facilitating the calculation of quality adjusted life years (QALYs) 
(Briggs et al., 2006, Briggs and Sculpher, 1998).  
However, a key limitation of Markov models is the “Markov Assumption”, which refers to 
the ‘memory-less’ feature. Whereby, if a patients moves from one state to another the 
model has ‘no memory’ of where the patient has come from or when. This makes it 
difficult to build history into the model, as the probability of moving out of a state is not 
dependent on the previous states that the patient experienced before entering that state 
(Briggs et al., 2006, Briggs and Sculpher, 1998, Drummond et al., 2007). This has 
implications on future transition probabilities where it is not feasible to assign different 
transition probabilities to patients categorised by the nature or timing of their condition. 
However, building time dependent transition probabilities into the model and/or including 
additional distinctive disease states can control for this limitation (Briggs and Sculpher, 
1998). 
To overcome the disadvantages of decision trees and Markov models they can be used 
simultaneously when for example, a decision tree is more suitable for modelling a 
particular prognosis and the Markov model provides the time element (Drummond et al., 
2007). 
 
Cohort Simulation  
By summing the costs and outcomes for all possible ‘states of the world’ (mutually 
exclusive states that can occur), weighted by the likelihood of that ‘state of the world’ 
occurring, the expected costs and outcomes can be estimated. This calculation in a Markov 
model also needs to take into account the length of time patients spend in each health state. 
Such a calculation is referred to as cohort simulation. It involves multiplying the 
proportion of the cohort (e.g. 1,000 patients) ending in one state in a cycle by the relevant 
transition probability to derive the proportion starting in another state. This is repeated for 
subsequent cycles and can be set up in a transparent and convenient manner in a spread 
sheet.  Calculating the expected costs involves adding the cost of each state weighted by 
the proportion of the cohort in the state and adding across the cycles. The costs are 
discounted as appropriate. Estimating the expected survival involves adding the proportion 
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of the living cohort(s) for each cycle and adding across the cycles. This is repeated for each 
intervention, following which the costs and outcomes can be compared. 
 
Other Types of Decision Models 
Where more complex modelling is required, first order Markov modelling can be used 
instead of the cohort modelling described above. Or if more intricate modelling is 
necessary dynamic transition models or discrete event simulations can be performed.  
Dynamic transition models offer a means of modelling the direct and indirect effects of 
communicable disease control programmes. They assume a risk of infection, which is a 
function of the number of infectious individuals in the population at any given time. They 
are appropriate when an intervention impacts on a pathogen’s ecology or on disease 
transmission (Pitman et al., 2012). While these models are useful for modelling 
interactions, as the characterisation of the problem under analysis becomes more detailed, 
the interactions required in the model may become large and complex and/or geographical 
and spatial proximity may become necessary. In these situations discrete event models are 
more suitable (Roberts et al., 2012). 
Discrete event simulation modelling offers a means of simultaneously modelling health 
events occurring to an individual along with that individual’s interactions with others, the 
health system and general environment. It moves over time and the health events are 
mutually exclusive (Karnon et al., 2012). These models are useful for complex models 
representing patient events, when resource constraints are required and when the 
interaction between groups has a substantial impact on the results (Roberts et al., 2012).  
 
2.2.3 Identifying and Synthesising Evidence 
Identifying relevant evidence for a decision analytical model should be done in a 
systematic way in line with evidence based medicine. Various methods of identifying data 
are proposed such as starting with the highest quality studies (e.g. randomised trial data) 
and working down, or only employing high quality studies (Tunis et al., 2003). Where such 
studies do not exist, for example for novel technologies at the early stage in their lifecycle, 
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expert opinion can be used as a legitimate data source. According to O’Hagan (1998) and 
O’Hagan and Luce (2003) when eliciting expert opinion one must realise that they are 
unlikely to be experts in probability/statistics, therefore it is important that the language 
used is familiar to the expert. When eliciting expert opinion simple expressions from their 
knowledge, in the form of median, quartiles etc. can be elicited, to which some sensible 
distribution can be fitted (O'Hagan and Luce, 2003). This probability distribution should 
appropriately represent the expert’s knowledge and uncertainty about the parameter 
(O'Hagan et al., 2006). There are different means of eliciting expert opinion.  For example, 
if individual opinions are sought, structured workbooks with closed ended questions can be 
employed. Alternatively, where group opinion is sought after, a group interview containing 
five to eight experts is recommended. Here, Delphi, modified Delphi or nominal group 
techniques can be employed. The Delphi technique involves the anonymous elicitation of 
expert opinion via a survey/questionnaire, following which a summary of the results is 
provided to the experts and the sequence is repeated until a stopping point is reached 
(Normand et al., 1998).  A disadvantage of this technique is that is considered to force 
consensus, which may underestimate true parameter uncertainty (Philips et al., 2006). To 
avoid forced consensus Philips et al. (2006) recommend the use of modified Delphi panels.  
For example, a two stage Delphi panel which involves holding face-to-face meetings with 
the experts and a moderator during which items where disagreement has occurred in the 
initial survey can be discussed. After which the survey is repeated (Normand et al., 1998).  
Another alternative is the nominal group technique which facilitates the pooling of experts’ 
knowledge and judgement to arrive at estimates which are a genuine product of the group’s 
dialogue (McDonald et al., 2009). Within each of these techniques the experts chosen 
should hold credibility in their field, be from a variety of practical settings and 
geographical locations (Philips et al., 2006). While these methods are useful, they are not 
flawless and it may be difficult to elicit expert opinion on variables for which there is no 
existing evidence (Vallejo-Torres et al., 2008). Philips et al. (2006) advocate that 
regardless of what method is used to identify data for parameter inputs, it should be 
documented and be transparent and consistent with the objectives of the model. It is often 
the case that data identified requires mathematical and statistical processing before it can 
be incorporated into the model. In such cases, it is recommended that the pre-model data 
be presented along with the transformed data (Philips et al., 2006). 
The expanding role for economic evaluations means that evidence from a variety of 
sources, including other clinical, cost and health-related quality of life evidence, is required 
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for a number of reasons (Philips et al., 2006, Buxton et al., 1997, Sheldon, 1996).  Firstly, 
it is uncommon that all of these parameters would be informed by a single source. 
Secondly, economic evaluations need to consider all relevant comparators and it is rare that 
a single study or trial will include all the alternatives considered relevant in an economic 
evaluation. Thirdly, economic evaluations require a time horizon sufficient to capture the 
differences in costs and effects between technologies. A single trial is unlikely to have 
sufficient follow up to satisfy this criterion, so to bridge the gap between evidence 
generated in trials and what is expected to happen in the longer term, evidence will have to 
be extrapolated into the future (Drummond et al., 2007).  Thus, it is likely that data from a 
number of sources, i.e. ‘multiplicity’, will inform each parameter. Consequently,  evidence 
will have to be synthesised (Spiegelhalter et al., 2004). 
In light of this need for evidence synthesis, following evidence identification, Bayesian 
frameworks are increasingly employed to synthesise evidence for use in decision analytical 
models (Spiegelhalter et al., 2004, Briggs et al., 2006, Drummond et al., 2007, Sutton, 
2001, Ades, 2003). A Bayesian approach refers to the formalisation of the process of 
learning from experience, which is in line with the incremental nature of health care 
advances (Spiegelhalter et al., 2004). A formal Bayesian approach, using Bayes’ theorem, 
begins with a probability distribution describing prior beliefs about the parameter arising 
from external sources (prior distribution). When new information is provided (likelihood 
function) the prior distribution is updated to give a new updated belief about the data 
(posterior distribution) (Welton et al., 2012).  Owing to its flexible nature (compared to 
frequentist or classical statistical approaches) it has many advantages, such as being able to 
incorporate background information and facilitating sequential updating as new 
information becomes available (Lau et al., 1992, Prevost et al., 2000, Jones, 1995)  
In this study, a fixed-effects meta-analysis is employed to synthesise the available 
evidence.  This type of analysis assumes that all the studies employed are evaluated as 
having a common treatment effect. That is to say, the true outcome is the same in all the 
studies and differences observed are owing to randomness or sampling error (Spiegelhalter 
et al., 2004). The meta-analysis in this study adopts a Bayesian perspective and makes two 
further assumptions about the information being synthesised. Firstly, it is assumed that the 
baseline parameters being measured are identical between studies. Assuming identical 
parameters implies that the parameters are alike, suggesting that the data can be pooled and 
the individual studies or units can be ignored (Spiegelhalter et al., 2004, Cochrane, 2002). 
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Secondly, it is assumed that the information is exchangeable between the studies. This is a 
formal expression of the idea that there is no systematic justification for differentiating 
between variables from each study.  Here then the ‘true’ treatment effect in each study is 
considered a random quantity drawn from some population distribution.  Under broad 
conditions, the assumption of exchangeability is mathematically equivalent to assuming 
the parameters were drawn at random from a population distribution. Thus, under these 
assumptions the analysis can be considered the same as a traditional random-effects meta-
analysis. In a random-effects meta-analysis the true intervention effect is assumed to be 
randomly observed from a common population distribution, thus the effects from the 
different studies are not necessarily equal (Spiegelhalter et al., 2004). 
By assuming exchangeability, in a fixed-effects meta-analysis, a Bayesian approach to 
multiplicity can be applied. Here all the outcomes from the different studies can be 
integrated into a single model, in which it is assumed that the parameters are drawn from 
some common prior distribution whose parameters are unknown. Box 2.1 presents a 
hypothetical example of a fixed-effects meta-analysis technique (assuming exchangeability 
and independent parameters).  
 
Box 2.1 Sample Evidence Synthesis  
 
Assuming the parameter of interest, θ, is the number of deaths occurring following a 
procedure. Four studies (AB, CD, EF, and GH) report mortality outcomes following this 
procedure as shown below. Assuming identical parameters and exchangeable information 
the results from the four studies can be pooled to estimate θ.  Letting α denote the number 
of deaths per study and n the number of 
patients per study, θ is the sum of α 
divided by the sum of n:   
∑ αi  
∑ ni  
 . This is 
shown below, where the ∑ α    and 
∑ n  121 so θ  /121 0.0    
Study α β n θ 
AB 1 19 20 
 CD 0 26 26 
 EF 2 47 49 
 GH 1 25 26 
 
 
4 117 121 0.03 
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2.2.4 Handling Uncertainty - Probabilistic Sensitivity Analysis 
In every economic evaluation, and its decision analytical model, uncertainty and 
heterogeneity occur (Drummond et al., 2007, Briggs et al., 2006).  There are various types 
of uncertainties which can occur. Stochastic or first order uncertainty refers to the fact that 
individuals faced with the same probabilities and outcomes will experience the 
disease/technology differently. This is owing to random variability in outcomes between 
identical patients (Briggs et al., 2012). Structural uncertainty refers to fact that it is 
uncertain if the structural assumptions in a model actually reflect reality, so is concerned 
with the assumptions inherent in the model (Briggs et al., 2012). Parameter uncertainty 
refers to the notion that the probabilities which govern outcomes are uncertain, i.e. the 
uncertainty in estimating the parameter of interest (Briggs et al., 2012). While 
heterogeneity relates to the extent to which inter-patient variability can be accounted for by 
patients’ characteristics (Briggs et al., 2012).  
Uncertainties are costly and increase the risk of making the incorrect decision regarding 
the cost effectiveness of a technology and its comparators. Incorrect decisions impose a 
cost on society, owing to delayed access to beneficial technologies and exposure to 
technologies later shown to be ineffective. Also, there are costs associated with attempting 
to reverse incorrect decisions made owing to uncertainty surrounding the results (Briggs et 
al., 2006, Claxton, 1999b). Thus, the uncertainties defined above need to be handled. 
With respect to structural uncertainty, the impact of the model assumptions can be 
examined using sensitivity analysis. Determining which assumptions to consider for a 
scenario analysis is based on judgement by the analyst and decision maker (Drummond et 
al., 2007). 
Parameter uncertainty refers to the accuracy with which input parameters are calculated. 
Imprecision can arise from using limited sample evidence to estimate input parameters 
such as probabilities, costs, utilities and treatment effects for populations (Briggs et al., 
2006, Drummond et al., 2007). For many years, such uncertainty was only handled through 
deterministic sensitivity analysis (Glick, 2007, Drummond et al., 2007) but this has 
disadvantages and a thorough assessment of how this uncertainty impacts on the analysis 
of results is needed. The disadvantages include that it is only suited for a small number of 
parameters in practice, problems arise when parameters are correlated and it has no 
suitable summary measure of the implications of the uncertainty (Drummond et al., 2007, 
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Claxton, 2005b). Probabilistic sensitivity analysis therefore has emerged as an alternative 
to handle parameter uncertainty. 
Probabilistic sensitivity analysis (PSA) provides a means of addressing joint uncertainty in 
model parameters. Probabilistic models facilitate the incorporation of uncertainty from 
input parameters and are a means of describing the implications of uncertainty on output 
parameters (Briggs et al., 2006).  There are three elements to conducting a PSA: 
characterising uncertainty in input parameters; propagating uncertainty through the model 
and presenting the implications of parameter uncertainty (Section 2.2.5).           
The joint implications of parameter uncertainty in a model can result in a distribution of 
possible cost effectiveness relating to the technologies under consideration. This is another 
type of uncertainty, decision uncertainty (Briggs et al., 2006), which is discussed in 
Section 2.2.5.                                                                                                                                            
Characterising Uncertainty in Input Parameters 
To characterise uncertainty about the input parameters in a model the first step is to assign 
probability distributions. This involves replacing the point estimates of probabilities, costs 
and utilities with specified probability distributions so as to reflect the uncertainty around 
them (Drummond et al., 2007).  This assignment of distributions can be applied to 
characterise uncertainty in probability, cost and utility/effect parameters. This can be done 
in three ways.  
The first way of characterising uncertainty involves using sample data. This requires fitting 
a parametric distribution and generating a distribution from bootstrapped samples. The 
second means of characterising uncertainty is based on the employment of secondary data. 
Whereby, distributions are assigned to the parameters based on information reported in the 
literature. With a beta distribution for example, this information includes the number of 
events which occurred and did not occur. The third way of characterising uncertainty relies 
on employing experts. Whereby, distributions are assigned using information obtained 
from experts in the field of study using available elicitation methods.  
If characterising uncertainty using secondary data, probability distributions have to be 
assigned. Common distributions employed are the normal, log-normal, beta and gamma 
distributions. In selecting a distribution the logical constraints on the parameter, the type of 
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data and the estimation method employed for the parameter are used. That is to say, one is 
matching what is known about the model input parameter with the characteristics of the 
distribution. Thus, the choice of distribution is not arbitrary, it is guided by the form of the 
data, type of parameter and the estimation process (Claxton, 2005b).  Box 2.2 provides 
descriptions of common probability distributions.  
 
Box 2.2 Common Probability Distributions 
Normal Distribution 
The normal distribution is continuous in nature and when large numbers of measurements are 
plotted a bell shaped form is revealed (Bradley, 2007). The curve is symmetrical about the mean 
(μ), so the area to the left of mean is 0.5 and area to the right of the mean is 0.5. This type of 
distribution is always considered a candidate distribution to represent uncertainty owing to the 
central limit theorem. 
 
According to the Central Limit Theorem, the sampling distribution of the mean will always be 
normal, regardless of the distribution of the underlying data, where there is sufficient sample size. 
 
Log Normal Distribution 
The log normal distribution ranges from zero to positive infinity and is positively skewed (Vose, 
2007). The natural logarithm of its value generates a normal distribution.   
Beta Distribution 
The Beta distribution is employed to model the proportion of successes (n) in a binomial trial and 
ranges from zero to one taking a wide range of shapes. Here, the probability of success (p) is a Beta 
(α, β) random variable (Koop, 200 ). These parameters correspond to the number of events 
occurring (α) and number of non-events (β).  
 
Dirichlet Distribution 
The Dirichlet distribution is the multinomial extension of the beta distribution.  It is multivariate in 
nature, with one parameter per category.  As its components take values (0, 1) it is considered 
flexible and computationally convenient for parameters with categories (Koop, 2003). 
 
Gamma Distribution           
The Gamma distribution is useful for continuous variables, particularly those considered to be 
highly skewed. It is constrained on the interval zero to positive infinity (Vose, 2007).   
  
 
Given that probability parameters can only take values between zero and one and the 
probabilities of mutually exclusive events must sum to one, suitable distributions here are 
constrained to those which obey these rules, influenced by their method of estimation. 
Owing to these constraints on probabilities, often the beta distribution is considered 
suitable (Briggs et al., 2006). Here α and β represent the number of successes and failures 
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(α + β   sample size (n)). Also, as it is the conjugate of the binomial distribution it is easy 
to update as new information becomes available.  
Similar to probability parameters, cost parameters also have rules to take into 
consideration. Namely they are non-negative, count parameters. Often cost data is made up 
of counts of resource use weighted by unit costs. The count nature of these parameters 
suggest a Poisson distribution or its conjugate, the gamma distribution, would be suitable 
for cost parameters as it is constrained to values between zero and positive infinite. The 
normal distribution could also be used for cost parameters, appealing to the central limit 
theorem, as long as the constraints are not violated. Alternatively, the lognormal 
distribution could be used as both it and the gamma distribution can reflect the skewness 
often present in cost data (Briggs et al., 2006).  
Similarly, the theoretical constraints for utility parameters (negative infinity at the lower 
end representing the worst possible health state and one at the upper end representing 
perfect health) influences the distribution employable. Here the beta, gamma, normal or 
lognormal distributions could be applied (Briggs et al., 2006). Care must be taken with 
states close to zero (e.g. death) and close to one. Also, as values less than one are possible 
the properties of some distributions are violated. A transformation of X = 1 – U, offers a 
solution such that X is a utility decrement.  Here X is constrained on the interval 0 to 
positive infinity so can be fitted with a Gamma or log normal distribution (Briggs et al., 
2006). 
With respect to relative risk parameters, as the confidence limits for such parameters are 
estimated on the log scale (because they are made up of ratios) the lognormal distribution 
is considered the most suitable distribution (Briggs et al., 2006). Finally, if the parameter 
has categories, for example health states, the data is considered multinomial.  In this 
instance, a multivariate generalisation of the beta distribution with parameters 
corresponding to the number of categories in the multi-nominal distribution can be used, 
this is the Dirichlet distribution (Briggs et al., 2006).  
Propagating Uncertainty through the Model - Probabilistic Sensitivity Analysis 
Having assigned probability distributions, the next stage of the probabilistic sensitivity 
analysis (PSA) is to assess the implications of the uncertainty surrounding all of the input 
parameters simultaneously on the model results (Drummond et al., 2007). The most 
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common means of propagating this uncertainty is to employ a Monte Carlo simulation with 
a large number of iterations e.g. 1,000 (Claxton, 2005b, Drummond et al., 2007). Here 
each iteration involves a random draw from each input parameter distribution. This gives a 
large number (e.g. 1,000) of expected costs and effects which reflect the joint parameter 
uncertainty in the decision model, which can be employed to inform the adoption decision. 
 
2.2.5 Presenting Cost Effectiveness Results  
Cost Effectiveness Plane 
A cost effectiveness (CE) plane is a four quadrant diagram which plots the incremental 
costs and effects (or benefits) of the technology under evaluation compared to the 
alternative (Black, 1990). The incremental costs are plotted on the vertical axis and effects 
are plotted on the horizontal axis. On Figure 2.1, Point “A” represents a point estimate for 
the incremental cost and effect of a hypothetical technology under consideration against a 
comparator.  
If the health technology under consideration is more effective and less costly than the 
alternative, the impact falls in the South-East quadrant on Figure 2.1. Under these 
conditions the technology under consideration is said to dominate the alternative and is the 
recommended technology. There is also dominance where the technology under 
consideration is more costly and less effective than the comparator. Here the impact falls in 
the North-Western quadrant on Figure 2.1 and the comparator should be recommended. 
The decision is more ambiguous however when the technology under consideration is 
more effective and more expensive (North-Eastern quadrant on Figure 2.1) or less effective 
and less expensive (South-Western quadrant on Figure 2.1). In these scenarios an external 
measure is required to choose between alternatives (Morris et al., 2007, Drummond et al., 
2007). 
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Figure 2.1 Sample Cost Effectiveness Plane 
 
Source: Adapted from Morris et al. (2007) Pp. 254 and Drummond et al. (2007) Pp. 40 
 
 
As discussed in the previous section, probabilistic models can be executed to handle 
uncertainty. They provide the distribution of increment cost, incremental effect and the 
joint effect distribution. The results of the simulation yield a large number of points 
(corresponding to the simulation e.g. 1,000) which can be plotted in a similar fashion to 
Figure 2.2. In this sample CE plane all the coordinates from the simulation lie in the north 
eastern quadrant. Here the vertical plane represents the uncertainty surrounding the costs 
and the horizontal plane represents the uncertainty in effectiveness. As per the case with 
one co-ordinate, here in the north-eastern and south-western quadrants an external measure 
is required to decide between alternatives (Morris et al., 2007, Drummond et al., 2007).  
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Figure 2.2 Sample Cost Effectiveness Plane from Probabilistic Sensitivity 
Analysis 
 
Source: Adapted from Briggs et al. (2006) Supplementary material  
 
Incremental Cost Effectiveness Ratio 
The Incremental Cost Effectiveness Ratio (ICER) provides a measure of the additional cost 
per additional unit of health gain produced by one alternative when compared to another 
(Briggs, 2001). The ICER is calculated as the additional cost of the technology under 
consideration over the comparator (change in cost, ΔC) divided by the additional health 
gain from the technology under consideration over the comparator (change in effects, ΔQ) 
(Stinnett and Paltiel, 1997): 
                      (2.1) 
 
The Monte Carlo simulation for the PSA yields a large number (e.g. 1,000) of expected 
costs and effects which reflect the joint parameter uncertainty in the decision model. The 
average of these expected costs and benefits are used to estimate the ICER in a 
probabilistic model. The ICER can also be presented on the CE plane as the slope of the 
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line joining the point determined by the average incremental costs and effects of the 
technology and the origin. On Figure 2.1 this is the slope of the line joining points A and 
O. 
Once calculated, this ICER can be compared to an external threshold value to assess if the 
technology can be accepted. The threshold value (or ceiling ratio), to which the ICER is 
compared, represents the maximum that society (or the health care provider) is willing to 
pay for an additional unit of effect/health gain. This is used to assess if the technology 
represents an efficient use of resources, considering the opportunity cost of implementing 
this new intervention (McCabe et al., 2008, Briggs et al., 2006, Drummond et al., 2007).  
The dashed line passing through the origin on Figure 2.1 represents the acceptable ceiling 
ratio. If the ICER is less than the ceiling ratio, the intervention is considered to be good 
value for money and should be implemented (Briggs, 2001). So for example, using point 
“A” on Figure 2.1 (representing incremental costs and effects) and recalling that the ICER 
is the slope of the line joining the point determined by the incremental costs and effects of 
the technology (A) and the origin (O), the slope of OA is less than the ceiling ratio, 
therefore the technology can be considered cost effective.  
In the UK, the threshold value or nationally accepted ceiling ratio is currently considered 
to range between £20,000 and £30,000  (Rawlins et al., 2009). A range, as opposed to a 
fixed value, is used as it allows for consideration of the degree of uncertainty around the 
ICER calculation; the innovative nature of the technology under consideration; the 
characteristics of the condition and patient population  for whom the technology is meant 
and wider societal costs and benefits (Simon, 1994). 
Incremental Net Benefit 
The incremental net benefit (INB) is an alternative to the ICER in considering the cost 
effectiveness of a technology. Recalling that the ICER is the ratio of the change in costs to 
change in effects (Equation 2.1) and if the ICER is less than the ceiling ratio (RT) the 
technology is considered cost effective:            .   (2.2) 
Rearranging this, it can be said that the technology is cost effective if the monetary net 
benefit (incremental net benefit) is greater than zero. Where the monetary net benefit is the 
change in effects multiplied by the ceiling ratio, representing the amount the decision 
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maker is willing to pay for each unit of increased effectiveness less the additional costs:  
            –               (2.3) 
That is to say, for net benefit to be positive the monetary benefit must be greater than the 
incremental cost (Drummond et al., 2007):        
                  (2.4) 
Cost Effectiveness Acceptability Curve 
Owing to the issues with ICERs and the lack of cost effectiveness summary measure with 
the cost effectiveness plane, the cost effectiveness acceptability curves (CEAC) can be 
used to summarise decision uncertainty. Recall the decision rule which indicates that on 
the incremental cost effectiveness plane (Figure 2.2) points falling below and to the right 
of a line with a slope equal to the ceiling ratio indicate the technology is cost effective. 
Using the results of the Monte Carlo simulation, the probability of the technology being 
cost effective is estimated as the number of points falling in this region as a proportion of 
all the points.  This can be used to summarise uncertainty as the probability that the 
technology is cost effective at that ceiling ratio. This can be repeated for all potential 
values of the ceiling ratio, with lines through the origin representing different willingness 
to pay thresholds for additional units of effectiveness. The probability of cost effectiveness 
at each ceiling ratio can be plotted on the CEAC. For example, if on a hypothetical 
Incremental Cost Effective (ICE) plane, at a ceiling ratio of £5,500/QALY, 65% of the 
points lie in the cost effectiveness region, so there is a 65% probability that the technology 
is cost effective at this ceiling ratio.  
Repeating this for other ceiling ratio values show that as the ceiling ratio varies, evidence 
in favour of the intervention being cost effective varies also. The CEAC therefore 
summarises the evidence supporting the intervention being cost effective for various values 
of the ceiling ratio (O’Brien and Briggs, 2002), which represents the decision uncertainty 
in the economic evaluation (Drummond et al., 2007). Figure 2.3 presents an example of a 
CEAC where the proportion of the points considered cost effective for threshold values 
ranging from £0 to £100,000 are plotted for a hypothetical technology. The ceiling ratio 
values are on the x-axis and probability of the intervention being cost effective is on the y-
axis.  
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The dashed arrows on Figure 2.3 illustrate how to read the curve to estimate the probability 
that the technology is cost effective. Choosing a ceiling ratio of £20,000/QALY, on the 
horizontal axis, move up along the dashed arrow until the curve is reached. Then move 
leftward to the vertical axis, to read the probability that the technology is cost effective at 
the £20,000/QALY ceiling ratio (shown by the vertical dashed arrow). In this example, the 
probability that the technology is cost effective at the £20,000/QALY ceiling ratio is 
99.6%. 
 
Figure 2.3 Sample Cost Effectiveness Acceptability Curve 
Source: Adapted from Briggs et al. (2006) Supplementary material  
In addition, to overcoming the issues associated with using ratios and confidence intervals 
CEACs also provide more information on uncertainty than the former. Firstly, where the 
curve intersects with the y axis this is the p-value (one sided) for the difference in costs, as 
a ceiling ratio of £0/QALY implies that only costs matter in the cost effectiveness 
calculation (Drummond et al., 2007, O’Brien and Briggs, 2002). Secondly, the ICER can 
be plotted as a vertical line on the same figure as the CEAC. However, the ICER will not 
automatically be at the 50% point. This is because the CEAC corresponds to the median 
difference in costs and effects, whereas the ICER corresponds to the mean difference in 
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costs and effects (Fenwick et al., 2001). Thirdly, the shape of the CEAC is determined by 
the joint uncertainty in the differences in costs and effects (Fenwick et al., 2004). 
 
Multiple Cost Effectiveness Acceptability Curves 
Patients are rarely homogeneous which gives rise to patient subgroups. As patient 
characteristics influence model parameters they also influence cost effectiveness results. 
So where an intervention can be applied to several patient types the decision to provide 
that intervention can be made independently on patient characteristics.  Economic 
evaluations therefore should consider and allow for patient sub-groups. This includes 
producing multiple CEACs, one for each patient group so as to consider different treatment 
decisions for different patient subgroups (Briggs et al., 2006). 
Also, for the same group of patients there can be multiple treatment options. As outlined 
above, decision models should include all relevant treatment options. When more than two 
interventions are being compared multiple CEACs can be presented, whereby there is an 
acceptability curve representing each treatment option. As the interventions are mutually 
exclusive, the CEACs should vertically sum to a probability of one.  
 
2.3 TOOLS AND TECHNIQUES FOR THE RESEARCH 
PRIORITY SETTING DECISION - VALUE OF 
INFORMATION ANALYSIS 
As outlined in Section 2.1, economic evaluations can also address research priority setting 
decisions. Such decisions consider if there is value in collecting additional information on 
the technology. Value of information (VOI) analysis is the proposed method for estimating 
this worth of future information. 
As economic evaluations performed using the methods discussed in previous section are 
populated with existing information, the resulting decisions based on expected net benefit 
(ENB) are subject to uncertainty. This implies that there is a probability that the decision 
made is the wrong decision. That is to say, the decision is correct given existing 
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information but once the uncertainties resolve, a different decision might be made. Owing 
to the costs associated with making the wrong decision, including the opportunity costs of 
the benefits and resources foregone, this poses a problem. The expected cost of the 
aforementioned uncertainty is jointly determined by the probability of making the wrong 
decision based on current information and the associated costs of a wrong decision. These 
estimates of the expected cost of uncertainty can be used to calculate the value of 
additional information via Bayesian VOI (Chalkidou et al., 2008, Chilcott, 2003).  
VOI analysis (using the results of the PSA) can address four related questions concerning 
the collection of further evidence (Eckermann et al., 2010): 1) Is further research 
worthwhile? 2) Is the cost of the proposed research design less than the expected value 
from the research? 3) What is the optimal design for collecting further evidence? And 4) 
how can research funding be best prioritised for alternative economic evaluations? To 
address the value of collecting further information, and the related questions, different 
levels of VOI analysis can be employed: Expected Value of Perfect Information (EVPI); 
Expected Value of Perfect Information about specific parameters (EVPPI) and Expected 
Value of Sample Information (EVSI). Each of these VOI methods is based on the 
difference in payoffs to the decision with and out information, which is used to value the 
information.  
 
2.3.1 Expected Value of Perfect Information 
The value of eliminating all uncertainty is referred to as Expected Value of Perfect 
Information (EVPI), as after all having perfect information removes uncertainty and 
eliminates the probability of making the wrong decision. Given the objective of health care 
systems to maximise health gains subject to a budget constraint, EVPI can be considered to 
represent the maximum health care systems are willing to pay for further information to 
inform the adoption decision in the future. Thus, placing an upper bound on the value of 
future research (Briggs et al., 2006, Claxton, 1999a, Claxton and Posnett, 1996, 
Eckermann and Willan, 2007, Willan and Pinto, 2005, Claxton and Sculpher, 2006).  
EVPI is estimated using the expected costs, effects and cost effectiveness parameters from 
a DAM and PSA as follows (Ades et al., 2004, Briggs et al., 2006, Felli and Hazen, 1998, 
Sculpher and Claxton, 2005): the expected costs (C) and effects (Q) along with the ceiling 
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ratio (λ) can be used to estimate net benefit (NB) for intervention j (as per equation 2.3), as 
follows:     
                  (2.5). 
Assuming intervention j has unknown parameters (θ) and given current information the 
adoption decision is made based on the intervention that generates the maximum expected 
net benefits (ENB) over all iterations of the simulation (whereby, each iteration presents a 
possible value for θ):  
         (   )      (2.6) 
If there was perfect information it would be known how the uncertainty resolves in each 
iteration and therefore the value of θ would be known with certainty. Consequently, the 
intervention with the maximum NB given the value of θ would be chosen in each iteration: 
      (   )      (2.7) 
Therefore, if the true value of θ was known, the value of the optimal decision at these 
known values could be obtained by maximising over j, maxjNB(j, θ). However, it is not 
known where the uncertainty around θ will resolve. So the expected value of the decision 
made with perfect information is estimated by averaging the maximum NB over the joint 
distribution of θ, given by: 
         (   )      (2.8) 
To estimate EVPI the maximum expected net benefits given current information is 
subtracted from the expected maximum net benefits given perfect information. 
               (   )           (   )  (2.9) 
Box 2.3 provides a worked example using just five iterations with two interventions X and 
Y. Here, given current information the optimal decision would be to choose intervention Y 
as it has the highest expected net benefit (average of the net benefit over five iterations) of 
£39. However, if there was perfect information the decision maker could make a different 
decision for each iteration, choosing the intervention with the maximum net benefit for 
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each resolution of uncertainty. So in iteration one intervention Y would have been chosen, 
for the second iteration intervention X would be chosen, for the third iteration intervention 
Y etc. Nevertheless, it is not known in advance which is correct so the expected net benefit 
with perfect information is calculated as the expectation of the maximum net benefit, 
which here is £41.40.  The EVPI then is the difference between the expected net benefit 
with perfect information and the expected net benefit with current information (£41.40 - 
£39 = £2.40). As shown in the last column this is equivalent to the opportunity loss which 
was estimated as the expected difference between the optimal choice and choice under 
perfect information per iteration (£2.40).  
 
Box 2.3 Illustration of Expected Value of Perfect Information Calculation 
       
 Iteration # ENB/Treatment Optimal Choice Maximum NB Opportunity Loss  
  X Y     
 1 27 36 Y 36 0  
 2 36 30 X 36 6  
 3 42 60 Y 60 0  
 4 33 30 X 33 3  
 5 42 39 X 42 3  
 Expectation 36 39  41.40 2.40  
        
Source: Adapted from (Briggs et al., 2006) 
 
Population Expected Value of Perfect Information 
Given the public good characteristics of information, including non-rivalry, once 
information is produced for one patient it can be used to inform treatment decisions for all 
patients at no additional cost (Claxton et al., 2001, Culyer, 1999, Samuelson, 1954, 
Sculpher et al., 2006, Briggs et al., 2006, Claxton, 1999a, Claxton and Posnett, 1996). 
Therefore, the population EVPI (pEVPI) can be estimated. This is the maximum benefit 
more information could yield, as well as estimating the maximum return from research 
efforts in an area. Thus, it is a useful method when setting research priorities, identifying 
decision problems where the costs of uncertainty are high and where further information 
would be most valuable (Claxton and Posnett, 1996). The pEVPI is calculated using 
estimates of current and future patient numbers (I), over the lifetime of the new 
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intervention (T) in each time period (t) discounted at a discount rate (r) as follows (Briggs 
et al., 2006, Claxton et al., 2001):  
           ∑
  
(   ) 
 
         (2.10) 
Determining the estimates of current and future patient numbers (I) and the lifetime of the 
new intervention (T) can be complicated to assess. It should consider far enough into the 
future so as to reflect important differences between alternative technologies, the duration 
of treatment and duration of treatment effects (Philips et al., 2006).  
Expected Value of Perfect Information and the Ceiling Ratio 
Recalling that expected net benefit is estimated using the ceiling ratio, (        ), 
the EVPI can be estimated for different values of the ceiling ratio and plotted as a curve. 
The EVPI reaches a point of inflection where the ceiling ratio equals the ICER. At this 
point the incremental NB is zero (if only two technologies under consideration): it is the 
point of most uncertainty between the technologies.  Figure 2.4 presents an example. Here 
the pEVPI reaches its point of inflection (£6.7 million) at a ceiling ratio of £2,500/QALY. 
Where there are two technologies under consideration this point of inflection is also the 
maximum pEVPI. Owing to the reliance on the ceiling ratio when estimating net benefit, 
there can be different EVPI estimates for different technologies for different patient 
populations, as well as different estimates the same technology can employed for different 
indications, patients and health care systems with different nationally accepted ceiling 
ratios (Briggs et al., 2006). 
The EVPI is low when the ceiling ratio is less than the ICER and the intervention is not 
expected to be cost effective. Here additional information will have little effect in changing 
the adoption decision. In these circumstances, current evidence may be sufficient to reject 
the technology. However, if a higher ceiling ratio was chosen, the EVPI would increase. 
This is because the probability of error (decision uncertainty) increases and the 
consequences of making the wrong decision are valued more highly. Alternatively, if the 
ceiling ratio is greater than the ICER and the intervention is expected to be cost effective, 
generating additional information as the ceiling ratio increases is unlikely to change the 
decision. This is explained by the reduction in decision uncertainty as the technology 
appears increasingly more cost effective. Thus, as the ceiling ratio increases the probability 
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associated with making the wrong decision decreases which tends to reduce the EVPI. 
However, more value is placed on the consequences associated with making the incorrect 
decision which tends to increase the EVPI (Briggs et al., 2006). What happens in this 
trade-off between making the wrong decision and the consequences of a wrong decision 
depends on the elements in the decision.  
 
Figure 2.4 Sample Population Expected Value of Perfect Information Curve 
 
Source: Adapted from Briggs et al. (2006) Supplementary material  
 
Using Expected Value of Perfect Information 
Estimating the value of conducting future research using EVPI therefore is dependent on 
the uncertainty surrounding estimates of costs and effects, the expected cost effectiveness 
of the technology, existing evidence and size of the patient population who can potentially 
benefit from the additional research. It is suggested that as EVPI represents the maximum 
potential worth of future research it can be used in addressing the first question associated 
with collecting further information: Is further research worthwhile? However, as perfect 
information is not achievable, EVPI alone is not sufficient to determine the potential for 
conducting future research. It must be compared to the costs of undertaking the research, 
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which are dependent on the type and size of the research project. Whereby, if the EVPI is 
greater than the costs, it is potentially cost effective to conduct research to gather more 
information (Briggs et al., 2006, Eckermann et al., 2010). Thereby, attempting to address 
the second question associated with collecting further information: Is the cost of the 
proposed research design less than the expected value from the research? (Eckermann and 
Willan, 2007). 
 
2.3.2 Expected Value of Perfect Information for Parameters  
Having investigated if further research is worthwhile using EVPI, attention turns to 
assessing what is the optimal design for collecting further evidence? (Question 3, 
(Eckermann and Willan, 2007)). One consideration here is to establish on which 
parameters further information will be most valuable, i.e. for which parameters will a 
reduction in uncertainty most likely influence the decision. This can include identifying 
suitable end points or better estimates of existing parameter points to be included when 
collecting further evidence (Briggs et al., 2006, Claxton et al., 2001). The value of 
reducing uncertainty surrounding individual or groups of parameters in a decision 
analytical model can be estimated using similar methods to EVPI. Whereby, the EVPI for a 
parameter (EVPPI) is estimated as the difference between the ENB with perfect 
information, about the parameter of interest, and the ENB with current information (Ades 
et al., 2004, Briggs et al., 2006, Brennan et al., 2007). 
In a decision analytical model with uncertain parameters θ, the value of perfect information 
about the parameter/subgroup of parameters (φ) are of interest. If there was perfect 
information it would be known how φ resolves, then the alternative with the maximum 
ENB could be chosen by averaging the ENB over the remaining uncertain parameters (ψ), 
where φ ᴗ ψ  θ. That is to say, with a value for φ the ENB over the remaining uncertainties 
(ψ) is estimated and the alternative with the maximum ENB (j) is selected: 
          (     )      (2.11) 
However, the true value(s) of φ are unknown so the expected value of the decision with 
perfect information is found by averaging the maximum ENBs over the distribution of φ: 
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            (     )      (2.12) 
As for the expected value of the decision made with current information, as per EVPI 
(Equation 2.6),  the optimal decision is made based on the intervention that generates the 
maximum ENB over all iterations of the simulation, as φ ᴗ ψ  θ.  
The EVPPI for the parameter/sub group of parameters (φ) is the difference between the 
expected value of the decision made with perfection information on φ and the decision 
made with current information:  
      =             (     )           (   )  (2.13) 
Similar to estimating the EVPI, the results from the decision analytical model and PSA are 
used here to calculate the EVPPI. The simulation needs to be run for the parameters ψ with 
each value for φ. Values for φ are selected using an outer loop. The simulation is then run 
for each value of φ to generate the expected cost and effect which are used to estimate the 
ENB (this is the inner loop). These steps are repeated until there is sufficient sampling 
from the distribution of φ. Owing to the requirement for an inner and outer loop, estimating 
EVPPI is more computationally intensive than the EVPI estimation. The number of 
iterations in each loop is arbitrary but should reflect the number of parameters in φ and ψ. 
For example, if there is only one parameter in φ and ten in ψ, then the inner loops should 
have more iterations than the outer loop. However, if there are an equal number of 
parameters in φ and ψ then an equal number of iterations in both loops are reasonable. 
These steps are described in further detail in Box 2.4.  
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Box 2.4 Monte-Carlo Algorithm for Calculation of Expected Value of Perfect 
Parameter Information 
Preliminary Steps ~ Adoption Decision 
1. Set up a decision model comparing different strategies and set up a decision rule, for 
example, ICER ≤ λ. 
2. Characterise the uncertain parameters with probability distributions. 
3. Simulate L iterations (e.g. l = 10, 000) sample sets of uncertain parameter values (Monte 
Carlo). 
4. Work out the baseline adoption decision given current information, that is, the strategy 
giving the highest estimated ENB, from the average of l simulations. 
 
Partial EVPI for a Parameter Subset of Interest 
 
5. Obtain a sample value for the parameter of interest  ( ) from its prior distribution, given 
by   . For example,    ~ Beta (     ). This step corresponds to the outer-level 
simulation. Note these parameters of interest are a subset of the entire set of parameters (φ 
ᴗ ψ  θ). 
6. Run the Monte Carlo simulation which was set up in the preliminary steps to estimate the 
expected net benefit of the technology given this perfect information on  , which is fixed 
at the sample value    obtained in the outer loop.  
In running this simulation all remaining uncertain parameters (ψ) are simulated over l 
iterations (e.g. l = 10,000 times) varying according to their probability distribution 
conditional on    . This corresponds to the inner-level simulation.  
7. Calculate the expected net benefit of each strategy given the perfect information about the 
parameter of interest ( ). The technology chosen is the one with the highest estimated 
expected net benefit for the sampled value of φ. 
8. Repeat steps 5-7 j times (e.g. j = 10,000 times) and calculated the average net benefit of the 
revised decisions given perfect information on  . 
9. Calculate and record the average net benefit of each strategy across all the inner loop 
iterations and then calculate the maximum of those average net benefits.  
10. Across all l outer loop iterations, calculate the average of the average net benefit for each 
strategy and the average of the maximum net benefits. 
11. To estimate the EVPPI then across the two strategies get the difference between the 
average maximum net benefit and the maximum average net benefit of each strategy 
calculated in step 7. 
Source: Adapted from Brennan et al. (2007)  
 
Selecting Parameters or Groups of Parameters  
Additional parameter information is only valuable for those parameters for which 
additional information would change the decisions. Generally, parameters with more 
uncertainty, which are more closely related to the differences in NB, will have higher VOI 
attached to them.  
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As NB is a function of many parameters, often resolving uncertainty about single 
parameters will have little impact on NB and subsequently will have little impact on 
changing the decision. Consequently, considering groups of parameters, so that the joint 
uncertainty is resolving, is more meaningful and closer to what would be collected in a 
study. This process is also the first step to estimating EVSI (Section 2.3.3) and setting 
research priorities. A good strategy is to conduct EVPPI on small groups of parameters. 
This may mean grouping parameters according to the baseline risk/ natural history of the 
disease; based on vulnerability to selection bias; quality of life etc. Parameters with little 
effect on NB will have smaller VOI. It is important to note that the EVPI for groups of 
parameters is not equal to the sum of all the individual parameter EVPIs (Claxton et al., 
2001).  
Also, parameter specific and device specific characteristics should be considered when 
selecting parameters and estimating EVPPI. These characteristics can mean that different 
parameters may be applicable for different time frames, for different populations etc. Thus, 
when estimating EVPPI, especially at the population level, there should be an appropriate 
match between the parameters included, the time frame selected and the population 
estimates employed.  
Figure 2.5 presents sample EVPPI results, showing the EVPPI for six groups of parameters 
estimated using a ceiling ratio of £2,200. Alternatively EVPPI could be plotted against a 
range of ceiling ratios as per the EVPI (shown on Figure 2.4).  
Advantages of Expected Value of Perfect Information for Parameters 
EVPPI measures the sensitivity of the decision problem to uncertainty in particular 
parameters. This has several advantages over traditional sensitivity analyses. Firstly, a 
linear relationship between the parameters and NB is not required for estimating EVPPI. 
Secondly, as EVPPI is driven by uncertainty surrounding the decision it examines the 
impact of parameters on this uncertainty. Finally, the VOI estimates are consistent with the 
general health system objective of maximising health care subject to a budget constraint. 
This implies that the VOI can be compared to the costs of conducting research as well as 
contributing to the research design by identifying on which parameters should additional 
information be collected on (Briggs et al., 2006). 
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Figure 2.5 Sample Expected Value of Perfect Information for Parameters 
 
Source: Adapted from Briggs et al. (2006) supplementary material. 
 
 
2.3.3 Expected Value of Sample Information 
As indicated above, EVPI and EVPPI can be used to begin addressing the questions 
surrounding the collection of further evidence. However, EVPI and EVPPI do not fully 
answer questions one to three outlined at the outset (1) Is further research worthwhile for 
this economic evaluation? 2) Is the cost of the proposed research design less than the 
expected value from the research? 3) What is the optimal design for collecting further 
evidence?). Eckermann et al. (2010) and others (Briggs et al., 2006, Claxton, 1999a) 
suggest that while having the EVPI greater than the cost of additional research is 
necessary, it is not sufficient to determine if further research should be collected. To fully 
address those three questions and the fourth question (How can research funding be best 
prioritised for alternative economic evaluations?) the VOI framework should be extended 
to analyse the value of sample information for a particular sample size (n) and particular 
research design. Thus, the marginal benefits of sampling for a patient population and the 
marginal costs of sampling must be examined. The Expected Value of Sample Information 
(EVSI) assesses the value of the trial (generation sample information) representing the 
amount by which the expected opportunity cost of making a decision is reduced (Willan 
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and Pinto, 2005). It is estimated by predicting possible sample results to form a number of 
possible predicted posterior means as follows (Ades et al., 2004, Briggs et al., 2006). 
To estimate EVSI a process similar to that used to estimate EVPI and EVPPI is employed. 
However, in estimating EVSI a sample is drawn rather than assuming perfect information 
about parameters. Thus, the reduction in uncertainty resulting from sample information is 
captured; uncertainty is not eliminated. Here, the approach described in the previous sub-
sections is extended, where there is more than one uncertain parameter and the value of 
sample information about a parameter, or subset of parameters φ, can be estimated over the 
remaining parameters (θ - φ   ψ).  
If φ and ψ are independent then a sample of n on φ provides the sample result D. If D were 
known the ENB could be averaged over the prior distribution of ψ and the posterior 
distribution of φ given D: 
            (     )       (2.14) 
However, D is unknown so the expectation of the maximum ENB over the predictive 
distribution of D, conditional on φ, is taken and averaged over the prior distribution of φ:  
              (     )       (2.15) 
As above, the EVSI is the difference between the expected value of the decision made with 
sample information and that with current information: 
                    (     )           (   )   (2.16) 
So when estimating EVSI, the predicted sample results need to be combined with prior 
information regarding parameters and predicted posteriors. To do this with conjugate priors 
is computationally intensive and inner and outer loops are required as a sample value for D 
from the predictive distribution conditional on   is required. Following which a sample 
from the prior of   is needed and the posterior distribution of φ given D. Another sample 
of D is taken from the predictive distribution of D conditional on the revised φ. Following 
this the inner loop is run again. This process is repeated until a sufficient sample is drawn 
from the distribution of φ (corresponding to the outer loop) (Briggs et al., 2006). Note this 
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can also be done without conjugate priors, which is more computationally intensive, using 
Markov Chain Monte Carlo methods using specific software such as WinBUGS.  
With respect to the sample size, the greater n is, the more possible sample results there are. 
Consequently, the predicted posteriors are some distance from the prior. As n increases, 
there is more uncertainty about the posterior distribution and it becomes more likely that 
the sample information will change the decision. When the mean ENB over the predicted 
posteriors are estimated they are greater than those with current information. Therefore, the 
EVSI is positive and increases as n increases. In addition, the predicted posteriors can 
resolve anywhere across the prior distribution so the variance of the predicted posterior 
tends towards the prior variance and concurrently the EVSI tends towards the EVPPI. 
Thus, the EVSI for a given n approaches the EVPI as n approaches infinity (Briggs et al., 
2006, Claxton and Posnett, 1996). This corresponds with the consideration of EVPI as the 
maximum benefit possible from sample information (Claxton and Posnett, 1996). For a 
worked example of EVSI see Box 2.5.  
Population Expected Value of Sample Information 
As for the estimates of EVPI, population EVSI can also be estimated. This indicates the 
benefits of sample information for current and future patients. It is calculated using 
estimates of current and future patient numbers (I), over the lifetime of the new 
intervention (T) in each time period (t) discounted at a discount rate (r) as follows (Claxton 
and Posnett, 1996, Eckermann et al., 2010) 
           ∑
  
(   ) 
 
         (2.17) 
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Box 2.5 Example of Expected Value of Sample Information  
 
Preliminary Steps ~ Adoption Decision 
1. Set up a decision model, with parameters θ (φ ᴗ ψ  θ), comparing different strategies and 
set up a decision rule, for example, ICER ≤ λ. 
2. Characterise the uncertain parameters with probability distributions. 
3. Simulate l iterations (e.g. l = 4) sample sets of uncertain parameter values (Monte Carlo). 
4. Work out the baseline adoption decision given current information, that is, the strategy 
giving the highest estimated ENB, from the average of l simulations. 
 
Estimating EVSI 
The algorithm has 2 nested loops. 
5. As per step 3 above generate l outputs corresponding to the parameters not of interest (ψ) 
by sampling from their prior distributions.  
a. Suppose the set parameters not of interest, ψ, contains three parameters i.e. 
  (        )   
b. Sample values for each parameter are drawn from their prior distributions in each 
iteration.         
 For example, if    had a beta distribution a sample value of     is drawn 
 from the prior distribution in each simulation:         (     ).  
 This is repeated for          . 
6. Suppose a trial with sample size ns and follow-up period tf   collects information on the 
parameters of interest (    (     )). To model this, an outer loop is used in which 
samples for these parameters of interest are drawn from their prior distribution. 
a. For example, if    has a Gamma distribution,   ̃        (     ) and if    has a 
beta distribution,   ̃      (     ). 
b. This sample information from the hypothetical trial can be used to update the α and 
β values for the parameters of interest (     )  given the posteriors ( ̃       ̃). 
 So for       ̃              (         ̃ ) and  ̃  (      )     ). 
 For   :  ̃              (    ̃  ) and  ̃  (     )  (    ̃ ). 
c. An inner loop then runs j times to generate an output for the parameter of interest 
corresponding to its posterior distribution..  
For example,   ̂         ( ̃   ̃ ) and  ̂       ( ̃   ̃ )  
d. The Monte Carlo simulation (step 3) is then run using the sample estimates for the 
parameters of interest and the simulated values of the parameters not of interest 
and the expected net benefits for each strategy is estimated (this can be done for 
multiple ceiling ratios). 
7. The average net benefit of each strategy across all j inner loop iterations then can be 
calculated.  Following which the maximum of those average net benefits can be estimated. 
8. Then across all the outer loop iterations the average of the average net benefit for each 
strategy can be calculated and average of the maximum net benefits is estimated. 
9. The EVSI can then be estimated be getting the difference between the average maximum 
net benefit and the maximum average net benefit of each strategy (calculated in step 8). 
Source: Adapted from Ades et al.  (2004) and Brennan et al. (2007) 
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Determining Optimal Sample Size – Expected Net Benefit of Sampling  
By comparing the EVSI with the expected costs of sampling, the optimal sample size can 
be defined. The costs of sampling are defined in terms of financial resource costs (fixed 
and variable costs) and the opportunity costs. The latter include the foregone benefit for 
patients who are in the study (the population who stand to benefit from the research results 
are “used up”); the ENB foregone by those patients being treated with the inferior 
treatment in the trial and those who are not enrolled in the trial who receive the standard 
treatment while the trial is under way, therefore foregoing the future ENB (Cinto, 2008, 
Claxton and Posnett, 1996, Willan and Pinto, 2005, Ades et al., 2004). The difference 
between the EVSI and the expected costs of sampling is the Expected Net Benefit of 
Sampling (ENBS). The ENBS reaches a maximum at the optimal sample size. If the 
maximum ENBS is greater than the fixed costs of conducting the additional research then 
demands for additional evidence are efficient and justified (Claxton, 1999a, Claxton and 
Posnett, 1996, Eckermann and Willan, 2007).  
Expected Value of Sample Information and Ceiling Ratio 
EVSI also depends on the ceiling ratio, so different ENBS and different optimal sample 
sizes will be estimated at different ceiling ratios. Given the definition of ENBS above, it is 
apparent that it reflects a similar relationship to that between EVPI and the ceiling ratio 
and EVSI and the ceiling ratio. Ceiling ratios are central in determining the value of 
research and optimal samples sizes and ultimately research design decisions (Briggs et al., 
2006, Cinto, 2008). 
 
2.3.4 Prioritising Research 
Value of information (VOI) analysis provide a formal means for decision makers to decide 
if there is value in collecting further evidence to inform future adoption decisions. These 
techniques offer a means of determining what additional evidence is needed and the type of 
additional evidence that would be most valuable. Efficient research design therefore is 
determined by characteristics of the decision problem, prior information and the monetary 
value of health outcomes (i.e. ceiling ratio). Determining the optimum research design is 
not a binary decision about whether the research should be collected, nor is it only about 
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determining optimal sample size. A wider consideration of research design dimensions 
need to be considered, such as how to allocate patients between arms, the range of 
combination of types of studies that could be conducted to inform uncertain parameters etc. 
(Cinto, 2008). The following issues also require consideration: can the evidence be 
provided once approval has been granted for the technology, what type of research is 
feasible and who should pay for the collection of that data. In light of these issues and 
those arising from the characteristics of medical devices, such as the device-clinician 
learning curve, incremental innovations etc., in assessing cost effectiveness, the challenge 
to develop methods which address these issues is presented (Taylor and Iglesias, 2009).  
Policy developments, including Access with Evidence Development schemes, have 
emerged as a means of reducing uncertainty and increasing value for money, while 
balancing evidence generation and patient access. Such schemes track performance and 
link it to reimbursement; these are explained in further detail in the next section.  
 
2.4 POLICIES FOR COLLECTING ADDITIONAL 
INFORMATION  
2.4.1 Performance Based Risk Sharing Agreements 
As discussed in Section 2.1, there are two related decisions to be made concerning 
adoption (Is the technology cost effective?) and collecting further research (Is there value 
in collecting further evidence?).  As outlined in Section 2.3, Bayesian VOI techniques can 
be used to inform the latter, by determining if there is value in generating further evidence. 
After all, evidence collection is an expensive and lengthy process, during which time 
patients who could benefit from the technologies later proven to be cost effective are losing 
out.  
So determining the cost effectiveness of a technology compared to its alternative(s) 
informs decision makers when deciding to grant access/coverage of a technology. 
Traditionally, this is a dichotomous decision: yes or no, whereby a suitable technology is 
granted coverage and unsuitable ones are not (Miller and Pearson, 2008). However, in 
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practice there are ambiguities, unique technologies etc. and dichotomous decisions are not 
always appropriate (Kamerow, 2007).  
In addition to uncertainty about the decision and scarce evidence, decision makers are 
coming under increased pressures to become “early adopters” of new technologies. 
Tensions result between payers who grant coverage and patients who want access to new 
technologies (Mortimer et al., 2011, Booth et al., 2007, Tunis and Pearson, 2006, 
Chalkidou et al., 2008). Also, generating further evidence following adoption of a 
technology is difficult. If a technology is widely available people are less unlikely to enrol 
in a trial where there would randomisation between the standard and new treatments etc.  
A proposed means to overcome these difficulties, which goes beyond tradition 
dichotomous coverage decision and coordinates and structures additional data collection, 
while employing economic evaluation methods, are Performance Based Risk Sharing 
Agreements. Such schemes track technology performance in a specified group, which can 
be used to influence reimbursement levels. Interest in performance tracking of technologies 
is increasing owing to desires amongst payers and producers to increase certainty and 
achieve value for money (Garrison et al., 2012).   
Garrison et al. (2012) propose the term “Performance Based Risk Sharing Agreements” 
(PBRSA) to collectively describe the various types of schemes which exist. Under their 
definition, PBRSAs have five characteristics. Firstly, it is a programme for data collection 
which is agreed upon between the manufacturer and the payer. Secondly, the programme is 
initiated following regulatory approval, but prior to full diffusion of the technology. 
Thirdly, price and reimbursement of the technology are linked to the programme outcomes, 
either explicitly or implicitly. Fourthly, the primary aim of the programme is to reduce 
uncertainty about expected health outcomes; efficacy in a heterogeneous population; long-
term endpoints; size and value of cost offsets; response rates amongst patient population 
etc. Fifthly, the programme provides a different distribution of risk between the payer and 
manufacturer than usual evidence generation methods. 
Based on those criteria, Garrison et al. (2012) propose a taxonomy of the various schemes 
available, presented in Figure 2.6. Here PBRSAs are categorised PBRSAs into three types: 
Cost sharing agreements, those which aim to provide coverage while the evidence base 
develops and those which aim to manage utilisation and control the cost effectiveness of a 
new technology in the real world, where performance is linked to reimbursement. 
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Figure 2.6 A Taxonomy of Performance Based Risk Sharing Arrangements 
Source: Garrison et al. (2012) 
 
The first type of scheme, cost sharing agreements between the payer and the provider, refer 
to when access to the technology is available for all patients but budgets or utilisation is 
capped or discounts (perhaps based on volume) are applied.  
The second are those which aim to manage utilisation and control the cost effectiveness of 
a new technology in the real world, where performance is linked to reimbursement, for 
example outcome guarantee schemes.  Here performance at patient level can be linked to 
reimbursement for a new technology in two ways. Payment can be linked to the process of 
care, whereby reimbursement is specified ex-ante to depend on the clinical decision 
making process. Or alternatively, the focus can be on ex-post reimbursement, whereby 
intermediate or clinical endpoints can be measured. For example, with “outcomes 
guarantees” payment is received for responders only. While with “conditional treatment 
continuation” continuous payment is dependent on intermediate endpoints. 
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The third type of scheme is those which aim to provide coverage while the evidence base 
develops. In contrast, with these types of schemes, for example Coverage with Evidence 
Development schemes (also known as Access with Evidence Development), there may not 
be a pre-specified agreement as to how the results will impact price, revenues etc. Here all 
patients might receive the new technology (“only with research”) or only those patients 
included in a trial or registry receive the new technology (“only in research”).  
To determine the suitability and viability of any PBRSA, the potential value of the 
additional evidence that it is expected to generate needs to be assessed. In addition, the 
expected value of that information should be greater than the expected costs of generating 
the evidence (Garrison et al., 2012). Thus, to assess if a proposed PBRSA meets these 
requirements, results from a decision analytical model and VOI analysis should be used to 
estimate the expected net benefit of sampling (ENBS) (This examines the difference in the 
expected net benefit from the scheme (EVSI) and the expected costs, described in Section 
2.3). If ENBS is positive, the potential value of the additional evidence expected from the 
PBRSA is greater than its expected costs and the PBRSA is considered cost effective.  
As indicated at the outset of this thesis, one aim is to examine the suitability and feasibility 
of employing PBRSAs for novel medical technologies with evolving evidence. Access 
with Evidence Development (AED) schemes, as a form of PBRSA, have received 
considerable attention in recent years and are used internationally as a means of handling 
the need for further evidence, monitoring performance and granting coverage. While 
acknowledging that there are many types of PBRSAs, the focus in thesis will primarily be 
on AED schemes which are discussed in further detail in the following sub-sections.  
 
2.4.2 Introduction to Access with Evidence Development 
Schemes  
AED schemes offer an alternative to an outright rejection for promising technologies, 
where current evidence is insufficient to demonstrate effectiveness/cost effectiveness 
(Chalkidou et al., 2008).  Here restricted coverage is granted to patients for a specific 
period during which time additional evidence on risks, costs and effectives can be 
collected. This temporary coverage provides a way of generating additional evidence 
without widespread diffusion, the latter of which has significant costs if coverage has to be 
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discontinued (Lindsay et al., 2007, Turner et al., 2010, Pearson et al., 2006, Tunis and 
Pearson, 2006, Trueman et al., 2010, Tunis and Chalkidou, 2007). As discussed in Section 
2.1, there are ethical issues surrounding the randomisation of patients between 
technologies when the technology under review is widely available outside the scheme. 
Also, there can be logistical issues surrounding how and who to recruit, as well as 
difficulties sourcing funding for such schemes. 
AED schemes also address concerns regarding the generation of further evidence post 
adoption, discussed in Section 2.1. Unsurprisingly research has shown (Griffin et al., 2011) 
that there is a negative relationship between further evidence generation and adoption, 
whereby once coverage for a technology is granted, the likelihood of collecting further 
evidence decreases. However, a technology which is considered cost effective can have 
persisting uncertainties and evolving evidence. AED schemes can be useful here where 
further evidence is required as it offers an alternative to the affirmative “yes” in a 
dichotomous coverage decision, to ensure evidence is collected without delaying patients’ 
access to the promising but unproven technology. Whereby, evidence generation and 
funding is linked to the recommendation by the national HTA agency, e.g. NICE in the UK 
(Chalkidou et al., 2007) 
 
2.4.3 Types of Access with Evidence Development Schemes 
Different forms of AED schemes have been implemented in various ways over the past 15 
years across Australia, Canada, France, Italy, The Netherlands, United Kingdom and the 
United States, for pharmaceutical and medical device technologies (Stafinski et al., 2010). 
In the US, for example through the Centres for Medicare and Medicaid, AED is 
implemented by enrolling patients in a clinical trial to gain access to a technology while 
evidence is gathered (Mortimer et al., 2011, Tunis and Pearson, 2006). Examples of this 
include colorectal cancer drugs  (Carino et al., 2006) and Positron Emission Tomography 
(PET) (Lindsay et al.). In Australia, the Medical Services Advisory Committee uses 
temporary listings on the Medical Benefits Schedule to collect additional information for 
promising technologies (Mortimer et al., 2011). While in the UK, NICE can issue an “only 
in research” recommendation rather than just “yes” or “no”. This enables additional 
evidence collection while partial coverage is granted for the purposes of research 
(Mortimer et al., 2011, Neumann et al., 2011, Briggs et al., 2010).  
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Only in Research (OIR) refers to a situation where coverage for a technology is only 
available to patients who are involved in research, for example, enrolled in a trial or 
registry. Here the purchaser may be paying for the research or the purchaser may have 
rejected the technology and requested further information where the obligation and 
responsibility for generating this additional information lies with the manufacturer (Walker 
et al., 2012). 
Alternatively, Only with Research (OWR) refers to a situation where a positive coverage 
decisions is conditional on additional evidence being generated which will influence the 
decision to continue, expand or withdraw with technology (Carlson et al., 2010). Here 
reimbursement is granted for the technology but further research is mandatory, which may 
be funded by the purchaser, manufacturer or other (Walker et al., 2012). 
 
2.4.4 Advantages of Access with Evidence Development Schemes 
Reviews by Stafinski et al. (2010) and others (Briggs et al., 2010, Hutton et al., 2007, 
Neumann et al., 2011) have identified the advantages of AED schemes for patients, 
providers, decision makers/payers and industry manufactures. The chief purpose of AED 
schemes is to generate further information, while granting conditional coverage. As 
information displays the two necessary characteristics of public goods, non-rivalry and 
non-excludability (Stiglitz, 1999),  additional evidence should resolve the uncertainties 
surrounding the parameters and decision for all patients. Non-rivalrous consumption means 
that consumption of a good by one individual does not detract from another. Non-
excludability suggests it is impossible to exclude anyone from consuming a good, again for 
information this would mean it cannot be provided privately (Stiglitz, 1999).  
For patients, the main advantage is the access to promising medical technologies earlier in 
the technologies’ life cycle, which will improve health outcomes. Such new technologies 
may not be made available in a tradition dichotomous decision making environment. Thus, 
these schemes can result in greater treatment options for patients (Stafinski et al., 2010, 
THETA, 2009, U.S., 2009b, U.S., 2009a, Briggs et al., 2010, Hutton et al., 2007, 
Committee, 2006). 
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For providers, AED schemes also provide access to technologies earlier in their lifecycle 
that without AED may not be available, thus increasing options available for their patients. 
The schemes also provide a means of linking research and data collection to decision 
making. This contributes to ensuring an appropriate quality of care is being provided  
(Stafinski et al., 2010, U.S., 2009b, U.S., 2009a, Committee, 2006, THETA, 2009) 
(Network, 2006, Carapinha, 2008, Hutton et al., 2007). 
AED schemes also offer a means of managing and supporting decision-making under 
uncertainty for decision makers, including payers. This can include supporting 
reimbursement decisions by ensuring “value for money” and affordability. Employing 
scarce resources more efficiently should improve equality of access to promising 
technologies and reduce biases against promising technologies which ultimately can 
improve population health. Controlling evidence generation directly links research and 
decision making. This collaboration between industry and decision makers promotes good 
clinical practice while reducing uncertainty through evidence generation (2010) (U.S., 
2009b, U.S., 2009a, Committee, 2006, THETA, 2009, Network, 2006, NHS, 2008c, 
Tonks, 1994, OHTAC, 2006, PATH, 2009, Carino et al., 2004, Médicale, 2004, Briggs et 
al., 2010, Hutton et al., 2007, Neumann et al., 2011). 
With respect to industry stakeholders and manufactures, AED schemes can improve the 
return on research and development investments and incentivise future innovations. This is 
achieved by protecting prices and securing patient access to novel technologies with 
immature evidence bases, which may have been rejected in a traditional dichotomous 
setting. Indeed it provides faster, more flexible and more secure market access for 
technologies. This can provide manufacturers with the opportunity to differentiate their 
products early in the product lifecycle and avoid biases towards promising technologies. 
Linking research and decision making offers industry and decision makers the opportunity 
to work together, promoting good clinical practice and evidence generation (Stafinski et 
al., 2010, Hutton et al., 2007, Neumann et al., 2011, Médicale, 2004, Network, 2006, 
Carino et al., 2004, Tonks, 1994, THETA, 2009, U.S., 2009c). 
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2.4.5 Disadvantages of Access with Evidence Development 
Schemes 
Despite the attractiveness of AED schemes and potential benefits for patients, industry, 
providers and decision makers, there are some outstanding concerns and disadvantages of 
AED schemes. While access to promising technologies is attractive, AED schemes by their 
nature only grant partial access. Thus, some patients or subgroups can be denied access if 
they do not meet scheme criteria which some (Wadman, 2005, Groeneveld, 2006)  argue is 
inequitable owing to coercion, whereby access is limited to only those who enrol in the 
trial. However, others (Miller and Pearson, 2008, Kamerow, 2007, Pearson et al., 2006) 
have indicated that these arguments are unfounded where the available evidence does not 
provide adequate confidence in the technology under review and without the schemes there 
would not be access to that technology. Having access conditional on study participation 
may also be considered a drawback. The main disadvantage however, lies in the fact that 
these are promising technologies. The additional evidence collected may indicate they are 
unsafe and/or ineffective and coverage needs to cease. Removing access can be difficult, 
owing to patient resistance and risk exposure.  For example, if withdrawal is owing to 
safety concerns there may have been a health risk for patients. This may have litigation 
implications for providers, payers and industry who had raised expectations (Hutton et al., 
2007, Stafinski et al., 2010, Staginnus, 2009, Chapman et al., 2003, Carino et al., 2004).  
While there are obvious benefits for manufactures for their products to be included in such 
schemes in terms of market access, AED schemes can reduce the incentive for 
extensive/sufficient evidence generation prior to the initial evaluation. There is a worry 
that AED schemes may even become an ‘opt-out’ for earlier, costly data collection efforts 
e.g. clinical trials. This may make trial recruitment difficult and randomisation unethical, 
all which further reduce the size and quality of initial evidence bases (NHS, 2008c, Tonks, 
1994, Hutton et al., 2007, U.S., 2009b). As outlined in the Chapter 1, such concerns are 
already real for medical devices where there are no formal evidence collection 
requirements for market access and there are disincentives for research.  
There is also a heavy administration, reporting, monitoring and financial burden with AED 
schemes and physicians must be willing to participate (Stafinski et al., 2010, Carapinha, 
2008, NHS, 2008c, U.S., 2009a, Hutton et al., 2007). Setting up such schemes is also 
complex, requiring consensus on a range of issues such as data collection parameters, 
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administration arrangements, what constitutes sufficient evidence of a benefit etc. (Levin et 
al., 2007) (Carapinha, 2008, NHS, 2008c).  
It also can be difficult to secure funding for such schemes owing to the high risks involved 
(Network, 2006, Carino et al., 2004). This includes financial risks. For example, an 
investment may have been made in a technology which is later shown not to be cost 
effective. Profits may also be impacted if the AED scheme delays access to the full market 
where for example, in a traditional dichotomous setting full coverage would have been 
granted at the outset (U.S., 2009b, Hutton et al., 2007, U.S., 2006). As mentioned earlier, 
there may be a risk of litigation if the technology is found to be unsafe or ineffective. Also, 
withdrawing access owing to cost effectiveness is exposing decision makers to risk (U.S., 
2009b, Hutton et al., 2007). Finally, there is the risk that the scheme does not actually 
resolve the uncertainty or address an appropriate decision (Carino et al., 2004).  
 
2.4.6 Future for Access with Evidence Development Schemes 
In light of these disadvantages there are several challenges which need to be addressed for 
using AED schemes (Tunis and Pearson, 2006). Firstly, standards of evidence for the 
optimal scenario (whereby unconditional coverage would be granted) and the worse-case 
scenario (where uncertainty is considered too great for any coverage) need to be defined. 
For the technology to be considered for an AED scheme their evidence base should lie 
between the two extremes. Secondly, robust criteria should be established to rank 
technologies by priority based on the quality of existing evidence when considering them 
for an AED. Thirdly, AED schemes need to improve the quality of evidence rather than 
generate new uncertainties. Different stakeholders can have different views on what 
additional information is required, so a clear focus should be maintained when designing 
AED schemes.  With respect to how the evidence should be collected, registries and 
clinical trials are both considered suitable (Miller and Pearson, 2008). Fourthly, ethical 
concerns must be addressed concerning patient enrolment etc. A final major challenge is 
ensuring there is appropriate management and sustainable funding of AED projects in the 
long term (Tunis and Pearson, 2006).  
Experience and commentary on AED schemes conducted to date reveal consensus amongst 
stakeholders on the potential for AED schemes to reduce uncertainty but challenges and 
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concerns relating to design and implementation persist (Stafinski et al., 2010, Hutton et al., 
2007, Briggs et al., 2010, Neumann et al., 2011, Tunis and Pearson, 2006). Trueman et al. 
(2010) propose criteria indicating where AED schemes are deemed to be suitable. Here it 
is recommended that AED schemes be employed for technologies which are theoretically 
valid but evidence is insufficient. AED schemes are also most useful where persisting 
uncertainty is owing to clinical or cost effectiveness outcomes, which are expected to 
improve, rather than financial or budgetary impacts. Here it is expected that data collection 
will resolve the uncertainty and traditional coverage tools are not appropriate. Lastly, for 
AED schemes to be successful there should be stakeholder agreement on how the 
additional evidence can be collected and in a reasonable timeframe.  
While AED schemes are not new and still face challenges (e.g. transaction costs; outcome 
measurement and information technology infrastructure (Neumann et al., 2011)) they do 
provide a means of improving evidence bases in an ethical manner (Pearson et al., 2006). It 
is recognised that their full potential and appropriateness along with “best practice” 
guidelines for implementation are yet to be realised and they should be considered as a 
developing experimental policy (Miller and Pearson, 2008). In light of this, case studies are 
needed to examine how best AED schemes could provide input into decision making 
processes in real time. Such case studies need to consider the likelihood that further 
research will reduce the uncertainty; value of money of the additional research; 
implications of a positive recommendation on the evidence bases; current data collect 
initiatives; feasibility of new initiatives and patient access issues (Chalkidou et al., 2007).    
This thesis presents such a case study by examining the cost effectiveness and value of 
collecting further information, for Transcatheter Aortic Valve Implantation (TAVI) in the 
UK in treating severe Aortic Stenosis (AS). The UK is a suitable location as the health care 
decision making processes here are considered one of the most unequivocal internationally. 
Meanwhile, TAVI was chosen as it is a novel technology which has received considerable 
attention internationally as one of the key medical advances in the last decade and is 
considered the future of cardiology.  
The next section considers suitable frameworks for using the tools and techniques 
described in Section 2.2-2.4, for conducting the economic evaluation of the case study 
being considered in this thesis.   
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2.5 TRADITIONAL FRAMEWORKS FOR CONDUCTING 
ECONOMIC EVALUATIONS 
Given the tools and techniques for conducting economic evaluations, described in previous 
sections, attention turns to how they can be used in conducting economic evaluations of 
novel expensive medical devices with evolving evidence. Here the suitability of three 
frameworks is considered. 
 
2.5.1 A Framework for Conducting Economic Evaluations  
An eight step framework for conducting economic evaluations, illustrated in Figure 2.7., 
has been proposed by Drummond et al. (1987) (2007).  While, this eight step framework is 
commendable for its simplicity and transparency, it can give a false impression that 
economic evaluations just involve completing and summarising a balance sheet using a 
cost and effect for each technology  (Morris et al., 2007).  
 
Figure 2.7 Drummond’s Framework for Economic Evaluation 
 
 Source: Adapted from Drummond et al. (2007) 
 
1. Define the Health Intervention & Study Persepective 
2. Identify & Describe the Alternatives 
3. Identify, Measure & Value all Relevant Costs 
4. Identify, Measure & Value All Relevant Benefits 
5. Discount Future Costs and Benefits 
6. Perform a Sensitvity Analysis 
7. Perform a Marginal Analysis 
8. Make Recommendations 
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As discussed in Section 2.2, single point estimates are not sufficient for estimating the 
differences in costs and effects. In fact, it is likely that data from a number of sources will 
be required to inform each parameter thus requiring synthesis of the evidence 
(Spiegelhalter et al., 2004). Decision analytical modelling offers a means of representing 
the complexities of decision problems in a logical form and are especially useful where 
evidence is scarce and  needs to be synthesised and used to extrapolate beyond trial 
endpoints  (Buxton et al., 1997). Decision analytical modelling is not explicit in the eight 
step framework proposed by Drummond et al. (1987) (2007), but as discussed in Section 
2.2 it is recommended. Also, the framework does not consider the value of collecting 
additional information, thereby overlooking the research priority setting decision. 
 
2.5.2 A Framework Incorporating Decision Analytical Modelling 
into Economic Evaluations 
Briggs et al. (2006) propose a framework for economic evaluations which explicitly 
includes decision analytical modelling and consideration of future research. This 
alternative framework, presented in Figure 2.8, indicates six distinctive stages to 
developing a decision model for conducting an economic evaluation, using the tools and 
techniques describes in Section 2.2-3.  
 
Figure 2.8 Conducting Economic Evaluations with Decision Analytical 
Models 
      
Source: Adapted from (Briggs et al., 2006) 
1. Define the Decision Problem 
2. Structure the Decision Model 
3. Identify & Synthesis Evidence 
4. Deal with Uncertainty & Heterogeneity 
5. Presenting Uncertainty  in Costs, Effects & Cost Effectiveness 
6. Value of Additional Research 
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This framework informs both adoption and research priority decisions using decision 
analytical modelling.  However, with health technologies, especially novel medical 
devices, there can be incremental innovations and learning curves which result in an 
evolving evidence base. As new information becomes available during the lifecycle of the 
technology, the adoption and research decisions are influenced and could change. This 
framework, proposed by Briggs et al. (2006), does not account for evolving evidence, nor 
does it indicate how it should be captured and managed, both of which are imperative for 
medical devices, given their characteristics (described in Section 1.2.1).  
 
2.5.3 An Iterative Framework for Economic Evaluations 
As suggested at the end of the previous sub-section, evidence bases for technologies can 
evolve, reflecting incremental innovations and movements along learning curves.  The 
evolving nature of health technologies, their evidence bases and the effect of this on the 
aforementioned decisions, suggest an economic evaluation should not be a once off 
activity. According to Sculpher et al. (1997) and Fenwick et al. (2000), economic 
evaluations should be re-performed as evidence bases develop throughout the lifecycle of 
the technology. Thus, economic evaluations should be performed on an iterative basis so as 
to incorporate the learning about the technology. This implies that as new evidence 
becomes available the model should be updated to ensure consistency in decision making 
about the provision of the technology and research and development prioritisation to 
ensure access and value for money (Fenwick et al., 2000). 
Sculpher et al. (1997) (2006) propose a five step framework which can be used for  
conducting economic evaluations on an iterative basis, illustrated in Figure 2.9. This 
iterative approach provides greater confidence in the cost effectiveness estimates  used to 
inform decisions throughout the lifecycle of the technology, as they incorporate best 
available evidence at the time decisions are being made (Fenwick et al., 2000, Sculpher et 
al., 1997, Sculpher et al., 2006, Fenwick et al., 2006, Claxton, 2004, Claxton, 2005a, 
Vallejo-Torres et al., 2008, Boyd et al., 2010). Also, because the evaluations are performed 
throughout the lifecycle of the technology there are efficiency savings. For example, 
performing an economic evaluation early in a technology’s lifecycle can avoid inefficient 
and costly studies on technologies which are unlikely to be considered cost effective. This 
promotes prioritisation of research monies for technologies which are more likely to be 
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considered cost effective. Thus, iterative economic evaluations can increase the speed of 
decision making, account for new information as it comes available and reduce costs in the 
long run, while reducing uncertainty surrounding cost effectiveness estimates (Boyd et al., 
2010). In reducing uncertainty, evaluating technologies earlier and more frequently 
through the proposed iterative framework, decision makers aim to make better quality 
decisions. 
 
 
Figure 2.9 Iterative Approach to Economic Evaluations 
 
Source: Adapted from Sculpher et al. (2006) 
 
The iterative framework proposed by Sculpher et al. (1997) (2006) is a step towards 
addressing the evolving nature of health technologies’ evidence bases, while 
simultaneously accounting for uncertainty through the explicit inclusion of decision 
analytical modelling, especially for medical devices. However, it has two shortcomings. 
Firstly, while the framework proposed by Sculpher et al. (1997) (2006), indicates that 
economic evaluations should not be once off, the framework is linear. This suggests that 
following data collection and re-analysis in stage 5 the process is complete. However, this 
is often not the case, particularly for medical devices. As outlined in Section 1.2.1, the 
unique characteristics of medical devices give rise to incremental innovations and 
movements along the learning curve which lead to evolutions in the technology’s evidence 
base. These evolutions take place throughout the lifecycle of the device. Consequently, two 
iterations of an economic evaluation may not be sufficient. Secondly, the framework 
proposed by Sculpher et al. (1997) (2006) does not consider the relationship between 
access and additional evidence collection. As discussed in Section 2.4, performance 
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tracking linked to reimbursement is increasingly important, as it provides a means of 
generating more evidence, which can reduce uncertainty and increase value for money. 
Consideration of such schemes therefore should be intrinsic in economic evaluations.  
 
 
2.6 A CONTINUOUS ITERATIVE FRAMEWORK FOR 
ECONOMIC EVALUATIONS 
Having considered the existing frameworks for conducting economic evaluations it is 
evident that they have developed overtime. The initial model proposed in 1987, developed 
in subsequent years by Drummond et al., is a concise and transparent framework. 
However, it does not explicitly provide provisions for the inclusion of decision modelling, 
which is an essential when evidence from different sources are required, necessitating 
extrapolation   etc., and VOI. The framework proposed by Briggs et al. (2006), overcomes 
these omissions. However, it assumes economic evaluations are static and once off. While 
the latter is addressed in the Sculpher et al. (1997) (2006) framework, that too fails to 
adequately address the complexities arising from the unique characteristics of medical 
devices and excludes the consideration of performance based risk sharing agreements.  
 
Thus, a framework for the cost effectiveness of novel expensive medical devices, capable 
of capturing evolving evidence is warranted. To address this, a continuous iterative 
framework is conceptualised here (presented in Figure 2.10). 
 
The first stage of the proposed continuous iterative framework is to identify the decision 
problem, as per the frameworks considered in the previous section. In line with the ISPOR 
– SMDM guidelines (Roberts et al., 2012, Caro et al., 2012), a clear statement outlining the 
decision problem, disease, treatments etc. should be written at the outset. This will identify 
the technology under consideration, the alternatives, the time frame, perspective to be 
taken etc. (described further in Section 2.2.1). 
Once the problem under consideration has been clearly identified a decision analytical 
model can be constructed. As discussed in Section 2.2.2, decision analytical modelling has 
become a requirement in economic evaluations owing to the need for evidence to be 
synthesised and extrapolated. An appropriate type of decision model should be selected 
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and constructed to accurately reflect current understanding of the theory and practice of the 
condition and treatment under review.  
 
Figure 2.10 A Continuous Iterative Framework for Economic Evaluations 
 
Source: Author’s Own 
 
Next, all relevant and available evidence should be identified; this may require a literature 
search. Having identified all relevant evidence it will need to be synthesised. As discussed 
in Section 2.2.3, given their flexible nature Bayesian approaches to synthesising evidence 
are advocated, as they provide a means of formalising the process of learning from 
experience.  
Given the use of decision analytical modelling, parameter uncertainty is inevitable and 
needs to be accounted for. The most common means of handling parameter uncertainty is 
probabilistic sensitivity analysis (PSA). As explained in Section 2.2.4, this involves 
characterising uncertainty about the input parameters, by assigning probability 
distributions to each parameter and propagating the uncertainty throughout the model using 
a Monte Carlo simulation.  
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The Monte Carlo simulation provides a large number of expected costs and effects which 
can be used to reflect the joint parameter uncertainty in the decision model. These results 
can be used for a cost effectiveness analysis to estimate an Incremental Cost Effectiveness 
Ratio (ICER), Incremental Cost Effectiveness (ICE) plane and incremental net benefits to 
inform the adoption decision. Also, a Cost Effectiveness Acceptability Curve (CEAC) can 
be constructed to reflect decision uncertainty (see Section 2.2.5 for description of these 
methods). Therefore, using the results of the simulation decision makers can decide to 
adopt or not adopt the technology under review. 
Irrespective of the adoption decision made, a Value of Information (VOI) analysis (using 
the model results) can be performed to assess the value in collecting further information. 
As outlined in Section 2.3, the Expected Value of Perfect Information (EVPI) assesses the 
value of eliminating all uncertainty about the adoption decision. The Expected Value of 
Perfect Parameter Information (EVPPI) considers for which parameters perfect 
information would be most valuable. Finally, Expected Value of Sample Information 
(EVSI) estimates the net benefit if the decision was based on sample information. This can 
be compared to the expected costs of sampling to estimate the Expected Net Benefit of 
Sampling (ENBS) to determine efficient research designs. 
Hence, using the results of the simulation for the cost effectiveness and the VOI analyses 
decision makers can make one of four decisions (in line with Eckermann and Willan 
(2008)): 
i. Adopt the technology and collect more information. 
ii. Adopt the technology and do not collect more information. 
iii. Do not adopt the technology and collect more information. 
iv. Do not adopt the technology and do not collect more information.  
 
Even if the decision not to collect more primary information (ii and iv) is made additional 
external information may become available over time. External information refers to 
evidence generated outside the health technology assessment (HTA) system where the 
evaluation is taking place and/or information generated outside the control of decision 
makers in that system. The latter could be a result of evidence generation (trial or registry) 
in another jurisdiction. For example, if a clinical trial conducted in the United States 
releases results, decision makers in the United Kingdom can avail of this information even 
though they had no control over its collection, dissemination etc. Alternatively, external 
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evidence may become available if the technology is being used in clinical practice and 
practitioners, professional organisations etc., record the outcomes in a database.  Once 
available, this additional external evidence can be employed to re-assess the adoption and 
research priority setting decisions for that technology. In light of the new evidence, the 
decision model may require re-structuring, to reflect updated knowledge on the 
technology, all the available evidence will need to be synthesised and probability 
distributions will need to be assigned.  The PSA can be performed again, the results of 
which can be used to inform the adoption decision and the VOI analysis for the research 
priority setting decision. After which, additional evidence can be collected if necessary 
and/or additional external evidence may become available and the decisions can be re-
assessed as the evidence base evolves again. 
Alternatively, if the decision to collect additional information is made (i and iii) 
consideration is given to how this additional evidence should be collected. As discussed in 
Section 2.4, Performance Based Risk Sharing Agreements (PBRSA), like Access with 
Evidence Development (AED), provide a means of collecting additional evidence by 
granting limited access to the technology for a specific patient group for a pre-defined 
time. This permits performance tracking, while generating further evidence, which can 
subsequently be linked to reimbursement. As outlined in Section 2.4, the suitability and 
value of a proposed PBRSA needs to be assessed. The results of the decision analytical 
model and VOI analysis (from previous steps in the framework) can be used to estimate 
the potential value of the evidence a proposed PBRSA will generate (Expected Value of 
Sample Information (EVSI)). This can be compared to the expected cost of the PBRSA to 
measure the Expected Net Benefit of Sampling (ENBS). If the ENBS is positive, the 
potential value is greater than the costs and the PBRSA is suitable. The additional evidence 
generated from a PBRSA, along with any additional external evidence available, can be 
used to re-structure the decision analytical model and all available evidence can be 
synthesised. This ensures that the model includes all available information on the 
technology. Following this, the PSA can be performed again to inform the adoption and 
research priority setting decisions and additional evidence can be collected and the 
decisions can be re-assessed as the evidence base evolves again.  
This proposed framework encourages decision makers to perform iterations of the decision 
analytical model continuously. This ensures that evolutions in the evidence base, owing to 
incremental innovations, movements along the learning curve etc., are reflected and 
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decisions about adoption of the technology and further evidence generation are based on 
the best available data at that time.  
Following on from the iterative approach describe by Sculpher et al. (1997) (2006) other 
frameworks (for example Vallejo-Torres et al. (2008) see below) have developed which 
aim to capture the HTA process in the UK whereby each guidance document identifies a 
date on which the decision will be reviewed. The framework proposed by Vallejo-Torres et 
al. (2008) also proposes conducting economic evaluations throughout the lifecycle of a 
technology, explicitly medical devices, employing Bayesian techniques iteratively. Their 
framework consists of three stages. Stage One, the early phase, captures the very early 
development phase of a device, in which expert opinion is elicited to inform the evaluation 
(see Section 2.2.3). Stage Two, the mid-phase, employs early evidence available which 
updates prior elicited beliefs. In stage three, the late stage, all available evidence is 
formally synthesised to inform external decision makers (Vallejo-Torres et al., 2008).  
While the Continuous Iterative Framework for conducting economic evaluations proposed 
here has similarities with these existing frameworks and the HTA process in practice, it has 
several advantages.  Firstly, the framework presented in this thesis is applicable to any 
health technology with evolving evidence. Secondly, the framework presented in this 
thesis is more flexible than that proposed by Vallejo-Torres et al. (2008); it does not 
restrict iterations to specific stages in the development of the technology. Thirdly, the 
framework presented in this thesis is designed to be both proactive and reactive to 
evolutions in the evidence base. Finally, it explicitly includes the consideration of how 
additional evidence could be collected and formally incorporates the consideration of 
PBRSAs. 
 
2.7 CONCLUSION 
As outlined in this Chapter, owing to scarce resources choices have to be made concerning 
the adoption and commissioning of further research for health technologies. Economic 
evaluations provide a means of assessing the costs and benefits of competing health 
technologies under consideration. Decision modelling and probabilistic analysis are 
increasingly being used to conduct such evaluations, the results of which can be presented 
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using ICERs, cost effectiveness planes, cost effectiveness acceptability curves and net 
benefits, which can be used to address the adoption decision. While VOI analyses can be 
employed to address the research priority setting decision.  
In recent years, when there is value in collecting additional research health care providers, 
payers and manufacturers are increasingly interested in tracking performance of 
technologies to generate further evidence and link this to reimbursement. Such policies and 
agreements, collectively referred to as Performance Based Risk Sharing Agreements 
(PBRSA), aim to reduce uncertainty and increase value for money by generating further 
evidence on the technology.  
As outlined in Section 2.5, frameworks for conducting economic evaluations have been 
developing over the years. These are employed routinely for medicines, capital projects 
etc. However, employing these frameworks for economic evaluations of medical devices is 
relatively unexplored. The lack of formal requirements for economic evaluations, as well 
as the distinctive characteristics of medical devices (presented in Section 1.2.1), contribute 
to a lack of evidence on long term outcomes and evolving evidence owing to incremental 
innovations which increase uncertainty. The latter present challenges in conducting 
economic evaluations of novel expensive medical devices. As a result, the existing 
frameworks taken into account in this thesis are considered insufficient for an economic 
evaluation of novel expensive medical devices, like the case study under consideration in 
this thesis. 
To overcome the drawbacks of the existing frameworks, a continuous iterative framework, 
developed in Section 2.6, is proposed. This framework incorporates decision analytical 
modelling, probabilistic analysis and VOI analysis to inform the adoption and research 
priority setting decisions, on a continuous iterative basis as the evidence base evolves. The 
framework also includes the consideration of PBRSA and externally produced evidence. 
Therefore, it is capable of handling uncertainty and evolving evidence to inform the 
adoption and research priority setting decisions. 
The remainder of the thesis presents an application of the proposed continuous iterative 
framework for the case study considering the cost effectiveness of Transcatheter Aortic 
Valve Implantation (TAVI). The thesis is arranged as follows: Chapter 3 presents a 
literature review of TAVI and Aortic Stenosis (AS), to identify the research question. 
Chapter 4 presents the decision analytical model and evidence synthesis. These are used to 
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estimate the cost effectiveness and VOI analysis of TAVI, for different patient groups 
(operable and inoperable) given current information (pre-trial). Chapters 5 and 6 reconsider 
the cost effectiveness of TAVI as the evidence base evolves with the publication of the 
first trial data in an iterative manner, for inoperable and operable patients respectively. 
Chapter 7 investigates where to go now with TAVI given evolved evidence for operable 
and inoperable patients. Finally, Chapter 8 concludes by discussing the challenges faced 
and lessons learnt from the economic evaluation performed, which are applicable when 
investigating the cost effectiveness of novel technologies with evolving evidence bases.  
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CHAPTER 3 LITERATURE REVIEW ON 
TRANSCATHETER AORTIC VALVE 
IMPLANTATION 
 
3.1 INTRODUCTION 
As outlined in Chapter 2, the rapid pace of innovation amongst health technologies 
presents a significant challenge for health care systems. This challenge is twofold. Firstly, 
decision makers within health systems must determine for whom technologies are suitable, 
while delivering an equitable health service.  Secondly, as health care expenditures are 
rising, value for money is sought after. As discussed in the previous chapter, in response to 
these demands, economic evaluations are increasingly being incorporated into the decision 
making process. Economic evaluations can inform decision makers regarding the cost 
effectiveness of technologies, compared to its’ alternative(s), for different patient groups 
and for setting research priorities. In the case of medical devices, this must be done while 
recognising their challenging characteristics (described in Chapter 1). 
One discipline in medicine which has seen substantial developments in recent decades is 
cardiovascular disease. According to the British Heart Foundation (2012), cardiovascular 
disease is the main cause of death in the UK (responsible for approximately one third of all 
deaths).  While there are numerous types of cardiac diseases, heart valve diseases, such as 
Aortic Stenosis (AS), are considered an important public health issue owing to poor 
prognosis and high prevalence amongst the increasing elderly population (Nkomo et al., 
2006). The traditional treatment for severe AS is invasive and owing to the characteristics 
of the patient population (elderly with significant co-morbidities) approximately one third 
of patients are denied the procedure annually (Iung et al., 2005). Given the increasing 
patient population and the poor prognosis for those denied treatment, the development of a 
less invasive alternative, Transcatheter Aortic Valve Implantation (TAVI), is welcomed. 
Despite its potential, since being released in 2002, the evidence base for TAVI remains 
under developed and access to the procedure is limited across the US, Europe and the UK. 
Thus, TAVI represents a novel technology with high demand but scarce evidence, for 
which decision makers need to make recommendations on access and the collection of 
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further evidence early in its lifecycle. For these reasons, TAVI was chosen as a case study 
in this thesis, to examine how economic evaluations can be applied iteratively to examine 
the cost effectiveness of and value of collecting further evidence on novel expensive 
medical devices, with evolving evidence.  To commence the process, this Chapter presents 
a description of the epidemiological background of AS, the traditional treatments available 
and the TAVI procedure. Following this, the evidence base for TAVI available at the point 
at which the case study commenced (2009) is reviewed. The subsequent chapters will 
examine the cost effectiveness of TAVI and the need for further research at key points in 
the evidence development of TAVI, in line with the continuous iterative framework 
developed in Chapter 2. 
 
3.2 EPIDEMIOLOGICAL BACKGROUND OF AORTIC 
STENOSIS 
Aortic Stenosis (AS) is the most common type of degenerative valvular heart disease (Van 
Brabandt and Neyt, 2008), present in 1-2% of the population aged over 65 (Chikwe et al., 
2003). AS refers to the narrowing of the aortic valve (NHS, 2008b) and is caused by an 
age-dependent, progressive build-up of calcium in the aortic valve. The condition is 
particularly prevalent amongst the elderly, who have significant co-morbidities such as 
pulmonary hypertension, diabetes mellitus, renal failure, severe lung disease, mitral valve 
disease, hypertension, recent stroke, aortic regurgitation, cancer, porcelain aorta etc. 
(Cribier et al., 2006, Cribier et al., 2004, Vahanian et al., 2008, Webb et al., 2007).  
The narrowing of the aortic valve, arising from AS, results in impaired outflow of blood 
from the heart (NHS, 2008b). Consequently, the left ventricle needs to pump harder to 
maintain a normal circulatory blood flow. Under normal conditions the aortic valve allows 
blood to flow forwards out of the heart and prevents back flow. With AS however, the 
aortic valve is narrowed so the valve is unable to open properly. Therefore, the blood 
cannot flow as effortlessly out of the heart. This puts a strain on the heart, as it must work 
harder, and over time the heart muscle may thicken so as to pump the blood harder through 
the narrowed valve (NICE, 2008). This results in symptoms such as chest pain brought on 
by exertion, angina, breathlessness, dizziness and fainting and ultimately ventricular 
hypertrophy (enlarged ventricles) and heart failure can result (NHS, 2008b). So without 
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intervention the increased pressure on the left ventricle results in symptoms of congestive 
cardiac failure and there is increased risk of sudden death (Chikwe et al., 2003, Legrand et 
al., 1991). 
Risk factors for AS include a bicuspid aortic valve (where the aortic valve has only two 
leaflets instead of three), coronary artery disease, increased age, male gender and high 
cholesterol levels (Chikwe et al., 2003). Owing to the degenerative nature of valvular 
diseases, like AS, as populations age disease prevalence increases. In Europe, for example, 
it is estimated that 23% of the population will be older than 65 by 2030 (EuroStat, 2012). 
As a result, the related workloads
 
and financial pressures on national health services are 
expected to continue (Majeed, 2005). While prevention of aortic valve disease is optimal, 
with 17.2% of the European population over 65 in 2009 (EuroStat, 2012) reducing 
symptoms and treating AS is an immediate priority.  
 
3.3 TRADITIONAL TREATMENT FOR AORTIC STENOSIS  
Treatment for Aortic Stenosis (AS) is usually required only when the disease is considered 
severe or symptomatic. Severe AS is defined as a valve area less than or equal to 0.6cm
2
 of 
body surface area and/ or a mean aortic gradient of ≥ 50mmHg (Iung et al., 2005). This 
treatment requires replacement of the aortic heart valve, referred to as Aortic Valve 
Replacement (NHS, 2008b).  
 
3.3.1 Surgical Aortic Valve Replacement 
Over the past 40 years, patients with severe AS have received surgical valve replacement 
(AVR), which has been demonstrated to reduce the symptoms of AS and prolong life 
(Leon et al., 2006). AVR involves the replacement of the diseased valve with an artificial 
prosthesis. This is conducted through a median sternotomy approach, involving open heart 
surgery, where the patient is placed  on a heart and lung machine (heart-lung bypass) 
(NHS, 2008b). To be eligible for AVR four pre-conditions are necessary, according to the 
American College of Cardiology/American Heart Association Guidelines (Leon et al., 
2006). These include the presence of cardiac symptoms; concomitant coronary artery 
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bypass graft surgery; concomitant surgery of the aorta or other heart valves and left 
ventricular systolic dysfunction (ejection fraction less than 50%).  
The artificial prosthesis inserted during AVR can be mechanical or biological. Mechanical 
prostheses are constructed from synthetic materials such as metals, whereas biological 
prostheses are made from biological materials such as porcine or bovine tissue (Van 
Brabandt and Neyt, 2008).  Biological prostheses have a risk of structural failure resulting 
in the need for re-operation. While mechanical prostheses have a risk of thromboembolism 
and anticoagulant haemorrhage (Van Brabandt and Neyt, 2008).  
Since its introduction, perioperative patient management techniques for AVR continue to 
improve and it has been proven to significantly improve AS symptoms and prolong life. As 
demonstrated by increases in valve durability and clinical benefits published over time 
(Leon et al., 2006). Owing to the ageing nature of AS patients however, AVR patients are 
often found to require prolonged hospital stays and have increased risks of renal failure, 
stroke and heart failure. 
Also, during or post AVR there is a risk of death and complications. Operative mortality 
for symptomatic AS patients receiving AVR varies between 2% and 30%. Strokes are also 
a major concern owing to haemorrhage, aortic cannulation at the site, hypoperfusion and 
emboli from the calcified valve. Other major complications possible amongst these patients 
include chest infection, pleural effusion, post-operative bleeding, wound infections and 
acute renal failure (Chikwe et al., 2003).  
Given the invasive nature of the procedure and risks associated with it, there are several 
risk indicators for surgical AVR. These are advanced age; female gender; severe chronic 
obstructive pulmonary disease; severely reduced left ventricular function; advanced renal 
or liver failure; diabetes mellitus; NYHA class III and IV; congestive heart failure and 
recurrent neurological insults (Leon et al., 2006, Van Brabandt and Neyt, 2008, Iung et al., 
2005). 
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3.3.2 Medical Management  
Since the 1980’s, the number of patients being denied AVR has increased to approximately 
one third of patients, owing to high surgical mortality (Iung et al., 2005). In the absence of 
AVR, patients receive conservative treatment, which involves no valve replacement, just 
medical therapy and occasionally balloon valvuloplasty (Leon et al., 2006). Without valve 
replacement, the prognosis for patients with severe AS is poor. Even with aortic balloon 
valvuloplasty and pharmacological treatments, symptoms are only marginally relieved in 
the short term and the disease continues to progress, resulting in death. This is owing to 
significant complications, re-stenosis and further deterioration which can occur within 6-12 
months (Braunwald, 2002). Thus, these patients require frequent and prolonged 
hospitalizations and consume a high level of health care resources.  As a result, these 
patients are considered to be a significant economic burden to the health care system, with 
poor quality of life and high mortality (average survival is 2-3 years) (Legrand et al., 
1991)). 
 
3.3.3 Risk Groups 
Given the nature of the disease, the associated risk factors and evidence to date, Aortic 
Stenosis (AS) patients can be categorised as operable or inoperable. To determine into 
which categories patients fit, predictive risk models and functional classification systems 
can be employed (Leon et al., 2006). These include functionality scales such as the New 
York Heart Association (NYHA) and the European System for Cardiac Operative Risk 
Evaluation (EuroScore) (Van Brabandt and Neyt, 2008).  
European System for Cardiac Operative Risk Evaluation (EuroScore 
The logistical EuroScore is a method for predicting the likelihood of death during or 
shortly after heart surgery, i.e. operative mortality. It identifies a number of risk factors and 
assigns a weight to each factor, which are used to estimate mortality on an individual basis. 
The factors include age, gender, previous cardiac surgery, pulmonary disease, angina, left 
ventricular ejection fraction, neurological dysfunction, pulmonary pressure etc. The 
EuroScore is widely used in Europe owing to its simplicity, user-friendly design and 
validity in predicting operative mortality on an individual basis for high risk patients 
(Roques et al., 2003). For example, patients with a logistical EuroScore > 20% would be 
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considered at high surgical risk. While the predictive nature of the scoring system is 
considered to be very good, a disadvantage is that it tends to overestimate mortality 
(Karabulut et al., 2003).  To overcome this disadvantage the EuroScore can be used in 
conjunction with a functionality classification system, such as the New York Heart 
Association (NYHA) system. 
New York Heart Association (NYHA)  
The New York Heart Association (NYHA) functionality classification system indicates the 
functional status of patients with heart failure. It is a four-point semi-quantitative index, 
commonly employed owing to its useful ability to correlate clinical status with quality of 
life and survival (Kubo et al., 2004). The four classes are ordered by increasing disability. 
Patients in class I have cardiac disease without limitations on physical activity. Patients in 
class II have cardiac disease which impairs some physical activity. Patients in class III 
have cardiac disease with associated limitations in physical activity, though they are 
comfortable at rest. Finally, patients in class IV have cardiac disease which inhibits any 
physical activity without discomfort (NYHA, 1964). These classes are summarised in 
Table 3.1.  
Table 3.1 New York Heart Association Classification  
Class Functional Classification 
I Patients have cardiac disease but without the resulting limitations of physical 
activity. Ordinary physical activity does not cause undue fatigue, palpitation, 
dyspnoea or angina pain 
II Patients have cardiac disease resulting in slight limitation of physical activity. 
They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnoea or angina pain 
III Patients have cardiac disease resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary physical activity causes fatigue, 
palpitation, dyspnoea or angina pain 
IV Patients have cardiac disease resulting in inability to carry on any physical 
activity without discomfort. Symptoms of cardiac insufficiency or of the angina 
syndrome may be present even at rest. If any physical activity is undertaken, 
discomfort is increased 
 Source: (NYHA, 1964) 
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While these tools are useful, they can be imprecise by excluding less common risk factors. 
It is therefore recommended that patient classification be based on a combination of 
objective quantitative prediction models (e.g. NYHA and EuroScore) and subjective 
assessment by clinical teams (Leon et al., 2006). 
So in the case of Aortic Stenosis patients using those tools, patients can be classified into 
inoperable and operable patients as follows. Those with high operative risk, e.g. Logistical 
EuroScore ≥ 20, and who are in NYHA class ≥ III (which is common amongst elderly 
patients with significant co-morbidities), require AVR but are often are denied the 
procedure, owing to the increase risk associated with surgery  (Iung et al., 2005). Surgical 
mortality increases by 8.8%  overall in patients aged over 65 years old (Leon et al., 2006). 
These patients are classified as inoperable patients, as AVR is not a viable treatment 
option. Thus, the treatments available for these patients are medical management or TAVI. 
Patients with a lower operative risk, i.e. Logistical EuroScore < 20 and in NYHA Class 
II/III, are usually considered to be operable. For the purposes of this thesis, the operable 
patient group is further divided into low and high risk operable patients. Low risk, operable 
patients are those who are always considered suitable for surgery (low operative mortality 
~5%, NYHA Class ≤ II). The treatments available for these patients are AVR and TAVI. 
High risk, operable patients are those who may be considered either eligible or ineligible 
for surgery depending on age, co-morbidities and other factors influencing operative 
mortality and function status (medium operative mortality ~ 15%, NYHA class II/III). The 
treatments available for these patients are AVR, TAVI and medical management. 
 
3.4 TRANSCATHETER AORTIC VALVE IMPLANTATION 
(TAVI) 
The increasing number of patients being denied AVR since the 1980’s, as well as the 
intrusive nature of AVR has led to the development of an alternative method for valve 
replacement – Transcatheter Aortic Valve Implantation (TAVI). It involves the insertion of 
a new valve through a thin tube (a catheter) into the heart. Access to the aortic valve with 
TAVI is achieved transluminally through the femoral artery or vein. I.e. the catheter is 
inserted into the body via a large blood vessel, found for example in the groin 
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(transfemoral route) or via a mini-thoracotomy and apical puncture of the left ventricle (the 
transapical approach). In the latter, a small cut is made in the chest, through which the 
valve is inserted. In both procedures, a balloon catheter is advanced into the left ventricle 
over a guide wire and is positioned within the opening of the affected aortic valve (NHS, 
2008b, NICE, 2008). After which, the existing aortic valve is dilated to make room for the 
new prosthetic valve. This new valve is mounted on a metal stent, following which it is 
directed into position and is expanded either by self-expansion or balloon inflation 
techniques. Once the new valve is installed, the existing aortic valve becomes redundant. A 
key advantage of the TAVI procedure is that it can be performed under a local anaesthetic. 
Therefore, it is considered minimally-invasive and avoids the emotional and physical 
trauma, prolonged hospital stay and long recovery associated with AVR. Consequently, it 
can be considered suitable for patients with high operative risk (NHS, 2008b).  
There are currently two manufactures of TAVI which have earned the CE Mark approval 
in Europe, the Medtronic CoreValve device and the SAPIEN device by Edwards 
Lifesciences. For the purposes of this thesis, no differentiation is made between the devices 
or the insertion methods; they are all treated as one technology. 
In contrast to AVR, there are several contradictions for TAVI which can limit its use 
(listed in Table 3.2). These include the diameter of the annulus; the presence of asymmetric 
heavy valvular calcification; dimension of the aortic root and presents of apical lung valve 
thrombus (Vahanian et al., 2008).  
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Table 3.2 Contraindications for TAVI 
Universal Contraindications for TAVI 
- Aortic annulus which is less than 18mm or greater than 25mm for balloon-expandable and less 
than 20mm or greater than 27mm for self-expandable devices. 
- Bicuspid valves; because of the risk of incomplete deployment of the prosthesis (Zegdi 2008) 
- The presence of asymmetric heavy valvular calcification, as it may compress the coronary 
arteries during TAVI (Webb 2007).  
- Aortic root dimension greater than 45mm at the aorto-tubular junction for self-expandable 
prostheses. 
- Presence of apical lung valve thrombus 
 
Contraindications for the Transfemoral Approach 
- Where the iliac arteries display severe calcification, tuortusosity, a small diameter or where 
aorto-femoral bypass was previously performed; 
- Where there is severe angulation of the aorta; severe atheroma of the aorta arch; coarctation, 
aneurysm of the abdominal aortic with protruding mural thrombus; 
- Where bulky atherosclerosis is present in the ascending aorta and the arch, as detected by TEE 
(transoesophageal echocardiography); 
- Where the aorta is ascending transversely. 
 
Contraindications for the Transapical approach  
- If previous surgery was performed on the lung valve using a patch; 
- Where there is calcified pericardium; 
- If there is severe respiratory insufficiency; 
- Where the lung valve apex in non-reachable. 
Source: (Vahanian et al., 2008) 
 
 
3.5 CURRENT EVIDENCE BASE FOR TRANSCATHETER 
AORTIC VALVE IMPLANTATION  
To determine the effectiveness, cost effectiveness and availability of TAVI a literature 
review was conducted. The literature was identified through searches of PubMed, Google 
Scholar and from reference lists in retrieved articles in April 2009. In general, the literature 
providing clinical evidence reported on procedural death, mortality in the short term and 
events occurring post procedure. These events included stroke, myocardial infarction, 
cardiac tamponade, valve thromboembolism, paravavular leaks, vascular events etc. For 
the purposes of this thesis these events (defined in Appendix III) are termed “procedure 
related events” or PREs.  
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3.5.1 Effectiveness Evidence 
Since the first use of TAVI in 2002, the annual number of procedures has been increasing, 
particularly for high risk patients. Between 2002 and 2008 over 1,000 high risk patients 
displaying symptoms of severe AS were treated using TAVI (Vahanian et al., 2008). These 
procedures were performed under special clinical arrangements and results were recorded 
in registries. No randomised clinical trials were performed at this time (Thomas, 2009). 
The procedures carried out up to 2009 were mainly on high risk patients, older than 80 
years of age, with a Logistic EuroScore over 20% who displayed contraindications for 
surgery (Vahanian et al., 2008). Thus, despite first being used in 2002, by 2009, when this 
study commenced, TAVI’s evidence base was still relatively immature. Given the 
characteristics of medical devices, discussed in Section 1.2.1, this was not surprising. 
In 2008, Vahanian et al. (2008) published a review of early clinical results of TAVI. This 
review distinguished between transfemoral and transapical results and found the following. 
Procedure success for the transfemoral approach was found to be approximately 90%, with 
good valve function and valve area between 1.5 to 1.8 cm
2 
(Vahanian et al., 2008). 
Mortality at 30 days ranged between 5-18%. While acute myocardial infarction occurred in 
2-11% of cases, coronary obstruction was rare (<1%). Initially, approximately 50% of 
cases displayed mild-moderate aortic regurgitation; however with the development of 
prostheses this reduced to approximately 5%. The main causes of mortality and morbidity 
were vascular complications (10-15%). Stroke was experienced in 3% to 9% of patients 
and between 4% and 8% of patients had atrioventricular blocks which required the 
installation of pacemakers (Vahanian et al., 2008).  Long term results (beyond 30 days or 
one year) were sparse in 2009. Of those that did report long term results, average survival 
with clinical improvement was 70-80%  (Vahanian et al., 2008).  For patients treated using 
the transapical aortic valve implantation the success rate was also approximately 90%. 
Here the mortality rate ranged between 9-18% and 0-6% of patients experienced a stroke  
(Vahanian et al., 2008).  Table 3.3 summarises these results.  
The evidence available on TAVI up to 2008, as reported by Vahanian et al. (2008), 
suggested that the technology was suitable for patients with symptoms of severe AS, it was 
haemodynamic and provided clinical improvement for up to two years (Vahanian et al., 
2008). However, owing to questions regarding safety and long term durability it was 
recommended that the use of the procedure should be limited to high risk patients or those 
with contraindications for surgery (Vahanian et al., 2008).  
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Table 3.3 Effectiveness Results for TAVI 2002-2008    
 Transfemoral Approach Transapical Approach 
Number of Cases ~ 900 > 300 
Success Rate ~90% ~90% 
Mortality Rate at 30 days 5-18% 9-18% 
Stroke 3-9% 0-6% 
Myocardial Infraction 2-11%  
Coronary Obstruction <1%  
Aortic Regurgitation ~50%  ~5%  
Prosthesis embolization ~1%  
Vascular complications 10-15%  
Artioventricular blocks 4-8%  
Long Term Survival 70-80%  
Source: (Vahanian et al., 2008) 
 
As suggested by Vahanian et al. (2008), the most representative and best data available  in 
2008 was evidence from early registries and case studies published in the literature. Such 
short term, non-randomised, high risk patient focused evidence is common amongst 
medical devices in the early stage of their lifecycle, as discussed in Chapter 1.  In this 
thesis the review of effectiveness literature is expanded and developed beyond that from 
Vahanian et al. (2008). The literature review considered publications up to and including 
2009. Here 17 papers with effectiveness evidence from case series and registries, reporting 
short term results for the TAVI procedure, were found. The studies are listed in Table 3.4 
and are discussed below. 
TAVI Literature 
The literature review for TAVI revealed 17 papers with effectiveness evidence on short 
term results, from case series and small early TAVI registries from France, Germany, 
Austria, Canada and USA. USA (See Appendix II for search strategy). Sample sizes 
ranged from 1 to 86 patients and the average was 31 (median = 30). Having identified and 
reviewed the relevant literature, evidence on mortality and procedure related events (PREs) 
were extracted per patient following TAVI as follows. This evidence will be used to form a 
data base on the effectiveness of TAVI.  
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Table 3.4 Effectiveness Literature Reviewed 
- Indicates missing information 
 
Criber et al. (2004) presented results on six patients, all in New York Heart Association 
(NYHA) Class IV, who received an anterograde TAVI procedure in France, between April 
2002 and August 2003. Five patients were male and the average age was 75±12 years. The 
procedure was considered successful in five patients. Vascular events were reported for 
only one patient. One patient died immediately from cardiac causes, while three patients 
AUTHOR Year Location N 
TAVI Literature    
(Cribier et al., 2004) 2002-2003 France 6 
(Hanzel et al., 2005) 2003 USA 1 
(Sack et al., 2005) June  – July 2005 Germany 2 
(Cribier et al., 2006) 2003 France 36 
(Grube et al., 2006) Feb  - Nov 2005 Germany 25 
(Lichtenstein et al., 2006) - Canada 7 
(Webb et al., 2006) Jan - July 2005 Canada 18 
(Berry et al., 2007) Mar 2005 – Feb 2007    13 
(Eltchaninoff et al., 2007) 2003 - 2005 France 36 
(Grube et al., 2007) Aug 2005 – Feb 2007 Canada, Germany 86 
(Marcheix et al., 2007) Dec 2005 - Aug 2006 Canada 10 
(Walther et al., 2007) - Germany, Austria, USA 59 
(Webb et al., 2007) - Canada 50 
(Descoutures et al., 2008) Oct 2006- April 2007 France 66 
(Svensson et al., 2008) Dec 2006 – Feb 2008 - 40 
(Walther et al., 2008) Feb 2006 – Mar 2007 - 50 
(Ye et al., 2009) - Canada 26 
    
AVR Literature    
(Gehlot et al., 1996) 1987-1996 UK 103 
(Milano et al., 1998) 1981-1995 Italy 355 
(Gilbert et al., 1999) 1985-1996 Germany 455 
(Aupart et al., 2006) 1984-2003 France 1,133 
(Eichinger et al., 2008) 1971-1992 USA 322 
    
Stroke Literature    
(Bando et al., 2003) 1977-2001 Japan 812 
(Melby et al., 2007) 1993-2005 USA 245 
(Alsmady et al., 2009) 2001-2008 - 64 
81 
 
died during the first eight weeks. One vascular event was reported within the first 30 days. 
This was an early study which concluded that TAVI may become an important treatment 
option for non-surgical patients in the future.  
The first report of a technically successful retrograde TAVI procedure was made by 
Hanzel et al. (2005). Here a single TAVI procedure was performed on an 84 year old male, 
in the USA. The patient had severe AS, congestive heart failure and a previously failed 
valve replacement. There was no evidence of bleeding or myocardial infarction and the 
procedure was considered successful. In 2005 also, Sack et al. (2005) reported outcomes 
for two patients who received the TAVI procedure in Germany. At follow up, both patients 
were alive, aortic insufficiency was reduced and minimal regurgitation was reported for 
one patient.  
Criber et al. (2006) reported results from a single centre pilot trial delivering TAVI in 
France in August 2003, with  36 patients. All patients were in NYHA Class IV; the average 
age of patients was 80±7 and 57% were male. Post-procedure, 27 procedures were 
considered successful. At nine month follow up, 11 patients were alive. Overall, the rate of 
major adverse events within 30 days was 26%. Five cases of major paravavular leakages 
were reported within the first 30 days. The study reported that zero cases of myocardial 
infractions and pacemaker insertions were reported in the same period, which is useful for 
constructing the data base. 
Grube et al. (2006) reported results from a single centre registry study conducted in the 
Siegburg Heart Centre, Germany, with 25 patients. The average logistical EuroScore prior 
to receiving the procedure was 11%.  The average age of patients was 80.3±5.4, of whom 
80% were female. Grube et al. (2006) reported that two patients converted to AVR, i.e. did 
not receive the TAVI procedure. Device and procedural success was 88%, corresponding 
to 21 patients. Meanwhile, 18 patients survived to discharge with no adverse events 
occurring within 30 days of leaving the hospital. The study also reported that within the 
first 30 days zero cases of valve thromboembolism, myocardial infarction, endocarditis and 
major paravavular leaks were reported. There was one case of cardiac tamponade and five 
vascular events in the same period. Despite the small sample size, this study provides a 
thorough description of the clinical results of TAVI, especially with respect to procedure 
related events.  
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Lichtenstein et al. (2006) reported outcomes on seven patients who received the TAVI 
procedure in Canada. All patients were considered high risk, the average age of patients 
was 77±9 and five were male. The average NYHA classification was III and surgical 
mortality risk, measured by logistical EuroScore, was 35±6%. No intraprocedural deaths 
were reported and at follow up (average 87±56 days) six patients were alive. 
Unfortunately, this study did not report on any procedure related event, thus provides little 
contribution to the effectiveness evidence base. 
Webb et al. (2006) reported results from 18 patients who received the TAVI procedure in 
Canada. The average age of these high risk patients was 81±6 years, 72% of who were 
male. The average logistical EuroScore was 26.2%±13.1% and 67% of patients had 
logistical EuroScore greater than 20%. The procedure was considered successful in 14 
patients and no intraprocedural deaths were reported. At a follow up (75±55 days), 16 
patients were alive. With respect to PREs, within 30 days zero cases of endocarditis and 
myocardial infarction were reported and two cases of vascular events were reported. 
Again, the reporting of zero events here is useful for when the evidence will be 
synthesised.  
Berry et al. (2007) presented results for 11 patients who received the TAVI procedure, 
aged 82±10 years, of whom 54% were male. One patient suffered a stroke and five died 
post-procedure, while four others died within four months of discharge. One patient was 
reported as having vascular events within the first 30 days. It was also reported that three 
patients had pacemakers fitted within the first 30 days. No other events were reported here.  
Grube et al. (2007) reported outcomes on 86 patients who received TAVI in Germany and 
the USA. This was the largest number of patients reported in a single study in the literature 
review. Here patients were either 80 years or more with a logistical EuroScore greater than 
20% or 75 years or more with a logical EuroScore greater than or equal to 15% or aged 
greater than or equal to 65 with significant pre-specified risk factors. The average age of 
patients was 81.3±5.2 and the average logistical EuroScore was 23.4 ±13.5%. Reported 
device success was 88%, while procedural mortality was 6%. Also, six patients converted 
from TAVI to AVR. Over all 30-day mortality was reported as 22%. While combined 
death, stroke and myocardial infarction was 22%. Examining the incidence of procedural 
related events individually, zero cases of major paravavular leaks and endocarditis were 
reported within the first 30 days.  While six patients experienced cardiac tamponade, one 
83 
 
had a myocardial infarction and one had a pacemaker inserted within the first 30 days. 
Despite reporting on the largest number of patients, this study did not report on any other 
events.  
Marcheix et al. (2007) reported results from 10 patients who received the TAVI procedure 
between December 2005 and August 2006 in Canada. The average age of the patients was 
81.3 years and 50% were male. The median NYHA class was III. The median logistical 
EuroScore was 32% and 80% of patients had a logistical EuroScore greater than 20%. The 
reported 30-day mortality rate was 20%. One patient died five days after the procedure 
from a major stroke and a second patient died at day 20, also from a stroke. With respect to 
PREs, one case of major paravavular leakage was reported; three cases of access site 
events; two cases of vascular events and three pacemakers were implanted within 30 days. 
Also, zero incidences of endocarditis and myocardial infarction were reported within the 
first 30 days. Albeit reporting on small patient numbers, the reporting of zero events 
occurring in this study is very useful.  
Walther et al. (2007) reported outcomes on 59 patients from a clinical study which 
collected evidence from February 2006 until October 2006. The patients were enrolled in 
clinics in Leipzig, Vienna, Frankfurt and Dallas. The average age of patients was 81.4±5.8 
years and 74.6% were female. The average logistical EuroScore for these patients was 
26.8%±13.5%. Successful valve positioning was performed in 53 patients and two patients 
had to convert to AVR. Eight patients died in hospital without valve dysfunction (13.6%) 
and survival was 75.7±5.9% at follow up (110±77 days). With respect to PREs, four 
myocardial infractions were reported within the first 30 days. Despite the large study 
population, the authors did not report on any other PREs.  
Webb et al. (2007) reported results from 50 patients who received the TAVI procedure in 
Canada. All patients were high risk and severely symptomatic. The average age of patients 
was 82±7 years and 40% were female. The average logistical EuroScore was 28%. 
Mortality at 30 days was 12% and procedure success was reported to increase from 76% in 
the first 25 patients to 96% in the second 25 patients. One patient had to be converted to 
AVR from TAVI. This study reported on a wide range of PREs occurring within 30 days, 
as follows:  zero cases of endocarditis; one case of cardiac tamponade; one incidence of 
myocardial infarction; two patients had access site events; two patients has vascular events; 
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and one patient had to have a pacemaker implanted. This study is very useful as it reports 
on a wide range of procedure related events for a substantial number of patients. 
Descoutures et al. (2008) reported outcomes for 66 patients who received TAVI in France. 
Here, the average logistical EuroScore was 20±14%, 39 patients were considered 
unsuitable for AVR, 12 of which underwent TAVI and 27 were treated medically or 
redirected to AVR. This is the first study to consider AVR and TAVI side by side. Of the 
eleven considered suitable for TAVI, one patient converted to AVR. Following the TAVI 
procedure major paravavular leak was reported for one patient; one case of cardiac 
tamponade was reported and zero myocardial infractions. In addition, six cases of vascular 
events were reported. Another French study, Eltchaninoff et al. (2007), reported results for 
TAVI procedures performed between 2003 and 2005 in France for 36 patients. A 57% 
success rate was reported. With respect to procedure related events, five cases of major 
paravavular leaks were reported. Unfortunately, no other events were reported on in this 
study; a disappointment considering the size of the study population.  
Svensson et al. (2008) reported outcomes from 40 patients who received a TAVI procedure 
between December 2006 and February 2008 in the USA. The average age of patients was 
83.61 years and 48% were female. The average logistical EuroScore was 35.5%±15.3%. 
All valves were successfully delivered and 35 were considered to be successfully seated. 
Owing to complications, two cases required conversion to AVR. There were seven deaths 
within 30 days and another two deaths occurred before discharge at day 42 and 72. No 
strokes were reported immediately post procedure. Kaplan-Meier survival was estimated to 
be 81.8%±6.2% at one month and 71.7±7.7% at three months. With respect to PREs, zero 
incidents of valve thromboembolism were reported; two cases of major paravavular leaks 
and six incidents of myocardial infarction were reported within the first 30 days. 
Considering the size of the study population and the range of events reported on, this study 
is a useful contribution for this thesis.   
Walther et al. (2008)  reported on 50 patients who received the TAVI procedure at a single 
centre in Germany. All patients had a high perioperative risk profile and the logistical 
EuroScore was 15.8±9.1%. The average age of patients was 82.4±4.6 years and 78% were 
female. TAVI was successfully performed in 47 patients. Three patients had to be 
converted to AVR. No prosthesis migration or embolization was observed. Survival at one 
month was 92±3.8%; at six months 73.9±6.2% and at one year survival was 71.4±6.5%. 
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Mortality observed was owing to the overall health condition and was not valve related. 
With respect to PREs, within the first 30 days two patients had pacemakers fitted. No other 
PREs were reported on here, which is unfortunate given the size of the patient group. 
Finally, Ye et al. (2009) reported outcomes for 26 patients who underwent TAVI in 
Canada between October 2005 and January 2007. The average age of patients was 80±9 
years and 50% were male. With respect to functionality, 77% were in NYHA Class III or 
IV and logistical EuroScore was 11±6%. Six patients died within the first 30 days. Of 
those patients who survived 30 days, three subsequently died. With respect to 
complications, zero cases of valve thromboembolism and access site events were reported 
within the first 30 days. Meanwhile, during this time period one patient had a myocardial 
infarction and two reported vascular events.  Given the modest patient population 
considered here, a reasonable range of procedure related events were reported upon.  
AVR Literature 
At the same time, a literature review for long term effectiveness of the AVR procedure was 
also conducted, using similar methods to those described earlier (See Appendix II for 
search strategy).  This was necessary owing to the scarce evidence on long term TAVI 
results. The literature review revealed five papers reporting short and longer term results 
for patients following AVR. The results of which were from registries in the USA, France, 
Germany, UK and Italy, with an average of 457 patients (ranging from 103 to 1,049).  
Gehlot et al. (1996) reported the outcomes from 322 patients who received the AVR 
procedure between June 1971 and December 1992 in the USA. The average age of patients 
was 82.7 years, 53% were male and 86% of the patients were in NYHA Class III or IV. 
Survival at five years was 60.2%. Within the first 30 days, two cases of endocarditis were 
reported and 35 patients had to have pacemakers fitted. Unfortunately, no other procedure 
related events were reported on here.  
Milano et al. (1998) reported outcomes from 355 patients who received the AVR procedure 
(63% with mechanical prosthesis and 37% with bio prosthesis) between 1981 and 1995 in 
Italy. The average age of patients was 74±4 years, 53% were males and 78% of patients 
were in NYHA class III or IV.  In-hospital mortality was 7.6%, which decreased to 4.6% in 
the latter three years. There were 55 late deaths. With respect to procedure related events 
(PREs), within 30 days seven cases of valve thromboembolism, two cases of major 
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paravavular leaks and one incidence of endocarditis were reported. With respect to PREs 
after 30 days and up to one year, Milano et al. (1998) reported 23 cases of repeat 
hospitalisations; 18 cases of valve thromboembolism; two cases of major paravavular leaks 
and three cases of endocarditis. Also, 27 patients were reported to have had a fatal 
procedure related event after 30 days and within one year. Reporting of results in this study 
is very comprehensive and will be valuable for this thesis.  
Gilbert et al. (1999) reported outcomes for 103 patients over 80 years of age who received 
an AVR procedure between 1987 and 1996 in the UK. The median age was 82 years and 
92% of patients were in NYHA class III or IV. Overall mortality was 18.4%, late 
complications were uncommon and 92% of patients were in NYHA class I or II at follow 
up. With respect to PREs within 30 days, zero incidences of myocardial infarction and four 
cases of vascular events were reported. In addition, 11 patients had to have pacemakers 
implanted. Beyond 30 days and up to one year following AVR, eight patients had to be re-
hospitalised and one patient had endocarditis. The reporting of short and long term results 
in this study is valuable owing to TAVI’s underdeveloped evidence base. 
Aupart et al. (2006) reported outcomes for 1,113 patients who received the AVR procedure 
in France between 1984 and 2003. The average age of patients was 72.6 years and 63% 
were male. The average NYHA class of the patients was 2.3 and 36% of patients were in 
NYHA class III or IV. Operative mortality was 2.8% and there were 330 late deaths 
reported. At follow up, 98% of patients were in NYHA classes I or II. Aupart et al. (2006)  
did not report outcomes on PREs occurring within 30 days. PREs occurring post one year 
were reported as follows: 18 cases of vascular events; 22 re-hospitalisations; 39 valve 
thromboembolisms and 24 cases of endocarditis. With respect to fatal PREs post 30 days, 
19 were reported. The large study population and detailed reporting of procedure related 
events here is valuable for this study. 
Eichinger et al. (2008) reported outcomes for 455 patients who received AVR in Germany 
between January 1985 and December 1996. The average age of patients enrolled in the 
study was 72.5±9 years and 53% were male. With respect to functional status, 44.8% of 
patients were in NYHA class III or IV. Mortality at 30 days was 5.3%. The most frequent 
cause of death was congestive heart failure. Eichinger et al. (2008) only reported PREs 
post 30 days the following were reported: 16 access site events; 56 re-hospitalisations; 70 
cases of valve thromboembolism; 10 major paravavular leaks and 18 cases of endocarditis. 
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With respect to late fatal PREs 36 were reported. This study provides strong evidence on 
long term outcomes.  
Stroke 
Stroke is a significant complication following any cardiac surgery, including valve 
replacement (Caswell, 2003). In particular, according to Chikwe et al. (2003), stroke is a 
risk associated with valve replacement owing to the emboli of the calcified valve, the 
aortic annulation site, hypo-perfusion and haemorrhage. The TAVI and AVR literature 
presented above did not provide sufficient evidence on the incidence of strokes so an 
additional literature review was conducted, using the same approach as described earlier, to 
identify stroke risk. Chikwe et al. (2003) summarised the natural history of AS and 
regurgitation and reported 3% stroke risk for patients undergoing AVR. This stroke risk 
was confirmed by Caswell et al. (2003), who reported that 3% stroke rates have been 
observed in several studies including Puvimanasinghe et al. (2001) (based on a meta-
analysis) and Bando et al. (2003) reported the results from 812 patients who received the 
AVR procedure in Japan, between May 1977 and December 2001. The median age of the 
patients 58 years, 41% were male and 60% of patients were in NYHA class II or IV.   
This stroke rate was maintained in later studies. Melby et al (2007) reviewed the outcomes 
from 245 patients who received the AVR procedure at a single site in the US between 1993 
and 2005. The average age of the patients was 83.6±2.9 years and 53% were women. With 
respect to functional status, the average NYHA class was 3.1±0.9 and 78% of patients 
were in NYHA class III or IV. Operative mortality at 30 days was 9% and survival after 
surgery at one year was 82%. Permanent stroke was observed in 8 patients (3%).  In 
addition, Alsmady et al. (2009) reported the outcomes from 64 patients who received AVR 
between January 2001 and December 2008. The average age of patients was 49.4±16.9 
years and 39% of the patients were female. With respect to functional status 75% of 
patients were in NYHA class III or IV. Operative mortality was 3.1% and two patients 
(3%) experienced major stroke post operatively.  
Estimating Probabilities 
The procedure related events (PREs) extracted from the 25 papers, discussed above, are 
presented as a data set examining the effectiveness of TAVI in Table 3.5 below. The 
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probabilities are estimated as the number of events occurring as a proportion of event that 
could have occurred. The number of events which occurred is denoted by α, the number of 
events that could have occurred is denoted by n and the number of events which did not 
occur is denoted by β (n- α). The probabilities are estimated using these parameters. For 
example, Webb et al. (2007) reported one conversion from TAVI to AVR, there were 49 
patients who could have converted to AVR. Thus, α 1, n  9, so the probability of 
conversion as reported by Webb et al. (2007) is 0.02 (1/49). Similarly, Criber et al. (2006) 
reported five cases of major paravavular leaks (α 5). A total of    patients could have 
incurred a major paravavular leak (n =34) and 29 patients did not incur a major 
paravavular leak (β 29). The probability of major paravavular leaks, as reported by Criber 
et al. (2006), is 0.15 (5/34). 
Having reviewing the effectiveness literature, it became apparent that there was little 
consistency in how the studies reported procedure related events (PREs). Some studies 
explicitly reported where zero incidences of an event occurred. Other studies did not report 
where zero incidents of an event occurred. So it is unclear if non-reporting meant zero 
events occurred or if that the event had just been omitted from the reported results. Thus, in 
extracting data from the publications a distinction is made between non-reporting of an 
event and no events occurring. Where it is reported in a paper that zero events occurred for 
a PRE, these were counted in estimating the probability. Where an event is not reported, it 
is assumed to be missing information and was not included in estimating the probability. 
For example, Webb et al (2006) reported zero cases of endocarditis and myocardial 
infarction and two cases of vascular events. However, there was no mention of pacemaker 
implantations or valve thromboembolism. So in extracting evidence, to build a data set, 0 
was recorded as the number of endocarditis and myocardial infractions and 2 was recorded 
for vascular events as reported by Webb et al (2006). For all other PREs, nothing is 
recorded for Webb et al. (2006) in the constructed data set.  These results and those for the 
remaining studies and procedure related events (PREs) are presented in Table 3.5. 
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Table 3.5 Effectiveness Literature Review Findings 
Paper Event α β N Probability 
TAVI LITERATURE      
Criber et al  2004 Vascular Events 1 4 5 0.20 
Hanzel et al (2005) - - - - - 
Sack et al 2005 - - - - - 
Criber  et al 2006 Major Paravavular Leak 5 29 34 0.15 
 Myocardial Infarction 0 34 34 0.00 
 Pacemaker Implantation 0 34 34 0.00 
      
Grube  et al 2006 Probability Of Converting To AVR 2 20 22 0.09 
 Valve Thromboembolism 0 22 22 0.00 
 Major Paravavular Leak 0 22 22 0.00 
 Endocarditis 0 22 22 0.00 
 Cardiac Tamponade 1 21 22 0.05 
 Myocardial Infarction 0 22 22 0.00 
 Vascular Events 5 17 22 0.23 
Lichtenstein et al 2006 - - - - - 
      
Walther et al 2006 Probability Of Converting To AVR 3 43 46 0.07 
 Pacemaker Implantation 2 44 46 0.04 
      
Webb et al 2006 Endocarditis 0 18 18 0.00 
 Myocardial Infarction 0 18 18 0.00 
 Vascular Events 2 16 18 0.11 
      
Berry et al 2007 Vascular Events 1 10 11 0.09 
 Pacemaker Implantation 3 8 11 0.27 
      
Eltchaninoff et al 2007 Major Paravavular Leak 5 29 34 0.15 
      
Grube et al 2007 Probability Of Converting To AVR 6 70 76 0.08 
 Major Paravavular Leak 0 76 76 0.00 
 Endocarditis 0 76 76 0.00 
 Cardiac Tamponade 6 70 76 0.08 
 Myocardial Infarction 1 75 76 0.01 
 Pacemaker Implantation 1 75 76 0.01 
      Marcheix et al 2007 Major Paravavular Leak 1 9 10 0.10 
 Endocarditis 0 10 10 0.00 
 Myocardial Infarction 0 10 10 0.00 
 Access Site Events 3 7 10 0.30 
 Vascular Events 2 8 10 0.20 
 Pacemaker Implantation 3 7 10 0.30 
      
Walther et al 2007 Probability Of Converting To AVR 2 55 57 0.04 
 Myocardial Infarction 4 53 57 0.07 
      
Webb et al 2007 Probability Of Converting To AVR 1 48 49 0.02 
 Endocarditis 0 49 49 0.00 
 Cardiac Tamponade 1 48 49 0.02 
 Myocardial Infarction 1 48 49 0.02 
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Table 3.5 Continued      
Paper Event α β n Probability 
 Access Site Events 2 47 49 0.04  
 Vascular Events 2 47 49 0.04 
 Pacemaker Implantation 1 48 49 0.02 
      
Descoutures   et al 2008 Probability Of Converting To AVR 1 10 11 0.09 
 Major Paravavular Leak 1 10 11 0.09 
 Cardiac Tamponade 1 10 11 0.09 
 Myocardial Infarction 0 11 11 0.00 
 Vascular Events 6 5 11 0.55 
      
Svensson  et al 2008 Probability Of Converting To AVR 2 35 37 0.05 
 Valve Thromboembolism 0 37 37 0.00 
 Major Paravavular Leak 2 35 37 0.05 
 Myocardial Infarction 6 31 37 0.16 
      
Ye et al 2009 Valve Thromboembolism 0 26 26 0.00 
 Myocardial Infarction 1 25 26 0.04 
 Access Site Events 2 24 26 0.08 
 Vascular Events 0 26 26 0.00 
AVR LITERATURE      
Geholt et al 1996 Endocarditis 2 285 287 0.01 
 Pacemaker Implantation 35 243 278 0.13 
Milano et al 1998 Valve thromboembolism 7 321 328 0.02 
 Major paravavular leak 2 326 328 0.01 
 Late Hospitalisations 23 305 328 0.07 
 Late Valve Thromboembolism 18 310 328 0.05 
 Late Major Paravavular Leak 2 326 328 0.01 
 Late Endocarditis 3 325 328 0.01 
 Late Fatal PRE 27 46 73 0.37 
      
Gilbert et al 1999 Myocardial infarction 0 82 82 0.00 
 Vascular Events 4 78 82 0.05 
 Pacemaker implantation 11 71 82 0.13 
 Late Hospitalisations 8 76 84 0.10 
 Late Endocarditis 1 83 84 0.01 
      
Aupart et al 2006 Vascular Events 18 707 725 0.02 
 Late Hospitalisations 22 1079 1101 0.02 
 Late Valve Thromboembolism 39 1062 1101 0.04 
 Late Endocarditis 24 1077 1101 0.02 
 Late Fatal PRE 19 85 104 0.18 
      
Eichinger et al 2008 Access Site Events 16 415 431 0.04 
 Late Hospitalisations 56 375 431 0.13 
 Late Valve Thromboembolism 70 361 431 0.16 
 Late Major Paravavular Leak 10 421 431 0.02 
 Late Endocarditis 18 413 431 0.04 
 Late Fatal PRE 36 154 190 0.19 
Stroke Bando et al 2003 20 759 779 0.03 
 Meldby et al 2007 8 237 245 0.03 
 Alsmady et al 2009 2 60 62 0.03 
- Indicates no events were reported 
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3.5.2 Cost Effectiveness Evidence 
As indicated above, evidence surrounding Transcatheter Aortic Valve Implantation (TAVI) 
was scarce in 2009 and accordingly access to TAVI was limited for patients. There were 
no published randomised control trials (RCTs) comparing TAVI to surgical valve 
replacement (AVR) or medical management; there was little evidence on long-term 
outcomes following TAVI and information on the quality of life impact of TAVI relative 
to comparators was limited. Consequently, it could be considered that the potential for 
TAVI to increase life years and quality of life for AS patients was yet to be fully 
demonstrated.  
Despite immature evidence, decision makers like NICE, needed to make access decisions 
and set research priorities while balancing safety concerns and pressures from 
stakeholders. For example, patients want access to the technology; manufactures want their 
technology on the market etc. Balancing these pressures, while collecting further evidence 
and reducing access delays, has associated opportunity costs.  Granting access prior to 
establishing sufficient efficacy can result in mortalities and morbidities and increases 
litigation risks. While delaying access to a technology, which is later shown to have 
adequate efficacy and to be cost effective, results in mortalities and morbidities and 
reduces manufactures profits. As outlined in Chapter 2, economic evaluations can aid 
decision makers in making these coverage decisions and setting research priorities, even 
when evidence is scarce. Using an iterative framework the adoption and research decisions 
can be re-assessed as new evidence becomes available.     
In addition to the literature review on the clinical effectiveness of TAVI, a comprehensive 
literature search was conducted for literature relating to costs, cost effectiveness and 
quality of life associated with TAVI (See Appendix II for search strategy). Two reports 
were identified: a Belgian Health Care Knowledge Centre (KEC) report (Van Brabandt and 
Neyt, 2008) and one by Bazian Ltd (Bazian, 2008) from the UK. Both of these reports 
found that no previous cost effectiveness analysis had been performed.  
The Belgian KEC report (Van Brabandt and Neyt, 2008) contained a systematic review of 
the published evidence up to 2008 which consisted of registries and single patient 
outcomes (as discussed above). The report found that there were no data available on the 
performance of TAVI from randomised clinical trials (RCTs). Only evidence on short term 
outcomes was available, from published observational series.  According to the report, 
92 
 
these publications indicated that TAVI was feasible in eligible patients but there are risks 
of complications and mortality, influenced by age and co-morbidities. Based on their 
observations, Van Brabandt and Neyt  (2008) concluded that evidence from RCTs were 
needed to confirm TAVI performance. Without such clinical studies they considered it 
difficult to perform a reliable economic evaluation. They reported AVR device costs as 
€ ,000 and TAVI device costs ranging from €19,610 to €20, 98, depending on 
manufacturer chosen (this was equivalent to £18,565  to £19,311 at the time (Oanda, 
2012)). Also, the report stated that while it is anticipated that TAVI will offer shorter 
lengths of stay and improve quality of life (QoL) outcomes, data on safety, efficacy, 
effectiveness, QoL and cost data are yet to be gathered. 
The Bazian report (Bazian, 2008) presents an economic analysis, commissioned by the 
East Midlands Specialist Commissioning Group in the UK, employing a model which 
considers the local clinical and cost impact of TAVI in the East Midlands region. A one 
year time horizon is used and severe AS patients aged 75 years of age or older, unsuitable 
for AVR were considered. The base case results revealed that the cost of the procedure was 
approximately £18,000 (2008 prices). With 50 patients per annum in the patient group in 
the region, costs were estimated as £900,000, per annum.  If TAVI was extended to all AS 
patients costs were estimated as £2.8 million, per annum. No comparator was used in the 
evaluation and no effectiveness measures were included, thus this can only be considered a 
partial evaluation.  
So not only was clinical effectiveness evidence scarce at the time, so too were economic 
evaluations. Both reports discussed above (Van Brabandt and Neyt, 2008, Bazian, 2008) 
indicated that the TAVI evidence base was immature and further evidence was needed. 
While this scarcity was highlighted, it was recognised that evidence from early case studies 
and series do exist. In addition, health outcomes from surgical valve replacement (AVR) 
existed at time. Thus, despite scarce data, economic evaluations using decision analytical 
modelling (see Chapter 2 for methods) are feasible, so long as current understanding of 
theory and practice can be reflected in the model (Roberts et al., 2012, Caro et al., 2012). 
Thereby, the adoption and research priority setting decisions can be informed. 
While previous efforts at establishing the cost effectiveness of TAVI were incomplete, in 
this thesis the importance of capturing early experiences with the technology is 
acknowledged. This in line with Lilford et al. (2000), who indicate that the learning curve 
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should not be ignored. Despite the challenges associated with collecting evidence prior to 
the technology stabilising, it is important that randomised evidence is collected before it is 
too late to randomise. The latter can occur when clinicians firmly consider the technologies 
not to be in equipoise even if such claims are not substantiated) (Lilford et al., 2000). 
Waiting for the technology to stabilise can give rise to larger numbers of clinicians who are 
prematurely optimistic (Fitch et al., 1999). 
 
3.5.3 Availability of TAVI in the UK 
As outlined above, TAVI is a less invasive treatment for patients with severe AS. 
Therefore, patients considered at too high a risk for AVR could potentially benefit from the 
less invasive valve procedure that is TAVI.  Since the first use of TAVI in 2002, the rate of 
TAVI procedures has been increasing, particularly for high risk patients (Cribier et al., 
2004, Cribier et al., 2002a, Vahanian et al., 2008, Iung et al., 2005, Van Brabandt and 
Neyt, 2008). Despite the increase in usage and the release of early registry results, 
evidence surrounding the effectiveness and cost effectiveness of TAVI is still scarce. 
Evidence available when this case study began (2009) was based on early generations of 
devices, inserted in relative inexperienced centres only reporting short-term outcomes. As 
discussed in Chapter 1, this is a common phenomenon for medical devices.  
Consequently, the NICE Interventional Procedure Guidance (Number 266, 2008) (Thomas, 
2009) at this time, recommended the use of TAVI only where special arrangements for 
clinical governance, consent, audit and research are in place. This guidance was owing to 
the lack of evidence, particularly with respect to long term outcomes. While 
acknowledging the safety concerns associated with scarce data it also recognised that 
patients who are denied the treatment are at risk of death and complications.  So it was 
recommended that a team of professionals including specialist doctors with experience, 
cardiac surgeons, cardiac anaesthetist and interventional cardiologists should be involved 
in deciding the suitability of a candidate for the procedure. Also, the procedure could only 
be carried out in units which have specialists in heart and blood vessel surgery available in 
case of emergency (NICE, 2008). This recommendation was to be considered for revision 
in May 2011.  In addition, NICE Guidelines recommend that all TAVI procedures 
performed in the UK since 2007 are recorded through the Central Cardiac Audit Database 
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to form the UK TAVI Registry. At the time this case study commenced, results from this 
registry had not been published.  
Similarly in the USA at this time, the U.S. Food and Drug Administration had not granted 
approval for TAVI for operable or inoperable patients. Which meant neither TAVI 
manufacturers could market their device in the US and its use was limited to 
investigational use (Edwards, 2010). In Europe however, TAVI devices were approved 
since 2007 (Piazza et al., 2008b, Bauernschmitt et al., 2009) and an increasing number of 
procedures were being performed. These informed the registries and case series presented 
in the literature review in Section 3.5.1. 
So when this case study commenced, clinical and cost effectiveness evidence on TAVI was 
scarce and concerns regarding vascular complications; stroke rates; long term 
consequences of paravavular leaks and the incidence time and predictors of atrioventricular 
blocks persisted. More and longer term evidence, expected to resolve uncertainties, was 
required. In 2009, collection of this evidence had begun, via the PARTNER trial in the US 
and other European trials and registries (Vahanian et al., 2008), however evidence from 
these was not expected for some time. 
 
3.6 CONCLUSION 
As outlined in the sections above, Transcatheter Aortic Valve Replacement (TAVI) is a 
novel treatment which has the potential to offer a real treatment alternative to patients with 
severe AS. Although evidence is currently scarce, decision makers still need to make 
adoption research priorities setting decisions. As demonstrated in Chapter 2, economic 
evaluations can inform such decisions, using decision analytical modelling.  
TAVI therefore presents an opportunity to investigate the cost effectiveness of a novel 
technology with high demand for access but an immature evidence base. This study aims 
to estimate the cost effectiveness of TAVI to determine the suitability of adoption and to 
assess the value of generating further information, using decision analytical modelling and 
probabilistic sensitivity analysis considering the uncertainty surrounding the parameter 
estimates.  
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In subsequent chapters, a decision analytical model (DAM) is constructed and employed 
iteratively to estimate the costs and benefits of TAVI compared to AVR and medical 
management. While previous economic assessments, reviewed in Section 3.5.2, suggested 
that further research is necessary, no formal quantitative assessment of the value this 
additional evidence could generate was performed. Rather than waiting for the trial 
evidence, early economic evaluations, which include a formal assessment of the value of 
additional information a trial will provided, are advocated. Therefore, in this thesis a 
decision analytical model is constructed and populated with evidence as available, to 
determine the cost effectiveness of TAVI and value of generating further evidence, using 
the continuous iterative framework conceptualised in Chapter 2.  
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CHAPTER 4 ESTIMATING THE COST 
EFFECTIVENESS OF TRANSCATHETER AORTIC 
VALVE IMPLANTATION 
 
4.1 INTRODUCTION 
To test the suitability of the continuous iterative framework for economic evaluations of 
expensive medical device technologies, a case study is warranted.  The case study chosen 
is Transcatheter Aortic Valve Implantation (TAVI) for the treatment of severe, 
symptomatic patients with AS in the United Kingdom (UK), as it is expensive novel 
technology with an immature evidence base for which demand is great.  
As discussed in Chapter 3, at the time this case study began (2009) evidence on TAVI 
outcomes (particularly long term outcomes) were scarce and previous efforts to examine its 
cost effectiveness were only partial evaluations (Van Brabandt and Neyt, 2008, Bazian, 
2008).  Employing the methods for conducting economic evaluations (described in Chapter 
2) and what is known about the natural disease history of AS and the treatment effects of 
TAVI and its comparators (explained in Chapter 3), a decision analytical model (DAM) is 
constructed. This facilitates a probabilistic sensitivity analysis (PSA) and Bayesian value 
of information (VOI) analysis for a full economic evaluation to address the following 
questions (in line with objectives two and three): Is TAVI cost effective compared to its 
alternative(s) given current evidence? Is it worthwhile collecting further evidence on 
TAVI?  
4.2 PATIENT GROUPS 
In evaluating the cost effectiveness of TAVI for treating AS, the NHS perspective is taken 
and consideration is given to three patient groups based on risk (discussed in Section 
3.3.3). Patient characteristics vary across patient risk groups, influencing model 
parameters, which in turn influences cost effectiveness results. Thus, considering different 
risk groups of patients allows the study to incorporate the heterogeneous nature of AS 
97 
 
patients. The three AS patient sub-groups considered in this study are low risk operable, 
high risk operable and high risk inoperable. 
For the purposes of this study, low risk operable patients are defined by an operative 
mortality of 5% and are assumed to be eligible for surgical valve replacement (AVR). So 
the treatment choice is between TAVI and AVR. While six age/gender groups are 
considered in the analysis, the base case is assumed to be 60 year old males with an 
operative mortality of 5%.  
The treatment options available to high risk operable patients, with an operative mortality 
of 15%, are more ambiguous. Currently, these patients may be considered eligible or 
ineligible for AVR depending on co-morbidities and other factors. So for these patients the 
choice is between TAVI, AVR and medical management. Again, six age/gender groups are 
considered in the analysis, however the base case for these patients is assumed to be 70 
year old males with an operative mortality of 15%.  
High risk inoperable patients are assumed to be ineligible for surgery, owing to their high 
operative mortality (20%) and co-morbidities. Therefore, currently only medical 
management is available to these patients. So in the analysis of high risk inoperable 
patients the treatment choice is between TAVI and medical management.  Again, six 
age/gender groups are considered in the analysis and the base case is assumed to be 80 year 
old males with an operative mortality of 20%.   
The operative mortality rates reported above are based on, although not identical to, the 
EuroSCORE measure (see Section 3.3.3) and aim to reflect various risk factors related to 
patient characteristics, type and severity of disease, as well as risks associated with the 
procedures (Nashef et al., 1999, Roques et al., 1999). Table 4.1 summarises the base case 
characteristics for each risk-group and the devices considered. 
Table 4.1 Patient Groups 
Patient Group Operative 
Mortality 
Alternative Treatments 
   
Low Risk Operable Patients 5% TAVI versus AVR 
High Risk Operable Patients 15% TAVI versus AVR versus Medical Management 
High Risk Inoperable Patients 20% TAVI versus Medical Management 
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4.3 THE DECISION ANALYTICAL MODEL TO 
INVESTIGATE THE COST EFFECTIVENESS OF 
TRANSCATHETER AORTIC VALVE IMPLANTATION 
Employing a decision analytical model (DAM) (explained in Chapter 2) provides a means 
of using all available information to inform decision makers when making coverage 
decisions and setting research priorities for novel expensive technologies where evidence 
is scarce. This is particularly suitable as it facilitates evidence synthesis, an important step 
in the evaluation where the evidence base is underdeveloped. For this case study, a DAM 
is constructed and populated with the best available evidence from published literature at 
the time (2009). The model was conceptualised to reflect current understanding of theory 
and practice of the disease and treatment pathways for patients with severe symptomatic 
AS receiving TAVI or one of its comparators (AVR or medical management). Including 
AVR and medical management ensures that all possible interventions are incorporated. In 
conceptualising the model, the guidelines and practices outlined by the ISPOR-SMDM 
Task Force on Modelling Good Research Practices (Roberts et al., 2012, Caro et al., 2012) 
(discussed in Chapter 2), were adhered to.  
The identification of the decision problem and conceptualisation of the model were 
informed by reviewing effectiveness literature on AS and the devices (described Chapter 
3). In addition, the model structure and development was informed by a steering group. 
This group included clinical and policy experts (as advocated by Roberts et al. (2012) and 
Caro et al. (2012)), including cardiologists, cardiac surgeons, public and private (industry 
based) health economists and other public and private representatives (see Appendix I for 
group member details). The steering group formally met on two occasions
2
. The first 
meeting in May 2009, provided background information on the disease, technology and 
access arrangements for TAVI in the UK. A second meeting was held eight months later 
where the conceptualisation of the DAM constructed and data sources identified were 
                                                 
2
 11
th
 May 2009 in University of Glasgow and 12
th
 January 2010 in University of Glasgow 
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presented to the committee for approval. Following this a report on the model was 
circulated to the steering group members for further comments and agreement
3
.  
 
4.3.1 Decision Analytical Model Structure 
To depict the nature of the disease and outcomes of the technologies (TAVI, AVR and 
medical management) a DAM, split into two components, corresponding to two time 
periods in the model, was employed.  The first component considered the initial phase of 
treatment for a patient with AS, who could be managed medically; receive an AVR or 
TAVI procedure, corresponding to a 30 day period.  This initial phase took the patient up 
to the point at which they have recovered from any procedure received and its short term 
outcome (success or failure) is known.  The second phase involved a longer term 
projection of costs and life-expectancy after the initial phase over the estimated lifetime of 
the patient (20 years). These time horizons are suitable as they capture the anticipated 
health effects associated with the disease and interventions.  
Decision Tree 
The initial 30 day phase was modelled using a decision tree, Figure 4.1.  The decision tree 
began with a decision, represented by a decision node, between the three treatment options 
available for those suffering from AS: AVR, TAVI, and medical management. The 
alternatives included in the specific analysis depended on the risk group under 
consideration, as discussed above. As explained in the review of the treatment (in Chapter 
3), for those who receive AVR there is a risk of operative mortality, stroke and major or 
minor procedure related event (PRE). These PREs incur costs and impact utility. The 
model distinguishes between minor PREs, which are assumed to resolve with appropriate 
medical care, and major PREs, which are assumed to result in a state equivalent to valve 
implantation failure. Within the model, major disabling stroke is assumed to be equivalent 
to death in terms of utility in the short term, while incurring a substantial cost. Other major 
PREs include valve thromboembolism, major paravavular leak, endocarditis and 
myocardial infarction. Minor PREs for the purpose of the model include: access site 
events, minor vascular events and pacemaker implantation. (These PREs are defined in 
                                                 
3
 This report was subsequently submitted to the Scottish Health Technologies Group on 29
th
 
November 2010. 
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Appendix III.) For patients who experience minor or no PREs, the procedure is assumed to 
be successful and patients are deemed to have experienced a successful valve replacement.  
Patients who experience major disabling stroke or major PREs  (shown on one branch on 
Figure 4.1) are assumed to be left in a state no better than their original manifestation of 
AS (termed persistent AS/failed valve replacement (VR)). In this state, the valve is 
assumed to be no longer offering benefits to utility.  
Patients receiving TAVI follow the same pathway as those receiving AVR, except that 
during the TAVI procedure there may be a need to convert to AVR.  If this occurs the 
outcomes are assumed to be equivalent to AVR for those patients. 
Finally, patients receiving medical management receive appropriate medical care and no 
valve replacement. This does not cure AS but offers transient relief and these patients 
remain in a state no better than their original manifestation of AS (persistent AS/ failed 
VR). 
 
Figure 4.1 Decision Analytical Model: Short Term Component - The Decision 
Tree 
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Markov Model 
The second phase of the model was presented using a Markov state transition model, 
Figure 4.2. This component of the DAM represents the longer term prognosis of the 
patient. There are three states in the Markov model: functioning valve replacement, 
persistent AS/failed valve replacement and death. Outcomes from the initial 30 day phase 
(the decision tree) determine in which of these three states a patient enters the longer-term 
model.  Each cycle of the Markov model is one year in duration and the model is run for 20 
years (by which time most patients have died). The cycle length is considered enough to 
capture anticipated clinical events, side effects of the interventions etc.   
 
Figure 4.2 Decision Analytical Model: Long Term Component – The Markov 
Model 
 
 
 
 
 
 
 
 
 
 
 
 
In the initial cycle, the functioning valve replacement state is populated with patients who 
had a successful valve replacement (TAVI or AVR), with or without minor PREs, within 
the first 30 days. The persistent AS/ failed valve replacement state is populated with 
patients who had a valve replacement (TAVI or AVR) but suffered a major disabling 
stroke or major PREs or patients who received the medical management treatment in the 
first 30 days. The death state is populated with those who did not survive either valve 
replacement procedure in the first 30 days.  
AS/ Failed VR 
Procedure Related Event 
Death 
Functioning VR 
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In subsequent cycles, patients in the functioning valve replacement state are at risk of a late 
major procedure related event (PRE) that could be fatal, or if non-fatal results in loss of 
valve functioning, meaning that they move to the persistent AS/failed valve replacement 
state. In addition, patients in the functioning valve replacement state are at risk of death 
from natural causes. Patients in the persistent AS/failed valve replacement state are at risk 
of death from both AS and natural causes.  
 
4.3.2 Decision Analytical Model Parameters 
Transition probabilities 
There are ten transition probabilities in the decision tree and four in the Markov Model. 
For patients receiving a valve procedure (TAVI or AVR) there is the risk of death within 
30 days (this includes intra-procedural death), for those who survive there is the risk of 
major disabling stroke, major and minor PREs. In addition, for TAVI patients there is a 
probability of converting to AVR. Finally, for those who receive medical management, 
there is the probability that AS persists. In the longer term, there is a risk of death risk 
(from both valve functioning and persistent AS) of major non-fatal, late PREs and risk of 
fatal late PREs.  
Costs 
Throughout the DAM, costs are applied to both states and events to estimate the costs of 
the alternatives. In the decision tree, the cost of the intervention is applied. This includes 
the cost of the device, procedure, in-patient care and any necessary follow-up care. Where 
patients convert from TAVI to AVR the costs of both interventions are applied. Where 
PREs are experienced, costs are applied to reflect the costs of treatment. Also, there is an 
annual cost associated with each health state. These state costs are based on expected 
hospitalisations for each state, medication costs, costs of long-term care and costs 
associated with any late PREs.  
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Utilities 
To estimate the impact on QALYs, owing to the procedures, utility values were applied to 
the health states and events in the DAM. Disutilities were assigned to the AVR and TAVI 
procedures; these were incorporated to reflect the impact of the initial valve procedures. 
Disutilities were also applied to any PREs experienced as a result of the valve procedure. 
In addition, utilities were applied to the persistent AS/failed valve replacement and 
functioning valve replacement health states. These state utilities are based on estimated 
utility by NYHA class per state and are reduced by the disutility associated with PREs 
where relevant.  
The Decision Analytical Model TAVI Specific Parameters 
One of the principles of the modelling reported here is to explore the potential uncertainty 
related to the relative effectiveness of TAVI compared to AVR. This is imperative in this 
early TAVI model owing to scarce TAVI evidence.  Thus, while the base case assumption 
of the model is that TAVI is comparable to AVR in a number of key respects, flexibility is 
built into the model for the possibility that TAVI differs in a number of key areas. 
 
4.4 POPULATING THE DECISION ANALYTICAL MODEL 
To populate the DAM, point estimates for the transition probabilities, costs and utilities for 
events and states were required. As outlined in Chapter 3, TAVI is a novel treatment for 
which data is scarce, so following the identification of relevant evidence (presented in 
Chapter 3), it needed to be synthesised.  
 
4.4.1 Transition Probabilities  
Short Term – Decision Tree 
As discussed above, the decision tree component of the DAM includes the probability of 
converting from TAVI to AVR and procedure related events (PREs) immediately 
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following the procedure and in the long term. Here, the PREs likely to occur (as identified 
at the model conceptualisation stage) are grouped into major and minor PREs. To populate 
the DAM, the results from the literature (presented in Chapter 3) were synthesised to 
provide estimates of major PREs causing persistent AS/valve failure within 30 days; minor 
PREs within 30 days, which do not result in valve failure; probability of major disabling 
stroke within 30 days; probability of converting from TAVI to AVR and major PREs in the 
follow up period. In doing so, the number of events per study was pooled across all the 
studies and divided by the total number of patients to give the probability of that event 
occurring. The total number of patients was pooled from all the studies. The pooling 
process employed was a fixed effects meta-analysis, which assumed that information is 
exchangeable and the baseline being measured is identical (see Chapter 2 for description).  
However, as mentioned in Chapter 3, there were inconsistencies across the studies with 
respect to how the results were reported. While some authors explicitly reported zero cases 
of an event occurring, others excluded events in their reporting. Thus, in synthesising the 
evidence a distinction between non-reporting of an event and no events occurring was 
required. For papers reporting zero events occurring for a PRE, they were included in the 
denominator for estimating the probability. In contrast, where an event was not reported, it 
was assumed to be missing and the study was excluded from the denominator for 
calculating the probability. For example, to estimate the probability of a myocardial 
infarction in the first 30 days post procedure for TAVI, 17 papers were examined. Of the 
17 papers only 10 reported on myocardial infarction, of which five papers reported zero 
observations of myocardial infarction in this time period. To estimate the probability of 
myocardial infarction, the observations from the 10 papers reporting on myocardial 
infarction are included. The number of events occurring was summed, which is equal to 13 
(α) and the number of events that could have occurred is 340 (n, the total number of 
patients in the 10 papers reporting on myocardial infarction). The probability of 
myocardial infarction is estimated by dividing 13 by 340 which equates to 0.05. This was 
repeated for other PREs, conversions and stroke. These data and calculations are presented 
in Table 4.2. Where, as outlined in Chapter  , α refers to the number of events which 
occurred, β refers to the number of events which did not occur, n is the total number of 
events which could have occurred (α + β = n). The probability was calculated as the 
proportion of events which occurred from the total number of events which could have 
occurred (α /n). 
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The data in Table 4.2 was used to estimate the probability of total major and minor PREs. 
These are calculated by grouping the PREs into major and minor (as per Table 4.2) and 
summing each category. The results of these calculations are provided in Table 4.3. Note, 
for the probability of operative mortality within 30 days; major stroke following valve 
replacement within 30 days; major procedure related events following valve replacement 
within 30 days and major procedure related events after 30 days within one year a baseline 
absolute risk was employed in the AVR arm and relative risks were applied to calculate the 
risk in the TAVI arm.   Absolute risks were employed in both arms of the model for all 
other probabilities.  
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Table 4.2 Data Extracted From Literature – Grouped by Procedure Related 
Event 
Event/ Literature α β n Probability 
CONVERSION TAVI TO AVR     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 - - - - 
Grube  et al 2006 2 20 22 0.09 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 3 43 46 0.07 
Webb et al 2006 - - - - 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 6 70 76 0.08 
Marcheix et al 2007 - - - - 
Walther et al 2007 2 55 57 0.04 
Webb et al 2007 1 48 49 0.02 
Descoutures   et al 2008 1 10 11 0.09 
Svensson  et al 2008 2 35 37 0.05 
Ye et al 2009 - - - - 
 17 281 298 0.06 
MAJOR DISABLING STROKE - AVR     
Bando et al 2003 20 759 779 0.03 
Meldby et al 2007 8 237 245 0.03 
Alsmady et al 2009 2 60 62 0.03 
 30 1056 1086 0.03 
MAJOR PROCEDURE RELATED EVENTS – TAVI 
Valve thromboembolism     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 - - - - 
Grube  et al 2006 0 22 22 0.00 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 - - - - 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 - - - - 
Marcheix et al 2007 - - - - 
Walther et al 2007 - - - - 
Webb et al 2007 - - - - 
Descoutures   et al 2008 - - - - 
Svensson  et al 2008 0 37 37 0.00 
Ye et al 2009 0 26 26 0.00 
 0 85 85 0.00 
Major paravavular leak     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 5 29 34 0.15 
Grube  et al 2006 0 22 22 0.00 
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Table 4.2 Continued     
Event/ Literature α β n Probability 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 - - - - 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 5 29 34 0.15 
Grube et al 2007 0 76 76 0.00 
Marcheix et al 2007 1 9 10 0.10 
Walther et al 2007 - - - - 
Webb et al 2007 - - - - 
Descoutures   et al 2008 1 10 11 0.09 
Svensson  et al 2008 2 35 37 0.05 
Ye et al 2009 - - - - 
 14 210 224 0.06 
Endocarditis     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 - - - - 
Grube  et al 2006 0 22 22 0.00 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 0 18 18 0.00 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 0 76 76 0.00 
Marcheix et al 2007 0 10 10 0.00 
Walther et al 2007 - - - - 
Webb et al 2007 0 49 49 0.00 
Descoutures   et al 2008 - - - - 
Svensson  et al 2008 - - - - 
Ye et al 2009 - - - - 
 0 175 175 0.00 
Cardiac tamponade     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 - - - - 
Grube  et al 2006 1 21 22 0.05 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 - - - - 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 6 70 76 0.08 
Marcheix et al 2007 - - - - 
Walther et al 2007 - - - - 
Webb et al 2007 1 48 49 0.02 
Descoutures   et al 2008 1 10 11 0.09 
Svensson  et al 2008 - - - - 
Ye et al 2009 - - - - 
 9 149 158 0.06 
Myocardial infarction     
Criber et al  2004 - - - - 
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Table 4.2 Continued     
Event/ Literature α β n Probability 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 0 34 34 0 
Grube  et al 2006 0 22 22 0.00 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 0 18 18 0.00 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 1 75 76 0.01 
Marcheix et al 2007 0 10 10 0.00 
Walther et al 2007 4 53 57 0.07 
Webb et al 2007 1 48 49 0.02 
Descoutures   et al 2008 0 11 11 0.00 
Svensson  et al 2008 6 31 37 0.16 
Ye et al 2009 1 25 26 0.04 
 13 327 340 0.04 
MINOR PROCEDURE RELATED EVENTS - TAVI 
Access site events     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 - - - - 
Grube  et al 2006 - - - - 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 - - - - 
Berry et al 2007 - - - - 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 - - - - 
Marcheix et al 2007 3 7 10 0.30 
Walther et al 2007 - - - - 
Webb et al 2007 2 47 49 0.04 
Descoutures   et al 2008 - - - - 
Svensson  et al 2008 - - - - 
Ye et al 2009 0 26 26 0.00 
 5 80 85 0.06 
Vascular Events     
Criber et al  2004 1 4 5 0.20 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 - - - - 
Grube  et al 2006 5 17 22 0.23 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 - - - - 
Webb et al 2006 2 16 18 0.11 
Berry et al 2007 1 10 11 0.09 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 - - - - 
Marcheix et al 2007 2 8 10 0.20 
Walther et al 2007 - - - - 
Webb et al 2007 2 47 49 0.04 
Descoutures   et al 2008 6 5 11 0.55 
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Table 4.2 Continued     
Event/ Literature α β n Probability 
Svensson  et al 2008 - - - - 
Ye et al 2009 2 24 26 0.08 
 21 131 152 0.14 
Pacemaker     
Criber et al  2004 - - - - 
Hanzel et al (2005) - - - - 
Sack et al 2005 - - - - 
Criber  et al 2006 0 34 34 0.00 
Grube  et al 2006 - - - - 
Lichtenstein et al 2006 - - - - 
Walther et al 2006 2 44 46 0.04 
Webb et al 2006 - - - - 
Berry et al 2007 3 8 11 0.27 
Eltchaninoff et al 2007 - - - - 
Grube et al 2007 1 75 76 0.01 
Marcheix et al 2007 3 7 10 0.30 
Walther et al 2007 - - - - 
Webb et al 2007 1 48 49 0.02 
Descoutures   et al 2008 - - - - 
 10 216 226 0.04 
MAJOR PROCEDURE RELATED EVENTS – AVR 
Valve thromboembolism     
Geholt et al 1996 - - - - 
Gilbert et al 1999 - - - - 
Milano et al 1998 7 321 328 0.02 
 7 321 328 0.02 
Major paravavular leak     
Geholt et al (1996) - - - - 
Milano et al (1998) 2 326 328 0.01 
Gilbert et al (1999) - - - - 
 2 326 328 0.01 
Endocarditis     
Geholt et al (1996) 287 2 285 0.01 
Milano et al (1998) 328 1 327 0.00 
Gilbert et al (1999) - - - - 
 615 3 612 0.00 
Cardiac tamponade     
Geholt et al (1996) - - - - 
Milano et al (1998) - - - - 
Gilbert et al (1999) - - - - 
     
Myocardial infarction     
Geholt et al (1996) - - - - 
     
MINOR PROCEDURE RELATED EVENTS – AVR 
Access Site Events     
Geholt et al (1996) - - - - 
Milano et al (1998) - - - - 
Gilbert et al (1999) - - - - 
Aupart et al (2006) - - - - 
Eichinger et al (2008) 16 415 431 0.04 
 16 415 431 0.04 
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Table 4.2 Continued     
Event/ Literature α β n Probability 
Vascular Events     
Geholt et al (1996) - - - - 
Milano et al (1998) - - - - 
Gilbert et al (1999) 4 78 82 0.05 
Aupart et al (2006) 18 707 725 0.02 
Eichinger et al (2008) - - - - 
 22 785 807 0.03 
Pacemaker Implantation     
Geholt et al (1996) 35 243 278 0.13 
Milano et al (1998) -  -  
Gilbert et al (1999) 11 71 82 0.13 
Aupart et al (2006) - - - - 
Eichinger et al (2008) - - - - 
 46 314 360 0.13 
LATE PROCEDURE RELATED EVENTS - AVR   
Hospitalisations    
Gilbert et al (1999) 8 76 84 0.10 
Milano et al (1998) 23 305 328 0.07 
Aupart et al (2006) 22 1079 1101 0.02 
Eichinger et al (2008) 56 375 431 0.13 
 109 1835 1944 0.06 
Valve thromboembolism     
Gilbert et al (1999) - - - - 
Milano et al (1998) 18 310 328 0.05 
Aupart et al (2006) 39 1062 1101 0.04 
Eichinger et al (2008) 70 361 431 0.16 
 127 1733 1860 0.07 
Major paravavular leak     
Gilbert et al (1999) - - - - 
Milano et al (1998) 2 326 328 0.01 
Aupart et al (2006) - - - - 
Eichinger et al (2008) 10 421 431 0.02 
 12 747 759 0.02 
Endocarditis     
Gilbert et al (1999) 1 83 84 0.01 
Milano et al (1998) 3 325 328 0.01 
Aupart et al (2006) 24 1077 1101 0.02 
Eichinger et al (2008) 18 413 431 0.04 
 46 1898 1944 0.02 
Cardiac tamponade     
Gilbert et al (1999) - - - - 
Milano et al (1998) - - - - 
Aupart et al (2006) - - - - 
Eichinger et al (2008) - - - - 
 0 0 0 0.00 
Late Fatal PREs 
Gilbert et al (1999) - - - - 
Milano et al (1998) 27 46 73 0.37 
Aupart et al (2006) 19 85 104 0.18 
Eichinger et al (2008) 36 154 190 0.19 
  82 295 367 0.22 
- Indicates missing information  
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Table 4.3 Transition Probability Estimation 
Procedure Related Event α β n Probability 
Conversion from TAVI to AVR 17 281 298 0.06 
Major disabling stroke 30 1056 1086 0.03 
     
Major Procedure Related Events – TAVI  see Box 4.1    0.12 
 
Minor Procedure Related Events - TAVI 
    
Access site events 5 80 85 0.06 
Vascular Events 21 131 152 0.14 
Pacemaker 10 216 226 0.04 
    0.24 
     
Major Procedure Related Events – AVR see Box 4.1    0.12 
 
Minor Procedure Related Events - AVR 
    
Access site events 16 415 431 0.04 
Vascular Events 22 785 807 0.03 
Pacemaker 46 314 360 0.13 
    0.19 
Late Procedure Related Events     
Hospitalisations  109 1835 1944 0.06 
Valve thromboembolism 127 1733 1860 0.07 
Major paravavular leak 12 747 759 0.02 
Endocarditis 46 1898 1944 0.02 
Cardiac tamponade 0 0 0 0.00 
    0.17 
     
Fatal Procedure Related Events 82 295 367 0.22 
     
 
 
As discussed above, the probability of minor and major PREs were calculated by summing 
the probabilities of each PRE in that category. As the evidence base here was 
underdeveloped, concerns around the suitability of the point estimates calculated were 
raised, particularly the probability of major PREs occurring within 30 days following AVR 
and TAVI.  The estimates produced, using the methods described above, were inconsistent 
with what was expected from consultation with literature and experts owing to the poor 
evidence base. In light of these concerns, the probability of major PREs was assumed to be 
the same for AVR and TAVI in the base case. This common probability was calculated by 
averaging the absolute probabilities obtained from the literature across AVR and TAVI. In 
addition, in cases where no incidences of a major PRE were reported, but expert opinion 
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indicated it may occur, a small amount (0.01) is added to each estimate to allow for the 
small chance of such events occurring. Using this method, the probability of major PREs 
occurring within 30 days is estimated at 0.12. This calculation is shown in Box 4.1.  
 
Box 4.1 Calculation of Major Procedure Related Events within 30 Days 
Following Valve Replacement 
      
 Major procedure 
related complications 
Probability 
AVR 
Probability 
TAVI 
Pooled + 0.01  
     Probability α β n  
 Valve thromboembolism 0.021 0.000 0.02 6 407 413  
 Major paravavular leak 0.006 0.063 0.04 22 530 552  
 Endocarditis 0.005 0.000 0.01 6 784 790  
 Cardiac tamponade 0.000 0.057 0.03 5 153 158  
 Myocardial infarction 0.000 0.038 0.02 10 412 422  
 Probability of Early Major PRE    0.12     
        
 
 
Therefore, the transition probabilities employed in the DAM were as follows (presented in 
Table 4.4). The probability of major PREs following AVR and TAVI was 0.12. The 
probability of minor PREs for AVR was 0.19. The probability of minor PREs following a 
TAVI procedure was greater than that for AVR, at 0.24. This is owing to the catheter 
insertion with TAVI.  The probability of a major disabling stroke was estimated to be 0.03 
for AVR and TAVI. Also, there was a probability of converting from TAVI to AVR, 0.06.    
Operative mortality varies in the model according to patient type. As outlined in Table 4.1, 
low risk operable patients were assumed to have a 5% operative mortality rate, high risk 
operable patients were assumed to have 15% operative mortality and for high risk 
inoperable patients’ operative mortality was assumed to be 20%.  
As outlined earlier, a principle of the modelling reported here was to explore the potential 
uncertainty related to the relative effectiveness of TAVI compared to conventional valve 
replacement.  The base case assumption of the model was that TAVI is comparable to 
AVR in a number of key respects (Table 4.4). However, flexibility was built into the model 
to represent the potential for differential outcomes for TAVI in a number of key areas. 
Here the relative impact of TAVI was represented by a ratio parameter which if set to unity 
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represents equality of outcomes, while values below unity represent superiority for TAVI. 
For example, the relative cost of TAVI compared to AVR with respect to the procedure, 
hospital stay and post discharge care were all set to a value below unity reflecting the 
assumption that TAVI is cheaper than AVR with respect to each of these outcomes. 
Long Term Model – Markov Model 
In the long-term component of the DAM, the Markov model, similar techniques for 
estimating the transition probabilities were employed. Again, the available published 
evidence was synthesised to estimate the transition probabilities. For those in the 
functioning valve replacement state the probability of a PRE occurring is 0.17 per cycle, 
this was estimated in a similar way to the adverse events in the decision tree (Table 4.3).  
Whereby, the probability of non-fatal PREs in the long run was estimated by summing 
across the different PREs considered. For those who have a late PRE, 22% of those events 
were expected to be fatal. While the remaining non-fatal PREs result in failure of the 
valve, returning the patient to a state equivalent to the original AS state (persistent 
AS/valve failure state).  In addition to experiencing a fatal PRE, patients in the functioning 
valve state of the model were at risk from death from natural causes.  This natural 
mortality rate is assumed to follow the background age/gender adjusted mortality rates, but 
with a standardised mortality ratio of 1.5, to adjust for the fact that patients undergoing 
valve replacement are likely to be at higher risk of death than the average patient 
population of the same age/gender.  
For patients in the persistent AS/ Failed valve replacement state of the model, the life 
expectancy is assumed to be just 3 years (Legrand et al., 1991) or three cycles of the 
model. In the model this was presented as a 0.33 probability of death. Table 4.4 presents 
the complete transition probabilities employed in the model, including details of the Beta 
distributions applied to reflect uncertainty.  
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Table 4.4 Transition Probabilities for TAVI Decision Analytical Model 
TRANSITION PROBABILITIES Dist Probability             
(95% CI) 
α β N 
Short term - 0-30 days      
Probability of converting from TAVI to AVR Beta 0.06                               
(0.03-0.09) 
17 281 298 
Probability of major stroke following AVR Beta 0.03                    
(0.02-0.05) 
30 1056 1086 
Probability of major stroke following TAVI Beta 0.03                    
(0.02-0.05) 
30 1056 1086 
Probability of early major PREs AVR Beta 0.12                   
(0.09-0.17) 
      See Table 4.3 
 
Probability of early major PREs TAVI Beta 0.12                   
(0.09-0.17) 
Probability of early minor PREs AVR Beta 0.19              
(0.15-0.23) 
Probability of early minor PREs TAVI Beta 0.24                
(0.17-0.32) 
Probability of death 30 days all causes AVR Beta +  -  
Probability of death 30 days all causes TAVI Beta +  -  
Probability AS persisting following MM  Beta 1  -  
      
Long term - post 30 days      
Probability fatal PRE 
 
Beta 0.22                       
(0.18-0.27) 
82 285 367 
Probability of late non-fatal PRE Beta 0.17                  
(0.13-0.18) 
See Table 4.3 
Probability death from AS state 
¶ Beta 0.33                        
(0.23-0.43) 
33 67 100 
Probability death from AS state - Medical 
Management
¶ 
Beta 0.33                        
(0.24-0.43) 
33 67 100 
   mean se 
Mortality from natural causes (mr)  ‡ - - 
Relative risk of death due to AS (rrsmrAS) Log N 1.5 
(0.96-2.24) 
0.38 0.22 
Mortality from persistent AS/ failed valve 
replacement  
 mr* smrAS   
     
TAVI SPECIFIC PARAMETERS     
Relative stroke risk Log N 1.00                              
(0.82-1.21) 
-0.01 0.1 
Relative risk of operative mortality with TAVI Log N 0.90                          
(0.74-1.09) 
-0.11 0.1 
Relative risk of major PREs causing valve 
failure 
Log N 1.00                              
(0.82-1.21) 
-0.01 0.1 
Relative risk of PREs causing valve failure Log N 1.00                             
(0.56-1.76) 
-0.01 0.29 
Relative cost of procedure Log N 0.73                       
(0.59-0.88) 
-0.32 0.1 
Relative cost of hospital stay Log N 0.51                       
(0.42-0.62) 
-0.67 0.1 
Relative cost of post-discharge care Log N 0.16                       
(0.13-0.19) 
-1.84 0.1 
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+ Low risk 5%; medium risk 15% and high risk 20%.   ‡ Standard life tables ¶(Legrand et al., 
1991)  Note as the model is a highly stylised version of the complexities of everyday clinical 
practice in this challenging patient group there are a number of limitations to the modelling 
developed and implemented.  In particular, the co-morbidities for patients with higher operative 
mortality risks are likely to increase, and this is not explicitly modelled at present.  α: the number 
of events occurring; β the number of events which did not occur and n the number of events which 
could have occurred; Log N = Log Normal. 
 
The Decision Analytical Model TAVI Specific Parameters 
As outlined earlier, a principle of the modelling reported here was to explore the potential 
uncertainty related to the relative effectiveness of TAVI compared to AVR.  The base case 
assumption of the model was that TAVI is comparable to AVR in a number of key respects 
(listed in Table 4.3) and flexibility was built into the model to vary TAVI outcomes in a 
number of key areas.  These included: relative stroke, operative mortality, probability of 
PREs and the relative cost of TAVI compared to AVR with respect to the procedure, 
hospital stay and post discharge care. The relative impact of TAVI was represented by a 
ratio parameter which was initially set to unity to represent equality of outcomes.  This was 
varied in an analysis of uncertainty and could be set to non-unity values to give different 
outcomes of TAVI (in either direction) compared to AVR. To account for the uncertainty 
surrounding these parameters a log normal distribution was applied. This distribution was 
suitable as the confidence limits for these parameters are calculated on the log scale owing 
to the relative risks being made up of ratios. 
 
4.4.2 Cost Parameters  
Costs were applied to the states and events through the DAM. Firstly, in the decision tree 
the costs per branch were identified, measured and valued. The branch costs include the 
device, procedure, length of stay and follow-up care costs. The cost of the AVR device was 
£2,000 and the TAVI device was £12,000 (Kennon et al., 2008), indicating that the TAVI 
device is six times more expensive than the AVR device. (Note the costs of the devices are 
only approximate, due to the commercial nature of these data.) The procedure cost for 
AVR was £3,580 and for TAVI it was £2,360 (Kennon et al., 2008). Meanwhile, for 
patients who only receive medical management the cost of that medication was estimated 
to be £16 per month. Balloon valvuloplasty was not included in the model as it was only 
recommended in specified circumstances, according to the American College of 
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Cardiology/American Heart Association (Leon et al., 2006) and was not widely used in the 
UK. 
With respect to length of stay costs time spent in the intensive care unit (ICU), high 
dependency unit (HDU) and on the general ward were all included. AVR patients were 
estimated to spend two days in ICU, two days in HDU and six days on a general ward, so 
the total length of stay was ten days (Expert opinion and (Gehlot et al., 1996, Straumann et 
al., 1994)).  TAVI patients meanwhile were estimated to spend half a day in ICU, one and 
half days in HDU and six days on the general ward. So total length of stay for TAVI 
patients was eight days (Expert opinion (Gehlot et al., 1996, Straumann et al., 1994). The 
expected costs for ICU stay was £1,690 per day, HDU £570 per day and the general ward 
was estimated to cost £210 per day (Kennon et al., 2008). Therefore, while the costs of the 
procedures were assumed to have a slight advantage towards AVR, it was in the hospital 
length of stay that the main advantage of the TAVI procedure was realised, with TAVI 
patients spending less time in the more costly departments (ICU and HDU). However, it 
was assumed that time on the general ward will be similar for the two devices.  These costs 
are presented on Table 4.5. 
 
Table 4.5 Decision Tree Branch Costs 
     AVR TAVI MM 
 Resource 
Use AVR 
Resource 
Use TAVI 
Resource 
Cost £ 
SE  (95% CI)  (95% CI) 
Device Cost*     2,000 12,000 16 
Procedure Cost*     3,580 
(2,986-4,167) 
2,360 
(1,990-3,349) 
 
Hospital Stay (Days)       
ICU  2^ N 0.5^ 1,690*N 300 3,380 845  
HDU  2^ N 1.5^ 570*N 200 1,140 855  
General Ward  6^ N 6^ 210*N 50 1,260 1,260  
Hospital Stay Total 10 8   5,780 
(4,143-7,492) 
2,960 
(1,997-4,110) 
 
Post Discharge  (Probability of Requiring)    
Cardiac Rehab   0.9* B 0.1* 2940*N 500 2,646 294  
Nursing Home  0.5* B 0.23* 854†‡N 50 427 196  
Post Discharge Total     3,073 
(2,198-3,968) 
490 
(1,997-4,110) 
 
Total     14,433 18,080 16 
*(Kennon et al., 2008) ^ Expert opinion (Gehlot et al., 1996, Straumann et al., 1994) †(Netten, 
1996)  ‡ 1  Days at £61/day N Indicates Normal Distribution is applied B Indicates Beta 
Distribution is applied. MM: Medical Management. 
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Following discharge from hospital, a greater proportion of patients who received AVR will 
require cardiac rehabilitation and/or temporary nursing home care. The probability of AVR 
patients requiring cardiac rehabilitation was 90%, while for TAVI patients there was only a 
10% chance of requiring it (Kennon et al., 2008). In addition, there was a 50% chance that 
following AVR patients will require temporary nursing home care, while for TAVI 
patients this was reduced to 23% (Kennon et al., 2008). Cardiac rehabilitation was 
estimated to cost £2,940 while temporary nursing home stays were estimated to last 14 
days and cost £61 per day (Kennon et al., 2008). So the total costs of each technology in 
the decision tree were £14,433 for AVR, £17,810 for TAVI and £16 for medical 
management (Table 4.5). 
To calculate the costs per state in the Markov model, expected hospitalisations based on 
NYHA class, probability of requiring permanent nursing home care and routine drug 
therapy were included. Applying hospitalisation rates per NYHA class (Ahmed et al., 
2006) to the proportion of patients per NYHA class from the Revive Trials (Cribier, 2008) 
provided estimates of the probability of requiring hospitalisation. This was estimated to be 
53% for those in the persistent AS/failed valve replacement state and 7% for those in the 
functioning valve replacement state. Average hospitalisation costs (estimated to be £3,316 
(Kennon et al., 2008)) were applied to these probabilities. It was also recognised that even 
with functioning valve replacement some patients would require permanent nursing home 
care. So for patients in the persistent AS/failed valve replacement state, the likelihood of 
requiring nursing home care was assumed to be 50% (Kennon et al., 2008). While for 
patients in the functioning valve replacement state, the probability of requiring nursing 
home care was only 10% (Kennon et al., 2008).  These probabilities were applied to the 
cost per nursing home stay (£11,133 (Netten, 1996)). In addition, routine drug therapy 
medication costs (£188 (Kennon et al., 2008)) were added to estimate the cost of the 
functioning valve replacement and persistent AS/failed valve replacement states. The 
annual costs for each health state were estimated as £1,533 for functioning valve 
replacement and £7,512 for failed valve replacement (Table 4.6). 
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Table 4.6 Costs of Functioning & Persistent AS/ Failed Valve Replacement 
Health States 
 Probability α β Dist Unit Cost £ Cost £ 
(95% CI) 
Functioning Valve Replacement State 
     Hospitalisations 0.07* 53 704 Beta 3,316† 232 
Nursing Home 0.10† 76 681 Beta 11,133‡ 1,113 
Routine Drug Therapy 1.00 
   
£188
† 188 
Total   1,533 
(1,300-1,790) 
Persistent AS/Failed Valve Replacement State 
Hospitalisations 0.53* 401 356 Beta 3,316† 1,757 
Nursing Home 0.50† 379 379 Beta 11,133‡ 5,567 
Routine Drug Therapy 1.00 
   
188
† 188 
Total   7,512 
(7,096-7,919) 
* (Ahmed et al., 2006) †(Kennon et al., 2008) ‡(Netten, 1996) 
Procedure Related Event Costs 
The costs of the procedure related events (PREs) were determined from the event costs and 
a weighting, representing each event as a proportion of the total events (Table 4.7). Box 
4.2 presents an example of how the weights were estimated. Column A in Box 4.2 lists the 
probability of each major PRE (Ai) and the total probability of major PREs (∑A = 0.12). 
To estimate the weight for each major PRE, the probability of it occurring was divided by 
the probability of all major PREs (Ai/∑A). For example, the probability of valve 
thromboembolism was 0.02 and the total probability of major PREs was 0.12; so the 
weight assigned to valve thromboembolism is 0.13 (0.02/0.12). Thus, valve 
thromboembolism represents 13% of all the major PREs. This was repeated for the other 
four PREs. Note, the weight assigned to the five PREs sums to one (∑B = 1). To estimate 
the total cost of major PREs, the weight of each PRE was multiplied by its unit cost (Bi*Ci) 
and these were summed (∑C). For example, the weight assigned to valve 
thromboembolism was 0.13; this is multiplied by £639 to give £83. This was repeated for 
the other PREs and summed to get the total cost of major PREs, £985. This process was 
repeated for minor and late major PREs (Table 4.7). Note a Bayesian technique was used 
such that zero probabilities of events in the data are assigned a non-zero weight to allow 
for a small chance of such events occurring.  Normal distributions were applied to the costs 
of treating PREs. This distribution was suitable in this model, as a tight distribution was 
applied and no negative values were yielded. A discount rate of 3.5% was applied. 
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Box 4.2 Calculation of Procedure Related Event Costs 
       
 Major Procedure Related Events Probability* Weight
+ 
 
Event 
Cost £^ 
Cost £ 
(95% CI) 
 
  A B = Ai/∑A C B*C  
 Valve thromboembolism 0.02  0.13 639 83  
 Major paravavular leak 0.04 0.33 210 69  
 Endocarditis 0.01 0.06 5,149 319  
 Cardiac tamponade 0.03 0.28 630 176  
 Myocardial infarction 0.02 0.20 1,683 338  
 Total 0.12  1.00  985 
 
 
 
4.4.3 Utility Parameters 
Utility values were applied to the states and events in the DAM. Firstly, to reflect the 
disutility associated with the TAVI procedure a disutility of 0.0035 QALYS (Rao et al., 
2007) was applied for six weeks (four weeks in the decision tree and two weeks in Markov 
model). Similarly, to reflect the disutility associated with the AVR procedure a disutility 
0.012 QALYS (Rao et al., 2007) was applied for 13 weeks (four weeks in the decision tree 
and nine weeks in Markov model).  
Secondly, utilities were applied to the health states (persistent AS/failed valve replacement 
and functioning valve replacement). To estimate these, the proportion of patients per 
NYHA class per state (from the Revive Trials (Cribier, 2008)) was multiplied by utility 
estimates for each NYHA class (provided by Maliwa et al. (2003)). For example, it was 
estimated that in the functioning valve replacement state, 59% of patients were in NYHA I, 
28% in NYHA II, 10% in NYHA III and 3% in NYHA IV. These proportions were 
multiplied by the utility associated with each class and summed to estimate the utility 
associated with that class. So the utility associated with functioning valve replacement was 
0.77 and the utility of being in the persistent AS/ failed valve replacement state was 0.54. 
These calculations are shown in Table 4.8. A Dirichlet distribution was applied to model 
the uncertainty surrounding the proportion of patients in each NYHA class, to estimate the 
utility associated with having AS, a failed valve replacement resulting in persistent AS and 
functioning valve replacement as there were categories in the variable. 
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Table 4.7 Decision Analytical Model Procedure Related Events Costs 
 Probability* Weight
+ Event 
Cost £^ 
SE Dist Cost £ 
(95% CI) 
Major Disabling Stroke 0.03 1.00 11,450 500 Normal 344 
(193-562) 
Major PREs AVR       
Valve thromboembolism 0.02 0.13 639 100 Normal 83 
Major paravavular leak 0.04 0.33 210 50 Normal 69 
Endocarditis 0.01 0.06 5,149 300 Normal 319 
Cardiac tamponade 0.03 0.28 630 95 Normal 176 
Myocardial infarction 0.02 0.20 1,683 300 Normal 338 
 0.12 1.00    985 
(717-1,309) 
Major PREs TAVI       
Valve thromboembolism 0.02 0.13 639 100 Normal 83 
Major paravavular leak 0.04 0.33 210 50 Normal 69 
Endocarditis 0.01 0.06 5,149 300 Normal 319 
Cardiac tamponade 0.03 0.28 630 95 Normal 176 
Myocardial infarction 0.02 0.20 1,683 300 Normal 338 
 0.12 1.00    985 
(717-1,309) 
Minor PREs AVR       
Access site events 0.04 0.19 198 48 Normal 38 
Vascular Events 0.03 0.14 198 48 Normal 28 
Pacemaker 0.13 0.66 4,649 500 Normal 3,091 
 0.19 1.00    3,158 
(2,397-
3,954) 
Minor PREs TAVI       
Access site events 0.06 0.24 198 48 Normal 48 
Vascular Events 0.14 0.57 198 48 Normal 113 
Pacemaker 0.04 0.18 4,649 500 Normal 853 
 0.24 1.00    1,014 
(587-1,608) 
Late PREs – Non-Fatal 
Hospitalisations  0.06 0.32 3,316 500 Normal 1,070 
Valve thromboembolism 0.07 0.39 639 100 Normal 251 
Major paravavular leak 0.02 0.09 210 50 Normal 19 
Endocarditis 0.02 0.14 5,149 300 Normal 791 
Cardiac tamponade 0.01 0.06 630 95 Normal 36 
 0.17 1.00    2,077 
(1,764-2,590) 
 
* Probabilities were estimated in Table 4.2.  
+
 Weights are calculated from the absolute probabilities 
such that costs can be presented as conditional on the event occurring.  A Bayesian technique is 
used such that zero probabilities of events in the data are assigned a non-zero weight to allow for a 
small chance of such events occurring. 
^ 
Event costs were sourced from: (Kalra et al., 2005, Kennon 
et al., 2008, NHS, 2008a)   
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Procedure Related Event Utilities 
The procedure related event (PRE) utilities were determined from the event utility and a 
weighting, representing each event as a proportion of the total events (Table 4.9), as per the 
PRE costs.  The utility of major PREs following AVR and TAVI was 0.03, utility of minor 
PREs following AVR and TAVI were 0.04 and 0.02 and the utility of longer term PREs 
was 0.03.  Normal distributions were applied to the utilities of treating PREs. This was 
feasible as the utility was transformed in to a utility decrement X (X = 1-U) (see Section 
2.2.4 for description). A discount rate of 3.5% was applied. 
 
 
Table 4.8 Decision Analytical Model Health State Utilities 
Event / State
¥ Utility by 
NYHA Class* 
Proportion† Dist Utility 
(95% CI) 
Duration 
(wks.) 
Utility of AS     
I 0.85 0.01 Dirichlet 0.01  
II 0.71 0.09 Dirichlet 0.06  
III 0.57 0.57 Dirichlet 0.32  
IV 0.43 0.34 Dirichlet 0.15  
    0.54     
(0.54-0.55) 
 
Utility of Functioning Valve Replacement    
I 0.85 0.59 Dirichlet 0.5  
II 0.71 0.28 Dirichlet 0.2  
III 0.57 0.10 Dirichlet 0.06  
IV 0.43 0.03 Dirichlet 0.01  
    0.77     
(0.75-0.79) 
 
     
Utility Hit following TAVI   0.00 5‡ 6  
Utility Hit following AVR   0.012‡ 13  
*(Maliwa et al., 2003) †(Cribier, 2008) ‡(Rao et al., 2007) ¥ See Table 3.1 for definition of NYHA 
states. 
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Table 4.9 Decision Analytical Model Procedure Related Event Utilities 
 Prob* Weight
+ Utility^ SE Dist Utility 
(95% CI) 
Major Disabling Stroke 0.03 1.00 0.00 0 - 0.00 
       
Major PREs AVR       
Valve thromboembolism 0.02 0.13 0.04 0.008 Normal 0.01 
Major paravavular leak 0.04 0.33 0.04 0.008 Normal 0.01 
Endocarditis 0.01 0.06 0.01 0.002 Normal 0.00 
Cardiac tamponade 0.03 0.28 0.02 0.005 Normal 0.01 
Myocardial infarction 0.02 0.20 0.04 0.008 Normal 0.01 
 0.12 1.00    0.03 
(0.02-0.04) 
Major PREs TAVI       
Valve thromboembolism 0.02 0.13 0.04 0.008 Normal 0.01 
Major paravavular leak 0.04 0.33 0.04 0.008 Normal 0.01 
Endocarditis 0.01 0.06 0.01 0.002 Normal 0.00 
Cardiac tamponade 0.03 0.28 0.02 0.005 Normal 0.01 
Myocardial infarction 0.02 0.20 0.04 0.008 Normal 0.01 
 0.12 1.00    0.03 
(0.02-0.04) 
Minor PREs AVR       
Access site events 0.04 0.19 0.01 0.002 Normal 0.00 
Vascular Events 0.03 0.14 0.01 0.002 Normal 0.00 
Pacemaker 0.13 0.66 0.05 0.004 Normal 0.03 
 0.19 1.00    0.04 
(0.03-0.04) 
Minor PREs TAVI       
Access site events 0.06 0.24 0.01 0.002 Normal 0.00 
Vascular Events 0.14 0.57 0.01 0.002 Normal 0.01 
Pacemaker 0.04 0.18 0.05 0.004 Normal 0.01 
 0.24 1.00    0.02 
(0.01-0.02) 
LATE PREs        
Hospitalisations  0.06 0.32 0.02 0.005 Normal 0.01 
Valve thromboembolism 0.07 0.39 0.04 0.008 Normal 0.02 
Major paravavular leak 0.02 0.09 0.04 0.008 Normal 0.00 
Endocarditis 0.02 0.14 0.01 0.002 Normal 0.00 
Cardiac tamponade 0.01 0.06 0.02 0.005 Normal 0.00 
 0.17 1.00    0.03 
(0.02-0.04) 
 
*Probabilities were estimated in Table 4.2.  + Weights are calculated from the absolute 
probabilities such that costs can be presented as conditional on the event occurring.  A Bayesian 
technique is used such that zero probabilities of events in the data are assigned a non-zero weight to 
allow for a small chance of such events occurring. ^ (Sullivan, 2006) 
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4.5 INVESTIGATING THE TAVI DECISION ANALYTICAL 
MODEL 
As outlined above, owing to scarce evidence the TAVI decision analytical model (DAM) 
model was populated with data extracted from published literature, early registry data and 
expert opinion in 2009. To ensure plausibility of estimates and to verify the model a 
variety of checks were performed to examine the stability in the model and the 
distributions around the model input and output parameters. 
Firstly, suitability of the distributions around the input parameters was examined. As 
discussed earlier, a distinction was made between the reporting of zero events occurring 
and non-reporting of events. The effect of this differentiation was investigated by 
generating the descriptive statistics for model inputs (See Appendix IV Table a) for two 
scenarios. In the first scenario, the literature which did not report events were excluded (as 
per the parameterisations above), this yielded a smaller sample size (NS) for the 
denominator.  In the second scenario the literature which did not report events were 
included, yielding a larger sample size (NL) for the denominator. The Monte Carlo 
simulation was run for each scenario (NS and NL) and the resulting descriptive statistics 
were analysed. This analysis resulted in the following concerns: the different sample sizes 
yielded differences in the range around the point estimates for the PREs and some of the 
relative risk parameters and the standard errors around the event costs and event utilities 
were inconsistent.  
To address these concerns a number of steps were taken. Firstly, with respect to 
constructing the probability of PREs, only literature reporting events was included 
(corresponding with NS). Secondly, as the relative risk parameters were considered too 
narrow to reflect expert opinions on the expected differences between TAVI and AVR they 
were widened. Specifically, the range for the relative risk of having a major PRE within 30 
days following TAVI was increased from 0.85-1.17 to 0.50-1.50. Also, the range for the 
relative risk of death due to AS was increased from 1.27-1.75 to 1.00-2.00. Thirdly, the 
standard errors surrounding the event costs and utilities were examined to ensure no 
negative costs or utilities were yielded in the PSA (the latter are feasible owing to the 
employment of the normal distribution).  
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Secondly, the descriptive statistics were examined for stability. Firstly, the DAM model 
was run twice (NS1 and NS2) where it was expected that the range surrounding the 
parameters would be constant. This however was not the case, so to improve stability in 
the model the number of iterations was increased tenfold, from 1,000 to 10,000 (See 
Appendix IV Tables b and c). Secondly, how the random numbers were being drawn was 
investigated. In Microsoft Excel (the programme used to operate this model) when using 
the randomise statement in Visual Basic macros, the random number generator in the 
random function should generate a new series of random numbers each time you use it as 
the seed is reset each time.  In previous versions of Excel resetting the “seed” was an 
issuing when making random draws. This was investigated for the model by amending the 
macro to include resetting the seed after every draw and the model was run.  The results 
were not found to be different as Microsoft Excel 2003 or newer was used. Thirdly, the 
model outputs were examined to confirm stability. This included producing ICERs; 
incremental cost effectiveness planes; plotting incremental net benefit and incremental net 
benefit curves for two runs of the model (NS1 and NS2). The latter, along with the 
descriptive statistics and analysis of outputs for two runs of the model confirmed stability 
in the model. 
Thirdly, covariance in the model was examined using an ANOVA analysis, which 
estimates the variance between the parameters in the model. Here the proportion sum of 
squares for the incremental cost and incremental benefit parameters were estimated. This 
determined that a small number of variables were having a consistent influence on the 
outputs. These are relative risk of procedure related event following TAVI (rrvre_TAVI); 
relative risk of death due to aortic stenosis (rrsmras) and probability of death owing to 
aortic stenosis (pdeath_as) (See Appendix IV Table d). Following the ANOVA analysis, 
the correlation co-efficient was estimated for each version of the model (low and high risk 
operable and high risk inoperable) between the two output parameters i.e. costs and effects. 
The results indicate correlation between costs and effects is high, especially for the costs 
and effects of TAVI and medical management (see Appendix IV Table e). Given this 
strong correlation a second ANOVA analysis was performed on the costs, effects and life 
years for each intervention against all input parameters. The results indicated that the 
following variables had a consistent influence on the outputs: probability of fatal procedure 
related event (platefatalvre); relative risk of death due to aortic stenosis (rrsmrAS); relative 
risk of procedure related event following TAVI (rrevre_TAVI); probability of death owing 
to aortic stenosis (pdeath_AS); cost of failed valve replacement or aortic stenosis 
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(cfv_AS); cost of functioning valve replacement (cfn) and the residual (see Appendix IV 
Table f). 
These investigations concluded that the Monte Carlo simulation should use 10,000 
iterations (increased from 1,000 initially) and there is plausibility and stability in the inputs 
(confirmed though the ANOVA and correlation coefficients).  
 
4.6 COST EFFECTIVENESS ANALYSIS 
Using the DAM, the economic evaluation was undertaken from the perspective of the UK 
National Health System (NHS).  A Monte Carlo simulation with 10,000 iterations was 
used to propagate the uncertainty in the individual model parameters, reflected by the 
probability distributions assigned, through the model to produce a distribution of expected 
costs and expected QALYs associated with each procedure (methods described in Chapter 
2). The mean values of these distributions are used to calculate the incremental cost-
effectiveness ratio (ICER) in terms of the expected incremental costs associated with TAVI 
compared to AVR per incremental QALY gained, for low risk operable patients. This is 
repeated for high risk operable patients and inoperable patients.  
A sensitivity analysis is performed to determine the effect of changes in the price of the 
TAVI device on the cost effectiveness of TAVI. Currently, the TAVI device is expensive, 
as expected with a new, innovative, high-tech device. However, over time owing to erosion 
of patents, recouping research and development costs, incremental innovations and 
increased competition it is anticipated the price may decrease.  Similarly, future evidence 
owing to incremental innovations and movements along the learning curve, may illustrate 
greater reductions in the relative risk of operative mortality associated with TAVI than the 
10% conservatively assumed here, this would give a much greater potential health gain. 
The impact of such changes on the cost effectiveness of TAVI is explored through a 
sensitivity analysis.  
Having examined if TAVI is cost effective compared to its comparators, for the three 
patient groups, a Bayesian VOI is employed to investigate if there is value in collecting 
additional evidence. The Expected Value of Perfect Information (EVPI) investigates what 
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society would be willing to pay to eliminate all the uncertainty surrounding the coverage 
decision. This is calculated as the difference in the net benefit of the decision made with 
perfect information and that with current information (Fenwick et al., 2008) for the three 
patient groups. (See Chapter 2 for a description of these methods.) 
 
4.7 COST EFFECTIVENESS ANALYSIS RESULTS FOR 
TAVI 
 
4.7.1 Cost Effectiveness Results for Low Risk Operable Patients – 
TAVI versus AVR      
The first patient-group considered is the low risk operable patient group. As these patients 
are eligible for AVR, with an operative mortality of 5%, a cost effectiveness analysis of 
TAVI versus AVR is performed. A cohort of 1,000 patients enter the decision tree and 
Markov model and using the parameter estimates and transition probabilities, the cost and 
QALYs per person over a 20 year period are estimated for AVR and TAVI. This facilitates 
the calculation of an ICER and is repeated for a number of age/gender groups. The results 
are presented in Table 4.10. 
The results indicate only a 0.005 reduction in all-cause mortality at the end of year one 
between TAVI and AVR. The survival estimates from the model (Figure 4.3), illustrate for 
TAVI and AVR survival is considerably similar over the 20 years considered.  With 
respect to quality of life, the estimates from the model suggest that TAVI offers marginally 
more QALYs per patient at the end of year one (0.01 QALYs) ( Figure 4.4.) 
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Figure 4.3 Survival Estimates for AVR and TAVI 
 
 
 
Figure 4.4 Quality of Life Estimates for AVR and TAVI 
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Table 4.10 Cost Effectiveness Analysis Results: Low Risk Operable Patients* - TAVI versus AVR 
  
AVR 
  
TAVI 
 
TAVI vs. AVR 
 
LYs Costs £ QALYs LYs Costs £ QALYs ∆ Costs ∆ QALYs 
 
 
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
 
ICER £/QALY 
Deterministic:   Males (age, yrs) 
       60 5.98 31,421 3.61 6.01 35,802 3.64 4,381 0.03 155,669 
70 5.09 29,169 3.13 5.11 33,538 3.16 7,407 0.03 171,487 
80 3.96 26,132 2.49 3.98 30,538 2.51 4,406 0.02 199,953 
   Females (age, yrs)        
60 6.27 32,095 3.76 6.30 36,480 3.79 4,384 0.03 151,529 
70 5.54 30,336 3.38 5.57 34,711 3.41 4,375 0.03 162,867 
80 4.39 27,335 2.74 4.41 31,694 2.77 4,359 0.02 187,201 
Probabilistic:   Males (age, yrs) 
60 6.14 31,509 3.68 6.18 35,906 3.71 4,397 0.03 147,617 
 
(5.47-6.94) (27,859-35,897) (3.33-4.04) (5.43-7.08) (32,069-40,730) (3.33-4.14) (2,047-6,958) (-0.11-0.19)  
70 5.20 29,270 3.18 5.23 33,641 3.21 4,371 0.03 163,815 
 
(4.50-5.98) (25,725-33,4510 (2.80-3.57) (4.49-6.09) (30,044-38,096) (2.81-3.63) (2,196-6,728) (-0.90-0.16)  
80 4.04 26,168 2.52 4.06 30,528 2.54 4,360 0.02 191,811 
 
(3.34-4.80) (22,805-29,991) (2.12-2.94) (3.33-4.88) (27,302-34,496) (2.13-2.98) (2,520-6,306) (-0.07-0.13)  
  Females (age, yrs) 
60 6.45 32,239 3.84 6.49 36,622 3.87 4,383 0.03 154,364 
 
(5.77-7.25) (28,585-36,609) (6348-4.23) (5.73-7.38) (32,703-41,472) (3.48-4.29) (1,942-7,064) (-0.12-0.20)  
70 5.68 30,426 3.44 5.71 34,788 3.46 4,362 0.03 164,202 
 
(4.97-6.47) (26,790-34,665) (3.07-3.83) (4.96-6.57) (31,086-39,425) (3.07-3.89) (2,119-6,802) (-0.11-0.18)  
80 4.46 27,332 2.77 4.49 31,697 2.80 4,365 0.02 181,220 
 
(3.77-5.25) (23,940-31,321) (2.39-3.18) (3.77-5.32) (28,343-35,763) (2.40-3.22) (2,365-6,461) (-0.08-0.14)  
Sensitivity Analysis:  TAVI Cost Neutral        
 
6.14 31,520 3.68 6.17 32,259 3.71 739 0.03 26,190 
 
(5.46-6.93) (27,898-35,861) (3.324.07) (5.42-7.05) (28,546-36,897) (3.32-4.13) (-1,642-3,273) (-0.12-0.19)  
  Lower Relative Risk of Operative Mortality 
 
6.15 31,556 3.69 6.31 36,356 3.79 4,800 0.10 45,723 
 
(5.46-6.97) (27,961-35,905) (3.39-4.22) (5.55-7.22) (32,467-41,250) (3.39-4.22) (2,406-7,437) (-0.04-0.26)  
*Operative mortality risk assumed to be 5%   Shaded row – base case: 60 year old males 
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Deterministic Cost Effectiveness Results 
The cost effectiveness of TAVI compared to AVR is estimated for low risk operable 
patients based on evidence synthesised from the literature, as discussed earlier. The 
deterministic cost effectiveness results (Table 4.10) are estimated using the point estimates 
for the transition probabilities, costs and utilities presented in the previous section. For the 
base case (60 year old males) the results illustrate that for these patients TAVI is more 
costly (£4,381) and more effective (0.03 QALYs) than AVR. The ICER is estimated at 
£199,942, which is outside the range usually considered cost effective in the UK (£20,000-
£30,000 per QALY (Rawlins et al., 2009)). Therefore, compared to AVR, TAVI cannot be 
considered cost effective in treating severe AS amongst low risk operable patients. 
Similarly, for the other five patient groups (males aged 70 and 80 and females aged 60, 70 
and 80) TAVI is also more expensive and generates more QALYs than AVR. However, 
each of the ICERs are greater than £30,000/QALY (Table 4.10). 
Probabilistic Cost Effectiveness Results 
The mean costs and QALYs produced from the probabilistic sensitivity analysis (PSA) and 
Monte Carlo simulation are presented in Table 4.10 also. The probabilistic cost 
effectiveness results reveal for the base case (60 year old males) TAVI is more expensive 
(£4,397; 14%) and more effective (0.03; 1%) than AVR. Using the mean costs and effects 
generated in the PSA, the ICER is estimated as £147,617/QALY. This is outside the range 
usually considered cost effective in the UK (£20,000-£30,000 per QALY  (Rawlins et al., 
2009)) so TAVI cannot be considered cost effective compared with AVR for treating low 
risk operable patients with severe AS. The probabilistic results for the remaining five 
patient groups also indicate that TAVI is more expensive and generates more QALYs than 
AVR, however the ICERs are greater than £30,000/QALY (Table 4.10). 
The incremental cost effectiveness (ICE) plane (Figure 4.5) illustrates the existence and 
extent of uncertainty surrounding the incremental cost and effect (measured by QALYs) by 
plotting the additional benefits and costs of the TAVI procedure over AVR for 60 year old 
males. The ICE Plane for low risk operable patients indicates that there is considerable 
uncertainty surrounding the existence of a benefit advantage for TAVI compared to AVR, 
as well as some uncertainty surrounding the extent of this benefit advantage. The average 
incremental QALYs are 0.03 and range from -0.23 to 0.42 (95% CI provided in Table 
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4.10). However, there is little uncertainty surrounding the fact that TAVI is more 
expensive than AVR, although the extent of the additional cost is uncertain. The average 
incremental cost is £4,397 and ranges from -£59 to £10,127 (95% CI provided in Table 
4.10). The ICE plane illustrates there is high correlation between the costs and QALYs. 
This was confirmed by estimating the correlation coefficient between the cost and effects 
for each treatment (rAVR = 0.61; rTAVI =0.85). The high correlation may be as a result of 
how the costs and QALY parameters were both constructed using the procedure related 
events (PREs).  
The cost effectiveness acceptability curve (CEAC) (Figure 4.6), shows the decision 
uncertainty surrounding the cost effectiveness of each procedure, by plotting the 
probability of TAVI and AVR being cost effective against a range of ceiling ratios. For 
example, at a ceiling ratio of £30,000 per QALY the probability that AVR is cost effective 
is 85% and the probability that TAVI is cost effective is just 15%. 
 
Figure 4.5 Incremental Cost Effectiveness Plane: Low Risk Operable Patients 
-TAVI versus AVR 
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Figure 4.6 Cost Effectiveness Acceptability Curve: Low Risk Operable 
Patients - TAVI versus AVR 
 
Sensitivity Analysis 
As outlined earlier, it is anticipated that over time the price of the TAVI device will 
decrease owing to erosion of patents, as more competitors enter the market etc. A 
sensitivity analysis is used here to examine the impact of a reduction in the price of the 
TAVI device on its cost effectiveness. Reducing the cost of the device by £3,647 would 
result in TAVI being cost neutral (i.e. total cost of TAVI equals total cost of AVR). This is 
calculated as the difference in total procedural costs for AVR and TAVI (£18,080- 
£14,433, Table 4.5). With TAVI cost neutral there would only be slight health advantage 
due to the lower operative mortality associated with this risk-group. In this scenario, the 
ICER is £26,190/QALY which is within the usually accepted range making TAVI cost 
effective compared to AVR amongst low risk operable patients in this scenario. 
Future evidence may also illustrate greater reductions in the relative risk of operative 
mortality associated with TAVI than the 10% conservatively assumed here, owing to 
incremental innovations and movements along the learning curve. A second sensitivity 
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50% reduction in operative mortality. The analysis revealed that this would reduce the 
ICER to £45,723. These sensitivity analysis results are presented in Table 4.10. 
 
4.7.2 Cost Effectiveness Results for High Risk Operable Patients 
– TAVI versus AVR and AVR versus Medical Management 
The second patient group to be considered is the high risk operable group. Patients in this 
risk group are assumed to have an operative mortality of 15%. Owing to this operative 
mortality and potential co-morbidities, patients in this group may or may not be deemed 
eligible for AVR. A cohort of 1,000  patients enter the decision tree and Markov model and 
using the parameter estimates and transition probabilities the cost and QALYs per person 
over a 20 year period are estimated for AVR, TAVI and medical management. This 
facilitates the calculation of an ICER. This is repeated for a number of age/gender groups 
and the results are presented in Table 4.11.  
The results indicate only a 2% reduction in all-cause mortality at the end of year one 
between TAVI and AVR. While AVR provides a 7.5% reduction in all-cause mortality at 
the end of year one compared with medical management. The survival estimates from the 
model for TAVI, AVR and medical management are presented on Figure 4.7.  
Figure 4.7 Survival Estimates for AVR, TAVI and Medical Management 
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With respect to quality of life (Figure 4.8), TAVI offers marginally more QALYs per 
patient at the end of year one (0.01 QALYs). While AVR offers substantially better quality 
of life than medical management with a difference of 0.16 QALYs.  
 
Figure 4.8 Quality of Life Estimates for AVR, TAVI and Medical Management 
 
Deterministic Cost Effectiveness Results 
The deterministic cost effectiveness results (Table 4.11) are estimated using the point 
estimates for the transition probabilities, costs and utilities presented in the previous 
section. For the base case (70 year old males) the results illustrate that TAVI is more costly 
(£5,140) and more effective (0.06 QALYs) than AVR. The ICER is estimated at 
£89,142/QALY which is outside the range usually considered cost effective in the UK 
(£20,000-£30,000 per QALY  (Rawlins et al., 2009)). Therefore, compared to AVR, TAVI 
cannot be considered cost effective in treating severe AS amongst high risk operable 
patients. Similarly, for the other five patient groups (males aged 60 and 80 and females 
aged 60, 70 and 80) TAVI is also more expensive and generates more QALYs than AVR 
and the ICERs are greater than £30,000/QALY for each age/gender group (Table 4.11). 
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With respect to AVR compared with medical management, for the base case (70 year old 
males) AVR was found to be more expensive (£12,777) and more effective (1.31 QALYs) 
than medical management. The ICER is estimated at £9,721/QALY, which is below the 
range usually considered cost effective in the UK (£20,000-£30,000 per  (Rawlins et al., 
2009)).  Therefore, amongst high risk operable patients AVR can be considered cost 
effective compared to medical management in treating severe AS. For the other five patient 
groups (males aged 60 and 80 and females aged 60, 70 and 80) AVR is also more 
expensive and generates more QALYs than AVR. Each of the ICERs are less than 
£30,000/QALY, so across the patient groups AVR can be considered cost effective 
compared with medical management in treating severe AS amongst high risk operable 
patients (Table 4.11). 
Probabilistic Cost Effectiveness Results 
The probabilistic cost effectiveness results (Table 4.11) revealed for the base case (70 year 
old males) TAVI is more expensive (£5,157; 19%) and more effective (0.06; 2%) than 
AVR. The ICER is estimated as £85,982/QALY. This is outside the range usually 
considered cost effective in the UK (£20,000-£30,000 per QALY  (Rawlins et al., 2009)) 
so TAVI cannot be considered cost effective compared with AVR for treating high risk 
operable patients with severe AS. The probabilistic results for the remaining five patient 
groups also indicate that TAVI is more expensive and generates more QALYs than AVR, 
however the ICERs are greater than £30,000/QALY (Table 4.11). 
With respect to AVR compared to medical management the probabilistic cost effectiveness 
results indicate in the base case (70 year old males) AVR is more expensive (£12,777; 
93%) and more effective (1.31; 82%) than medical management. The ICER is estimated as 
£9,721/QALY which is below the range usually considered cost effective. So AVR can be 
considered cost effective compared with medical management for treating high risk 
operable patients with severe AS. The probabilistic results for the remaining five patient 
groups also indicated that AVR is more expensive and generates more QALYs than 
medical management and the ICERs are less than £30,000/QALY (Table 4.11). So across 
the patient groups AVR can be considered cost effective compared with medical 
management in treating severe AS amongst high risk operable patients (Table 4.11)
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Table 4.11 a) Cost Effectiveness Results: High Risk Operable Patients* - TAVI Versus AVR & AVR Versus Medical Management 
 AVR TAVI Medical Management 
 LYs Costs £ QALYs LYs Costs £ QALYs LYs Costs £ QALYs 
 (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) 
Deterministic:   Males (age, yrs) 
60 5.35 28,691 3.23 5.45 33,867 3.30 3.03 13,802 1.54 
70 4.55 26,676 2.80 4.63 31,817 2.86 3.03 13,802 1.54 
80 3.54 23,958 2.23 3.61 29,051 2.27 3.03 13,802 1.54 
   Females (age, yrs) 
60 5.61 29,295 3.36 5.70 34,481 3.43 3.03 13,802 1.54 
70 4.96 27,721 3.02 5.04 32,879 3.08 3.03 13,802 1.54 
80 3.93 25,035 2.45 4.00 30,147 2.51 3.03 13,802 1.54 
Probabilistic:   Males (age, yrs) 
60 5.50 28,805 3.30 5.60 33,980 3.36 3.06 13,987 1.53 
 (4.88-6.20) (25,555-32,646) (2.97-3.65) (4.90-6.41) (30,478-38,369) (2.33-4.07) (2.33-4.07) (9,217-20,330) (1.20-1.98) 
70 4.65 26,698 2.84 4.73 31,854 2.90 3.05 13,920 1.53 
 (4.00-5.35) (23,5019-30,358) (2.50-3.20) (4.03-5.53) (28,532-35,930) (2.53-3.30) (2.23-4.01) (9,292-20,172) (1.20-1.98) 
80 3.61 23,963 2.25 3.67 29,051 2.30 3.06 13,944 1.53 
 (2.99-4.01) (20,984-27,380) (1.90-2.63) (3.02-4.43) (26,091-32,742) (1.93-2.70) (2.33-4.09) (9,254-20,377) (1.20-1.99) 
   Females (age, yrs) 
60 5.78 29,444 3.44 5.88 34,610 3.50 3.06 13,978 1.53 
 (5.17-6.50) (26,165-33,311) (3.12-3.78) (5.17-6.71) (31,062-39,006) (3.13-3.91) (2.33-4.08) (9,244-20,352) (1.19-1.98) 
70 5.07 27,772 3.07 5.17 32,947 3.14 3.05 13,900 1.53 
 (4.45-5.76) (24,580-31,433) (2.74-3.41) (4.47-5.94) (29,547-37,096) (2.77-3.52) (2.32-4.03) (9,166-20,022) (1.19-1.96) 
80 4.01 25,060 2.49 4.08 30,184 2.54 3.06 13,986 1.53 
 (3.38-4.49) (21,947-28,598) (2.14-2.84) (3.41-4.82) (27,118-33,934) (2.14-2.93) (2.33-4.11) (9,287-20.620) (1.20-2.93) 
Sensitivity Analysis:  TAVI Cost Neutral 
 4.65 26,712 2.84 4.73 28,194 2.90 3.06 13,952 1.53 
 (4.02-5.37) (23,561-30,461) (2.51-3.20) (4.06-5.54) (24,927-32,235) (2.53-3.30) (2.33-4.09) (9,202-20,410) (1.19-1.99) 
*Operative mortality risk assumed to be 15%; shaded row – base case  
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Table 4.11 b) Cost Effectiveness Results: High Risk Operable Patients* - TAVI Versus AVR & AVR Versus Medical Management 
 TAVI versus AVR  AVR versus Medical Management 
 ∆ Costs ∆ QALYS ICER £/QALY  ∆ Costs ∆ QALYS ICER £/QALY 
Deterministic:  Males (age, yrs) 
60 5,176 0.07 79,178  14,889 1.69 8,810 
70 5,140 0.06 89,142  12,874 1.26 10,213 
80 5,092 0.05 107,832  10,156 0.69 14,815 
   Females (age, yrs) 
60 5,186 0.07 76,623  15,492 1.82 8,512 
70 5,159 0.06 83,676  13,918 1.48 9,390 
80 5,111 0.05 99,442  11,233 0.91 12,303 
Probabilistic:  Males (age, yrs) 
60 5,175 0.07 78,245  14,818 1.76 8,401 
 (2,892-7,590) (-0.10-0.24)   (11,219-17,874) (1.43-2.08)  
70 5,157 0.06 85,982  12,777 1.31 9,721 
 (3,141-7,337) (-0.08-0.21)   (8,820-16,082) (0.94-1.67)  
80 5,088 0.05 107,377  8,820 0.94 13,850 
 (3,299-6,908) (-0.06-0.16)   (5,500-13,7290 (0.30-1.11)  
   Females (age, yrs) 
60 5,166 0.07 76,380  15,466 1.90 8,120 
 (2,860-7,590) (-0.12-0.25)   (12,005-18,446) (1.58-2.12)  
70 5,174 0.06 81,960  13,873 1.55 8,972 
 (3,043-7,488) (-0.09-0.22)   (10,157-17,121) (1.21-1.88)  
80 5,124 0.05 96,040  11,074 0.95 11,616 
 (3,289-7,043) (-0.07-0.18)   (6,673-14,610) (0.54-1.33)  
Sensitivity Analysis:  TAVI Cost Neutral 
 1,482 0.06 26,653  12,761 1.31 10,406 
 (-421-3,560) (-0.09-0.20)   (8,802-16,044) (0.93-1.66)  
*Operative mortality risk assumed to be 15%; shaded row – base case  
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The incremental cost effectiveness (ICE) planes (Figure 4.9a and 4.9b) illustrate the 
existence and extent of the uncertainty surrounding the incremental cost and incremental 
effect by plotting the additional benefit and costs of TAVI over AVR and AVR over 
medical management, presented side by side. With respect to TAVI versus AVR, there is 
no uncertainty with respect to the existence of differences in costs; TAVI is more 
expensive than AVR. However, there is considerable uncertainty surrounding the existence 
of differences in effectiveness. There is uncertainty surrounding the extent of the 
uncertainty in costs and effects. Similarly, AVR is more expensive and offer greater health 
benefit than medical management. However, there is considerable uncertainty surrounding 
the extent of differences in effects and costs for high risk operable patients. The average 
incremental cost of TAVI compared with AVR is £5,157 (ranging from £1,705 to £9,756) 
and incremental QALY is 0.06 (ranging from -0.21 to 0.41). The average incremental cost 
of AVR compared to medical management is £12,777 (ranging from £4,024 to £19,456) 
and the average incremental QALY is 1.31 (ranging from 0.59 to 1.93).  
The ICE plane illustrates there is high correlation between the costs and QALYs. This is 
confirmed by estimating the correlation coefficient between the cost and effects for each 
treatment (rAVR = 0.64; rTAVI =0.72 and r Medical management =0.98). This high correlation can 
be explained by the construction of the costs and QALY parameters, which are both 
heavily reliant on the transition probabilities.  
Figure 4.9 Cost Effectiveness Plane: High Risk Operable Patients 
a) TAVI versus AVR    b) AVR versus Medical Management 
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The CEAC (Figure 4.10) shows the decision uncertainty surrounding the cost effectiveness 
of each procedure, by plotting the probability of TAVI, AVR and medical management 
being cost effective against a range of ceiling ratios. For example, at a ceiling ratio of 
£30,000 per QALY the probability that AVR is cost effective is 98%, the probability that 
TAVI is cost effective is 2% and the probability that medical management is cost effective 
is 0. 
 
Figure 4.10 Cost Effectiveness Acceptability Curve: High Risk Operable 
Patients - TAVI versus AVR versus Medical Management 
 
Sensitivity Analysis 
As outlined earlier, TAVI is costly and its price is expected to decrease over time.  A 
sensitivity analysis demonstrates that small changes in the base case assumptions of the 
modelling could change these results.  For example, reducing the cost of the device by 
£3,647 (£18,080- £14,433 – Table 4.5) would result in TAVI being cost neutral. However, 
despite being cost neutral there is only a slight health advantage due to the lower operative 
mortality associated with this risk-group. This reduction in treatment costs results in an 
ICER of £10,401/QALY. This ICER is below the usually accepted range making TAVI 
cost effective compared to AVR amongst low risk operable patients in this scenario. 
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4.7.3 Cost Effectiveness Results for High Risk Inoperable Patients 
– TAVI versus Medical Management 
The third patient group considered is the high risk inoperable group. Patients in this risk-
group are assumed to have an operative mortality of 20%. Owing to this high operative 
mortality and potential co-morbidities, these patients are not deemed eligible for AVR. A 
cohort of 1,000 patients enter the decision tree and Markov model and using the parameter 
estimates and transition probabilities the costs and QALYs per person over a 20 year 
period are estimated for TAVI and medical management, facilitating the calculation of an 
ICER. This is repeated for a number of age/gender groups and the results are presented in 
Table 4.12. 
The results indicate a marginal difference in all-cause mortality at the end of year one 
between TAVI and medical management. This increases in year two to 8%, 11% in year 
three and 12% in year four. The survival estimates (Figure 4.11) demonstrate the 
superiority of TAVI after year one until year 11.  With respect to quality of life TAVI 
offers more QALYs (0.10) per patient at the end of year one than medical management 
(Figure 4.12). 
 
Figure 4.11 Survival Estimates for TAVI and Medical Management 
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Figure 4.12 Quality of Life Estimates for TAVI and Medical Management 
 
Deterministic Cost Effectiveness Results 
The deterministic cost effectiveness results (Table 4.12) are estimated using the point 
estimates for the transition probabilities, costs and utilities presented in the previous 
section. For the base case (80 year old males) the results illustrate that for these patients 
TAVI is more costly (£14,531) and more effective (0.61 QALYs) than medical 
management. The ICER is estimated at £23,650/QALY, which is within the range usually 
considered cost effective in the UK (£20,000-£30,000 per QALY  (Rawlins et al., 2009)). 
Therefore, compared to medical management, TAVI can be considered cost effective in 
treating severe AS amongst high risk inoperable patients. For the other five patient groups 
(males aged 60 and 70 and females aged 60, 70 and 80) TAVI is also more expensive and 
generates more QALYs than medical management and the ICERs are less than 
£30,000/QALY for each group. So across the age/gender groups TAVI can be considered 
cost effective compared with medical management in treating severe AS amongst high risk 
inoperable patients. 
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Probabilistic Cost Effectiveness Results 
The probabilistic cost effectiveness results (Table 4.12) reveal for the base case (80 year 
old males) TAVI is more expensive (£14,531; 103%) and more effective (0.65 QALYs; 
43%) than medical management. The ICER is estimated as £22,108, which is within the 
range usually considered cost effective in the UK (£20,000-£30,000 per QALY  (Rawlins 
et al., 2009)) so TAVI can be considered cost effective compared with AVR for treating 
high risk inoperable patients with severe AS. The probabilistic results for the remaining 
five patient groups also indicated that TAVI is more expensive and generates more QALYs 
than medical management. The ICERs are also less than £30,000/QALY for the remaining 
patient groups, so TAVI can be considered cost effective compared with medical 
management for these groups. 
The ICE plane (Figure 4.13) illustrates the existence and extent of the uncertainty 
surrounding the incremental cost and incremental effect by plotting the additional benefit 
and costs of the TAVI procedure over medical management. Here, there is some 
uncertainty with respect to the existence of differences in effectiveness and little 
uncertainty with respect to differences in costs. However, TAVI is likely to be more 
expensive and offer greater health benefits than medical management. The difference in 
costs is driven by the cost of the TAVI device. There is also considerable uncertainty 
surrounding the extent of differences in effects and costs. The average incremental cost of 
TAVI compared to medical management is £14,411 (ranges from £3,948 to £20,520) and 
the average incremental QALY is 0.65 (ranges from -0.34 to 1.39).  
The ICE plane illustrates there is high correlation between the costs and QALYs. This 
correlation was confirmed by estimating the correlation coefficient between the cost and 
effects for each treatment (rTAVI =0.74 and rMedical Management =0.99). An explanation for this 
high correlation lies in the construction of the costs and QALY parameters, which are both 
based on the transition probabilities.  
The CEAC (Figure 4.14) shows the decision uncertainty surrounding the cost effectiveness 
of each procedure, by plotting the probability of TAVI and medical management being 
cost effective against a range of ceiling ratios. For example, at a ceiling ratio of £30,000 
per QALY the probability that TAVI is cost effective is 86% and the probability that 
medical management is cost effective is just 14%.   
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Table 4.12 Cost Effectiveness Results: High Risk Inoperable Patients* - TAVI versus Medical Management  
 TAVI   Medical Management  TAVI versus Medical Management 
          
 LYs Costs £ QALYs LYs Costs £ QALYs ∆ Costs ∆ QALYS ICER £/QALY 
 (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)  
 
Deterministic:   Males (age, yrs) 
60 5.16 32,900 3.12 3.03 13,802 1.54 19,097 1.58 12,057 
70 4.39 30,956 2.71 3.03 13,802 1.54 17,154 1.17 14,669 
80 3.42 28,334 2.16 3.03 13,802 1.54 14,531 0.61 23,650 
   Females (age, yrs) 
60 5.23 32,706 3.02 3.35 13,802 1.64 17,769 1.38 12,906 
70 4.78 31,963 2.92 3.03 13,802 1.54 18,161 1.38 13,128 
80 3.79 29,373 2.38 3.03 13,802 1.54 15,570 0.83 18,668 
          
Probabilistic:   Males (age, yrs) 
60 5.31 33,002 3.19 3.06 13,962 1.53 19,040 1.66 11,500 
 (4.63-6.11) (29,607-37,106) (2.83-3.58) (2.34-4.07) (9,269-20,212) (1.20-1.97) (14,973-22,508) (1.28-2.03)  
70 4.49 30,988 2.75 3.06 13,948 1.53 17,040 1.22 13,971 
 (3.82-4.26) (27,874-34,811) (2.39-3.14) (2.35-4.07) (9,334-20,284) (1.20-1.98) (12,890-20,526) (0.81-1.60)  
80 3.48 28,353 2.18 3.06 13,942 1.53 14,411 0.65 22,108 
 (2.86-4.19) (25,491-31,820) (1.83-2.56) (2.33-4.06) (9,251-20,274) (1.19-1.98) (9,767-18,075) (0.22-1.05)  
   Females (age, yrs) 
60 5.57 33,608 3.32 3.06 13,963 1.53 19,645 1.79 10,976 
 (4.88-6.36) (30,173-37,779) (2.96-3.71) (2.35-4.08) (9,295-20,476) (1.20-1.99) (15,584-23,047) (1.41-2.16)  
70 4.90 32,049 2.98 3.07 14,002 1.53 18,047 1.44 12,512 
 (4.25-5.68) (28,789-36,136) (2.63-3.36) (2.33-4.09) (9,208-20,329) (1.20-1.99) (13,912-21,508) (1.06-1.81)  
80 3.86 29,403 2.40 3.06 13,955 1.53 15,448 0.87 17,689 
 (3.22-4.60) (26,432-33,039) (2.04-2.78) (2.33-4.07) (9,180-20,204) (1.19-1.98) (11,019-19,083) (0.46-1.27)  
*Operative mortality risk assumed to be 20%; shaded row – base case  
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Figure 4.13 Incremental Cost Effectiveness Plane: High Risk Inoperable 
Patients - TAVI versus Medical Management 
 
 
 
Figure 4.14 Cost Effectiveness Acceptability Curve: High Risk Inoperable 
Patients - TAVI versus Medical Management 
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4.8 VALUE OF FURTHER RESEARCH  
The potential value of undertaking further research is estimated using a Bayesian VOI 
analysis (described in Chapter 2). The expected value of perfect information (EVPI), 
estimates the value of eliminating all the uncertainties within the model, providing a 
maximum value for the return on further research. Having estimated EVPI per patient, the 
population EVPI (pEVPI) for one year is estimated, using the population estimates 
presented in Table 4.13. The annual population estimates for those with severe AS in the 
UK per patient risk group are as follows: 3,000 low risk operable patients; 2,250 high risk 
operable patients and 2,750 high risk inoperable patients (SHTG, 2009). As discussed in 
Chapter 2, it can be difficult to assess what is an appropriate time frame. Here one year is 
chosen as the timeframe, as it is the expected period over which a choice between TAVI, 
AVR and medical management is considered a viable decision. That is to say, beyond one 
year it is expected that advances in the medical device technology would make the decision 
obsolete/invalid, as per the characteristics of medical devices discussed in Section 1.2.1.   
 
Table 4.13 Population Estimates per Patient Group in the UK  
Patient Group UK* 
Low risk operable patients currently getting AVR 3,000 
High risk operable patients currently getting AVR or  medical management  2,250 
High risk inoperable patients currently not getting AVR just medical 
management 
2,750 
Total 8,000 
*Scottish Health Technologies Group (2009) 
 
Low Risk Operable Patients 
The EVPI per patient, when deciding between TAVI and AVR, is estimated using the net 
benefits from the PSA results. Here, the EVPI ranges from £5 to £360 per low risk 
operable patient, over the range usually considered cost effective (£20,000-
£30,000/QALY) (Rawlins et al., 2009) for one year.  
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Given the public good characteristics displayed by information, the EVPI for the 
population (pEVPI) can be estimated for the low risk operable population in the UK (3,000 
(SHTG, 2009). The pEVPI, over the range usually considered cost effective, is estimated 
to range from £15,917 to £1.08 million (Figure 4.15). These estimates provide a maximum 
value for the return of further research, suggesting there is value in collecting further 
information on low risk, operable patients. 
 
Figure 4.15 Expected Value of Perfect Information: Low Risk Operable 
Patients – TAVI versus AVR 
 
High Risk Operable Patients 
The EVPI per patient, when deciding between TAVI, AVR and medical management 
ranges from £0 to £10 per high risk operable patient over the range usually considered cost 
effective (£20,000-£30,000/QALY). Using the population estimates from Table 4.13, the 
pEVPI was calculated for one year for a population of 2,250. The pEVPI (2,250 (SHTG, 
2009), over the range usually considered cost effective, ranges from £0 to £23,433 (Figure 
4.16). The EVPI provide a maximum value for the return on further research, suggesting 
there is very little value in collecting further information on high risk, operable patients.  
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Meanwhile, the results indicate that the pEVPI reaches an inflection point at a ceiling ratio 
equal to the ICER £9,721/QALY. This corresponds to the point on the CEAC (Figure 4.10) 
where the decision between AVR and medical management is most uncertain. Here, the 
probability that medical management is cost effective is 41% and the probability that AVR 
is cost effective is 59%. Beyond this ceiling ratio the optimal treatment changes and AVR 
is more likely to be cost-effective compared with medical management.  The pEVPI curve 
has a second inflection point at the ICER for TAVI versus AVR (£85,982/QALY). This is 
where the decision about the cost effectiveness of TAVI versus AVR is most uncertain. At 
a ceiling ratio greater than £85,000/QALY, TAVI is more likely to be cost effective 
compared with AVR.  
 
Figure 4.16 Expected Value of Perfect Information: High Risk Operable 
Patients – TAVI versus AVR versus Medical Management 
 
High Risk Inoperable Patients 
The EVPI per patient, when deciding between TAVI and medical management, ranges 
from £360 to £1,247 per high risk inoperable patient, over the range usually considered 
cost effective (£20,000-£30,000/QALY). For these high risk inoperable patients the pEVPI 
over the range usually considered cost effective ranges from £998,775 to £3.43 million 
(Figure 4.17). These estimates provide a maximum value for the return of further research 
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and suggest there is some value in collecting further information on high risk, inoperable 
patients.  
The pEVPI curve has an inflection point at a ceiling ratio equal to the ICER 
(£22,108/QALY), corresponding to the point on the CEAC (Figure 4.14) where the 
decision is most uncertain. Here, the probability that TAVI is cost effective is 49% and the 
probability that medical management is cost effective is 51%. Beyond this ceiling ratio (i.e. 
> £22,108/QALY) the optimal treatment changes and TAVI is more likely to be cost-
effective compared with medical management.  As there are only two technologies 
considered here (TAVI and medical management) this inflection point is also the 
maximum pEVPI point.  
 
Figure 4.17 Expected Value of Perfect Information: High Risk Inoperable 
Patients – TAVI versus Medical Management 
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patients and £998,775 - £3.43 million for high risk inoperable patients, weighting these 
pEVPI estimates by the number of patients per group gives the total pEVPI for the total 
UK population of severe AS patients. This ranges from £486,641 - £1.27 million at the 
usually acceptable threshold (£20,000-£30,000 per QALY) (Figure 4.18).   This provides 
an upper bound on the potential value for additional research in the UK context, indicating 
there is value in generating evidence for TAVI within these bounds, where the evidence is 
appropriate for all patients irrespective of risk. This additional information can be 
employed in a subsequent cost effectiveness and VOI analysis in line with the continuous 
iterative framework developed in Chapter 2. 
 
Figure 4.18 Expected Value of Perfect Information for the UK Population 
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4.9 SUMMARY OF COST EFFECTIVENESS ANALYSIS 
RESULTS AND RESEARCH RECOMMENDATIONS 
This chapter presented a detailed description of the decision analytical model (DAM) 
proposed to estimate the cost effectiveness of TAVI in treating severe AS compared with 
AVR and medical management. The DAM contains a decision tree to model the initial 30 
days and a Markov model to capture the next 20 years in yearly cycles. Owing to data 
scarcity, the model is populated using a combination of data extracted from published 
literature, expert opinion etc., which yields parameter uncertainty.  
The results illustrate that for low and high risk operable patients TAVI cannot be 
considered cost effective compared to AVR and is subject to uncertainties.  In particular, 
there are two short-term uncertainties that must be taken into account when trying to 
understand the potential for TAVI to provide a cost effective treatment.  The first is the 
extent to which the high acquisition cost of the device can be offset by the reduction in 
hospital length of stay, particularly in high-dependency units.  The second is the potential 
for TAVI to reduce the operative mortality rate.  This analysis chooses a conservative 10% 
reduction; if a more optimistic view point could have been supported by evidence the 
ICER is reduced (though still outside the range usually considered cost effective). 
The cost effectiveness analysis of TAVI for high risk inoperable patients appears more 
positive.  This is largely due to the poor prognosis for AS patients who do not receive 
AVR, meaning that the potential patient benefit in this group is much higher.  
Nevertheless, with few costs to offset, the health service would have to fund the full cost of 
the device, which may prove a practical challenge in current resource constrained 
environments.    
Given the results and the novel nature of the device the appropriate question to ask is what 
further research could be performed to help improve decisions regarding TAVI in the 
future? The VOI analysis presented here attempts to summarise this potential.  If all 
uncertainties in the model could be resolved, the ‘value’ of this is estimated to be £751,967 
(Figure 4.18) for UK severe AS population in terms of the reduced cost of this uncertainty 
associated with making the incorrect decision (either to reject a cost effective technology 
or adopt a cost-ineffective one) at a ceiling ratio of £30,000/QALY. Suggesting there is 
some value in collecting further evidence on TAVI amongst the UK severe AS population.   
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There is however, a number of limitations to the analysis presented here. The model 
provides a highly stylised version of the complexities of everyday clinical practice in this 
challenging patient group. In particular, the co-morbidities for patients with higher 
operative mortality risks are likely to increase, and this is not explicitly modelled at 
present. For the low risk operable patients, it is not clear that the QALY approach 
adequately captures patient preferences for the less invasive technique compared to 
conventional surgery. Nevertheless, decisions do have to be made and it is clear that the 
potential for TAVI to bring huge patient benefits should not be ignored.  
The cost effectiveness and VOI analyses presented here represent the first cycle of the 
continuous iterative framework proposed in Chapter 2. Whereby, a decision problem is 
identified and employing available evidence the cost effectiveness of TAVI and the value 
of generating further evidence is investigated. The analysis reports that TAVI is cost 
effective for high risk inoperable patients, compared to medical management only. But 
there is some value in collecting additional evidence on operable patients also.  
As described previously, the analysis presented here is based on early evidence from pre-
trial published small single centre registries and case series up to 2009. According to Leon 
et al. (2006) evidence generation for new devices, such as TAVI, follow a natural 
sequence. Whereby, initially the first experiences with the device from small single centre 
registries and case series are published. Here the general operating principles are 
ascertained and feasibility is tested. Subsequently, multicentre registries are established 
where techniques are improved upon and efficacy is compared with the natural history of 
the disease and alternatives. Following this, random control trials (RCTs) begin to appear.   
Evidence generation for TAVI appears to be following this sequence. Subsequent to the 
initial evidence from the registries and case series employed in this analysis (described in 
Chapter 3), RCTs for high risk operable and inoperable patients are emerging. (Currently 
there are no plans for trials for low risk operable patients.) The results of these trials, when 
published, can be incorporated into this DAM in line with the proposed iterative 
framework. This will provide the opportunity to update the model parameters to reflect the 
best available data which may improve the fit of the model and reduce some uncertainties, 
in line with the continuous iterative framework proposed in Chapter 2. 
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CHAPTER 5 EVOLVING DATABASE FOR 
TRANSCATHETER AORTIC VALVE 
IMPLANTATION - INTEGRATING THE PARTNER 
TRIAL RESULTS FOR HIGH RISK INOPERABLE 
PATIENTS 
 
5.1 INTRODUCTION 
Despite the increasing number of TAVI procedures performed (detailed in Chapter 3), little 
evidence on the long term outcomes of the procedure were available for the first iteration 
of the decision analytical model (DAM) presented in Chapter 4. As outlined in Chapter 1, 
this is a common problem for novel expensive medical devices, where there are no 
regulatory requirements for clinical trials etc. Currently, in England and Wales the 
National Institute for Clinical Excellence (NICE) Interventional Procedure Guidance 
(Number 266, 2008) (NICE, 2008) recommends the use of TAVI only where special 
arrangements for clinical governance, consent, audit and research are in place. While in 
Scotland, the Scottish Health Technologies Group (SHTG) advice statement (Number 
005/11) does not recommended TAVI for routine treatment of patients with AS (NHS, 
2008b). Therefore, strict clinical and anatomical criteria are still required when 
recommending TAVI, which is yet to be demonstrated as being cost effective. 
So the publication of results from the Placement of Aortic Transcatheter Valves 
(PARTNER) trial in 2010 - 11 (Leon et al., 2010, Smith et al., 2011) was a welcomed 
evolution in the TAVI evidence base (Leon et al., 2006).  In this Chapter, evidence from 
the PARTNER trial (Leon et al., 2010) was incorporated into the TAVI DAM (developed 
in Chapter 4) to estimate the long term cost effectiveness of TAVI compared to medical 
management for high risk inoperable patients with severe AS. While the short term 
efficacy and effectiveness of TAVI for inoperable patients has been hinted at by case 
studies and published literature, it is yet to be demonstrated.  This re-analysis is in line with 
the proposed iterative framework for economic evaluations (Chapter 2), as the role of 
TAVI in treating patients with AS needs to be further investigated to inform adoption and 
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research priority setting decisions. Upon publication of the trial results there was no 
accompanying cost effectiveness analysis. 
 
5.2 EVOLVING TAVI EVIDENCE – THE PARTNER TRIAL 
The aforementioned PARTNER Trial, sponsored by Edwards Lifesciences
4
, began in April 
2007 and enrolled patients with severe AS in 25 centres (see Appendix V Table a for 
inclusion and exclusion criteria).  One of the centres was in Germany (Leipzig), three were 
in Canada (Quebec, Vancouver and Toronto) and the remaining 21 were across 15 states in 
the US (Leon et al., 2010). Motivation for the trial came from the lack of safety and 
effectiveness data surrounding the procedure and specifically the Edwards device (Penn, 
2012). Severe AS was defined in the trial as an aortic valve area of less than 0.8cm
2
, a 
mean aortic valve gradient of 4mm Hg or more or a peak aortic-jet velocity of 4.0m per 
second or more (Leon et al., 2010).  In addition, all patients were in New York Heart 
Association (NYHA) classes greater than I (see Table 3.1 for definition of NYHA classes) 
(Leon et al., 2010). The patients were then divided into two treatment groups, defined by 
their eligibility for surgery, determined by at least two surgeons.  
The study design (Figure 5.1) illustrates that a total of 3,105 patients were screened for 
inclusion in the trial. Of whom, 699 were considered operable and were included in the 
cohort comparing TAVI with surgical valve replacement (i.e. AVR) (Cohort A). A further 
358 patients were considered inoperable and were included in a second cohort comparing 
TAVI with standard therapy (i.e. medical treatment) (Cohort B).  
In the context of this thesis, Cohort A corresponds to high risk operable patients and 
Cohort B corresponds to high risk inoperable patients, in line with the previous chapter. 
Cohort B results were published in October 2010 and the Cohort A results were published 
in June 2011. In this Chapter, published Cohort B results will be used to re-examine the 
cost effectiveness of TAVI amongst high risk inoperable patients. The Cohort A results are 
incorporated in Chapter 6 to re-evaluate TAVI for high risk operable patients. 
                                                 
4 Edwards Lifesciences Corporation, Irvine, CA, manufacture of the Edwards Sapien Valve, one of 
two TAVI devices on the market at the time. 
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Figure 5.1 PARTNER Trial Design 
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Source: Adapted from Figure 1, Supplementary Appendix, Leon et al. (2010) 
 
5.3 INCORPORATING EVIDENCE FROM PARTNER 
COHORT B – INOPERABLE PATIENTS 
Incorporating the PARTNER evidence into the model, where available, resulted in some 
adjustments to the TAVI DAM, developed in Chapter 4 and revisions to the parameters. 
5.3.1 PARTNER B Evidence 
In October 2010, the results of PARTNER Cohort B were published.  This cohort 
compared inoperable patients receiving TAVI to those receiving medical management 
(Leon et al., 2010).  The study design and patient flows (Figure 5.2) show that this cohort 
initially included 358 patients, who were considered to have severe AS and deemed 
inoperable (unsuitable for cardiac surgery). Of these 179 patients were allocated to each of 
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the TAVI and medical management arms of the trial. In the medical management arm one 
patient withdrew from the trial and five died within the first 30 days. While 12 TAVI 
patients died in the same period. So at the end of the first 30 days, 173 patients received 
medical management and 167 received the TAVI procedure. During follow up (30 days to 
one year) a further four patients withdrew from the medical management arm and 84 more 
patients died. While in the TAVI arm, an additional 43 patients died during this time 
period. Thus, at one year follow up information on the clinical endpoints were available for 
all those who died; 85 medical management survivors and 124 TAVI survivors. This (pre-
model) data is presented in Appendix V Table b. 
 
 
Figure 5.2 PARTNER Trial Cohort B Patient Flow: TAVI versus Medical 
Management 
 
 
Source: Adapted from Figure 2, Supplementary Appendix, (Leon et al., 2010) 
 
 
5.3.2 Changes to the Decision Analytical Model 
Incorporating PARTNER B evidence, where available, into the DAM model (developed in 
Chapter 4) to investigate the cost effectiveness of TAVI compared with medical 
management, resulted in some adjustments to the decision tree component of the model. 
The initial conceptualisation of the DAM was dependent on knowledge about AVR and 
early TAVI experiences. The latter was based on early registries and small case series. As 
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the PARTNER Cohort B trial is the first to consider medical management compared to 
TAVI directly, evidence from the trial updates knowledge and understanding of the 
procedures and the disease pathways. Specifically, this informed the inclusion of 
conversions from TAVI to medical management, repeat TAVI procedures and death from 
medical management in the decision tree. These changes are illustrated on the revised 
decision tree (Figure 5.3). 
Prior to the PARTNER trial, experience with TAVI was limited, particularly with respect 
to late outcomes. While evidence from the PARTNER trial did not result in any structural 
amendments to the Markov model, it did offer the distinction between major and minor 
late procedure related events (PREs) (the latter incur a cost and utility hit only and do not 
result in valve failure). In addition, the data provided revised estimates for long run point 
estimates, such as late major procedure related events, which were previously informed by 
experience with AVR. 
 
Figure 5.3 Revised Decision Analytical Model for Inoperable Patients: Short 
Term Component – The Decision Tree 
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5.3.3 Parameterisation of the Decision Analytical Model – 
Inoperable Patients 
Transition Probabilities 
Cohort B of the PARTNER Trial compared TAVI to standard therapy (i.e. medical 
management) for severe AS patients considered inoperable. Outcomes and clinical 
endpoints from the two treatment arms presented by Leon et al. (2010) for 30 days and 1 
year (presented in Appendix V Table b) permitted the revision of the parameters used in 
the model to reflect the best data available. Here evidence from PARTNER B was used to 
replace the previously used evidence from the literature, where available, to revise the 
point estimates for the model parameters. A “replacement” strategy was adopted as 
PARTNER B evidence reflects the best available data at the time of publication. Whereas, 
the evidence used to populate the original model was based on early short term TAVI 
results and AVR experience. This is in line with the view that expert opinion can become 
irrelevant in the presence of large RCTs. Where it is considered that the accumulated 
empirical evidence dominates the expert opinion (NICE, 2004).  Therefore, an “updating” 
strategy would not have reflected optimal data at the time. For parameters where 
PARTNER evidence was unavailable, the point estimates from the original model (from 
published literature) were maintained.  
The point estimates for the transition probabilities using PARTNER Cohort B evidence 
(Leon et al., 2010) were calculated as follows. Leon et al. (2010) provided the number of 
times each event occurred (α). The total number of times that the event could have 
occurred was estimated as the number of patients at risk of the event (n) (i.e. those who 
had already died were removed). The probability of the event occurring is estimated as the 
proportion of events occurring (α) from the total that could have occurred (n).  
Box 5.1 provides an example. Leon et al. (2010) reported 30 cases of major bleeding 
within 30 days for TAVI patients and 40 cases within one year. It was deduced that 10 
major bleeding occurred post discharge up to one year. The arm consisted of 179 patients, 
six withdrew, one converted to AVR and four converted to medical management, so 168 
patients received the TAVI procedure. The probability of having a major bleeding in the 
first 30 days was the proportion of events which occurred (α   0) from the total that could 
have occurred (n=168), which is 0.179 (α/n =30/168). The probability of having a major 
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bleeding in the longer term was estimated similarly. The number of events that occurred (α 
=10) as a proportion of the total that could have occurred (n=118) which was 0.085 (α/n 
=10/118). The total number of events that could have occurred in the longer term was 
calculated as the number of patients who received the treatment minus those who died, had 
a major stroke or major PREs within the initial 30 days.  
 
Box 5.1 Example of Probability of Procedure Related Event Calculation for 
Inoperable Patient Group 
     
 Randomised to TAVI 
 
179 
 
 
 Withdrew 
 
6  
 Conversion to AVR 
 
1  
 Conversion to Medical Management 
 
4  
 Received TAVI Procedure (n) 
 
168  
 
   
 
 Major Complications, Major Stroke or Death within 30 days 50  
 Functioning Valve Replacement after 30 days  (n) 
 
118  
 
   
 
 TAVI: Major Bleeding - 30 days (α) 
 
30  
 TAVI: Major Bleeding - Within 1 Year 
 
40  
 TAVI: Major Bleeding - Post Discharge to 1 year: (α)  
 
10  
 
   
 
 Probability of Major Bleeding - 30 days (α/n)  (30/168) 0.179  
 Probability of Major Bleeding - Post Discharge to 1 year (α/n)  (10/118) 0.085  
     
 
Using the technique described above, the transition probabilities for the DAM were revised 
as follows (Tables 5.1-2). For the short term model, as one patient out of a potential 170 
converted from TAVI to AVR, the probability of converting from TAVI to AVR was 
estimated at 0.01. With respect to converting from TAVI to medical management, four 
patients experienced this out of 173 so the probability was 0.02. There was also a chance 
that the TAVI procedure would have to be repeated (0.02). Eleven patients died from all 
causes within 30 days following TAVI (0.07), while the risk of stroke was 0.05. The 
likelihood of early major PREs was 0.18 and early minor PREs was 0.58, estimated from 
the sum of the individual major and minor PREs (details provided in Table 5.2). For 
patients managed medically, the likelihood of requiring a balloon valvuloplasty was 0.83 
(114 out of a potential 138 patients). Finally, five patients managed medically, out of 138 
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died within 30 days, giving 0.04 probability of death from all causes from medical 
management.   
In the long term model, incorporating PARTNER B evidence revised the transition 
probabilities as follows for the TAVI arm: the probability of late fatal PREs was 0.23, late 
major PREs are 0.20 and late minor PREs were 0.19. The latter were estimated from the 
sum of the individual major and minor PREs (details provided in Table 5.2). While there 
was a 0.50 probability that medically managed patients in the persistent AS/failed valve 
replacements state will require a balloon valvuloplasty in the long run. One limitation of 
the PARTNER B results is that they are for 12 months duration only. So while it was 
feasible to isolate a mortality rate from natural causes from the functioning state (0.14) and 
persistent AS /failed valve replacement state for TAVI (0.60) and medical management 
(0.57) for year one, these were employed in the first cycle only. Subsequent cycles employ 
the natural mortality rate adjusted for age-sex and disease for mortality from the 
functioning valve state and a probability of death from persistent AS /failed valve 
replacement state of 0.33 (Legrand et al., 1991), as per the original model. These latter 
probabilities were employed so as to reflect the life-stage of the patients and to account for 
the diminishing benefits of the valve procedure as forecasted by Leon et al. (2010). These 
transition probabilities for the long term model are presented in Tables 5.1-2. 
As per the original model, the uncertainty surrounding each of the parameters was 
incorporated into the model through the assignment of probability distributions. The 
PARTNER B results identified the total number of patients and the number for whom 
events occurred. This information was used to specify a beta distribution for each 
probability. This information, along with the distributions, facilitated the running of a 
Monte Carlo simulation for a probabilistic sensitivity analysis (PSA). These distributions 
and the number of events occurring and not occurring are shown in Tables 5.1-2. All of the 
transition probabilities provided on Tables 5.1-2 represent absolute risk for each arm of the 
model, TAVI and medical management. 
As outlined previously, where PARTNER Cohort B provided no evidence for events 
expected to occur (and included in the original model, Chapter 4) point estimates from 
previously published literature, used in the original model, were maintained. This was the 
case for early and late cardiac tamponade and early access site events.  Table 5.3 presents 
the evidence that was employed to calculate the estimates shown in Table 5.2 for the 
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aforementioned PREs. Whereby, for each event the number of cases per study is pooled 
across and divided by the total number of patients to give the probability of that event 
occurring. For example, with respect to early access site events, Eichinger et al. (2008) 
reported 16 incidences of early access site events from a potential 431, giving a probability 
of early access site events of 0.04.  For early major PREs evidence was scarce prior to 
PARTNER so evidence from AVR studies were employed also and an average was taken 
across the studies (see Section 4.4.1). Here the total number of patients was pooled from all 
the studies. In addition, where no incidences of an event occurring were reported but expert 
opinion and priors indicated it may occur, a small amount was added to the data for each 
event in order to adjust for those with an observed zero probability to allow for the small 
chance of such events occurring. This was the case for the early major procedure related 
event cardiac tamponade, where 0.01 was added to each estimate. So the estimate of 
cardiac tamponade occurring therefore is 0.00 (from (Gilbert et al., 1999, Gehlot et al., 
1996, Milano et al., 1998))   added to 0.06 (from (Webb et al., 2007, Descoutures et al., 
2008, Grube et al., 2007, Grube et al., 2006)) plus 0.01, averaged to give 0.03 (Table 5.3).  
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Table 5.1 Transition Probabilities for TAVI Decision Analytical Model 
Updated For PARTNER B 
 
Transition probabilities Distribution Probability¶ 
(95% CI) 
α β n 
Short term - 0-30 days      
Probability of converting from TAVI to 
AVR 
Beta 0.01                                 
(0.00 - 0.02) 
1 169 170 
Probability of converting from TAVI to  
medical management 
Beta 0.02                                 
(0.01-0.05) 
4 169 173 
Probability of repeat TAVI procedure Beta 0.02                                 
(0.00-0.04) 
3 165 168 
Probability of major stroke following 
TAVI 
Beta 0.05                           
(0.03-0.09) 
9 159 168 
Probability of death 30 days all causes 
TAVI 
Beta 0.07                      
(0.03-0.11) 
11 157 168 
Probability AS persisting following 
medical management 
Beta 0.96                            
(0.93-0.99) 
133 5 138 
Probability of death following medical 
management 30 days 
Beta 0.04                         
(0.01-0.07) 
5 133 138 
Probability of balloon valvuloplasty 
(MM) 
Beta 0.83 
(0.76-0.88) 
114 24 138 
Probability of early major PRE Beta 0.18 
(0.12-0.24) 
Table 5.2 
 
 
Probability of early minor PRE Beta 0.58 
(0.48-0.69)   
 
Long term - post 30 days      
Probability PRE fatal (TAVI) Beta 0.23                         
(0.15-0.31) 
27 91 118 
Probability PRE major (TAVI Beta 0.20 
(0.13-0.29) 
   
Probability PRE minor (TAVI) Beta 0.19 
(0.12-0.27) 
Table 5.2  
Probability death from AS state – TAVI 
(year 1) 
Beta 0.60                          
(0.44-0.74) 
23 15 38 
Probability death from AS state - Medical 
Management (year 1) 
Beta 0.57                          
(0.49-0.65) 
76 57 133 
Probability death from AS state – post 1 
year* 
Beta 0.33 
(0.24-0.42) 
33 67 100 
Probability of requiring  balloon 
valvuloplasty 
Beta 0.50                            
(0.41-0.58) 
66 67 133 
Mortality from natural causes – TAVI 
(year 1) 
Beta 0.14 
(0.09-0.21) 
17 101 118 
Mortality from natural causes+ Log normal  - - -  
Relative risk of mortality from AS 
(rrsmras) 
Log normal 1.50 
(0.95-2.27) 
0.38 0.22  
 
      
¶ (Leon et al., 2010) *(Legrand et al., 1991) + Applied post one year. Mortality estimated 
according to standard life tables adjusted by rrsmras. α   number of events occurring. 
β  n- α (where n is the number of events which could have occurred).  
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Table 5.2 Procedure Related Event Probabilities for TAVI Decision Analytical 
Model Updated For PARTNER B 
Transition Probability Distribution Probability 
 (95% CI) 
Weight α β n 
Major PREs – TAVI     
Valve Thromboembolism
¶ beta 0.01 0.03 1 167 168 
Major paravavular leak
¶ beta 0.14 0.78 23 145 168 
Endocarditis
¶ beta 0.00 0.00 0 168 168 
Cardiac tamponade† beta 0.03 0.19 6 162 168 
Myocardial infarction
¶ beta 0.00 0.00 0 168 168 
Total  0.18 
(0.12-0.24) 
    
     
Minor PREs – TAVI     
Access site events† beta 0.04 0.07 7 161 168 
Vascular Events
¶ beta 0.15 0.27 26 142 168 
Pacemaker implantation
¶ beta 0.04 0.06 6 162 168 
Major Vascular Event
¶ beta 0.17 0.30 29 139 168 
Major Bleeding
¶ beta 0.18 0.31 30 138 168 
Total  0.58 
(0.48-0.69) 
   
     
Probability late PREs* TAVI     
Valve Thromboembolism† beta 0.00 0.00 0 118 118 
Major paravavular leak
¶ beta 0.13 0.62 15 103 118 
Endocarditis
¶ beta 0.02 0.08 2 116 118 
Cardiac tamponade† beta 0.01 0.05 1 117 118 
Stroke 
¶ beta 0.04 0.21 5 113 118 
Myocardial infarction
¶ beta 0.01 0.04 1 117 118 
Total  0.20 
(0.13-0.29) 
   
       
Late Minor PREs TAVI     
Repeat hospitalisations 
¶ beta 0.06 0.32 109 1835 1835 
Major vascular complications 
¶ beta 0.01 0.05 1 156 157 
Minor vascular complications 
¶ beta 0.02 0.09 2 155 157 
Major bleeding 
¶ beta 0.08 0.46 10 147 157 
New pacemaker 
¶ beta 0.02 0.09 2 155 157 
Total  0.19 
(0.12-0.27) 
    
       
α   number of events occurring. β  n- α (where n is the number of events which could have 
occurred). ¶(Leon et al., 2010)  †(Webb et al., 2007) (Descoutures et al., 2008) (Grube et al., 2007) 
(Grube et al., 2006) (Gilbert et al., 1999) (Gehlot et al., 1996) (Milano et al., 1998) (Eichinger et 
al., 2008) (Aupart et al., 2006) See Table 5.3. 
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Table 5.3 Estimation of Procedure Related Event Probabilities Using 
Literature  
Study  Probability α β n 
MAJOR PRE      
Cardiac tamponade – TAVI      
Webb et al. (2007)  0.02 1 48 49 
Descoutures  et al. (2008)  0.09 1 10 11 
Grube et al. (2007)  0.08 6 70 76 
Grube  et al. (2006)  0.05 1 21 22 
  0.06^ 9 149 158 
Cardiac tamponade – AVR      
Gilbert et al.  (1999)  0.00 0 0 0 
Geholt et al. (1996)  0.00 0 0 0 
Milano et al. (1998)  0.00 0 0 0 
  0.00* 0 0 0 
   
Cardiac tamponade  - Total 
¥ 
[(0.00* + 0.06^) + (0.01)]/2 = 0.03 
 
MINOR PRES - TAVI 
Access site events      
Eichinger et al.  (2008)  0.04 16 415 431 
  0.04 16 415 431 
LATE MAJOR PRES - 
Cardiac tamponade      
Gilbert et al.  (1999)  0.00 0 0 0 
Milano et al. (1998)  0.00 0 0 0 
Eichinger et al.  (2008)  0.00 0 0 0 
Aupart et al. (2006)  0.00 0 0 0 
  
0.00 0 0 0 
 
¥ 
Here no incidences of an event occurring are reported but expert opinion and priors indicated it 
may occur so a small amount is added to the data for each event in order to adjust for those with an 
observed zero probability to allow for the small chance of such events occurring. So the estimate of 
cardiac tamponade occurring therefore is the 0.00* added to 0.06^ plus 0.01 averaged to give 0.03. 
Cost Parameters 
For the cost analysis the value of the following resources were estimated: TAVI device; 
TAVI and medical management procedures; length of stay; hospitalisations and other costs 
incurred with PREs. The published PARTNER trial results provide no additional 
information on the cost of the TAVI procedure or length of stay but did provide 
information on the probability of medical management patients having a balloon 
valvuloplasty in the short (0.83) and long term (0.50). Therefore, the procedural costs for 
TAVI employed are as per the original model (updated to reflect 2010 prices using 
purchasing power parity (Officer and Williamson, 2011)). No additional UK resource costs 
or cost effectiveness analyse are published either at this time.  
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The state costs were updated using a revised rate of hospitalisations per state. As per the 
original model, hospitalisations per health state are estimated using probabilities of 
hospitalisations per NYHA state  (Ahmed et al., 2006) applied to the proportion of patients 
per NYHA state provided in Leon et al. (2010). This provided an updated cost for the 
functioning valve replacement state of £1,533 and £7,512 for the persistent AS/failed valve 
replacement state (Table 5.4).  
The costs of the procedure related events (PREs) were determined from the event costs and 
a weighting, representing each event as a proportion of the total events, as per Chapter 4. 
The PARTNER B data provided no additional unit cost information so the unit costs from 
Chapter 4 are maintained (but updated to reflect 2010 prices (Officer and Williamson, 
2011)) and the weights were updated with the revised probabilities.  The costs of major and 
minor PREs, within 30 days, following TAVI were £310 and £618. For major and minor 
PREs occurring beyond 30 days following TAVI the costs were estimated as £3,091 and 
£1,652 respectively.  Normal distributions are applied to the cost of treating PREs. As per 
the original model the costs were discounted at a rate of 3.5%.  
Quality of Life Parameters 
As per the original model, QALYs were derived for each health state adjusting for the 
condition, the procedure and PREs, as no additional quality of life information was 
available at the time. As with the costs, the impact on utility associated with the PREs was 
adjusted to account for the revised PRE probabilities. Here the utilities associated with the 
procedure related events (PREs) were determined using the event utilities and a weighting, 
representing each event as a proportion of the total events, as per Chapter 4. The utilities of 
major and minor PREs following TAVI within 30 days were 0.04 and 0.03, respectively. 
For major and minor PREs occurring beyond 30 days, following TAVI, the utilities were 
0.03 and 0.02 respectively.   
The PARTNER B data also provided additional information on NYHA classification of 
patients in each state. This permitted a re-estimate of the proportion of patients per class to 
update the utility of functioning valve replacement and failed valve replacement. The 
utility associated with AS was estimated at 0.54; utility of functioning valve replacement 
was 0.75 and the utility associated with failed valve replacement following TAVI was 0.63 
(Table 5.5). Normal distributions were applied to the utilities associated with the PREs. 
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While (as they are categories), a Dirichlet distribution was applied to model the uncertainty 
surrounding the proportion of patients in each NYHA class, to estimate the utility per 
health state. As per the original model the QALYs were discounted at a rate of 3.5%.  
Table 5.4 Revised Cost of Functioning & Persisting AS/ Failed Valve 
Replacement Health States for the TAVI Decision Analytical Model Updated 
for PARTER B 
COSTS Unit Cost 
£ 
Dist Prob α β Total Cost £ 
(95% CI) 
Cost of Functioning Valve Replacement 
Hospitalisations 3,390* beta 0.07¶ 11 146 246 
Nursing home 11,382+ beta 0.10* 16 141 1,138 
Drug Therapy 192*     192 
      1,578 
(1,313-1,871) 
Cost of Failed Valve Replacement 
Hospitalisations 3,390* beta 0.67¶ 106 51 2,280 
Nursing home 11,382+ beta 0.50* 79 79 5,691 
Drug Therapy 192*     188 
      8,163 
(7,694-8,634) 
 
¶(Leon et al., 2010) * (Ahmed et al., 2006) + (Netten, 1996) Costs updated to reflect 2010 prices 
using purchasing power parity (Officer and Williamson, 2011)). 
 
Table 5.5 Revised Utilities by NYHA Class for TAVI Decision Analytical Model 
Updated for PARTNER B 
NYHA Class Distribution Utility* Proportion
¶
 Utility 
(95% CI) Utility of AS      
I Dirichlet 0.82 0.00 0.00 
II Dirichlet 0.72 0.08 0.06 
III Dirichlet 0.59 0.48 0.28 
IV Dirichlet 0.51 0.44 0.22 
    0.56 
(0.56-0.57) Utility of Functioning Valve Replacement TAVI 
I Dirichlet 0.82 0.54 0.44 
II Dirichlet 0.72 0.29 0.21 
III Dirichlet 0.59 0.14 0.08 
IV Dirichlet 0.51 0.02 0.01 
   1.00 0.75 
(0.73-0.76) 
( 
Utility of Failed Valve Replacement TAVI 
I Dirichlet 0.82 0.02 0.02 
II Dirichlet 0.72 0.39 0.28 
III Dirichlet 0.59 0.45 0.27 
IV Dirichlet 0.51 0.14 0.07 
    0.63 
 
 
(0.62-0.66) 
*(Maliwa et al., 2003) ¶(Leon et al., 2010) 
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5.3.4 Analysis – Inoperable Patients 
An analysis similar to that employed in Chapter 4, was applied here for inoperable patients, 
with a UK NHS perspective. A Monte Carlo simulation with 10,000 iterations was used to 
propagate the uncertainty in the individual model parameters (reflected by the probability 
distributions assigned) through the model (methods described in Chapter 2). This produces 
a distribution of expected costs and QALYs associated with each procedure. The mean 
values of these distributions are used to calculate the incremental cost effectiveness ratio 
(ICER) in terms of the expected incremental costs associated with TAVI compared to 
medical management per incremental QALY gained. The uncertainty associated with the 
incremental costs and QALYs are presented through incremental cost effectiveness (ICE) 
planes. The decision uncertainty associated with the cost effectiveness of TAVI compared 
to medical management is presented in terms on a cost effectiveness acceptability curve 
(CEAC). These can be used to re-address the adoption decision. A sensitivity analysis is 
performed to assess the impact of improved TAVI outcomes on the cost effectiveness of 
TAVI. Finally, to re-address the research priority setting decision a Bayesian Value of 
Information (VOI) analysis is performed to investigate whether there is potential value in 
collecting additional evidence. The Expected Value of Perfect Information (EVPI) 
investigates what society would be willing to pay to eliminate all the uncertainty 
surrounding the coverage decision. The Expected Value of Perfect Parameter Information 
(EVPPI) investigates the potential value in collecting further information about specific 
parameters or groups of parameters. The Expected Value of Sample Information (EVSI) 
estimates the benefit of sampling. Following which a sensitivity analysis is performed. 
 
5.4 COST EFFECTIVENESS ANALYSIS RESULTS – 
INOPERABLE PATIENTS  
The cost effectiveness of TAVI versus medical management is estimated for high risk 
inoperable patients based on a mix of evidence from Cohort B of the PARTNER trial and 
the original estimates from the literature. The results indicate a 12% reduction in absolute 
risk in terms of all-cause mortality, at the end of year one, between TAVI and medical 
management. The model predicts that this steadily declines from year two onwards (Figure 
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5.4). Also, the results indicate that TAVI offers greater quality of life (14%) than medical 
management as per the PARTNER results in year 1.  
 
5.4.1 Deterministic Cost Effectiveness Results 
The deterministic cost effectiveness results (Table 5.6) are estimated using the point 
estimates for the transition probabilities, costs and utilities presented in the previous 
section. The results illustrate that for inoperable patients TAVI is both more costly 
(£16,111) and more effective (0.42 QALYs) than medical management. The ICER is 
estimated as £38,724 per QALY gained, which is just outside the level usually considered 
cost effective (£20,000-£30,000 per QALY (Rawlins et al., 2009)).  
 
Figure 5.4 Survival Estimates for TAVI and Medical Management 
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The Monte Carlo simulation produced the mean cost and QALYs for TAVI and medical 
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95% confidence interval around the incremental costs is £12,869-£19,365. The 95% 
confidence interval around the incremental benefits is 0.20-0.69. The probabilistic ICER is 
estimated as £37,390 per QALY gained, which is outside the level usually considered cost 
effective (£20,000-£30,000 per QALY(Rawlins et al., 2009)). 
Table 5.6 Cost Effectiveness Results: Inoperable Patients - TAVI versus 
Medical Management 
 LYs Costs (£)     
(95% CI) 
∆ 
Costs 
QALYs  
(95% CI) 
∆ 
QALYS 
ICER 
£/QALY 
Deterministic Results 
Medical 
Management 
2.22 12,290  1.18   
TAVI 2.50 28,401 16,111 1.59 0.42 £38,724 
Probabilistic Results 
Medical 
Management 
2.24 12,446  1.19   
(1.86-2.75) (9,353-16,468)  (1.00-1.43)   
TAVI 2.54 28,629 16,183 1.62 0.43 £37,390 
(2.12-3.06) (25,737-32,145)  (1.37-1.92)   
 
The ICE plane (Figure 5.5) illustrates the existence and extent of the uncertainty 
surrounding the incremental effect (measured in QALYs) and cost (these are the red points 
plotted on Figure 5.5). In this case, there is some uncertainty surrounding the existence of 
benefit for TAVI (over medical management), with TAVI being more effective. There is 
considerable uncertainty surrounding the extent of the differences in effects, owing to the 
probability PREs.  Furthermore, there is no uncertainty with respect to the existence of 
differences in costs, with TAVI being more expensive than medical management: this is 
driven by the cost of the TAVI device. However, there is some uncertainty surrounding the 
extent of the differences in cost. This is potentially driven by uncertainties surrounding the 
probability of PREs.  
The CEAC (Figure 5.6) represents the decision uncertainty surrounding the cost 
effectiveness of each treatment. At a ceiling ratio of £30,000 per QALY, the probability 
that TAVI is cost effective is 18% while the probability that medical management is cost 
effective is 82%.  If the acceptable ceiling ratio was increased to £40,000 per QALY the 
probability that TAVI is cost effective increases to 59%. 
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Figure 5.5 Incremental Cost Effectiveness Plane: Inoperable Patients - TAVI 
versus Medical Management 
 
Figure 5.6 Cost Effectiveness Acceptability Curves: Inoperable Patients - 
TAVI versus Medical Management 
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5.5 SCENARIO ANALYSES 
To date there is limited evidence of TAVI outcomes beyond one year. Commentators 
suggest that current data, from published trials and registries including PARTNER, relate 
to older generations of devices used in centres that were inexperienced at the time (Schaff, 
2011, Webb and Cribier, 2011). This is attributable to the characteristics of medical 
devices, such as incremental innovations, the device-clinician learning curve etc. (see 
Section 1.2.1). It is suggested that these shortcomings contribute to the high rate of PREs 
following TAVI, which may be resolved in the future (Schaff, 2011, Webb and Cribier, 
2011). Collecting further evidence, via trial or registry, could demonstrate if this is the case 
or if the high incidence of PREs is part of treating elderly ailing patients with severe AS. 
The value of such data collection is examined in the next section through a Bayesian VOI 
analysis. Before examining the value of collecting further information however, a scenario 
analysis is performed to analyse the impact of the suggested improvements in PREs on the 
cost effectiveness of TAVI. 
The scenario analysis indicates that if all PREs reported for TAVI are reduced by 25% 
(expert opinion (Toff, 2011)), TAVI would remain more expensive (£7,856; 41%) and 
more effective (0.56; 44%) than medical management. However, in such a scenario the 
ICER falls to £23,642/QALY, bringing it within the range considered cost-effective in the 
UK (£20,000-£30,000/QALY). The CEAC (Figure 5.7) demonstrates that at a ceiling ratio 
of £30,000/QALY the probability that TAVI is cost effective increases to 83% and the 
probability that medical management is cost effective falls to 17%. Thus, if future evidence 
demonstrates improved TAVI outcomes, in the form of reduced PREs, then TAVI could be 
considered cost effective for high risk inoperable patients in the UK.  
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Figure 5.7 Scenario Analysis: Cost Effectiveness Acceptability Curve: TAVI 
versus Medical Management 
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5.6.1 Is There Value in Collecting Further Evidence? 
The potential value of undertaking further research is estimated by determining the value 
of eliminating all the uncertainties in the model (i.e. the EVPI). The EVPI per patient, 
when deciding between TAVI and medical management ranges from £1 to £275 per 
inoperable patient for one year (based on PSA results in Section 5.4.2). 
The population expected value of perfect information (pEVPI) for the inoperable 
population in UK (2,750 from Table 4.13 (SHTG, 2009)), over the range usually 
considered cost effective, ranges from £1,441 to £756,649 over one year (Figure 5.8). 
These estimates provide a maximum value for the return of further research, suggesting 
there is some value in collecting further information on inoperable patients. The pEVPI 
reaches a point of inflection at a ceiling ratio equal to the ICER £37,390/QALY. This 
corresponds to the CEAC (Figure 5.6) where at £37,390/QALY the decision is most 
uncertain. Here the probability that TAVI is cost effective is 0.48 and probability that 
medical management is cost effective is 0.52. Beyond this ceiling ratio, the optimal 
treatment changes and TAVI is more likely to be cost effective compared with medical 
management. As there are only two technologies considered here the point of inflection is 
also the maximum pEVPI. 
Figure 5.8 Expected Value of Perfect Information: UK Inoperable Population
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5.6.2 On Which Parameters Is There Value In Collecting Further 
Information? 
As shown by the pEVPI, given current evidence there is some value in collecting 
additional information on inoperable patients. On which parameters this future evidence 
will be most valuable and how it should be collected is examined using expected value of 
perfect parameter information (EVPPI). Additional evidence could be collected using a 
specific UK clinical trial or expanding the existing UK TAVI Registry
5
. It is anticipated 
that both of these methods would have the power to collect additional information 
regarding short term transition probabilities; long term transition probabilities; resources 
consumed and quality of life/utility information for TAVI patients. In addition, a trial 
could collect this evidence on medical management as well as TAVI. This expectation is 
informed by what is currently collected in the UK TAVI registry (as per Ludmann (2010)) 
and what was collected in the PARTNER trial (see Appendix VI). These groups of 
parameters are shown in Table 5.7. 
Table 5.7 Parameter Groups for Further Evidence Generation   
     
1 Short Term 
Outcomes 
2 Short & Long 
Term Outcomes 
3 Quality of 
Life 
4 Resources 5 Medical 
Management  
- Major PRE 
TAVI 
- Minor PRE 
TAVI 
- Converting To 
AVR 
- Converting To 
MM 
- Repeat TAVI 
- Death 30 
Days TAVI 
- Major Stroke 
TAVI 
- Major PRE 
TAVI 
- Minor PRE 
TAVI 
- Converting To 
AVR 
- Converting To 
MM 
- Repeat TAVI 
- Death 30 Days 
TAVI 
- Major Stroke 
TAVI 
- Late PRE TAVI 
- Late PRE AVR 
- Late Minor PRE 
TAVI 
- Late Fatal PRE 
TAVI 
- MR TAVI 
- Death AS TAVI 
- Utility 
Functioning 
TAVI 
- Utility 
Persistent 
AS TAVI 
- Total LOS 
TAVI 
- Post 
Discharge 
TAVI 
- Cost 
Functioning 
TAVI 
- Cost 
Persistent AS 
TAVI 
- Death 30 Days 
Medical 
Management 
- Early Balloon 
Valvuloplasty 
- MR Medical 
Management – 1 Yr 
- MR Medical 
Management  > 1 Yr 
- Late Balloon 
Valvuloplasty 
 
 
  
   
   
                                                 
5
 As per NICE Guidelines all TAVI procedures performed in the UK since 2007 are recorded 
through the Central Cardiac Audit Database to form the UK TAVI Registry. 
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Using the expected net benefit (ENB) for TAVI compared to medical management, 
generated from the Monte Carlo simulation (Section 5.4), the EVPPI analysis measures the 
potential value in collecting further evidence on the parameter groups.  This was performed 
for each group of parameters individually (groups 1- 5), for all the groups simultaneously 
to represent a clinical trial and for groups 1-4 simultaneously to represent a registry, using 
a ceiling ratio of £30,000/QALY.  
The results of the EVPPI analysis are as follows (Figure 5.9). At a ceiling ratio of 
£30,000/QALY, the EVPPI for group 2 individually was the highest of the five groups, at 
£642,318. For the rest of the groups individually (1, 3, 4 and 5) there is little value in 
collecting information on them in isolation. When all the groups are considered 
simultaneously to represent a registry (groups 1 to 4)  the EVPPI was £404,030 and to 
represent a clinical trial (groups 1 to 5)  the EVPPI was £457,078,  for the UK inoperable 
population  (2,750 (SHTG, 2009)). The lower EVPPI results for the groups simultaneously, 
compared to those for Group 2 individually, are owing to the interactions between the 
variables. Figure 5.9 includes the pEVPI at £30,000/QALY to demonstrate that not all the 
uncertainty is resolved in assuming perfect information about the five groups of 
parameters. To determine how additional evidence should be collected the expected value 
and costs of the data collection methods need to be compared.  
Figure 5.9 Expected Value of Partial Perfect Information: UK Inoperable 
Population 
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5.6.3 How Should the Additional Evidence be Collected? 
As outlined above, the additional evidence could be collected via a registry or clinical trial. 
Registries use observation methods to collect data on specific outcomes, thus collect 
evidence on real clinical practice settings (Gliklich and Mack, 2009, Gliklich and Dreyer, 
2007). In contrast, clinical trials are usually randomised and focus on collecting 
information on efficacy in a controlled setting where conditions are ideal (Gliklich and 
Mack, 2009). It is recognised that some features of the two are similar; however clinical 
trials are more reliant on protocol development, guidance from advisory panels and 
biostatistics. While registries are thought to be a lower cost mode of collecting evidence 
(Gliklich and Mack, 2009).  The expected value of both methods is considered here 
through the Bayesian VOI analysis, using EVSI for inoperable patients.  
Clinical Trial 
The potential value of a hypothetical UK TAVI Trial for inoperable patients is considered 
here. This is calculated using the estimates of ENB from the PSA analysis (Section 5.4) 
and evaluates the worth of conducting a clinical trial, with five year follow up, by 
estimating the difference between the expected value of a decision made with sample 
information and the expected value of a decision made with current information. It is 
anticipated that such a trial would be powered to collect information on all five groups of 
parameters presented in Table 5.7. 
The EVSI analysis was conducted for a variety of trial sizes: 250, 500, 1,000 and 2,000 for 
the parameter groups (Table 5.7) individually and simultaneously. The results (Figure 
5.10) reveal that clinical trial collecting information on Groups 1-5 simultaneously has the 
highest EVSI, £459,663, at the largest sample size (2,000). Trials collecting information on 
the parameter groups individually have little value, across the sample sizes (except Group 
2, seventh series on Figure 5.10). 
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Figure 5.10 Expected Value of Sample Information for All Groups - Different 
Trial Sizes 
 
 
As outlined in Chapter 2, it is anticipated that there is a positive relationship between EVSI 
and sample size: as sample size increases there is more information, which reduces 
uncertainty, therefore increasing EVSI. As is evident from Figure 5.10 however, in this 
case the EVSI is downward sloping, illustrating the practical challenges associated with 
estimating EVSI. An initial solution to overcoming this problem would be to increase the 
number of iterations employed in the simulation. The results illustrated on Figure 5.10 are 
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Bayesian Statistics in Health Economics (CHEBS) at the University of Sheffield.  
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to the expected value of the sample information (EVSI) of the hypothetical trial. The 
difference between the expected costs and EVSI is the expected net benefit of sampling 
(ENBS).  
 
For example, the expected value (EVSI) for a trial with 2,000 patients is £459,663. The 
expected cost of this trial is £32,250,000 (estimated using fixed cost of £2.25 million and 
variable costs £30 million (£15,000 * 2,000 patients)). Comparing the expected costs and 
benefits gives a negative ENBS (-£31.8 million), indicating that a trial of this size and 
magnitude cannot be considered cost effective. This is repeated for different sample sizes. 
The ENBS results indicate that at a ceiling ratio of £30,000/QALY, across the four sample 
sizes, the ENBS for the trial is negative. Thus, the trial cannot be considered cost effective 
at the £30,000/QALY ceiling ratio (used to estimate EVSI).  
Supposing the nationally accepted ceiling ratio was increased to £50,000/QALY, across 
the sample sizes the trial would have a positive ENBS. Specifically, a trial with sample 
size of 2,000 would have the highest net benefit, £32.74 million. These ENBS results are 
presented on Figure 5.11.  
Using the expected cost estimates above, an approximation of for how long the information 
from the trial would have to be relevant for, for the costs of the trial to be recouped, can be 
calculated. This is estimated by dividing the expected trial cost by the EVSI. For example, 
a trial with sample size of 250 patients is estimated to cost £6.5 million (based on the fixed 
and variable costs from above). A clinical trial capable of collecting information on all 
parameters in groups 1-5 with this sample size has an EVSI of £306,540. Thus, to recoup 
the costs of the trial, the information collected from it would need to be relevant for over 
20 years. Similarly for a trial with 2,000 patients, the expected costs are £32.5 million 
(including NHS service costs) and the EVSI is £376,088. Thus, to recoup the costs of the 
trial, the information collected from it would need to be relevant for over 86 years (Table 
5.8). Given the nature of novel medical devices like TAVI, such trials are unlikely to yield 
information which is relevant for such long periods.   
These results indicate that at the current range for the nationally accepted ceiling ratio, i.e. 
what society is willing to for an extra QALY (£20,000-£30,000/QALY) and current 
evidence for high risk inoperable patients, there is little benefit in conducting a clinical 
trial. 
 177 
 
 
Figure 5.11 Expected Net Benefit of Sampling – Clinical Trial for Inoperable 
Patients 
 
 
Table 5.8 Expected Value of Sample Information: Clinical Trial - Inoperable 
Patients  
Sample 
Size 
EVSI @ 
£30,000/QALY 
Cost of Trial* £ Millions 
 Groups 1-5 6.25 
(n=250) 
10 
(n=500) 
17.5 
(n=1,000) 
32.5 
(n=2,000) 
  Years To Recoup Costs 
250 306,540 20.39    
500 340,425  32.62   
1,000 363,510   48.14  
2,000 376,088    86.42 
*Costs are based on fixed costs £2.25 million and variable costs of £15,000 per patient (Toff, 
2012), include NHS service costs. 
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are recorded through the Central Cardiac Audit Database (CCAD) (Ludmann, 2010). From 
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this database the UK TAVI Registry has developed through collaboration between the 
BSCIS and STCTS
6
, Department of Health and Special Commissioners and Health 
Technology Assessment and NICE. Appendix VI shows the evidence currently being 
collected in the UK TAVI Registry and what additional evidence could be collected 
through a registry.  
An alternative to a clinical trial would be to expand the existing UK TAVI Registry 
(Ludmann, 2010) to collect additional evidence. It is anticipated that an extension of the 
TAVI Registry could collect additional evidence on the following types of parameters 
associated with the TAVI procedure: short term probabilities only, all short and long term 
probabilities (including long term mortality), utility and resources consumed. These 
correspond to parameter groups 1-4 listed in Table 5.7. 
The EVPPI analysis performed in Section 5.6.2 illustrated the maximum potential worth of 
collecting data on TAVI only through an expanded UK TAVI Registry (consideration of 
groups 1-4 simultaneously). So if further data collection was to provide evidence on all the 
parameters contained in groups 1-4, it would be worth a maximum of £404,030 for the UK 
population, at a ceiling ratio of £30,000/QALY (see Figure 5.9).  
An EVSI analysis is conducted for a variety of sample sizes: 250, 500, 1,000 and 2,000, for 
the parameter groups 1 to 4 (Table 5.7) simultaneously to represent a registry. The results 
reveal that a registry collecting information on groups 1-4 simultaneously on 2,000 patients 
has an EVSI of £643,680.  This is repeated for the other trial sizes, illustrated on Figure 
5.10 (orange line) and Table 5.9.  
With respect to the expected costs of such a registry, it is estimated that the fixed costs of 
establishing such a registry would be £100,000 and the variable costs per patient would be 
£50 (based on expert opinion (Cunningham, 2012)). Using the sample sizes from before 
(250, 500, 1,000 and 2,000) the costs of the trial can be compared to the expected value of 
the sample information (EVSI) of the registry. The difference between the expected costs 
and EVSI is the expected net benefit of sampling (ENBS).  
For example, the expected value (EVSI) for a registry with 2,000 patients is £643,680. The 
expected cost of this trial is £200,000 (estimated using fixed cost of £100,000 and variable 
                                                 
6
 British Cardiovascular Intervention Society (BCIS), Society of Cardiothoracic Surgeons (SCTS) 
 179 
 
costs of £100,000 (£50 * 2,000 patients)). Comparing the expected costs and benefits gives 
a positive ENBS, £443,680, indicating that a registry of this size and magnitude can be 
considered cost effective. This is repeated for different sample sizes. The ENBS results 
indicate that at a ceiling ratio of £30,000/QALY across the four sample sizes the ENBS for 
the trial is positive. Thus, the registry can be considered cost effective at the 
£30,000/QALY ceiling ratio (used to estimate EVSI) (Figure 5.10).  
Using the expected costs estimates an approximation for how long the information from 
the registry would have to be relevant for, to recoup the costs of the registry can be 
estimated. This is calculated by dividing the expected registry cost by the EVSI. For 
example, a trial with sample size of 250 patients is estimated to cost £112,500 (based on 
the fixed and variable costs from above). A registry capable of collecting information on 
all parameters in groups 1-4 with this sample size has an EVSI of £662,085. Thus, to 
recoup the costs of the trial, the information collected from it would need to be relevant for 
just over two months. Similarly for a trial with 2,000 patients, the expected costs are 
£200,000 and the EVSI is £643,680. Thus, to recoup the costs of the trial the information 
collected from it would need to be relevant for almost 4 months. These results are 
summarised in Table 5.9. 
 
Table 5.9 Expected Value of Sample Information: Registry - Inoperable 
Patients  
Sample 
Size 
EVSI @ £30,000/QALY Cost of Registry* £ 
Groups 1-4 
112,500 
(n=250) 
125,000 
(n=500) 
150,000 
(n=1,000) 
200,000 
(n=2,000) 
  Years to Recoup Costs 
250 662,085 0.17 
   
500 653,153 
 
0.19 
  
1,000 648,000 
  
0.23 
 
2,000 643,680 
   
0.31 
*Costs are based on fixed costs £100,000 and variable costs of £50 per patient (Cunningham, 
2012).  
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Figure 5.12 Expected Net Benefit of Sampling – Proposed & Existing 
Registry for Inoperable Patients 
 
 
 
However, given that a TAVI Registry already exists in the UK one could assume that the 
fixed costs are sunk and only the variable costs (£50/patient) are applicable. In this 
instance, the ENBS is estimated as follows, for four sample sizes, ranging between 250 and 
2,000. At a ceiling ratio of £30,000/QALY the highest ENBS is for a trial with sample size 
of 250 patients, at £649,585. These results are presented as the solid line on Figure 5.12. 
This indicates that at the current nationally accepted ceiling ratio, i.e. what society is 
willing to for an extra QALY, there is benefit in collecting additional information using the 
existing UK TAVI Registry. 
The results from VOI analysis and ENBS indicate that there is value in collecting 
additional information. In particular, the results indicate that a registry would be a more 
cost efficient means of collecting the additional evidence than a trial. In line with the 
continuous iterative framework, presented in Chapter 2, this additional evidence could be 
collected using a Performance Based Risk Sharing Agreement (PBRSA) like Access with 
Evidence Development (AED). Whereby, the registry could be integrated into an AED 
scheme. This would ensure that evidence is collected while controlling who gets TAVI on 
a simultaneous basis.  
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5.7 COMPARISON OF ORIGINAL MODEL WITH UPDATED 
MODEL INCORPORATING PARTNER (COHORT B) 
EVIDENCE - INOPERABLE PATIENTS 
Model and Parameters 
As outlined previously, incorporating evidence from PARTNER B into the inoperable 
patient model, affords the opportunity to use the best data available to reflect current 
understanding of the treatment pathways and technologies. This facilitates a re-assessment 
of the cost effectiveness of TAVI on an iterative basis. This resulted in some structural 
changes to the model: inclusion of conversion from TAVI to medical management, repeat 
TAVI, death from medical management within 30 days and the distinction between major 
and minor PREs in the Markov model. It also provided current evidence for the transition 
probabilities in the short and long term such as stroke, PREs and mortality estimates. 
Previously, early short term experiences with TAVI, expert opinion and experiences with 
AVR had to be relied on to inform the model.  
These changes to the model and evidence resulted in the following changes to the 
transition probabilities (See Appendix VII).  With respect to conversions, the original 
model only included conversions from TAVI to AVR; updating the evidence with 
PARTNER B results reduced the probability of this by 83% to 0.01. Incorporating 
PARTNER B evidence increased the stroke risk associated with TAVI to 0.05. This is a 
67% increase on the baseline stroke rate employed in the original model (although it does 
fall within the upper range of the uncertainty modelled for the parameter). For inoperable 
patients, the original model assumed a 30 day all-cause mortality rate of 20% after TAVI, 
based on operative mortality risk. This is reduced to 7% following the inclusion of 
PARTNER B evidence. While for medically managed patients, a 30 day mortality rate of 0 
was used in the original model, based on expert opinion, this increased to 4% in the revised 
model.  
Incorporating PARTNER B evidence also increased early major PREs following TAVI by 
50% to 0.18. This is mainly attributable to the increase in paravavular leaks. The 
probability of early minor PREs also increased, by 120%, from 26% to 58%. This is 
attributable to the high incidence of major vascular events and major bleeding. The 
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likelihood of late fatal PREs increased slightly for TAVI patients from 0.22 to 0.23. While 
late major PREs increased by 17% for TAVI patients to 0.20. This is explained by the 
increase in paravavular leaks following TAVI and the inclusion of late strokes and late 
myocardial infarction (0.04 and 0.01 respectively). 
With respect to late mortality, there were also some changes from the original model. 
Death from the functioning valve replacement state in year 1 increased to 0.14 owing to the 
inclusion of PARTNER evidence. However, for subsequent years the natural mortality rate 
for age and sex, adjusted for the disease was maintained. Similarly, death from the 
persistent AS/failed valve replacement state increased for TAVI and medically managed 
patients by 82% and 73% respectively in year 1, however the mortality rate of 0.33 
(Legrand et al., 1991) is maintained for subsequent years.  
With regard to the cost parameters, the revised model included the costs of balloon 
valvuloplasty for 83% of medically managed patients in the short term and 50% of those in 
the persistent AS/failed valve state in the long run. The costs of long term care per state 
were also revised, to account for increased probability of requiring hospitalisation. These 
increased in the annual cost associated with the persistent AS/failed valve replacement 
state by 6% and the annual cost associated with the functioning valve replacement state by 
1%. These increases are explained by the 26% increase in the probability of requiring 
annual hospitalisations associated with the persistent AS/failed valve replacement state 
(0.67); and a less than 1% increase in the probability of requiring annual hospitalisations 
for those in the functioning valve replacement state (0.07). 
PARTNER provided updated estimates for the proportion of patients per NYHA class and 
these were used to replace estimates used in the original analysis, as per the PRE estimates. 
This ensures consistency for the patient population under consideration. Revising the 
utilities per state reduced the utility associated with having AS (by 4%) to 0.54, 
representing the greater severity of AS amongst this inoperable patient group. The utility 
associated with the functioning valve replacement state also decreased in the revised model 
by 3% to 0.75. However, the utility associated with the persistent AS/failed valve state 
increased by 22% for patients who received TAVI (0.63). This provided a differentiation 
between TAVI and medical management patients while in the same state, thus reflecting 
the benefit of the TAVI procedure, despite major PREs. In the original model, the state 
utilities were not varied to reflect heterogeneity between the patient types or procedures.  
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Thus, incorporating the PARTNER B evidence into the model provided revised parameters 
to reflect the best currently available data and facilitate differentiation between patient 
types and procedures to reflecting heterogeneity. Specifically, the PARTNER B evidence 
provided evidence on early and late outcomes following TAVI. This generally reduced the 
mortality parameters in the short run but increased them in year one. It increased major and 
minor PREs associated with TAVI in the short and long term. Also, additional costs 
associated with medical management and persistent AS/failed valve state were 
incorporated (balloon valvuloplasty). Previously, utilities were applied homogenously 
across patient and procedure types based on state only. The developed evidence base 
permitted the reflection of heterogeneity between patient groups and the different 
treatments through different state utilities varied by treatment. In contrast, the original 
model only incorporated heterogeneity between patient groups via treatment choice, 
operative mortality rates and the use of relative risk parameters between TAVI and AVR. 
Thus, the revised model provided an updated reflection of TAVI in practice. 
Cost Effectiveness Results 
The revised cost effectiveness analysis demonstrated that TAVI both extends life and 
improves quality of life in the longer term for those patients who otherwise would not 
receive a valve replacement. The average life years gained was 2.55 for patients receiving 
TAVI and 2.24 for patients receiving medical management.  This was a decrease compared 
to the original model (3.50 following TAVI and 3.05 following medical) which is 
explained by the increase in mortality in year 1 of the Markov model and higher rates of 
PREs. The latter resulted in more patients entering the persistent AS/failed valve 
replacement state which has a higher mortality rate than the functioning valve state. Figure 
5.13 presents the survival estimates from each model for comparative purposes, illustrating 
that the revised model has much steeper survival estimates than the original model. In 
addition, the difference between TAVI and medical management is narrower in the revised 
model. This steeper curve is explained by the higher one year mortality estimates for each 
state in the Markov model as informed by PARTNER B evidence. 
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Figure 5.13 Comparisons of Survival Estimates  
 
 
Results from both the original and the revised models indicate that TAVI is more costly 
and more effective when compared to medical management for inoperable patients. The 
incremental costs in the PARTNER B model are 12% greater and the incremental QALYs 
are 34% less than the original model. In the original model, the ICER (£22,108) was within 
the range usually considered acceptable but in the revised model the ICER is above this 
range (£37,390) (Table 5.10). 
 
Table 5.10 Cost Effectiveness Results Comparison PARTNER B and Original 
Model: Inoperable Patients 
    TAVI Medical Management ∆ 
Costs 
∆ 
QALYs 
ICER 
 
£/ 
QALY 
 Costs 
(£) 
QALYs LYs Costs 
(£) 
QALYs LYs 
ORIGINAL* 
 28,353 2.18 3.48 13,942 1.53 3.06 14,411 0.65 22,108 
PARTNER B
‡ 
 28,629 1.62 2.54 12,176 1.19 2.24 16,453 0.43 37,390 
*Presented in Chapter     ‡Presented in Section 5.4 
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Specifically, the costs associated with TAVI were estimated to be greater than suggested 
by the original model (£276; 0.9%) and the QALYs produced are less (0.56; 26%). 
Similarly, the costs and QALYs associated with medical management, based on the revised 
analysis, were both less than the values produced by the original model (£1,748; 13% and 
0.34; 22% respectively). These differences are explained by the higher probability of PREs 
and stroke associated with TAVI, the greater probability of death from the persistent 
AS/Failed valve replacement state and the inclusion of death within 30 days with medical 
management.  The ICE plane compares the additional costs and benefits of TAVI over 
medical management. As discussed in Section 5.4, there is little uncertainty surrounding 
the existence of benefit and cost differences for TAVI (over medical management) with 
TAVI being more effective and more expensive than medical management. There is 
however, some uncertainty surrounding the extent of the differences in effects and costs, 
though considerably less than that in the original model.   
 
Figure 5.14 Incremental Cost Effectiveness Plane Comparison: Inoperable 
Patients: Original and PARTNER B Models 
(a) Original Model     (b) PARTNER B Model 
  
 
Comparing the ICE planes (Figure 5.14) it is evident that the new evidence has reduced 
and shifted the amount of uncertainty present. Figure 5.14a illustrates the incremental cost 
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for the revised model with PARTNER B data. Here it is illustrated that the uncertainty 
surrounding the extent of differences in QALYs and costs particularly, has reduced 
compared to the original model. This is confirmed in the reduction of the 95% confidence 
interval around the incremental QALYs between the original model (0.22-1.05) and the 
PARTNER B model (0.22-0.68). Similarly, the 95% confidence interval around the 
incremental costs narrowed from the original model (£9,766-£18,075) and the PARTNER 
B model (£12,674-£18,902) indicating a decrease in uncertainty surrounding the input 
parameters. So incorporating the new evidence reduced the uncertainty. 
Comparing the CEACs from the re-analysis and the original analysis (Figure 5.15) 
demonstrates that the decision uncertainty in the original model was also reduced when the 
new evidence is incorporated. The probability that TAVI is cost effective compared with 
medical management (at a ceiling ratio of £30,000 per QALY) was 86% in the original and 
18% in the revised model. Figure 5.15 presents the two CEACs side by side, to illustrate 
the change in decision uncertainty.  
 
Figure 5.15 Cost Effectiveness Acceptability Curve Comparison: Inoperable 
Patients 
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costly and more effective compared with medical management in treating inoperable AS 
patients.  
Value of Information Analysis 
The VOI analysis estimated that the pEVPI between TAVI and medical management for 
the UK inoperable patient population (2,750 (SHTG, 2009)), using PARTNER evidence, 
over the range usually considered cost-effective, ranged from £1,270,699 to £3,512,503, 
over one year. This was marginally higher than that estimated in the original model which 
ranged from £988,775 to £3,428,480 for the UK inoperable population over one year.  
Figure 5.16 presents the pEVPI for the original model and PARTNER model side by side 
for comparative purposes. As illustrated here, the additional evidence marginally increased 
the pEVPI. So uncertainty remains and there is still some value in collecting further 
evidence on the costs and effects of TAVI compared with medical management, as 
confirmed by the EVPPI and EVSI. 
 
Figure 5.16 Expected Value of Perfect Information Comparison: Inoperable 
Population 
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5.8 COMPARISON WITH OTHER COST EFFECTIVENESS 
ANALYSES 
US Cost Effectiveness Analysis  
Subsequent to the cost effectiveness analysis employing the optimal data available 
(including PARTNER B) presented in this Chapter, a cost effectiveness analysis of TAVI 
compared to medical management was published by Reynolds et al. (2012). This analysis 
was exclusively based on the PARTNER Cohort B trial with a US perspective and 
estimated an ICER of $61,889 (£39,027
7
) per QALY. The paper concluded that at an 
acceptable ceiling ratio of $50,000 (£44,142
7
), TAVI is cost effective compared to medical 
management. Table 5.11 presents the results of the Reynolds et al. (2012) cost 
effectiveness analysis alongside the results produced in this study. Upon examination it is 
evident that the incremental costs between TAVI and medical management are higher in 
the Reynolds et al. (2012) paper, as are incremental life years gained and QALYs.   
Table 5.11 Comparison of Cost Effectiveness Results with Reynolds et al. 
(2012) 
   Costs ∆ 
Costs 
LYs LYGs QALY ∆ 
QALY 
ICER 
£/ 
LYG 
ICER 
£ /QALY 
Reynolds
$ 
TAVI 149,74
0 
 2.78  2.03    
  Control 69,90
3 
79,83
7 
1.20 1.58 0.73 1.30 50,21
2 
61,889 
           
Reynolds 
£* 
  
TAVI 94,42
6 
 2.78  2.03    
Control 44,08
1 
50,34
5 
1.20 1.58 0.73 1.30 31,66
4 
39,027 
          
PARTNER 
B 
TAVI 28,62
9 
 2.54  1.62    
 Control 12,44
6 
16,18
3 
2.24 0.30 1.19 0.43 53,94
3 
37,390 
*Applied average USD GBP exchange rate March 2011-12 of 0.6306 (Oanda, 2012) 
 “Reynolds” are the results of the Reynolds et al. (2012) cost effectiveness analysis and 
“PARTNER B” is the cost effectiveness results from the model developed in this thesis. 
 
                                                 
7
 Average USD GBP exchange rate March 2011-12 of 0.6306 applied (OANDA, 2012). 
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The higher costs and resource utilisation between the two models is explained by the 
difference in treatment pathways beyond the initial intervention: UK practice is reflected in 
this study, while Reynolds et al. (2012) reflects US practice. Specifically, there are 
differences in length of stay between the two models. Reynolds et al. (2012) report a 
higher length of stay
8
, particularly in the intensive care unit (4 versus 0.5 days). A key 
advantage of TAVI is the reduced length of stay particularly in high dependency unit 
(HDU) compared with surgical valve replacement. However, the length of stay reported by 
Reynolds et al. (2012) is similar to the total length of stay expected for AVR (as employed 
in Chapter 4). Also, Reynolds et al. (2012) only employs evidence from the PARTNER 
trial which is an account of early experiences with early generations of the TAVI devices. 
However, over time length of stay is reducing and particularly savings in higher 
dependency units are being seen, as there are incremental innovations and movements 
along the device-clinician learning curve. This is incorporated into the model in this study 
through a reduced length of stay and subsequent lower costs.  
The costs for medical management also differ significantly between the two models. This 
reflects the difference in routine care provided for medically managed patients in the US 
compared to the UK. In the UK a proportion receive balloon valvuloplasty and all receive 
some medication.  With respect to follow up costs there are also significant differences 
reported. In the US (as indicated by Reynolds et al. (2012)) there are higher follow up 
hospitalisations, rehabilitation days etc. compared to that modelled in this study. This 
reflects differences in routine care and costs of medicine in the two jurisdictions.  
With regard to differences in life expectancy, long term evidence (beyond two years) is 
scarce for TAVI and medically managed patients. So employing PARTNER only evidence 
(as per Reynolds et al.  (2012)) and a mix of evidence (as per the model presented in this 
study) yields different projections for life expectancy from the two procedures. Reynolds et 
al.  (2012) employed a survival analysis to estimate long term survival estimates, 
employing evidence from a locked data set and parametric survival models. In addition, 
EQ-5D results directly from the patient were used to estimate QALYs. While, the model 
developed in this thesis, explicitly includes the likelihood of PREs in the longer term based 
on evidence for 1 year. These have a negative impact on life expectancy and quality of life 
following TAVI. Also, the utilities employed in the study are generally similar. For 
                                                 
8
 These length of stay estimates were not provided in the original trial results publication. 
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example, baseline utility in Reynolds et al. (2012) was 0.57 for control group and 0.59 for 
TAVI patients while the model in this thesis used a utility of 0.56 with a range of 0.55-0.58 
in the probabilistic analysis for all patients. 
The key distinctions between the models therefore lie in the perspective taken and the 
evidence sources employed. The Reynolds et al. (2012) model employs evidence from 
PARTNER B only, a US based clinical trial. This trial is subject to limitations as indicated 
by the authors themselves (Reynolds et al. 2012) and others (Schaff, 2011) such as: early 
generation devices used, centres studied had early experience and in trial practice differs 
from typical community practice. The latter was highlighted in the differences in post 
discharge care for non-TAVI patients between Reynolds et al. (2012) and model developed 
here. Aside from the caveats outlined above, employing evidence from a single trial to 
inform a cost effectiveness analysis could potentially lead to a partial and/or biased 
economic evaluation (Griffin et al., 2011). In contrast, the model developed in this thesis 
attempts to reflect current understanding of the TAVI practice, by employing data from a 
variety of sources, i.e. PARTNER B evidence and evidence from published registries and 
case studies where PARTNER evidence is unavailable. 
Another explanation for the difference in conclusions drawn lies in location. Different 
jurisdictions by their nature have different “benchmarks” and standards owing to economic 
environment, costing systems and values. That is to say, what represents value for money 
in one economy may be higher or lower compared to another. The Reynolds et al. (2012) 
model was US based, where health care costs are higher than the UK and clinical practice 
differs. Therefore, the conclusions drawn in the two models are different, despite similar 
ICERs. While Reynolds et al. (2012) concludes that TAVI is cost effective they do issue 
limitations of the study and hint that the study may not be representative to wider 
populations owing to these limitations. These limitations are that PARTNER collected on 
early experience with early device generations, care delivered in the trial differs to routine 
practice and the long term projections of survival and quality of life go beyond the time 
horizon of the trial so are subject to uncertainties (Reynolds et al. 2012). Meanwhile, the 
model developed in this thesis could not conclude that TAVI is cost effective using the UK 
national standard of £20,000 to £30,000/QALY for the cost effectiveness threshold. 
However, if a ceiling ratio of £44,000/QALY been employed in this study (as suggested by 
Reynolds et al. (2012)) it would also have found TAVI to be cost effective (72% 
probability that TAVI is cost effective – Figure 5.6).  
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While the two studies disagree on their conclusions, they agree that this is not the end as 
far as investigating the cost effectiveness of TAVI. Where this thesis contributes to the 
literature specifically is that it ventures beyond a mere statement that further evidence is 
required by providing a quantitative estimate of the potential worth of this future evidence 
and investigating potential data collection strategies through VOI, namely the estimation of 
EVPI, EVPPI and EVSI. 
Belgian Cost Effectiveness Analyses 
In addition to the PARTNER cost effectiveness analysis published by Reynolds et al.  
(2012), a cost effectiveness analysis of TAVI for inoperable patients was also conducted 
by the Belgian Health Care Knowledge Centre (Neyt et al., 2011). This study employed a 
mix of evidence from PARTNER B and Belgian resource data. Neyt et al. (2011) estimated 
an ICER of € 7,  2/QALY for the baseline model (equivalent to £ 2,700 on date of 
publication
9
 (OANDA, 2011)). As illustrated in Table 5.12, the incremental costs, QALYs 
and LYGs were higher in the Belgian analysis than those produced in the analysis in this 
thesis. The key differences evident between the two models were the cost of the TAVI 
device and procedure (€ 0,917 (£ 5,7  9 versus £18,302);  Neyt et al. (2011) employed 
EQ-5D estimates when calculating quality of life; and the following procedure related 
events (PREs) were excluded from the baseline analysis: strokes, repeat procedures, 
vascular complications and major bleeding. In the model produced in this chapter, the 
PREs had a negative impact on mortality and utility. (In the scenario analysis, the ICER 
increased to over € 0,000/QALY when repeat hospitalisations, strokes etc. were included 
(Neyt et al., 2011)).   
Despite the ICER being greater than £30,000/QALY, Neyt et al. (2011) concluded that for 
inoperable patients the benefits of TAVI do seem to outweigh the risks and so it may be 
appropriate to consider TAVI with inoperable patients. This analysis therefore had similar 
findings to the model constructed in this thesis: TAVI is more effective and more 
expensive than medical management with an ICER greater than £30,000 and less than 
£40,000/QALY. However, similar to the Reynolds et al. (2012) analysis, a different 
conclusion is drawn based on a different acceptable ceiling ratio. (Note in Belgium there is 
no nationally suggested cost effectiveness threshold ((Cleemput, 2008)). This suggests that 
                                                 
9
 Converted as per Euro – GBP exchange rate on 22nd September 2011 (date of publication) 
(OANDA, 2011) 
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there is flexibility around the cost effectiveness decision in other jurisdictions, indicating 
there is scope for promising technologies like TAVI to be considered cost-effective despite 
high ICERs.  
 
Table 5.12 Comparison of Cost Effectiveness Results with Neyt et al. (2011) 
 ∆ Costs 
(95% CI) 
LYGs  
(95% CI) 
∆ QALY 
(95% CI) 
ICER: 
Cost/LYGS 
ICER: 
Cost/QALY 
Neyt € 31,856 1.16 0.92 31,856 37,432 
 (29,900, 38,600) (0.65-1.75) (-0.29-1.90)  
  
     Neyt £* 27,829 1.16 0.92 27,829 32,700 
 (26,120 - 33,720) (0.65-1.75) (-0.29-1.90) 
   
     PARTNER B 16,183 0.30 0.43 53,399 37,390 
(12,869-19,365) (-0.11 - 0.73) (0.20 - 0.69)  
      
*Applied average EUR GBP exchange rate on 22
nd
 September 2011 (date of publication) 
(OANDA, 2011) “Neyt” are the results of the Neyt et al. (2011) cost effectiveness analysis and 
“PARTNER B” is the cost effectiveness results from the model developed in this thesis. Note only 
total incremental costs were provided in Neyt et al. (2011). 
 
Other UK Cost Effectiveness Analyses 
A study by Watt et al. (2011), published in late 2011, examined the cost effectiveness of 
TAVI amongst severe AS patients considered unsuitable for AVR. This study concluded 
that TAVI was highly likely to be considered cost effective in the UK, with an ICER of 
approximately £16,100. The analysis employed PARTNER B data where appropriate and 
other data where PARTNER B data was unavailable. For example, for device failure rates, 
results from AVR only studies were employed, elsewhere values from a clinical steering 
group were employed. Table 5.13 presents a comparison of the results from Watt et al. 
(2011) and this thesis. 
The key differences between the model employed in Watt et al. (2011) and the model 
developed and employed in this thesis, lie in QALY results. Watt et al. (2011) report 45% 
higher QALYs for TAVI patients compared with the model presented here. This difference 
can be explained by the omission of long term PREs in Watt et al. (2011). Some adverse 
events are included in the post-operative period but none thereafter. Whereas, the model 
developed in this thesis explicitly includes short and long term PREs which have a 
 193 
 
disutility attached to them. Thus, the estimation of survival following TAVI between the 
two models is different which impacts on the QALY results. However, Watt et al. (2011) 
do not report life expectancy results so it is difficult to determine how big this difference 
is. Survival estimates are also clearly different for medically management patients leading 
to an estimate of 49% higher QALYs for medically managed patients compared to Watt et 
al. (2011).  
Other differences lie in treatment of PREs and inclusion of long term costs of care. As 
mentioned above, Watt et al. (2011) only included some early PREs such as stroke, 
paravavular leaks, pacemaker implantation, major vascular events and major bleeding. 
This is considerably less than those considered in the model in this thesis. With respect to 
costs, the costs for medically managed patients are more than twice those reported in Watt 
et al.  (2011). These high costs for medical management are attributable to the long term 
costs of care and balloon valvuloplasty (83% in short run and 50% in the long run). 
Meanwhile, there is only an 8% difference in costs for TAVI between the models. Watt et 
al. (2011) also cite the lack of longer term evidence as a limitation of the study but no 
formal quantitative analysis for the value of this additional information would yield is 
included.  
 
Table 5.13 Comparison of Cost Effectiveness Results with Watt et al. (2011) 
    Costs  ∆Costs QALYs   ∆QALYs ICER: 
£/QALYs 
Watt TAVI 30,200   2.36    
  Control   5,000 25,200 0.80 1.56 £16,200 
       
PARTNER B 
Model 
TAVI 28,629   1.62    
Control 12,446 16,183 1.19 0.43 £37,930 
“Watt” are the results of the Watt et al.  (2011) cost effectiveness analysis and “PARTNER B 
Model” is the cost effectiveness results from the model developed in this thesis. 
 
Another UK, though unpublished
10
(NHS, 2012), study is also underway, employing 
PARTNER B evidence.  This is a study funded by the NIHR HTA programme to 
                                                 
10
 Report expected February 2013 NHS (2012) 
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investigate the cost effectiveness of TAVI amongst patients who cannot undergo AVR. 
Preliminary (unpublished) results (Orlando, 2011) demonstrate they too employed 
PARTNER Cohort B data and survival analysis techniques to estimate the cost 
effectiveness of TAVI compared to medical management for inoperable patients. The 
results to date conclude that TAVI appeared cost effective for treating inoperable patients 
compared to medical management. Again the authors recommend future research is 
warranted and should be conducted but it is unclear on what basis this recommendation is 
made as it was not supported by a VOI analysis. 
 
5.9 DISCUSSION 
The publication of results from the first TAVI clinical trial, the PARTNER trial, with 12 
month follow-up, provided the eagerly awaited one year outcomes for inoperable patients. 
The DAM built in Chapter 4, to estimate the cost effectiveness of TAVI for inoperable 
patients with pre-trial information, is employed here again and populated with evidence 
from the first clinical trial, to re-assess the cost effectiveness of TAVI for inoperable 
patients, in line with the iterative approach conceptualised in Chapter 2. 
Having revised the model, to reflect current understanding about the intervention and 
treatment pathways available, an ICER of £37,390 per QALY is estimated for TAVI for 
inoperable patients compared to medical management. This ICER is just outside the range 
usually considered cost effective. Comparing the results from the two versions of the 
model indicated that in both cases TAVI is more expensive but offers greater benefit than 
medical management. Comparing the 12 month results of the original model with this 
revised PARTNER B model, illustrated that both models demonstrate mortality and health 
gains for TAVI over medical management. But as the ICER is outside the range considered 
cost effective, given current information, TAVI cannot be considered cost effective for 
high risk inoperable patients.  
The additional evidence provided by the clinical trial reduced the uncertainty surrounding 
differences in QALYs between TAVI and medical management. There is still however, 
value in collecting additional information, as demonstrated in the EVPI. The EVPPI and 
EVSI indicate there is most value in collecting additional evidence on short and long term 
transition probabilities (including mortality). This additional evidence could be collected 
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via a trial or registry. The expected trial and registry costs employed in the VOI analysis 
here suggest that a registry is more cost effective. A scenario analysis demonstrated that if 
this future information reported reduced PREs, TAVI could be considered cost effective. 
The cost effectiveness analysis performed here employs the best data available at the time. 
Demand for TAVI is growing, with significant vested interests in the UK, across Europe 
and the US. It is not surprising then that others have also examined the cost effectiveness 
analysis of TAVI compared to medical management for high risk inoperable patients. The 
comparison across studies here indicates that the perspective taken and the ceiling ratio 
employed as a benchmark, influence the conclusions drawn with respect to TAVI’s cost 
effectiveness. Consequently, different conclusions have been drawn across studies though 
the ICERs are comparable.  Some recommendations however are common across the 
studies.  
Firstly, each study acknowledged the heterogeneity amongst the different patient groups 
(operable and inoperable) and the need to consider the cost effectiveness of TAVI for both. 
Subsequent to the publication of Cohort B results, PARTNER published results on 
operable patients comparing TAVI to AVR (Cohort A). This evidence is employed in the 
next chapter, along with some exchangeable evidence from PARTNER B, to re-assess the 
cost effectiveness of TAVI for high operable patients in light of the evolving evidence base 
using the DAM on an iterative basis. 
Secondly, there is a need for further information. This was quantified in this thesis, through 
a Bayesian VOI analysis, which found there is some value in collecting additional evidence 
for this patient group. As indicated in the scenario analysis performed if commentators’ 
predictions are accurate and TAVI outcomes improve over time the ICER will decrease 
and TAVI may be considered cost effective in accordance within the acceptable ceiling 
ratio in the UK.  
Thirdly, linked to the need for further information, the conclusions drawn by the cost 
effectiveness study performed here and other published analyses indicate TAVI is a 
promising technology with persistent uncertainty around outcomes. Thus, further 
information is required to reduce this uncertainty.  This is acknowledged in the guidance 
procedures published by NICE and Scottish Health Technologies Group (SHTG). Where 
subsequent to publication of the PARTNER B evidence in England and Wales, NICE 
Interventional Procedure Guidance (Number 266, 2008) still held, recommending the use 
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of TAVI only where special arrangements for clinical governance, consent, audit and 
research are in place (Thomas, 2009). There is not however an outright rejection of TAVI, 
particularly in England and Wales where decision making is non-dichotomous. Here it is 
recognised that uncertainty persists and further information is required before making an 
outright decision. Through special arrangements evidence is being collected on suitable 
cases through the UK TAVI Registry. While in Scotland, the SHTG advice statement 
(Number 005/11) does not recommended TAVI for routine treatment of patients with AS 
(SHTG, 2011).  In Scotland, where the decision making system is currently dichotomous, 
there is a negative ruling on TAVI but this is reviewed at regular intervals. Such 
recommendations confirm the predictions of the model that TAVI evidence is evolving and 
is not yet considered sufficient to recommend TAVI, uncertainty persists and further 
information is required.  
Evolving evidence presents a persistent challenge for economic evaluations of medical 
devices. This is owing to the characteristics of novel expensive medical devices in the 
early stage of the technology lifecycle like TAVI. One means of gathering this evidence, 
while not delaying access, is to design and implement a Performance Based Risk Sharing 
Agreement (PBRSA) like an Access with Evidence Development (AED) scheme. This 
could ensure that evidence is collected while controlling who gets TAVI on a simultaneous 
basis. The UK TAVI Registry, as advocated previously, is an example of such an AED 
scheme, whereby every procedure performed is recorded in the registry under the 2007 
NICE Guidance on TAVI. These schemes are complex in design and organisation. These 
challenges are discussed for TAVI in a later chapter as the evidence base evolves even 
further with the anticipated publication of two and three year outcomes from the previously 
employed registries.  
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CHAPTER 6 EVOLVING DATABASE FOR 
TRANSCATHETER AORTIC VALVE 
IMPLANTATION – INTEGRATING THE PARTNER 
TRIAL RESULTS FOR OPERABLE PATIENTS  
 
6.1 INTRODUCTION 
While some short term efficacy and effectiveness results of TAVI for high risk operable 
patients have been published, AVR remains the standard therapy for treating severe AS 
(Smith et al., 2011). For example, in England and Wales, the National Institute of Clinical 
Excellence (NICE) Interventional Procedure Guidance (Number 266, 2008) (NICE, 2011) 
recommends the use of TAVI only where special arrangements for clinical governance, 
consent, audit and research are in place. While in Scotland, the Scottish Health 
Technologies Group (SHTG) advice statement (Number 005/11) does not recommended 
TAVI for routine treatment of patients with severe AS (SHTG, 2011). However, owing to 
the characteristics of novel expensive medical devices it is anticipated that their evidence 
evolves over time. After which, procedure guidance and advice statements can be reviewed 
and revised accordingly.   This is demonstrated here for high risk inoperable AS patients 
with publication of the first TAVI RCT, PARTNER.  
In light of this evolving evidence, the cost effectiveness of TAVI compared to AVR and 
medical management is re-evaluated here. This provides the opportunity to re-consider the 
adoption decision, in an iterative manner to reflect the current understanding of TAVI in 
practice, for high risk operable patients. A Bayesian value of information (VOI) analysis is 
also performed to re-assess the research priority setting decision. How the data is 
incorporated into the model and the cost effectiveness analysis results of TAVI using the 
new evidence are presented here to determine whether TAVI can be considered cost 
effective for high risk operable patients and given updated evidence whether there is value 
in collecting additional evidence. The revised results are compared to the original model 
for high risk operable patients as well as other cost effectiveness analysis.  
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6.2 TRANSCATHETER AORTIC VALVE IMPLANTATION’S 
EVOLVING EVIDENCE BASE 
As outlined in Chapter 5, the first results from the first TAVI RCT, the Placement of 
Aortic Transcatheter Valves (PARTNER), were published in 2010. The trial commenced 
in April 2007 and was sponsored by Edwards Lifesciences. All of the patients enrolled had 
severe AS and were in New York Heart Association (NYHA) classes greater than I (see 
Table 3.1) (Leon et al., 2010). In the trial, Cohort A compared TAVI with surgical valve 
replacement (AVR). Given the treatment choices and risk profile, this cohort corresponds 
to high risk operable patients in Chapter 4.  
Initially, 699 patients were allocated to the two cohorts for randomisation. Of these, 348 
patients were randomised into the TAVI arm and 351 into the AVR arm.  Following 
randomisation, 38 patients withdrew from the AVR arm, leaving 313 receiving the 
procedure. Similarly, four patients allocated to the TAVI arm withdrew from the trial, 
leaving 344 patients receiving the TAVI procedure. After 30 days, 22 patients who 
received AVR had died, while only 12 TAVI patients died during the same period.  
Figure 6.1 PARTNER Trial Cohort A Patient Flow Operable Patients: TAVI 
versus AVR 
 
Source: Adapted from Smith et al. (2011) :(S)28 
30 Days 
 
Operable Patients 
Randomised 
N =699 
TAVI 
N = 344 
AVR 
N = 313 
Dead = 12 
N = 332 
Dead = 22 
N =291 
Dead = 72 
N = 260 
 
 
Dead = 67 
N=246 
 
 
1 Year 
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Thus, at 30 day follow up information on the clinical endpoints were available for those 
who had died; 291 surviving AVR patients and 332 surviving TAVI patients. Between 30 
days and one year a further 67 patients died in the AVR arm. From the TAVI arm a further 
72 patients died in the same period. Thus, at one year follow up information on the 
endpoints were available for those who died; 246 AVR surviving patients and 260 
surviving TAVI patients. This evidence is used to update the transition probabilities as the 
TAVI DAM model is employed in an iterative manner. 
 
6.3 INCORPORATING EVIDENCE FROM PARTNER 
COHORT A – HIGH RISK OPERABLE PATIENTS  
6.3.1 Changes to the Decision Analytical Model 
As the PARTNER trial was the first to consider AVR compared to TAVI directly, 
evidence from the trial updates knowledge and understanding of the procedures and the 
disease pathways. This affords the opportunity to reflect the heterogeneity between 
technologies and make some structural changes to the decision tree. The latter being the 
inclusion of conversions from AVR to TAVI and TAVI to medical management and repeat 
TAVI (the latter two changes were made in Chapter 5 for inoperable patients also). These 
changes are illustrated on Figure 6.2 below. 
 
As per the model for inoperable patients, evidence and experience from the PARTNER 
trial did not result in any structural amendments to the Markov model but did offer the 
distinction between major and minor late procedure related events (PREs) (the latter incur 
a cost and utility hit only and do not result in valve failure) and provided revised point 
estimates. Prior to the PARTNER trial, experience with TAVI was limited, particularly on 
late outcomes. The PARTNER trial has therefore revised knowledge and understanding of 
the intervention beyond the initial 30 day in-hospital period. 
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Figure 6.2 Revised Decision Analytical Model: Short Term Component – The 
Decision Tree 
 
 
6.3.2. Parameterisation of the Decision Analytical Model for High 
Risk Operable Patients  
Transition Probabilities 
Cohort A of the PARTNER Trial compared TAVI with AVR for severe high risk operable 
AS patients. Extracting the outcomes and clinical endpoints from Smith et al. (2011) for 30 
days and 1 year (pre model data is presented in Appendix V, Table c) permitted the 
revision of the parameters used in the model,  thus reflecting the best data available. So 
PARTNER A evidence, where available, replaced previously employed evidence from the 
literature.  A “replacement” strategy was adopted as PARTNER Cohort A evidence 
reflected the best available data at the time of analysis. As the original model was 
populated with early short term TAVI results and AVR experience, an “updating” strategy 
would not have reflected best data available at the time. (Recall that the original model was 
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populated with very early TAVI experience and experiences with AVR.) Where 
PARTNER Cohort A did not provide evidence, the point estimates employed in the 
original model were maintained. The provision of evidence directly on TAVI from 
PARTNER Cohort A eliminated the need for the relative risk parameters employed in 
Chapter 4 
The revised transition probabilities were calculated as follows. Using the evidence 
presented in Smith et al. (2011) (Appendix V Table c) the number of times each event 
occurred was identified (α). The total number of times that an event could have occurred 
was estimated as the number at risk of that event (i.e. by removing those who died, 
converted and withdrew during the time frame in the data set (n)). The probability of each 
event occurring was estimated as the number of events that did occur (α) as a proportion of 
the total that could have occurred (n). Box 6.1 provides an example of this using major 
bleeding. The data set reported 32 cases of major bleeding within 30 days for TAVI 
patients and 49 major bleeding within one year. It was deduced that 17 cases of major 
bleeding occurred post discharge up to one year. The arm consisted of 344 patients, nine of 
whom converted to AVR and five who converted to medical management; thus 330 
patients received the procedure. The probability of having a major bleeding in the first 30 
days was the proportion of events which did occur (α = 32) from the total that could have 
occurred (n = 330), 0.097 (α/n, 32/330). The probability of having a major bleed in the 
longer term was estimated in a similar manner. Where the number of events that occurred 
(α = 17) estimated as a proportion of the total that could have occurred (n = 245), 0.069 
(α/n, 17/245). Using this method for all other events the point estimates for the DAM were 
re-calculated to incorporate the PARTNER A data.  
PARTNER A provided no evidence on medical management, which is also considered a 
treatment option in the model for high risk, operable patients in this thesis. The original 
model did not account for balloon valvuloplasty and had a 100% survival rate within the 
first 30 days, based on expert opinion. However, prior to publication of PARTNER Cohort 
A results, PARTNER Cohort B results were published (Leon et al., 2010) which provided 
estimates of mortality (0.04) and provision of balloon valvuloplasty for medical managed 
patients (0.83) within first 30 days. While the patients in the PARTNER Cohort B were 
considered high risk inoperable and, as such, are not the same as those considered high risk 
operable, these outcomes do update current knowledge and understanding of the medical 
management treatment. Thus, exchanging information between the two cohorts facilitates 
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the incorporation of the optimum evidence into the model to best reflect current practice. 
In the absence of other evidence, it was assumed that the data is directly exchangeable and 
medical management outcomes are the same for all patient risk groups.  
Box 6.1 Example of Probability of Procedure Related Event Calculation for 
Operable Patient Group 
     
 Randomised to TAVI  344  
 Conversion to AVR  9  
 Conversion to Medical Management  5  
 Received TAVI Procedure (n)  330  
     
 Major Complications, Major Stroke or Death w/in 30 days 85  
 Functioning Valve Replacement after 30 days (n)  245  
     
 TAVI: Major Bleeding - 30 days (α)  32  
 TAVI: Major Bleeding - Within 1 Year  49  
 TAVI: Major Bleeding - Post Discharge to 1 year (α)  17  
     
 Probability of Major Bleeding - 30 days (α/n)  (32/330) 0.097  
 Probability of Major Bleeding - Post Discharge to 1 year (α/n)  (17/245) 0.069  
 
Decision Tree 
Using the PARTNER evidence to estimate the transition probabilities in the short term 
model provided the following revised probabilities. As one patient from a potential 313 
patients converted from AVR to TAVI the probability of converting was 0.003 (1/313). 
With respect to major stroke within the first 30 days, 19 patients out of 312 had a major 
stroke giving a probability of a major stroke following AVR of 0.03. With respect to all-
cause mortality within 30 days following AVR, 22 patients out of 312 died giving a 
probability of 0.07. With respect to early PREs, there was a 0.05 probability of major PREs 
occurring following AVR and a 0.33 chance of minor PREs. These PREs are estimated by 
summing the probabilities of the individual PREs, shown in Table 6.2. 
For the TAVI arm, the likelihood of converting to AVR was 0.03, as nine patients from a 
potential 344 converted. Meanwhile, five patients out of a potential of 344 converted from 
TAVI to medical management, giving a probability of converting of 0.01. There is also a 
small chance that the TAVI procedure will have to be repeated. In the PARTNER Cohort 
A trial, seven out of 344 patients had to have a repeat TAVI procedure (0.02). Within the 
first 30 days, 12 patients had died from all causes within 30 days, giving a probability of 
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0.04. While for the same period, 19 patients suffered a stroke after TAVI, giving a 
probability of 0.06. The likelihood of early major PREs is 0.16 and early minor PREs 0.38 
following TAVI. These PREs are estimated by summing the probabilities of the individual 
PREs shown in Table 6.2.  
Finally, for the medical management arm the probability of death from all causes is 0.04 
and the likelihood of requiring a balloon valvuloplasty is 0.83 (these estimates are 
informed by PARTNER Cohort B evidence presented in Chapter 5).  
Markov Model  
The late PREs for the long term model are estimated by summing the probabilities of the 
individual PREs shown in Table 6.2. The probability of late fatal PREs was 0.10, late 
major PREs were 0.11 and late minor PREs were 0.22, following AVR. For the TAVI arm 
the probability of late fatal PREs was 0.12, late major PREs was 0.18 and late minor PREs 
was 0.28.  
One limitation of the PARTNER A results is that they are for 12 months duration only. 
While it was feasible to isolate a mortality from natural causes and mortality from the 
functioning and persistent AS /failed valve replacement state for one year these were 
employed in the first cycle only. For AVR patients, death from the functioning valve 
replacement state was 0.14, while death from persistent AS /failed valve replacement state 
was 0.18. While for TAVI patients, death from the functioning valve replacement state was 
0.15, while death from persistent AS /failed valve replacement state was 0.08. This allows 
for differentiation between technologies. Applying different mortality rates for the same 
state reflects the longer term implications of each treatment, which differ.  
Subsequent cycles (beyond one year) employed the natural mortality rate adjusted for age-
sex and disease and a probability of death from persistent AS /failed valve replacement 
state of 0.33 (Legrand et al., 1991), as per the original model. These probabilities were 
employed so as to reflect the life-stage of the patients and to account for the diminishing 
benefits of the valve procedure, as forecasted by Smith (2011). For medically managed 
patients in each cycle, the probability of death from the persistent AS /failed valve 
replacement state employed was 0.33 (as per (Legrand et al., 1991). These transition 
probabilities for the short and long term model are presented in Tables 6.1. All of the 
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transition probabilities provided on Tables 6.1-2 represent absolute risk for each arm of the 
model, AVR, TAVI and medical management. 
As per the original model, the uncertainty surrounding each of the parameters was 
incorporated into the model through the assignment of probability distributions (shown in 
Tables 6.1-2). The PARTNER Cohort A results identified the total number of patients and 
the number for whom events occurred. This information was used to specify a beta 
distribution for each probability.  
Where the PARTNER results did not provide information on an event occurring, the 
original estimate, as calculated in Chapter 4, was maintained (as per Chapter 5). This was 
the case for cardiac tamponade in estimating early major PREs and access site events for 
early minor PREs. Where for each event the number of cases per study was pooled across 
and divided by the total number of patients to give the probability of that event occurring. 
With respect to late PREs, the original estimate for hospitalisations was used. For early 
major PREs evidence was scarce prior to PARTNER so evidence from AVR studies was 
included also. Here the total number of patients was pooled from all the studies (AVR and 
TAVI together) and the average was estimated. Also, where no incidences of an event 
occurring were reported but expert opinion and priors indicated it may occur a small 
amount is added to the data for each event in order to adjust for those with an observed 
zero probability to allow for the small chance of such events occurring (see Table 5.3 for 
further  details of the calculation).   
Cost Parameters 
In the cost analysis the value of the following resources were estimated: TAVI, AVR and 
medical management devices; procedures; length of stay; hospitalisations and other costs 
incurred with PREs. No additional information on the cost of the TAVI, AVR or medical 
management procedure was provided in the published PARTNER A results. So the costs as 
per the original model are maintained but updated to reflect 2010 prices using purchasing 
power parity (Officer and Williamson, 2011)
11
.  
PARTNER A did however provide information on length of stay for patients in the 
operable arm. For AVR patients the length of stay in the intensive care unit reported was 
                                                 
11
 The costs as per Chapter 4 were employed but updated to reflect 2010 prices. 
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five days and seven days on the general ward. For TAVI patients PARTNER A reported 
three days in intensive care and eight days in the general ward. The revised cost of hospital 
stay for AVR patients was £10,142 and for TAVI patients £6,257. PARTNER A also 
provided data on the proportion of patients per NYHA class. These were used to update the 
probability of requiring hospitalisations in the long term model, which was used to 
estimate the cost of the functioning valve replacement and AS/Failed valve replacement 
states. While the cost of the functioning valve state for AVR patients was £1,561 and for 
TAVI patients was £1,514. The difference is explained by the two percentage point 
difference in probability of requiring hospitalisations (0.07 versus 0.05 for AVR and TAVI 
respectively).   The cost of the persistent AS/failed valve replacement state was £8,214 for 
AVR patients and £8,295 for TAVI patients. The variation is explained by the difference in 
probability of requiring hospitalisations (0.71 versus 0.78 for AVR and TAVI respectively, 
determined by NYHA classification) when the valve is no longer offering benefits to 
utility.  
These state and procedural costs are presented in Table 6.3, along with the distributions 
applied to the unit costs and resources consumed. Normal distributions were applied to 
procedure related costs, hospitalisation costs and post discharge care costs. With respect to 
the amount of resources consumed, a normal distribution was applied to the length of stay 
parameters and beta distributions to the probability of requiring post discharge care and 
resources consumed in each health state.  
The costs of the PREs were estimated as previously (but updated to reflect 2010 prices 
using purchasing power parity (Officer and Williamson, 2011) as per Chapter 5), with a 
weight assigned to each event and the unit cost. The PARTNER Cohort A data provided no 
additional unit cost information but the weights (which are a proportion of each event 
occurring) were updated to reflect the revised probabilities (Table 6.2)). The cost of major 
and PREs following AVR with the first 30 days were £1,055 and £781 respectively. 
Following TAVI, the cost of major and minor PREs within the first 30 days was £367 and 
£819. The cost of late major and minor PREs occurring after 30 days but within one year 
following AVR were £2,707 and £2,341. Following TAVI the cost of late major and minor 
PREs occurring after 30 days but within one year were £2,700 and £2,594 respectively. 
Normal distributions were applied to cost of treating PREs. Again here the costs are 
discounted at a rate of 3.5%. 
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Table 6.1 Transition Probabilities for TAVI Decision Analytical Model 
Updated for PARTNER A  
Transition Probability Distribution Probability                               
(95% CI) 
α β n 
Short term - 0-30 days      
Probability of converting from TAVI 
to AVR
¶ 
Beta 0.03                                  
(0.01-0.04) 
9 335 344 
Probability of converting from TAVI 
to  medical management
¶ 
Beta 0.01                                  
(0.00-0.03) 
5 339 344 
Probability of converting from AVR to 
TAVI
¶ 
Beta 0.003 
(0.00-0.12) 
1 312 313 
Probability of repeat TAVI procedure
¶ Beta 0.02                                              
(0.01-0.04) 
7 337 344 
Probability of major stroke following 
AVR
¶ 
Beta 0.03                                  
(0.01-0.05) 
8 304 312 
Probability of major stroke following 
TAVI
¶ 
Beta 0.06                                  
(0.03-0.08) 
19 311 330 
Probability of death 30 days all causes 
AVR
¶ 
Beta 0.07         
(0.04-0.10) 
22 290 312 
Probability of death 30 days all causes 
TAVI
¶ 
Beta 0.04                                  
(0.02-0.06) 
12 332 344 
Probability death 30 days all causes 
medical management‡ 
Beta 0.04                                  
(0.01-0.07) 
5 133 138 
Probability of balloon valvuloplasty 
medical management 
Beta 0.83 
(0.76-0.88) 
114 24 138 
Probability of early major PRE AVR Beta 0.05 
(0.02-0.07) 
Table 6.2 
 
Probability of early major PRE TAVI Beta 0.16 
(0.12-0.21) 
 
Probability of early minor PRE AVR Beta 0.33 
(0.29-0.40) 
 
Probability of early minor PRE TAVI Beta 0.38 
(0.31-0.44) 
 
Long term - post 30 days      
Probability PRE fatal (AVR)
 ¶ Beta 0.10                                  
(0.06-0.14) 
26 242 268 
Probability PRE fatal (TAVI)
 ¶ Beta 0.12                                 
(0.08-0.17) 
30 215 268 
Probability PRE late major (AVR) Beta 0.11 
(0.08-0.16) 
Table 6.2 
 
Probability PRE late major (TAVI) Beta 0.18 
(0.13-0.24) 
 
Probability PRE late minor (AVR) Beta 0.22 
(0.17-0.27) 
 
Probability PRE late minor (TAVI) Beta 0.28 
(0.22-0.35) 
 
Probability death from AS state - 
AVR
¶ ^ 
Beta 0.18                                  
(0.05-0.36) 
4 18 22 
Probability death from AS state - 
TAVI
¶^ 
Beta 0.08                                  
(0.03-0.15) 
6 67 73 
Probability death from AS state - 
Medical Management*^ 
Beta 0.33                          
(0.25-0.41) 
44 94 138 
Probability death from AS state – Post 
1 year* 
Beta 0.33                          
(0.24-0.42) 
33 67 100 
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Table 6.1 Continued      
Transition Probability Distribution Probability                               
(95% CI) 
α β n 
Morality from natural causes - AVR
¶¤ Beta 0.14                                  
(0.10 - 0.18) 
37 231 268 
Mortality from natural causes - TAVI
¶¤ Beta 0.15                                 
(0.10 -0.19) 
36 209 245 
Mortality from natural causes Log normal † - -  
Relative Risk of Death from AS Log normal 1.50 
(0.95-2.25) 
 
0.38 0.22  
¶ (Smith et al., 2011)  *(Legrand et al., 1991) † Standard life tables ‡(Leon et al., 2010)^ Only 
applied in year 1, there after Probability of death from AS state – Post 1 year is used ¤ Only applied 
in year 1, there after mortality from natural causes adjusted for AS is used. α   number of events 
occurring. β  n- α (where n is the number of events which could have occurred).  
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Table 6.2 Procedure Related Events Probabilities for TAVI Decision 
Analytical Model Updated for PARTNER A 
Procedure Related Events Dist Probability 
(95% CI) 
Weight α β n 
Major PREs AVR     
Valve Thromboembolism
¶ beta 0.00 0.00 0 312 312 
Major paravavular leak
¶ beta 0.01 0.14 2 310 312 
Endocarditis
¶ beta 0.00 0.07 1 311 312 
Cardiac tamponade* beta 0.03 0.65 9 303 312 
Myocardial infarction
¶ beta 0.01 0.14 2 310 312 
Total  0.05 
(0.02-0.07) 
   
Major PREs - TAVI     
Valve Thromboembolism
¶ beta 0.03 0.17 9 321 330 
Major Paravavular leak
¶ beta 0.11 0.64 35 295 330 
Endocarditis
¶ beta 0.00 0.00 0 330 330 
Cardiac tamponade† beta 0.03 0.19 10 320 330 
Myocardial infarction
¶ beta 0.00 0.00 0 330 330 
Total  0.16 
(0.12-0.21) 
    
Minor PREs - AVR     
Access site events* beta 0.04 0.12 12 300 312 
Vascular Events
¶ beta 0.01 0.02 2 310 312 
Pacemaker implantation
¶ beta 0.04 0.12 12 300 312 
Major Vascular Event
¶ beta 0.04 0.11 11 301 312 
Major Bleeding
¶ beta 0.21 0.64 67 245 312 
Total  0.33 
(0.29-0.40) 
    
Minor PREs - TAVI     
Access site events† beta 0.06 0.16 20 310 330 
Vascular Events
¶ beta 0.06 0.17 21 309 330 
Pacemaker implantation
¶ beta 0.04 0.10 13 317 330 
Major Vascular Event
¶ beta 0.12 0.31 38 292 330 
Major Bleeding
¶ beta 0.10 0.26 32 298 330 
Total  0.38 
(0.31-0.44) 
   
Probability late PREs* - AVR     
Valve Thromboembolism* beta 0.07 0.59 18 250 268 
Major paravavular leak
¶ beta 0.01 0.10 3 265 268 
Endocarditis
¶ beta 0.01 0.07 2 266 268 
Cardiac tamponade* beta 0.01 0.09 3 265 268 
Stroke 
¶ beta 0.02 0.16 5 263 268 
Myocardial infarction
¶ beta 0.00 0.00 0 268 268 
Total  0.11 
(0.08-0.16) 
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Table 6.2 Continued       
Procedure Related Events Dist Prob 
(95% CI) 
Weight α β n 
Probability late PREs* TAVI     
Valve Thromboembolism† beta 0.07 0.37 17 228 245 
Major paravavular leak
¶ beta 0.06 0.33 15 230 245 
Endocarditis
¶ beta 0.01 0.04 2 243 245 
Cardiac tamponade† beta 0.01 0.05 2 243 245 
Stroke 
¶ beta 0.03 0.18 8 237 245 
Myocardial infarction
¶ beta 0.00 0.02 1 244 245 
Total  0.18 
(0.13-0.24) 
   
Late minor PREs AVR     
Repeat hospitalisations 
¶ beta 0.12 0.57 33 235 268 
Major vascular complications 
¶ beta 0.00 0.02 1 267 268 
Minor vascular complications 
¶ beta 0.01 0.03 2 266 268 
Major bleeding 
¶ beta 0.07 0.31 18 250 268 
New pacemaker 
¶ beta 0.01 0.07 4 264 268 
Total  0.22 
(0.17-0.27) 
    
Late minor PREs TAVI     
Repeat hospitalisations 
¶ beta 0.18 0.63 43 202 245 
Major vascular complications 
¶ beta 0.00 0.01 1 244 245 
Minor vascular complications 
¶ beta 0.01 0.03 2 243 245 
Major bleeding 
¶ beta 0.07 0.25 17 228 245 
New pacemaker 
¶ beta 0.02 0.09 6 239 245 
Total  0.28 
(0.22-0.35) 
 
    
¶(Smith et al., 2011) * (Gehlot et al., 1996, Gilbert et al., 1999, Milano et al., 1998, Aupart et al., 
2006, Eichinger et al., 2008)  †See Table 5.    α   number of events occurring. n = number of 
events which could have occurred β  n- α. 
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Table 6.3 Cost Parameters for TAVI Decision Analytical Model Revised for 
PARTNER A 
COSTS Dist Unit 
Cost £ 
SE Dist   Total Cost 
£ (95% CI) 
Short term costs         
AVR Device  2,045*      £2,045 
AVR Procedure normal 3,660* 300     £3,660 
         
In hospital stay  -AVR     LOS 
D SE  
ICU normal 1,728† 300 normal 5¶ 0.19 8,639 
General Ward normal 215† 50 normal 7¶ 0.04 1,503 
       10,142 
(6,875-12,988) 
In hospital stay -TAVI    LOS 
D SE   
ICU normal 1,728† 300 normal 3¶ 0.19 5,183 
General Ward normal 215† 50 normal 8¶ 0.04 1,073 
       6,257 
(4,242-8,013) 
Post Discharge Care- AVR    Prob α β  
Cardiac Rehab normal 3006* 500 beta 0.90* 90 10 2,705 
Nursing home normal 873+ 50 beta 0.50* 50 50 437 
        3,142  
(2,177-3,995) 
Post Discharge Care - TAVI        
Cardiac Rehab normal 3006* 500 beta 0.10* 10 90 300 
Nursing home normal 873+ 50 beta 0.23* 23 77 201 
        501 
(347-637) 
Long term costs         
Cost of Functioning Valve Replacement AVR     
Hospitalisations  3,390*  beta 0.07
¶‡ 20 270 231 
Nursing home  11,382
+  beta 0.10
* 76 681 1,138 
Drug Therapy  192*      192 
        1,561 
(1,282-1,794) 
Cost of Functioning Valve Replacement TAVI      
Hospitalisations  3,390*  beta 0.05
¶‡ 17 301 184 
Nursing home  11,382
+  beta 0.10
* 76 681 1,138 
Drug Therapy  192*      192 
        1,514 
(1,243-1,743) 
Cost of Failed Valve Replacement AVR       
Hospitalisations  3,390*  beta 0.78
¶‡ 226 64 2,641 
Nursing home  11,382
+  beta 0.50
* 379 379 5,691 
Drug Therapy  192*      192 
        8,214 
(7,915-8,770) 
Cost of Failed Valve Replacement TAVI       
Hospitalisations  3,390*  beta 0.71
¶ ‡ 225 92 2,412 
Nursing home  11,382
+  beta 0.50
* 379 379 5,691 
Drug Therapy  192*      192 
        8,295  
(7,681-8,537) 
* (Kennon et al., 2008) 
+
 (Netten, 1996) †(Kalra et al., 2005, Kennon et al., 2008, NHS, 2008a)  ¶ 
(Smith et al., 2011) ‡ Based on hospitalisations by NYHA class. D Days 
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Quality of Life Parameters 
As per the original model QALYs were also derived for each health state adjusting for the 
condition, the procedure and PREs. PARTNER Cohort A (Smith et al., 2011) also 
published evidence on NYHA classification of patients. This permitted a re-estimation of 
the proportion of patients per class to revise the utility of functioning valve replacement 
and persistent AS/failed valve replacement states (in line with the revised transition 
probabilities). As PARTNER Cohort A (Smith et al., 2011) provided different proportions 
of patients in NYHA classifications for TAVI and AVR patients, different utilities for the 
functioning valve replacement state for each procedure could be estimated. This captures 
the heterogeneity between treatments.  The utility associated with AS or persistent AS was 
0.55. While the utility associated with the functioning valve replacement state following 
AVR was 0.75 and following TAVI was 0.78. Table 6.4 presents the expected utilities 
employed in the model and the range employed in the probabilistic analysis. Normal 
distributions were applied to the disutility hits associated with the PREs, while Dirichlet 
distributions were applied to the disutility associated with each NYHA classification. 
Again here the QALYs were discounted at 3.5%. 
As with the costs, the impact on utility associated with the PREs were adjusted to account 
for the revised probabilities of events occurring. The utility hit associated with major and 
minor PREs within one year following AVR were 0.03 and 0.04 respectively. Following 
TAVI, the utility hit associated with major and minor PREs within one year were 0.04 and 
0.03 respectively. With respect to late major and minor PREs the utility hit was 0.04 and 
0.02 for both TAVI and AVR. 
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Table 6.4 Utilities by NYHA Class for TAVI Decision Analytical Model Revised 
for PARTNER Cohort A 
NYHA Class Dist Utility* Proportion¶ Utility 
(95% CI) 
Utility of AS      
I Dirichlet 0.815 0.00 0.00 
II Dirichlet 0.720 0.05 0.04 
III Dirichlet 0.590 0.43 0.25 
IV Dirichlet 0.508 0.52 0.26 
    0.55 
( 0.55-0.56) 
Utility of Functioning Valve Replacement AVR    
I Dirichlet 0.815 0.55 0.45 
II Dirichlet 0.720 0.30 0.22 
III Dirichlet 0.59 0.13 0.08 
IV Dirichlet 0.508 0.02 0.01 
    0.75 
(0.74-0.76) 
Utility of Functioning Valve Replacement TAVI   
I Dirichlet 0.815 0.72 0.59 
II Dirichlet 0.72 0.19 0.14 
III Dirichlet 0.59 0.08 0.05 
IV Dirichlet 0.508 0.02 0.01 
    0.78 
(0.77-0.78) 
*(Maliwa et al., 2003) ¶(Smith et al., 2011) 
 
 
6.3.3. Analysis – High Risk Operable Patients 
Similar to the analyses conducted in Chapters 4 and 5, the economic evaluation here is 
undertaken from the perspective of the UK NHS. A Monte Carlo simulation with 10,000 
iterations is used to propagate the uncertainty in the individual model parameters (reflected 
by the probability distributions assigned) through the model to produce a distribution of 
expected costs and expected QALYs associated with each procedure. The mean values of 
these distributions are used to calculate the incremental cost effectiveness ratio (ICER) in 
terms of the expected incremental costs associated with TAVI compared to AVR and 
medical management per incremental QALY gained. The uncertainty associated with the 
incremental costs and incremental QALYs are presented through incremental cost 
effectiveness (ICE) planes. The uncertainty associated with the cost effectiveness of TAVI 
compared to AVR and medical management is presented in terms of a cost effectiveness 
acceptability curve (CEAC), to re-assess the adoption decision. Following this a Bayesian 
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VOI analysis is performed to estimate the value of collecting further information, given 
current, revised information. This corresponds with the research priority setting decision. 
 
6.4 COST EFFECTIVENESS ANALYSIS RESULTS – HIGH 
RISK OPERABLE PATIENTS 
When the DAM is revised to incorporate the best data available, including data from 
PARTNER Cohort A, the results indicate only a 3% reduction in all-cause mortality at the 
end of year one between TAVI and AVR. This is consistent with the 3% reported from 
PARTNER by Smith et al. (2011). Meanwhile, the model predicts a 33% reduction in all-
cause mortality at the end of year one between AVR and medical management. The 
survival estimates (Figure 6.3) illustrate the initial sharp decline, followed by a diminishing 
decrease for AVR and TAVI patients. This may be attributable to the underlying patient 
characteristics, especially age and co-morbidities, which dominate the benefits of the valve 
replacement over time.  
Figure 6.4 illustrates the difference in quality of life between the three treatment groups. 
For the first two years TAVI is marginally better than AVR and both are considerably 
better than medical management. Between years two and six AVR is better than TAVI, 
possibly owing to the rate of late PREs and mortality rates. After six years the model 
predicts that patients who received TAVI will have similar quality adjusted life years to 
AVR patients until death. Particularly, after year ten all patients have similar quality of 
life, irrespective of treatment. Again, this may be attributable to the underlying patient 
characteristics, which can over-ride the benefits of the valve replacement over time.  
 
6.4.1 Deterministic Cost Effectiveness Results 
The cost effectiveness of TAVI compared to AVR and medical management was estimated 
for operable patients based on a mix of evidence from the PARTNER Cohort A trial and 
the original estimates from the literature, as discussed earlier. The deterministic cost 
effectiveness results (Table 6.5) were estimated using the point estimates for the transition 
probabilities, costs and utilities presented in the previous section. The results illustrate that 
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for high risk patients TAVI is more costly (£6,995) and less effective (-0.11 QALYS) than 
AVR. As TAVI is more expensive and less effective than AVR, TAVI is dominated by  
 
Figure 6.3 Survival Estimates for AVR, TAVI and Medical Management 
 
 
Figure 6.4 Quality Of Life Estimates for AVR, TAVI And Medical Management 
Per Patient 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Su
rv
iv
al
 R
at
e
 
Years 
AVR
TAVI
Medical Management
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Q
u
al
it
y 
A
d
ju
st
e
d
 L
if
e
 Y
e
ar
s 
Years 
AVR QALYS
TAVI QALYS
Medical Management QALYS
 215 
 
Table 6.5 Cost Effectiveness Results: High Risk Operable Patients - AVR versus TAVI versus Medical Management 
 
 LYs Costs (£) Change in Costs QALYs Change in QALYS ICER 
 
 (95% CI)  (95% CI)  £/QALY 
Deterministic Results      
Medical Management 2.92 18,681  1.51   
AVR 3.45 29,561 10,880 2.18 0.67 16,276 
TAVI 3.45 36,557 6,995 2.07 -0.11 TAVI Dominated 
       
Probabilistic Results      
Medical Management 2.96  
(2.43-3.70) 
19,012  
(14,570-24,797) 
 1.54 
 (1.28-1.87) 
  
AVR 3.49 
(2.99-4.08) 
29,695 
 (25,657-34,082) 
10,684 
 (5,424-15,696) 
2.20  
(1.92-2.52) 
0.66  
(0.33-1.00) 
16,118 
TAVI 3.44  
(2.96-4.06) 
36,813  
(32,974-41,435) 
7,117 
(3,802-10,605) 
2.09  
(1.83-2.40) 
-0.11 
(-0.41-0.17) 
TAVI Dominated 
       
 
 216 
 
AVR and cannot be considered cost effective. With respect to AVR compared to medical 
management, AVR is more expensive (£10,880) and more effective (0.67 QALYs). The 
ICER is estimated at £16,276, which is within the range usually considered cost effective 
in the UK (£20,000-£30,000 per QALY  (Rawlins et al., 2009)).  Therefore, compared to 
medical management, AVR is cost effective in treating severe AS amongst high risk 
operable patients.  
 
6.4.2 Probabilistic Cost Effectiveness Results 
The probabilistic cost effectiveness results (Table 6.5) reveal that TAVI is more expensive 
(£7,117; 24%) and less effective (-0.11; 5%) than AVR, and is dominated by AVR. The 
incremental cost effectiveness (ICE) plane (Figure 6.5) illustrates the existence and extent 
of uncertainty surrounding the incremental cost and effect (measured by QALYs) by 
plotting the additional benefits and costs of the TAVI procedure over AVR. As the ICE 
plane shows there is uncertainty surrounding the existence of differences in effectiveness 
of TAVI compared to AVR. There is also uncertainty surrounding the extent of differences 
in effects and costs of AVR versus TAVI for high risk operable patients owing to 
uncertainty surrounding the PREs. However, there is little uncertainty about the existence 
of differences in costs, with TAVI being more expensive than AVR. This is driven by the 
cost of the TAVI device.  
In addition, in comparing AVR with medical management for high risk operable patients 
the ICER is £16,118 per QALY gained (Table 6.5). This is below the ceiling ratio level 
usually considered cost effective (£20,000-£30,000 per QALY  (Rawlins et al., 2009)).  So 
while AVR is more expensive (£10,684), it generates substantively higher benefits (0.66 
QALYs) than medical management, so is considered cost effective compared with medical 
management. The ICE plane (Figure 6.5b) shows there is some uncertainty with respect to 
the existence of differences in costs and effectiveness. The majority of co-ordinates are in 
the north-eastern quadrant, indicating that AVR is more expensive and offers greater health 
benefit than medical management. There is however considerable uncertainty surrounding 
the extent of differences in effects and costs (AVR versus medical management) for high 
risk operable patients. The higher cost is explained by the cost of the AVR device, 
procedure and in hospital stay and the greater benefit is owing to the mere transient relief 
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that medical management offers. Meanwhile, the extent of the differences is owing to 
uncertainty surrounding the PREs following AVR. 
The CEAC (Figure 6.6) shows the uncertainty surrounding the cost effectiveness of each 
procedure by plotting the probability of TAVI, AVR and medical management being cost 
effective against a range of ceiling ratios. For example, at a ceiling ratio of £30,000 per 
QALY the probability that AVR is cost effective is 98.7%, the probability that TAVI is 
cost effective is 0.2% and that medical management is cost effective is 1.1%. The vertical 
line is the ICER (£16,118) for AVR versus medical management, which is within the range 
considered cost effective.   
 
Figure 6.5 Incremental Cost Effectiveness Plane: High Risk Operable 
Patients  
a) TAVI versus AVR    b) AVR versus Medical Management 
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Figure 6.6 Cost Effectiveness Acceptability Curve: High Risk Operable 
Patients - TAVI versus AVR versus Medical Management 
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learning curve etc. (as discussed in Section 1.2.1). These estimates provide a maximum 
value for the return on further research, indicating there is some value in collecting further 
information on per patient basis here. This modest pEVPI corresponds with the little 
decision uncertainty present in the cost effectiveness analysis.  
As shown on Figure 6.7, the pEVPI reaches a point of inflection at a ceiling ratio equal to 
the ICER £16,118/QALY. This corresponds to the CEAC (Figure 6.6) where at ceiling 
ratio of £16,118/QALY, the decision between AVR and medical management is most 
uncertain. Here the probability that AVR is cost effective is 0.51 and probability that 
medical management is cost effective is 0.48. Beyond this ceiling ratio, the optimal 
treatment changes and AVR is more likely to be cost effective compared with medical 
management.  
  
Figure 6.7 Expected Value of Perfect Information: UK High Risk Operable 
Population  
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6.6 COMPARISON OF ORIGINAL MODEL WITH REVISED 
MODEL INCORPORATING PARTNER (COHORT A) 
EVIDENCE FOR HIGH RISK OPERABLE PATIENTS 
Model and Parameters 
 
Incorporating evidence from PARTNER into the high risk operable model afforded the 
opportunity to reflect the current understanding of TAVI amongst operable patients.  This 
resulted in some changes to the model such as the inclusion of conversions from TAVI to 
medical management, repeat TAVI procedures, death from medical management within 30 
days and the distinction between major and minor PREs in the Markov model. These 
revisions reflect current practice and provide the opportunity to incorporate the best 
evidence available for the transition probabilities in the short and long term such as stroke, 
PREs and mortality estimates. Previously, early short term experiences with TAVI, expert 
opinion and experiences with AVR were relied upon to inform the TAVI and medical 
management arms of the model.  
The changes to the model and revised evidence resulted in the following changes to the 
transition probabilities (See Appendix VII).  The original short term model only included 
conversions from TAVI to AVR. Updating the evidence with PARTNER Cohort A 
evidence, resulted in a 50% reduction in the probability of converting from TAVI to AVR 
to 0.03. Incorporating PARTNER Cohort A evidence resulted in the probability of stroke 
following AVR remaining constant at 0.03, but widened the 95% confidence interval from 
0.02-0.05 to 0.01-0.05. While the additional evidence increased the stroke risk associated 
with TAVI to 0.06. This is a 100% increase on the baseline stroke rate employed in the 
original model and widens the 95% confidence interval from 0.02-0.05 to 0.03 -0.09.  The 
original model assumed a 15% mortality rate for 30 day all-cause mortality for AVR and 
TAVI, based on operative mortality risk. However, employing evidence from PARTNER 
Cohort A reduced this 30 day all-cause mortality rate to 7% for AVR patients and 4% for 
TAVI patients and allowed for differentiation between technologies.  
As outlined above, the PARTNER evidence also revised the PREs. This resulted in a 
decrease in early major PREs following AVR by 58% to 0.05. This was attributable to the 
reduction in valve thromboembolism, paravavular leaks, endocarditis and myocardial 
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infarctions. While the early major PREs following TAVI increased by 33% to 0.16. This 
was owing to the increase in valve thromboembolism and paravavular leaks. The 
probability of early minor PREs meanwhile increased for AVR and TAVI patients by 73% 
and 46% respectively. This was attributable to the increase in major vascular events and 
major bleeding reported.   
Meanwhile, for medically managed patients evidence from PARTNER Cohort B was 
incorporated into the model to inform the treatment pathway. In the original model expert 
opinion was relied upon and a 30 day mortality rate of 0.00 was used. In the revised model 
for high risk operable patients this mortality rate is increased to 0.04. Also, the revised 
model includes the likelihood of balloon valvuloplasty in the short run (0.83). 
In the long-term model the likelihood of late fatal PREs decreased for AVR and TAVI 
patients by 55% to 0.01 and 45% to 0.12 respectively. While late major PREs decreased by 
35% for AVR patient and increased by 5% for TAVI patients to 0.11 and 0.18 respectively. 
This is explained by the reduction in paravavular leaks and endocarditis for AVR patients 
and the increase in paravavular leaks for TAVI patients. With respect to the probability of 
late strokes a differentiation was made between AVR and TAVI where the probabilities 
applied were 0.02 and 0.03 respectively. 
With regard to cost parameters, the revised model included the probability of requiring a 
balloon valvuloplasty for 83% of medically managed patients in the short term and 50% in 
the persistent AS/failed valve replacement state in the long run. As described in Section 
6.2, PARTNER Cohort A provided information on length of stay for AVR and TAVI 
patients which were incorporated into the in-hospital costs. There was a 20% increase in 
length of stay for AVR patients, with a 25% increase in time spent in higher dependence 
units. For TAVI patients there was a 38% increase in overall length of stay with a 50% 
increase in time spent in the intensive care unit. These revisions increased the overall cost 
of in hospital care by 75% for AVR patients and more than doubled the cost for TAVI 
patients. The costs of long term care per state were also revised which increased the cost of 
the persistent AS/failed replacement valve state following AVR of 9% and following 
TAVI by 10%. While the cost of the functioning valve replacement state increased by just 
2% for AVR patients and remained constant for TAVI patients at £1,541. These changes in 
costs were explained by the 47% increase in annual hospitalisations associated with the 
persistent AS/failed valve for AVR patients to 0.78 and 34% increase for TAVI patients 
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bringing the probability of hospitalisations to 0.71. While, for AVR patients in the 
functioning valve replacement state there was a less than 1% decrease in hospitalisations at 
a probability of 0.07, while there was a 28% decrease in annual hospitalisations for TAVI 
patients in the functioning valve replacement state (0.05). 
Revising the utilities per state resulted in a 2% increase in utility associated with having 
AS/persistent AS to 0.55. This reflects the difference between high risk operable and 
inoperable patients. The utility associated with the functioning valve replacement state 
following AVR decreased in the revised model by 3% to 0.75. While the utility associated 
with this state for TAVI patients increased by 1% to 0.78. This provided for differentiation 
between TAVI and AVR technologies.  
So incorporating the PARTNER Cohort A evidence into the model provided revised 
parameters to represent the best currently available data. Specifically, the PARTNER 
Cohort A evidence provided evidence on early and late PREs following TAVI which had 
previously been scarce, as well as updating AVR evidence. This generally reduced the 
probabilities of mortality and major PREs associated with AVR and increased PREs 
associated with TAVI.   Revising the model to incorporate evidence from PARTNER 
ensured that the current understanding of TAVI and its alternatives were reflected in the 
model. This provided the opportunity to differentiate between patient types, as previously 
common transition probabilities, costs and utilities were used for patients regardless of 
whether they were considered operable or inoperable. It also captured the heterogeneity 
between treatment types more explicitly than the original model, where relative risk 
parameters had to be employed owing to scarce data. 
Cost Effectiveness Results 
The revised cost effectiveness results demonstrated that AVR extends life and improves 
quality of life in the longer term for those patients who otherwise would not receive a valve 
replacement. Meanwhile, TAVI does not extend life or improve quality of life compared 
with patients who could receive an AVR. The average life years gained in the PARTNER 
Cohort A model was 3.44 for patients receiving TAVI, 3.49 for patients receiving AVR 
and 2.96 for patients receiving medical management.  This represents a decrease compared 
to the original model (4.73 following TAVI, 4.65 following AVR and 3.05 following 
medical management) which is explained by the increase in mortality in year 1 of the 
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Markov model and higher PREs. The latter resulted in more patients entering the persistent 
AS/failed valve replacement state which has a higher mortality rate than the functioning 
valve replacement state. Figure 6.8 presents the survival estimates from each model for 
comparative purposes, illustrating that the revised model has much steeper survival than 
the original model. This is explained by the higher one year mortality estimates for each 
state in the Markov model as informed by the PARTNER evidence. In addition, there is a 
significant difference between TAVI and AVR, with AVR offering greater survival until 
year 13. The difference in medical management is marginal in the revised model compared 
to the original.  
In the analysis of the revised model, incorporating PARTNER Cohort A evidence, the 
costs associated with TAVI were estimated to be just 16% higher than suggested by the 
original model while the QALYs produced were 28% less. Similarly, the costs associated 
with AVR based on the revised analysis incorporating the PARTNER trial evidence were 
higher (11%) than the values produced by the original model, while the QALYs were 23% 
less than value in the original model. These differences were explained by longer length of 
stay, the inclusion of repeat TAVI, higher rates of strokes and PREs which increase costs 
and have a disutility associated with them. 
 
Figure 6.8 Survival Curve Comparison: High Risk Operable Patients 
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Chapter 4 presented the results of the original cost effectiveness analysis for high risk 
operable patients using data from published literature. Where the model demonstrated that 
despite the uncertainties surrounding the incremental costs and benefits there is very little 
uncertainty regarding the cost effectiveness of TAVI over the range usually considered 
cost effective (£20,000-£30,000 per QALY) with an ICER of £85,982 QALY. At a ceiling 
ratio of £30,000 per QALY the probability that AVR is cost effective is 98%, while the 
probability that TAVI is cost effective is 2% and the probability that medical management 
is cost effective is 0%.   
When the model was revised to include the best data available, including data from 
PARTNER Cohort A, the results changed but the conclusion with respect to cost 
effectiveness does not, in fact the potential cost effectiveness of TAVI deteriorates. As 
TAVI is more expensive and offers fewer benefits than AVR it is dominated. At a ceiling 
ratio of £30,000 per QALY the probability that AVR is cost effective was 98.7%, while the 
probability that TAVI is cost effective was 0.2% and the probability that medical 
management is cost effective was 1.1%. Table 6.6 presents the costs, QALYs and ICERs 
for both versions of the model. 
When comparing AVR with TAVI the different versions of the model report different 
results, but neither recommends TAVI.  As discussed in Section 6.4 and 6.5, there is some 
uncertainty about the existence and extent of differences in effectiveness and costs. The 
ICE planes comparing TAVI and AVR produced in the original and updated revised 
models are compared in Figure 6.9. Here the points in Figure 6.9a represent the additional 
costs and benefits for the original model, while the points on Figure 6.9b represent 
additional costs and benefits for the revised, PARTNER Cohort A, model for comparative 
purposes. Comparing Figure 6.9 a and b it is visible that the uncertainty has shifted. 
Uncertainty regarding the existence of differences in QALYs still exists but the extent to 
which it exists has changed.  
This is illustrated in the change in the 95% confidence interval surrounding the incremental 
QALYs. In the original model the incremental QALYs ranged from -0.21 to +0.41 (95% 
confidence interval was –0.08 to 0.21) this has shifted and now ranges from -0.89 to +0.67 
(95% confidence interval is -0.53 to 0.30). There is still little uncertainty regarding the 
existence of difference in costs, with TAVI being more expensive, confirmed by the range 
and 95% confidence interval around the incremental costs. In the original model the 
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incremental costs ranged from £1,705 to £9,756 (95% confidence interval was £3,141 to 
£7,337). In the revised model with PARTNER Cohort A evidence this changed to -£5,123 
to £20,560 (95% confidence interval is £540 to £12,363).  
This shift is explained by the replacement strategy employed when updating with 
PARTNER evidence in the revised analysis. As outlined in Section 6.3.2, to incorporate 
the best evidence in the model the previous estimates from the literature employed in 
Chapter 4 were replaced with evidence from PARTNER where available.  The results 
clearly indicate that the original model underestimated the uncertainty in costs and effects 
for TAVI.  
Comparing the CEAC from the revised analysis with PARTNER Cohort A evidence with 
that produced from the original analysis demonstrates that the decision uncertainty in the 
original model is reduced, with the probability that TAVI is cost effective compared with 
AVR and medical management (at a ceiling ratio of £30,000 per QALY) being 2% in the 
original and 0.2% in revised model. Figure 6.10 presents the two CEACs side by side.  
 
 Figure 6.9 Incremental Cost Effectiveness Plane Comparison: High Risk 
Operable Patients 
a. Original Model      b. PARTNER A Model 
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Table 6.6 Cost Effectiveness Results Comparison PARTNER A and Original Model: High Risk Operable Patients  
 AVR TAVI Medical Management ICER 
AVR VS. 
TAVI 
£/QALY 
ICER AVR VS. 
MEDICAL 
MANAGEMENT 
£/QALY 
 Costs 
(£) 
QALYs LYs Costs 
(£) 
QALY LYs Costs 
(£) 
QALY LYs 
ORIGINAL* 26,698 2.84 4.65 31,854 2.90 4.73 13,920 1.53 3.05 85,982 9,721 
PARTNER A‡ 29,695 2.20 3.49 36,813 2.09 3.44 19,012 1.54 2.96 TAVI 
Dominated 
16,118 
            
*Presented in Chapter     ‡Presented in Section 6.4 
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Figure 6.10 Cost Effectiveness Acceptability Curve Comparison: High Risk 
Operable Patients 
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ceiling ratio increases the pEVPI in the revised model is less than the original model. So 
modest uncertainty remains and there is little potential value in collecting further evidence 
on the costs and effects of TAVI compared to medical management given the PARTNER 
evidence. 
 
Figure 6.11 Expected Value of Perfect Information Comparison: High Risk 
Operable Population 
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generation for novel medical devices, whereby attention is focused on the higher risk 
patients where most benefit is to be gained. It also may be owing to the discouraging 
results from the PARTNER trial which found no significant improvement between TAVI 
and AVR patients.  
The economic evaluation of TAVI performed and published by the Belgian Health Care 
Knowledge Centre (Neyt et al., 2011) (discussed in Chapter 5) also included an analysis of 
TAVI compared to AVR. Similar to the analysis in this thesis, Neyt et al. (2011) found that 
for high risk operable patients the additional benefits of TAVI were outweighed by the 
additional costs compared to AVR. This study employed a mix of evidence from 
PARTNER Cohort A and Belgian resource data and estimated an ICER of 
€7 9, 16/QALY (equivalent to £65 ,690 on date of publication12 (OANDA, 2011)) for the 
baseline model. This decreased to € 55, 61/QALY when the cost of the TAVI device is 
reduced by €10,000 (£8,7 6).  A second scenario analysis is used to assess the impact of 
setting the incremental benefit between AVR and TAVI to 0.10. In this scenario, the ICER 
decreases to approximately €205,000/QALY. Thus, even in the sensitivity analysis 
performed TAVI remains more expensive and only marginally more effective than AVR, 
so TAVI cannot be considered cost effective.   
The unpublished NIHR HTA study, funded by the NHS in the UK (referred to in Chapter 
5), also included a cost effectiveness analysis of high risk operable patients. Preliminary 
(unpublished) results  demonstrate that they employed PARTNER Cohort B data and 
survival analysis techniques to estimate the cost effectiveness of TAVI compared to AVR 
for operable patients (PARTNER Cohort A evidence was not available at the time of 
analysis) (Orlando, 2011). The report found that given the higher cost and fewer benefits of 
TAVI compared to AVR, that TAVI was dominated by AVR. This result is similar to that 
found by this study. However, the analysis conducted in this study employs more recent 
and suitable evidence and also conducted a VOI. 
 
                                                 
12
 Converted as per Euro – GBP exchange rate on 22nd September 2011 (date of publication) 
(OANDA, 2011) 
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6.8 DISCUSSION 
Transcatheter Aortic Valve Implantation (TAVI) offers a novel treatment option for 
patients suffering from severe Aortic Stenosis (AS). Publication of the PARTNER trial, 
with 12 month follow-up, offered the eagerly awaited one year outcomes for operable 
patients. Previously, TAVI had not been demonstrated to be appropriate for high risk 
operable patients, attention had focused on inoperable patients where most was to be 
gained as these patients were currently receiving little treatment benefit. Here, employing 
the DAM in an iterative manner, the cost effectiveness of TAVI for operable patients is re-
assessed. Whereby, PARTNER data, reflecting the best available data, is incorporated into 
the model to investigate the suitability of TAVI for high risk operable patients. 
Incorporating the PARTNER Cohort A results into the TAVI model afforded the 
opportunity to generate revised costs and effects for TAVI compared to AVR and medical 
management. The analysis revealed that TAVI was dominated by AVR when treating high 
risk operable patients, as it was more expensive and offered fewer benefits than AVR. The 
conclusion reached from these results is similar to that of the original model for the same 
group where it was also found that TAVI could not be considered cost effective compared 
to AVR. In the analysis of the revised model, the costs associated with TAVI were 
estimated to be slightly higher than suggested by the original model, while the QALYs 
produced were marginally less than those of the original model. Similarly, the costs 
associated with AVR based on the revised analysis incorporating the PARTNER Cohort A 
trial evidence were higher than the values produced by the original model and the QALYs 
were less. Comparing the results of the original model with the revised model suggests that 
the original model overstated the mortality associated with TAVI. In addition, the 
probability of PREs (including major stroke) identified in the PARTNER Cohort A 
evidence was greater than that used in the original model. The VOI analysis for the revised 
model, with PARTNER Cohort A evidence, suggests there is little value in collecting 
further evidence for high risk operable patients given current information.  
Despite the shortcomings of the data, the DAM employed offers an insight into the longer 
term benefits of TAVI amongst high risk operable patients by extrapolating the data for 20 
years. Such results offer decision makers an indication of the potential for further evidence 
in making coverage and access decisions regarding TAVI for severe stenosis patients 
deemed operable as the evidence base evolves. While using this additional evidence TAVI 
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remains not cost effective for high risk operable patients, some commentators, such as 
Schaff (2011), have argued this is owing to the early devices used and early experience of 
the centres studied. It is proposed that if further evidence were collected it may 
demonstrate better stroke rates and incidence of PREs which would improve health 
outcomes and subsequently improve the cost effectiveness of TAVI compared to AVR.  
As demonstrated throughout this thesis, TAVI is a promising technology for patients with 
severe AS. While there appears to be two distinctive markets for the technology, operable 
and inoperable patients, there may be opportunities to exchange information between 
models/patient groups. For example, evidence from PARTNER B was exchangeable across 
the patient types for updating the medical management treatment in the model.  
Owing to the characteristics and life stage of TAVI its’ evidence base is still evolving. 
Since the release of PARTNER evidence, longer term evidence from external sources for 
example, PARTNER, the registries employed in Chapter 4 and the UK TAVI registry are 
beginning to emerge in the literature. This information is incorporated into model for 
inoperable and operable patients in the next chapter. 
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CHAPTER 7 WHERE NOW WITH TAVI? 
 
7.1 INTRODUCTION  
As indicated previously, Transcatheter Aortic Valve Implantation (TAVI) is a novel 
medical device technology with an evolving evidence base. This presents a challenge in 
estimating cost effectiveness in a demanding health care environment, owing to the 
complex characteristics of medical devices, where resources are scarce and coverage 
decisions are required alongside the generation of evidence. Consequently, an iterative 
framework for economic evaluations is advocated whereby the cost effectiveness of the 
technology is reviewed following developments in the evidence base. This ensures that 
advances in the evidence base, owing to incremental innovations, movements along the 
learning curve etc., are incorporated into decision making to reflect current understanding 
of the technology and disease. 
Since the publication of the early results from the first clinical trial (PARTNER), other 
European Registries have released evidence on longer term TAVI outcomes amongst 
inoperable patients. Similarly, longer-term results for operable patients have been released 
from the PARTNER trial and short term results from the UK TAVI Registry. This provides 
the opportunity to re-assess the cost effectiveness of TAVI for each patient group and to 
ascertain if there is any value in collecting further evidence, given the evidence available. 
This ensures that decisions regarding TAVI can be based on the best available evidence. 
The decision analytical model (DAM) employed in Chapter 4, and updated in Chapters 5 
and 6, is employed again in this chapter to re-consider the cost effectiveness of TAVI for 
both inoperable and operable patients in light of the evolving evidence (i.e. the adoption 
and priority setting decisions).  
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7.2 EVOLVING EVIDENCE FOR INOPERABLE TAVI 
PATIENTS  
Inoperable patients are those for whom AVR is not considered suitable, as such only TAVI 
or medical management are viable treatment options. Since publication of the PARTNER 
Cohort B results (presented in Chapter 5) longer-term TAVI results for inoperable patients 
have been published from European TAVI Registries (Walther et al., 2012, Bleiziffer et al., 
2012) and Cohort B of the PARTNER trial (Makkar et al., 2012). These results provide 
evidence on the longer term procedure related events (PREs) (i.e. beyond year one) as well 
as evidence on mortality rates for years two and three for inoperable patients. 
Specifically, Bleiziffer et al. (2012) reported evidence from 580 patients, who received 
TAVI at the German Heart Centre in Munich, recorded in a registry which began in 2007. 
Follow up outcomes were available for 227 inoperable patients. Here it was reported that 
30 day survival was 88.5%, one year survival was 74.5% and two year survival was 64.4%. 
Meanwhile, the probability of paravavular leaks remained constant between years one and 
two at 0.08 and the probability of stroke in year two was estimated at 0.04 which was 
higher than year 1 (0.01). The probability of bleeding also increased between years one and 
two (0.19 versus 0.26). This increased risk of bleeding was highlighted in Bleiziffer et al. 
(2012) and the authors suggest that the results indicate bleedings may be a persistent 
problem following the TAVI procedure.   
Makkar et al. (2012) reported two year follow up outcomes from the 21 centres in the 
PARTNER Trial (Cohort B).  All-cause mortality at the end of year two was 43.3% for 
TAVI patients and 65% for standard therapy (i.e. medical management) patients. The 
overall risk of stroke following TAVI between years 1 and 2 was found to be 0.03, while 
risk of bleeding was 0.07. Makkar et al. (2012) also provided evidence on the likelihood of 
patients requiring a late balloon valvuloplasty following TAVI (2%) and medical 
management (3%). 
Walther et al. (2012) reported results for 299 inoperable patients collected between 
February 2006 and January 2010 from the European Registries. Overall, survival amongst 
these patients was 91% at 30 days; 73% at one year; 68% at year two and 58% at year 
three. It was reported that 10.7% of patients had one or more perioperative complications. 
However, this data was presented at an aggregate level and the type of events and number 
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of each event occurring could not be extracted from the evidence presented. Thus, Walther 
et al. (2012) informs mortality estimates only in this re-analysis.  
These longer-term outcomes, extracted from Bleiziffer et al. (2012), Makkar et al. (2012) 
and Walther et al. (2012) are reported in Table 7.1. Here the number of events occurring 
(α) the total number at risk (n) and the number of events that did not occur (n-α  β) are 
reported. To estimate the probability of an event occurring, the number of events occurring 
is divided by the number at risk (α/n). For example, Bleiziffer et al. (2012) report four 
incidences of stroke in year two. A total of 89 patients could have had a stroke in this time 
period, which gives a probability of 0.045 (4/89). 
 
7.2.1 Incorporating Longer-Term Results into the Decision 
Analytical Model for High Risk Inoperable Patients 
The longer-term results, on TAVI reported in Makkar et al. (2012), Walther et al. (2012) 
and  Bleiziffer et al. (2012), provide evidence on outcomes for TAVI patients beyond one 
year. This evidence was not previously available so assumptions were employed in the 
model to extrapolate out for the remaining 19 years of the model. The additional evidence 
therefore can be employed to update the evidence in the PARTNER B model. An 
“updating” strategy is employed here, as opposed to the “replacement” strategy adopted in 
Chapter 5.  Whereby, the evidence from Makkar et al. (2012), Walther et al. (2012) and 
Bleiziffer et al. (2012) are combined with the PARTNER B evidence. This strategy is 
considered optimal as Makkar et al. (2012), Walther et al. (2012) and Bleiziffer et al. 
(2012) provide longer term data which updates the transition probabilities. Evidence prior 
to PARTNER was immature and based on very early experiences with the device, as such 
the evidence provided by PARTNER was the best available at the time and replaced 
previous evidence. Here employing early PARTNER Cohort B (from (Leon et al., 2010)) 
and updating with Makkar et al. (2012), Walther et al. (2012) and Bleiziffer et al. (2012) 
ensures the best data available at the time is employed in the model. This synthesis of data, 
thus not relying on a single trial, is in line with the recommendations on iterative 
frameworks for economic evaluations and avoids partial or biased assessments (Sculpher et 
al., 2006).  
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Table 7.1 Mortality and Procedural Related Event Evidence - Makkar et al 
(2012), Walther et al. (2012) and  Bleiziffer et al. (2012) 
Paper - Parameter α β n Prob 
Bleiziffer et al (2012) 
    Mortality 
    30 Day All-Cause Mortality 27 200 227 0.12 
1 Year All-Cause Mortality 59 168 227 0.26 
2 Year All-Cause Mortality 82 145 227 0.36 
Procedure Related Events     
30 Day Stroke 10 193 203 0.05 
30 Day Major Paravavular Leak 22 181 203 0.11 
30 Day Major Bleeding 20 183 203 0.10 
1 Year Major Paravavular Leak 9 107 116 0.08 
1 Year Stroke  1 115 116 0.01 
1 Year Major Bleeding 22 94 116 0.19 
2 Year Major Paravavular Leak 7 82 89 0.08 
2 Year Stroke  4 85 89 0.04 
2 Year Major Bleeding  23 66 89 0.26 
     
Makkar et al (2012)     
Mortality     
2 Year All-Cause Mortality – TAVI 73 95 168 0.43 
2 Year All-Cause Mortality – Medical Management 117 62 179 0.65 
Late Procedures      
Late Balloon Valvuloplasty Year 1 – TAVI 2 90 92 0.02 
Late Balloon Valvuloplasty Year 2 – TAVI 2 90 92 0.02 
Late Balloon Valvuloplasty Year 2 – Medical 
Management 
2 60 62 
 
0.03 
Procedure Related Events – TAVI     
2 Year Stroke 3 89 92 0.03 
2 Year Myocardial Infraction 1 91 92 0.01 
2 Year Endocarditis 1 91 92 0.01 
2 Year Major Bleeding  6 86 92 0.07 
2 Year Pacemaker 2 90 92 0.02 
2 Year Rehospitalisation 10 82 92 0.11 
     
Walther et al (2012) 
    Mortality 
    30 Day All-Cause Mortality 24 243 267 0.09 
1 Year All-Cause Mortality 72 195 267 0.27 
2 Year All-Cause Mortality 85 182 267 0.32 
n indicates the number of patients at risk; α indicates the number of events occurring; β the number 
of events that did not occur (n- α ); probability is α /n. Note α and n were extracted from the 
literature and β and the probability of the event occurring were calculated by the author. 
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Box 7.1 provides an example of how PARTNER Cohort B evidence was updated using the 
aforementioned late results from the trial and European Registries. The pooling process 
employed here is equivalent to a fixed effects meta-analysis, involving the assumption that 
information is exchangeable and the baseline parameters being measured are identical. 
PARTNER Cohort B reported 30 incidences of early major bleeding; this corresponds with 
α PARTNER B i.e. the number of events reported occurring in PARTNER Cohort B. There 
were 168 in the sample (denoted n PARTNER B). Bleiziffer et al. (2012) reported 20 
incidences of major bleeding, which is α Bleiziffer. The number of events which could have 
occurred was 203 (n Bleiziffer). To update the transition probability the α (α PARTNER B and α 
Bleiziffer) and n (n PARTNER B  and n Bleiziffer) are summed to estimate the revised probability. 
This is calculated as follows: α = 30 + 20 = 50; n= 168+20    71; α/n= 50/371 = 0.13. 
This process is repeated for late major bleeding, major paravavular leaks and strokes in the 
short and long term (1 year and 2 year) and incorporates evidence from Makkar et al. 
(2012) for procedure related events (PREs) beyond one year (presented in Table 7.1). 
These PREs beyond one year updated with evidence from Makkar et al. (2012) were 
endocarditis, stroke, myocardial infarction, repeat hospitalisations, major bleeding and new 
pacemaker. 
 
 Box 7.1 Example of Updating PARTNER A Evidence 
      
 Early Major Bleeding TAVI α β n Probability 
 PARTNER B 30 138 168 0.18 
 Bleiziffer  20 183 203 0.10 
 PARTNER B + Bleiziffer 50 321 371 0.13 
      
 
 
The revised probabilities are shown in Table 7.2. Inclusion of evidence from Bleiziffer et 
al. (2012) resulted in the probability of stroke within 30 days remaining constant at 0.05. 
Major PREs after 30 days (early) following TAVI decreased from 0.18 to 0.16. This was 
owing to the reduction in major paravavular leaks from 0.14 to 0.12 following updating 
with Bleiziffer et al. (2012). Early minor PREs following TAVI also decreased when the 
transition probabilities were updated from 0.58 to 0.54. This was owing to the reduction in 
major bleeding (0.04) following updating. The transition probabilities in the first cycle of 
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the Markov Model were also revised as a result of evidence from Bleiziffer et al. (2012). 
The probability of fatal PREs in year one decreased from 0.58 to 0.54. The likelihood of 
major PREs in year one also decreased from 0.20 to 0.16. This was owing to the decrease 
in major paravavular leaks (0.13 to 0.10). However, late minor PREs within one year 
increased from 0.19 to 0.24, this was owing to the increase in major bleeding (0.08 to 
0.14).  
In previous iterations of the model, the probability of late PREs employed for cycle one of 
the Markov model were applied for the duration of the model. Publication of longer-term 
results in Bleiziffer et al. (2012) and Makkar et al. (2012), afforded the opportunity to 
update late PREs beyond one year. This resulted in an increase in major PREs following 
TAVI from 0.20 to 0.21 for year two onwards. This increase was owing to a rise in the 
number of strokes observed. Similarly, the likelihood of minor PREs beyond one year 
increased from 0.19 to 0.29. This was owing to the increase in major bleeding (0.08 to 
0.19).  
Thus, the inclusion of additional data for TAVI decreased the likelihood of PREs in the 
short term component of the model (first 30 days) and decreased the likelihood of PREs in 
the first cycle of the Markov model. The additional data on longer term outcomes 
increased the likelihood of PREs following TAVI after year one. The main contributors to 
these increases are increased strokes and bleedings. According to Walther et al. (2012) and 
Bleiziffer et al. (2012), while this occurs to a minority of patients it appears to be a 
persistent problem following the TAVI procedure.  
As per previous iterations of the model, the uncertainty surrounding each of the parameters 
was incorporated into the model through the assignment of probability distributions. The 
PARTNER B evidence combined with Makkar et al. (2012) and Bleiziffer et al. (2012) 
results, identified the total number of patients and the number for whom events occurred; 
this information was used to specify a beta distribution for each probability (Table 7.2). All 
of the transition probabilities provided on Table 7.2 represent absolute risk for each arm of 
the model, TAVI and medical management. 
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Table 7.2 Revised Transition Probabilities   
  Dist Prob  
(95% CI) 
α β n 
All-Cause Mortality 30 Days TAVI Beta 0.09 
(0.07-0.11) 
59 603 662 
Probability Of Major Stroke  TAVI* Beta 0.05 
(0.03-0.09) 
19 352 371 
Early  Major PRE TAVI      
Valve Thromboembolism beta 0.01 1 167 168 
Major Paravavular Leak* beta 0.12 45 326 371 
Endocarditis beta 0.00 0 168 168 
Cardiac Tamponade beta 0.03 6 162 168 
Myocardial Infarction beta 0.00 0 168 168 
  0.16 
(0.12-0.21) 
   
Early  Minor PRE TAVI      
Access Site Events beta 0.04 7 161 168 
Vascular Events beta 0.15 26 142 168 
Pacemaker Implantation beta 0.04 6 162 168 
Major Vascular Event beta 0.17 29 139 168 
Major Bleeding* beta 0.14 50 321 371 
  0.54 
(0.43-0.63) 
   
      
Late Fatal PREs TAVI Year 1* beta 0.22 
(0.17-0.27) 
51 183 234 
Late Major PRE TAVI Year 1      
Valve Thromboembolism beta 0.00 0 118 118 
Major Paravavular Leak* beta 0.10 24 210 234 
Endocarditis beta 0.02 2 116 118 
Cardiac Tamponade beta 0.01 1 117 118 
Stroke  beta 0.03 6 228 234 
Myocardial Infarction beta 0.01 1 117 118 
  0.16 
(0.11-0.22) 
   
Late Minor PREs TAVI Year 1      
Repeat Hospitalisations  beta 0.06 7 112 118 
Major Vascular Complications  beta 0.01 1 117 118 
Minor Vascular Complications  beta 0.02 2 116 118 
Major Bleeding * beta 0.14 32 202 234 
New Pacemaker beta 0.02 2 116 118 
  0.24 
(0.17-0.31) 
   
Late Major PRE TAVI Year 2      
Valve Thromboembolism beta 0.00 0 84 84 
Major Paravavular Leak* beta 0.13 22 151 173 
Endocarditis^ beta 0.02 3 173 176 
Cardiac Tamponade beta 0.01 1 83 84 
Stroke *^ beta 0.05 12 253 265 
Myocardial Infarction^ beta 0.01 2 174 176 
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Table 7.2 Continued      
  Dist Prob  
(95% CI) 
α β n 
  0.21 
(0.15-0.28) 
   
Late Minor PREs TAVI Year 2      
Repeat Hospitalisations ^ beta 0.10 17 159 176 
Major Vascular Complications  beta 0.01 1 83 84 
Minor Vascular Complications  beta 0.02 2 82 84 
Major Bleeding *^ beta 0.15 39 226 265 
New Pacemaker^ beta 0.02 4 172 176 
  0.29 
(0.23-0.38) 
   
* Indicates where updated by Bleiziffer et al (2012) ^ Indicates where updated by Makkar et al. 
(2012) The remaining values are maintained as per Table 5.1-5.2 in Chapter 5. 
 
 
Cost Parameters 
For the cost analysis, the values of the following resources were estimated: TAVI device; 
TAVI and medical management procedures; length of stay; hospitalisations and other costs 
incurred with PREs. Neither Makkar et al. (2012), Bleiziffer et al. (2012) nor Walther et al. 
(2012) provided additional information on the cost of the TAVI procedure or length of 
stay, so the estimates from Chapter 5 were maintained. The state costs were also 
maintained (cost for the functioning valve replacement state of £1,578 and £8,163 for the 
persistent AS/failed valve replacement state).  
With respect to the cost of PRES, these are estimated as previously with a weight assigned 
to each event and the unit cost. The weights, which are a proportion of each event 
occurring, are updated with the revised probabilities. The costs of early minor and major 
PREs were £319 and £651 respectively. The cost of late major and minor PREs in year one 
were £1,306 and £2,641 respectively. The cost of late major and minor PREs for year two 
onwards were £1,551 and £3,143 respectively. Normal distributions were applied to cost of 
treating PREs as per previous versions of the model. 
Quality of Life Parameters 
As per the original model presented in Chapter 4, QALYs were also derived for each 
health state adjusting for the condition, the procedure and PREs. As with the costs, the 
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impact on utility associated with the PREs were adjusted to account for the revised 
probabilities of events occurring. The utility of minor and major early PREs were 0.03 and 
0.04 respectively. The utility of minor and major PREs after one year were 0.02 and 0.04. 
And the utility of minor and major PREs for two years and beyond were 0.02 and 0.04.  
Makkar et al. (2012) provided updated NYHA classifications following TAVI and medical 
management in year two. This provided updated utilities for the functioning valve 
replacement and failed valve replacement states in year two and beyond, for TAVI and 
medical management respectively. The expected utility following a TAVI procedure was 
0.75 and following medical management was 0.65 in year two (Table 7.3). Makkar et al 
(2012) did not provide sufficient detail to differentiate between TAVI patients in the 
functioning and persistent AS/failed valve replacement states as per the Markov Model 
developed for this model, so 0.75 was applied to patients in both states from year 2 
onwards, (previously, this was 0.63). However, utility for patients in the persistent 
AS/failed valve replacement states is reduced by a utility hit associated with major PREs. 
Normal distributions were applied to the utility hits associated with the PREs, while a 
Dirichlet distribution was applied to the proportion of patients per NYHA class, used to 
estimate the utility per state. 
 
Table 7.3 Utilities by NYHA Class For TAVI Decision Analytical Model 
Updated with Longer Term Outcomes 
NYHA Class Distribution Utility* Proportion
¶
 Utility 
(95% CI) 
Utility Functioning Valve Replacement TAVI Year 2^ 
I Dirichlet 0.82 0.45 0.37 
II Dirichlet 0.72 0.43 0.31 
III Dirichlet 0.59 0.10 0.06 
IV Dirichlet 0.51 0.02 0.01 
   1.00 0.75 
(0.73-0.76) 
Utility of Failed Valve Replacement Medical Management Year 2 
I Dirichlet 0.82 0.10 0.08 
II Dirichlet 0.72 0.32 0.23 
III Dirichlet 0.59 0.48 0.28 
IV Dirichlet 0.51 0.10 0.05 
   1.00 0.65 
(0.62-0.67) 
*(Maliwa et al., 2003) ¶(Makkar et al., 2012)  ^ A common utility is applied for TAVI patients in 
functioning and persistent AS/Failed valve replacement states in year two onwards as it was not 
possible to ascertain the proportion of patients per state in the Markov Model developed here. 
However these utilities are differentiated by the utility reduction for each PRE in the Persistent 
AS/failed valve replacement state. 
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7.2.2 Analysis – Inoperable Patients 
A similar analysis to those employed in Chapters 4 and 5 was undertaken here for 
inoperable patients, using the UK NHS perspective. A Monte Carlo simulation with 10,000 
iterations was used to propagate the uncertainty in the individual model parameters, 
reflected by the probability distributions assigned, through the model. This produces a 
distribution of expected costs and expected QALYs associated with each procedure. The 
mean values of these distributions are used to calculate the incremental cost effectiveness 
ratio (ICER) in terms of the expected incremental costs associated with TAVI compared to 
medical management per incremental QALY gained. The uncertainty associated with the 
incremental costs and incremental QALYs are presented through incremental cost 
effectiveness (ICE) planes. The uncertainty associated with the cost effectiveness of TAVI 
compared to medical management is presented in terms of a cost effectiveness 
acceptability curve (CEAC). These facilitate the re-assessment of the adoption decision. 
Following this, the research priority setting decision is re-considered using a Bayesian VOI 
analysis is performed to estimate expected value of perfect information (EVPI). 
 
7.3 COST EFFECTIVENESS RE- ANALYSIS INOPERABLE 
PATIENTS  
The cost effectiveness of TAVI versus medical management was estimated for inoperable 
patients based on a mix of evidence from the PARTNER trial, Cohort B early (Leon et al., 
2010) and late (Makkar et al., 2012) as well as European Registries (Bleiziffer et al., 2012, 
Walther et al., 2012). The results indicate a 40% reduction in absolute risk in terms of all-
cause mortality at the end of year one between TAVI and medical management, which 
decreases to 23% at the end of year two. These mortality estimates for years one, two and 
three, correspond to observed mortality from the PARTNER trial  (Makkar et al., 2012) 
and European Registry (Bleiziffer et al., 2012, Walther et al., 2012). This is illustrated by 
the survival estimates on Figure 7.1. TAVI also offers significantly greater quality of life 
benefits compared with medical management as per the PARTNER results, with an 18% 
increase in quality of life per person compared to medical management in year two. The 
differences in quality of life for TAVI compared with medical management are shown on 
Figure 7.2. 
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Figure 7.1 Survival Estimates for TAVI and Medical Management 
 
Figure 7.2 Quality of Life Estimates for TAVI and Medical Management  
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7.3.1 Deterministic Cost Effectiveness Results 
The deterministic cost effectiveness results (Table 7.4) were estimated using the point 
estimates for the transition probabilities, costs and utilities presented in the previous 
section. The results illustrate that for inoperable patients TAVI is both more costly 
(£29,797) and more effective (1.55 QALYS) than medical management. The ICER is 
estimated as £19,259 per QALY gained, which is below the level usually considered cost 
effective (£20,000-£30,000 per QALY (Rawlins et al., 2009)).  
 
7.3.2 Probabilistic Cost Effectiveness Results 
A Monte Carlo simulation with 10,000 iterations was run to propagate the uncertainty 
represented by the assigned probability distributions into the model. This produced a 
distribution of expected costs and QALYs for TAVI and medical management. The mean 
values of these distributions are used to calculate the incremental cost effectiveness ratio 
(ICER). The mean cost and QALY are presented in Table 7.4. Here it is illustrated that for 
inoperable patients TAVI is both more costly (£30,121) and more effective (1.58 QALYs) 
than medical management. The incremental costs from the Monte Carlo simulation ranged 
from £19,532 to £41,521. While the incremental benefit ranged from 0.56 to 2.62 QALYs 
(95% confidence intervals reported in Table 7.4). The probabilistic ICER is estimated as 
£19,078 per QALY gained, which is below the level usually considered cost effective 
(£20,000-£30,000 per QALY (Rawlins et al., 2009)). So given the developed evidence 
base TAVI can now be considered cost effective compared to medical management for 
inoperable patients. 
The incremental cost effectiveness (ICE) plane (Figure 7.3) illustrates the existence and 
extent of the uncertainty surrounding the incremental effect and incremental cost (these are 
the red points plotted on Figure 7.3). In this case, there is no uncertainty surrounding the 
existence of benefit for TAVI (over medical management) with TAVI being more 
effective. There is however, some uncertainty surrounding the extent of the differences in 
effects.  Furthermore, there is no uncertainty with respect to the existence of differences in 
costs, with TAVI being more expensive than medical management: this is driven by the 
cost of the TAVI device. However, there is some uncertainty surrounding the extent of the 
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differences in cost. This (and the extent of uncertainty in differences in effects) is 
potentially driven by uncertainties surrounding the probability of PREs.  
 
Figure 7.3 Incremental Cost Effectiveness Plane: Inoperable Patients – TAVI 
versus Medical Management 
 
 
 
The cost effectiveness acceptability curve (CEAC) (Figure 7.4) presents the uncertainty 
surrounding the cost effectiveness of each treatment. Here the uncertainty identified in the 
incremental costs and incremental effects individually does not translate into decision 
uncertainty regarding the cost effectiveness of TAVI over the range usually considered 
cost effective. At a ceiling ratio of £30,000 per QALY the probability that TAVI is cost 
effective is 100% while the probability that medical management is cost effective is 0%.  
Indicating there is no decision uncertainty at this willingness to pay threshold. Whereas, at 
a ceiling ratio of £20,000 per QALY the probability that TAVI is cost effective is 67% 
while the probability that medical management is cost effective is 33%. Thus, the 
willingness to pay threshold employed can make a big difference to the decision 
uncertainty, however in this case it does not affect the adoption decision. 
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Table 7.4 Cost Effectiveness Results: Inoperable patients – TAVI versus Medical Management 
 LYS Costs (£) ∆ 
Costs £ 
QALY ∆ QALY ICER 
£/QALY 
Deterministic Results 
Medical Management 2.43 11,195  1.46   
TAVI 4.63 40,992 29,797 3.00 1.55 19,259 
 
Probabilistic Results 
Medical Management 2.44 
(1.98-3.01) 
11,307 
(8,461-14,702) 
 1.47 
(1.21-1.77) 
  
TAVI 4.71 
(3.93-5.63) 
41,428 
(36,727-46,822) 
30,121 
(24,546-36,076) 
3.05 
(2.59-3.56) 
1.58 
(1.05-2.15) 
19,078 
 
Value in parenthesis indicates 95% confidence interval.  
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Figure 7.4 Cost Effectiveness Acceptability Curve: Inoperable Patients – 
TAVI versus Medical Management 
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basis here. The pEVPI reaches an inflection point at a ceiling ratio equal to the ICER 
£19,078 QALY. This corresponds to the CEAC (Figure 7.4) where at £19,078/QALY the 
decision is most uncertain. Here the probability that TAVI is cost effective is 0.48 and 
probability that Medical Management is cost effective is 0.52. Beyond this ceiling ratio the 
optimal treatment changes and TAVI is more likely to be cost effective compared with 
medical management. As only two technologies are under consideration here (TAVI and 
medical management) this inflection point is also the maximum pEVPI. However, as 
indicated in the CEAC discussion, the ceiling ratio chosen, to represent willingness to pay, 
influences the results. For example, if a ceiling ratio of £20,000/QALY is chosen instead, 
the pEVPI is over £2 million, which would indicate there is value in collecting additional 
information.  
 
Figure 7.5 Expected Value of Perfect Information: UK Inoperable Population   
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7.3.4 Comparison of Original and PARTNER B Models with 
Revised Model Incorporating Longer-Term Outcomes for 
Inoperable Patients 
Model Inputs 
As outlined above, the additional evidence published by Makkar et al. (2012),  Bleiziffer et 
al. (2012) and Walther et al. (2012) provided the opportunity to update the PARTNER trial 
evidence for inoperable patients. This updating ensured the best available data was 
employed in the re-analyses of the cost effectiveness of TAVI compared with medical 
management for this patient group. The updating resulted in no structural changes to the 
model but provided revised estimates for mortality within 30 days from all causes; early 
stroke; early major and minor PREs; major and minor PREs within one year and evidence 
on PREs beyond one year. Mortality from all causes with 30 days increased from the 
PARTNER B model (0.09 versus 0.07). The probability of having a stroke within 30 days 
remained constant at 0.05. While the probability of early major and minor PREs were both 
reduced by 0.02. This was owing to the reduction in major paravavular leaks and major 
bleeding. The probability of fatal PREs in year one was also reduced to 0.22 (from 0.23). 
While the probability of late major PREs in year one was reduced by 0.04 to 0.20. This is 
owing to the reduction in major paravavular leaks and strokes. The probability of late 
minor PREs in year one increased by 0.04 owing to the increase in major bleeding. In 
previous versions of the model the probabilities of late PREs experienced in year one were 
applied for subsequent years.  Makkar et al. (2012),  Bleiziffer et al. (2012) and Walther et 
al. (2012), presented data on PREs beyond one year and provided the opportunity to update 
the evidence for PREs in year two. As a result the probability of late major PREs increased 
by 0.01, owing to the increase in the probability of stroke. The probability of minor PREs 
beyond one year increased by 0.10, due to the high occurrence of major bleeding observed 
in the updated evidence (See Appendix VII). 
Cost Effectiveness Results 
When the model is populated with the revised estimates and cost effectiveness is re-
examined, as discussed above, TAVI is found to extend life and improve quality of life. 
The average life years gained in the updated PARTNER B model for patients receiving 
TAVI was 4.71. This is a significant increase on the PARTNER B model (2.55) and the 
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original model (3.05). This increase is due to the longer term mortality evidence provided 
by  Makkar et al. (2012),  Bleiziffer et al. (2012) and Walther et al. (2012) which increased 
the 30 day mortality rate and decreased the 1 year and 2 year mortality rates significantly. 
Evidence from Makkar et al. (2012) also provided long term evidence on mortality 
following medical management. Here the average life years gained increased to 2.44 from 
2.24.  
In the re-analysis of the model, for inoperable patients, the costs associated with TAVI 
were estimated to be greater (£12,799; 145%) than suggested by the PARTNER B model. 
The QALYs produced in the re-analysed model were greater (1.43; 188%) than suggested 
by the PARTNER B model. These differences are explained by the revised probability of 
PREs and stroke associated with TAVI and the greater life expectancy for TAVI patients. 
Similarly, there is only a 7% difference between the costs of medical management from the 
re-analysis compared with the PARTNER B analysis. This is because the updated evidence 
provided little additional information on medically management patients. However, the 
QALYs were increased (0.28; 123%) owing to the additional evidence provided by 
Makkar et al. (2012) on NYHA classification and mortality. 
Results from the original, PARTNER B and updated PARTNER B models indicated that 
TAVI is more costly and more effective compared with medical management for 
inoperable patients. The incremental costs in the updated PARTNER B model were 183% 
greater and the incremental QALYs were over three times greater than the PARTNER B 
model (presented in Chapter 5). In the PARTNER B model the ICER (£37,390) was 
outside the range usually considered acceptable but in the updated PARTNER B model the 
ICER was below the range usually considered acceptable (£19,078). Table 7.5 presents a 
comparison of the results from the three versions of the model.  
The ICE plane compares the additional costs and benefits of TAVI over medical 
management. As discussed in Section 7.3.2, there was no uncertainty surrounding the 
existence of benefit and cost differences for TAVI over medical management with TAVI 
being more effective and more expensive. There was however some uncertainty 
surrounding the extent of the differences in effects and costs.  Comparing the ICE planes, 
Figure 7.6a represents the incremental costs and QALYS for the original model; Figure 
7.6b the PARTNER B model, and Figure 7.6c the updated PARTNER B model. Here it is 
illustrated that the uncertainty surrounding the extent of differences in QALYs and costs 
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particularly has shifted and increased. This shift to greater incremental costs and QALYs is 
explained by the reduction in mortality following TAVI; patients are surviving longer and 
incurring greater costs.  The change between the versions of the models is also attributable 
to the evidence employed and how it is incorporated. In this updated PARTNER B model 
the evidence employed in Chapter 5 was updated rather than replaced as was the case in 
moving from the original model to that presented in Chapter 5 (PARTNER B).  
Comparing the CEACs from the updated PARTNER B analysis with the PARTNER B 
model and the original analysis demonstrates that the decision uncertainty is considerably 
reduced as the evidence base develops. The probability that TAVI is cost effective 
compared with medical management (at a ceiling ratio of £30,000 per QALY) was 86% in 
the original model; this decreased when the evidence was replaced to 18% in the 
PARTNER B model and increases to 100% in the updated PARTNER B model. Figure 
7.7a-c presents the three CEACs side by side, to illustrate the changes in decision 
uncertainty as the cost effectiveness of TAVI for inoperable patients is re-examined. 
Thus, the original model the PARTNER B Model and the updated PARTNER B Model all 
suggest that TAVI is more costly and more effective compared with medical management 
in treating inoperable high risk AS patients. 
Value of Information Analysis 
The VOI analysis estimated that the pEVPI between TAVI and medical management for 
inoperable patients (2,750 (SHTG, 2009)), in the updated PARTNER B model at 
£30,000/QALY is £10,065 over one year. Overall this is lower than that estimated in the 
PARTNER B model which was £756,649 at £30,000/QALY for the UK inoperable 
population over one year. The pEVPI from the re-analysis of PARTNER B is also lower 
overall compared to the original analysis. Figure 7.8 presents the EVPI for the original 
model, PARTNER B model and updated PARTNER B model side by side for comparative 
purposes.  
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Table 7.5 Cost Effectiveness Results Comparison Updated PARTNER B, PARTNER B and Original Model: Inoperable Patients 
 
TAVI Medical Management  
 
Costs (£) QALYs LYs Costs (£) QALYs LYGs ∆  Costs ∆ QALYs ICER 
ORIGINAL* 28,353 2.18 3.48 13,942 1.53 3.06 14,441 0.65 22,108 
PARTNER B‡ 28,629 1.62 2.54 12,176 1.19 2.24 16,453 0.43 37,390 
UPDATED -PARTNER B† 41,428 3.05 4.71 11,307 1.47 2.44 30,122 1.58 19,078 
          
*Presented in Chapter     ‡ Presented in Chapter 5 † Presented in Section 7.3.2 
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Figure 7.6 Incremental Cost Effectiveness Plane Comparison: Inoperable Patients- Original, PARTNER B and Updated PARTNER B 
Models 
(a) Original Model     (b) PARTNER B Model     (c) Updated PARTNER B Model 
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Figure 7.7 Cost Effectiveness Acceptability Curve: Inoperable Patients Comparison - Original, PARTNER B and Updated PARTNER B 
Models 
(a) Original Model    (b) PARTNER B Model    (c) Updated PARTNER B Model 
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Figure 7.8 Expected Value of Perfect Information Comparison: Inoperable 
Patients - Original, PARTNER B and Updated PARTNER B Models 
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being considered cost effective and increasing the uncertainty surrounding the incremental 
costs and QALYs and adoption decision. The VOI analysis suggested that the value in 
collecting further information remained. The pEVPI at a threshold of £30,000/QALY was 
£756,649 for the UK inoperable population over one year. At this time there was much 
speculation about the likelihood of improved TAVI outcomes in the long-term, as new 
generations of devices were becoming available and centres were becoming more 
experienced (Schaff, 2011, Webb and Cribier, 2011). A scenario analysis tested the impact 
of such assumptions on the cost effectiveness of TAVI (in Chapter 5). The scenario 
analysis found if the incidence of all PREs following TAVI were reduced by 25%, TAVI 
could be considered cost effective compared to medical management for high risk, 
inoperable patients with an ICER of £23,642/QALY. 
Subsequently, late outcomes from early registries and the PARTNER trial emerged in 
spring 2012. This evidence was employed to update the PARTNER B evidence so as to 
include the best available data. (Evidence revealed reductions in PREs in the initial 30 day 
and one year period, though they were less than the 25% suggested in the scenario 
analysis.) The re-analysis, presented in this Chapter, demonstrated that TAVI could be 
considered cost effective for inoperable patients given current evidence (ICER = £19,078/ 
QALY). The revised VOI analysis demonstrated there was very little value in 
commissioning additional research for this patient group (at £30,000/QALY the EVPI for 
the population is £10,065). However, as the evidence base is still evolving, continued 
collection of data on TAVI outcomes, using existing means, is advisable. Thus, updating 
the model with evidence, as it became available, reduced the decision uncertainty 
surrounding the cost effectiveness of TAVI amongst inoperable patients compared with 
medical management.  
Concurrent to the release of these late TAVI outcomes, national health policies on access 
to TAVI were being revised. In late 2011, the Food and Drug Administration (FDA) 
approved TAVI for treating inoperable patients with severe AS in the US (Cadet, 2011). 
While in England and Wales, the National Institute of Clinical Excellence (NICE) 
Interventional Procedure Guidance (Number 421, 2012) recently approved the use of 
TAVI for inoperable patients provided patient/procedure details are entered into the UK 
Central Cardiac Audit Database (UK TAVI Registry) (NICE, 2012). While in Scotland, the 
Scottish Health Technologies Group (SHTG) advice statement (Number 005/11) issued 
prior to the release of the additional evidence does not currently recommend TAVI for 
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routine treatment of patients with AS (SHTG, 2011). The Scottish Government have 
though committed to reviewing this position (Scottish, 2012).  
This recent NICE guidance on TAVI provides an efficient and unambiguous process for 
collecting further evidence at a low marginal cost, relative to the costs of commissioning a 
new clinical trial, for this patient group in the UK. This data collection strategy may be 
considered a form of Access with Evidence Development (AED). Whereby, access to 
TAVI has been granted for inoperable patients, with clear instructions for further evidence 
collection. This data collection arrangement is formal in nature and offers a means to 
overcome the issues associated with further collection once access is granted. Griffin et al. 
(2011) identified a negative relationship between further evidence collection and granting 
access to a technology. Whereby, once access is granted to a technology the likelihood of 
collecting further evidence decreases. As outlined in Chapter 2, the obstacles to the success 
of AED schemes are grounded in the complexities surrounding the structures put in place 
for funding, administration (including reporting), access to the technology and incentives 
to comply.  
The UK TAVI Registry, referred to in the NICE Guidance, is populated with data from the 
Central Cardiac Audit Database (CCAD). This has been a functioning registry since 2007, 
recording all TAVI procedures performed in the UK (Ludmann, 2010). As the registry is 
already in existence the physical structure and resources are already in place. This 
encourages continued data collection, thereby reducing common complexities associated 
with collecting evidence after access is granted in a number of ways.  Firstly, as the 
database has existed since 2007 data entry is routine, this reduces the start-up costs and 
administration burden, making reporting straightforward. Secondly, as the requirement for 
reporting evidence is incorporated into the NICE Guidance, compliance is enforceable by 
the Care Guidance Commission (NICE, 2010). Thirdly, evidence published to date from 
the Registry has contributed to developing the TAVI evidence base which may have 
contributed to the guidance revision at national level. (To date only aggregate early 
outcomes from the Registry have been published  (Moat et al., 2011) these were not 
suitable for inclusion in this re-analysis). Finally, the guidance document clearly and 
legally identifies who has access to the technology. So as the guidance and data collection 
process is already in place, the traditional problems associated with collecting evidence 
after access is granted are reduced. Continual collection of evidence, via the UK TAVI 
Registry, as per the NICE guidance, ensures that up to date evidence will be available to 
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inform any future decisions regarding TAVI in this patient group, as advocated by the 
continuous iterative framework conceptualised in Chapter 2.  
While continued collection of the data currently included in the UK TAVI Registry is 
useful, expansion of the parameters in the UK TAVI Registry would be desirable. 
Currently, the Registry collects evidence on conversions, mortality, stroke and other 
procedure related events within the first 30 days. Mortality after one year is also recorded. 
The EVSI calculations, in Chapter 5, demonstrated that expanding the registry to include 
late procedure related events, resource consumption and quality of life parameters (listed in 
Appendix VI) has a positive net benefit. Such an expansion would enhance the UK TAVI 
Registry in informing future economic evaluations of TAVI, in line with the continuous 
iterative framework proposed in Chapter 2. 
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7.5 EVOLVING EVIDENCE FOR OPERABLE TAVI 
PATIENTS  
Operable patients are patients with high operative mortality for whom AVR is considered 
suitable. Here the treatment decision is between AVR and TAVI. In Chapters 4 and 6, 
medical management was included as a possible treatment for operable patients. However, 
it was repeatedly demonstrated to be less effective than AVR and TAVI and therefore it is 
excluded in the re-analysis presented here as patients would not be randomised to an 
inferior treatment.  
Since the publication of early PARTNER Cohort A results, longer-term evidence has also 
emerged for high risk operable patients on TAVI and AVR. This includes evidence on late 
procedure related events (PREs) and late mortality for TAVI and AVR from PARTNER 
Cohort A (Kodali et al., 2012) and late mortality outcomes following TAVI from the UK 
TAVI Registry (Moat et al., 2011). The emergence of this additional evidence affords the 
opportunity to re-analyse the cost effectiveness of TAVI compared to AVR for operable 
patients.  
Moat et al. (2011) reported on 870 TAVI procedures conducted in 25 centres in England 
and Wales between January 2007 and the end of December 2009. The logistical EuroScore 
of the patients averaged at 18.5% and ranged from 11.7 to 27.9. This range indicates the 
majority of these patients would have been considered operable, according to the model 
assumptions in this thesis, i.e. AVR was feasible, and so are included in this re-analysis of 
TAVI compared to AVR. The results reported in Moat et al. (2011) (Table 7.6) show that 
62 patients died within 30 days, 186 within one year and 229 within two years. Six patients 
converted from TAVI to AVR, while seven patients required a second procedure. With 
respect to PREs, 35 patients had a stroke (and survived) in hospital; 55 patients had 
vascular complications and 11 patients suffered a myocardial infarction and 141 patients 
required pacemaker insertion. 
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Table 7.6 Mortality and Procedure Related Events Reported in Moat et al. 
(2011) for TAVI Patients 
Event α β n Probability 
Stroke 35 829 864 0.04 
Myocardial Infarction 11 853 864 0.01 
Conversion to AVR 6 844 850 0.01 
Major Vascular Complications 55 814 869 0.06 
Repeat procedure 7 863 870 0.01 
Pacemaker 141 726 867 0.16 
Died within 30 days all causes 62 808 870 0.07 
Died within 1 year 186 684 870 0.21 
Died within 2 years 229 641 870 0.26 
Source: Moat et al (2011). Note α and n were extracted from the literature and β and the probability 
of the event occurring were calculated by the author. 
 
In addition to the registry data, Kodali et al. (2012) published longer term results from the 
PARTNER Cohort A trial detailing PREs beyond one year and mortality beyond one year. 
All-cause mortality for year two following AVR was estimated at 33% and following 
TAVI was 33 %. With respect to major PREs in year two following AVR, two cases of 
major paravavular leaks, five late strokes and two myocardial infarctions were reported. 
With respect to minor PREs in year two following AVR, Kodali et al. (2012) reported nine 
repeat hospitalisations, six major bleeding and three pacemakers implantations. Two years 
after a TAVI procedure, one case of endocarditis and six late strokes were reported. Also, 
the following minor PREs are TAVI in year two were reported: 15 repeat hospitalisations, 
one major vascular event, eight major bleeding events and two pacemaker implantations. 
These results were extracted from Kodali et al. (2012) and were employed to estimate 
probabilities of each event occurring, shown in Table 7.7. These probabilities are estimated 
as the proportion of events that occurred (α) from those that could have occurred (n). For 
example, following AVR in year two 16 (α) incidences of valve thromboembolism were 
reported. A total of 235 (n) patients could have had a valve thromboembolism, which gives 
a probability of 0.07 (α/n   16/2 5).  
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Table 7.7 Mortality and Procedure Related Events Beyond One Year 
Reported in Kodali et al. (2012) for TAVI and AVR Patients 
 
α β n Probability 
Major Late PREs Year 2 AVR 
    Major Paravavular Leak 2 233 235 0.01 
Endocarditis 0 235 235 0.00 
Stroke  5 230 235 0.02 
Myocardial Infarction  2 233 235 0.01 
     Major Late PREs Year 2 TAVI 
    Major Paravavular Leak 16 247 263 0.06 
Endocarditis 1 262 263 0.00 
Stroke  6 257 263 0.02 
Myocardial Infarction  0 263 263 0.00 
     Minor Late PREs Year 2 AVR 
    Repeat Hospitalisations  9 226 235 0.04 
Major Vascular Complications 0 236 236 0.00 
Minor Vascular Complications  0 237 237 0.00 
Major Bleeding  6 232 238 0.03 
New Pacemaker  3 236 239 0.01 
     Minor Late PREs Year 2 TAVI 
    Repeat Hospitalisations  15 248 263 0.06 
Major Vascular Complications 1 263 264 0.00 
Minor Vascular Complications  0 265 265 0.00 
Major Bleeding  8 258 266 0.03 
New Pacemaker  2 265 267 0.01 
     Fatal PREs Year 2 AVR 16 219 235 0.07 
Fatal PREs Year 2 TAVI 5 258 263 0.02 
     
All-Cause Mortality Year 2 AVR 
115 236 351 0.33 
All-Cause Mortality Year 2 TAVI 116 232 348 0.33 
     
Source Kodali et al. (2012). Note α and n were extracted from the literature and β and the 
probability of the event occurring were calculated by the author. 
 
 
7.5.1 Incorporating Longer-Term Results into the Decision 
Analytical Model for Operable Patients 
These longer-term published results from PARTNER Cohort A and the UK TAVI Registry 
are used to update the PARTNER Cohort A model presented in Chapter 6. Here an 
“updating” strategy is employed as opposed to a “replacement” strategy, as Kodali et al. 
(2012) and Moat et al. (2011) provided data which complements and updates the transition 
probabilities, i.e. early TAVI transition probabilities  (Moat et al., 2011) and late PREs for 
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AVR and TAVI (Kodali et al., 2012). Updating the PARTNER Cohort A data (employed 
in Chapter 6) ensures that the best, available data is employed in the model to re-assess the 
cost effectiveness of TAVI for operable patients compared to AVR. A pooling process is 
employed here equivalent to a fixed effects meta-analysis, involving the assumption that 
information is exchangeable and the baseline parameters being measured are identical. As 
outlined in Section 7.2, synthesising evidence from a variety of sources avoids the risk of 
biased assessment which can occur when relying on a single source (Sculpher et al., 2006).  
As per Section 7.2, the new evidence presented above was combined with the existing 
evidence to give revised transition probabilities. For example, (Box 7.2) PARTNER 
Cohort A reported 19 major strokes following TAVI within the first  0 days (α PARTNER A = 
19) from a total of 312 patients (n PARTNER A = 312). Subsequently, Moat et al. (2011) 
reported  5 cases of stroke within the first  0 days (α Moat = 35) and a total of 864 strokes 
could have occurred (n Moat   86 ). To update the transition probability the α (α PARTNER A 
and α Moat ) and n (n PARTNER A and n Moat) are summed to estimate the proportion of events 
occurring. This was calculated as follows 19+35=54; 312+864=1153; 54/1153=0.05. This 
was repeated for conversions from TAVI to AVR; repeat TAVI and death within 30 days 
following TAVI; PREs in short term for TAVI and year 2 for AVR and TAVI. The revised 
estimates are shown in Table 7.8.  
 
Box 7.2 Example of Updating PARTNER A Evidence 
Early Stroke α β n Probability 
PARTNER A 19 311 312 0.05 
Moat  35 829 864 0.04 
PARTNER A + Moat 54 1099 1153 0.05 
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Table 7.8 Revised Transition Probabilities  
Transition Probability Dist Probability 
95% CI 
α β n 
30 Day All-Cause Mortality TAVI* Beta 0.07 
(0.06-0.09) 
6
2 
808 870 
30 Day Stroke From TAVI* Beta 0.05 
(0.04-0.06) 
5
4 
1099 1153 
Conversion To AVR* Beta 0.01 
(0.01-0.02) 
1
5 
1179 1194 
Repeat TAVI* Beta 0.01 
(0.01-0.02) 
1
4 
110 1174 
Early Major PREs TAVI      
Valve Thromboembolism Beta 0.03 9 321 330 
Major Paravavular Leak Beta 0.11 3
5 
295 330 
Endocarditis Beta 0.00 0 330 330 
Cardiac Tamponade Beta 0.03 1
0 
320 330 
Myocardial Infarction* Beta 0.01 1
1 
1172 1183 
  0.17 
(0.13-0.22) 
   
Early Minor PREs TAVI      
Access Site Events Beta 0.06 2
0 
310 330 
Vascular Events Beta 0.06 2
1 
309 330 
Pacemaker Implantation* Beta 0.15 154 902 1056 
Major Vascular Event* Beta 0.08 9
3 
1051 1144 
Major Bleeding Beta 0.10 3
2 
298 330 
  0.45 
(0.40-0.51) 
   
Late Major PREs – Year 2 -AVR      
Valve Thromboembolism^ Beta 
0.05 
1
2 
223 235 
Major Paravavular Leak
†
 Beta 0.01 2 233 235 
Endocarditis
†
 Beta 0.00 0 235 235 
Cardiac Tamponade’ Beta 0.01 2 233 235 
Stroke 
†
 Beta 0.02 5 230 235 
Myocardial Infarction
†
 Beta 0.01 2 233 235 
  0.10 
(0.06-0.14) 
   
Late Major PREs – Year 2 – TAVI      
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Table 7.8 Continued      
Transition Probability Dist Probability 
95% CI 
α β n 
Valve Thromboembolism^ Beta 
0.06 
1
7 
246 263 
Major Paravavular Leak
†
 Beta 
0.06 
1
6 
247 263 
Endocarditis
†
 Beta 0.00 1 262 263 
Cardiac Tamponade’ Beta 0.01 3 260 263 
Stroke 
†
 Beta 0.02 6 257 263 
Myocardial Infarction
†
 Beta 0.00 0 263 263 
  0.16 
(0.12-0.21) 
   
Late Minor PREs – Year 2 – AVR      
Repeat Hospitalisations
†
 Beta 0.04 9 226 235 
Major Vascular Complications
†
 Beta 0.00 0 235 235 
Minor Vascular Complications
‡
 Beta 0.00 0 235 235 
Major Bleeding
†
 Beta 0.03 6 229 235 
New Pacemaker
†
  Beta 0.01 3 232 235 
  0.08 
(0.05-0.12) 
   
Late Minor PREs – Year 2 – TAVI      
Repeat Hospitalisations
†
 Beta 
0.06 
1
5 
248 263 
Major Vascular Complications  Beta 0.00 1 262 263 
Minor Vascular Complications
‡
 Beta 0.00 0 263 263 
Major Bleeding
†
  Beta 0.03 8 255 263 
New Pacemaker
†
  Beta 0.01 2 261 263 
  0.10 
(0.06-0.14) 
   
      
Year 2 Fatal PREs AVR Beta 0.07 
(0.04-0.10) 
1
6 
219 235 
Year 2 Fatal PREs TAVI Beta 0.08 
(0.05-0.11) 
2
0 
243 263 
      
‡Set to 0 as “major vascular complications” includes all vascular complications ^as per year one 
 ‘as per literature (original model) see Table 5.3 *updated to include Moat et al. (2011) † Updated 
to include Kodali et al. (2012). The remainder of the parameters are maintained from Tables 6.1-2 
in Chapter 6. 
 
 
Updating the transition probabilities estimated, using evidence from PARTNER Cohort A 
with Moat et al. (2011) (early TAVI transition probabilities) and Kodali et al. (2012)  (late 
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PREs following TAVI and AVR), decreased the probability of converting from TAVI to 
AVR (0.03 to 0.01). The probability of requiring a repeat TAVI procedure was also 
reduced (0.02 to 0.01). The 30 day all-cause mortality following TAVI increased from 0.04 
to 0.07 following the updating with Moat et al. (2011). Major strokes within 30 days 
following TAVI decreased from 0.06 to 0.05. The additional evidence from Moat et al. 
(2011) also increased early major PREs following TAVI from 0.16 to 0.17. This is 
attributable to the increase in myocardial infarctions. The probability of early minor PREs 
following TAVI also increased from 0.38 to 0.45. This is owing to the increase in 
pacemakers and major vascular events. 
As outlined above, incorporating evidence from Kodali et al. (2012) afforded the 
opportunity to differentiate between late PREs occurring during year one and beyond year 
one. This reduced the likelihood of late fatal PREs following AVR in year two, which 
decreased from 0.10 to 0.07. Also, the probability of late major and minor PREs following 
AVR in year two decreased from 0.11 to 0.10 and 0.22 to 0.08 respectively. The decrease 
in minor PREs is explained by the reduction in hospitalisations and major bleeding 
observed.  
With respect to patients who receive TAVI, the probability of late fatal PREs in year two 
decreased from 0.12 to 0.08. The probability of late major PREs in year two following 
TAVI also decreased from 0.18 to 0.16. This decrease is explained by the reduction in 
strokes observed. The probability of late minor PREs in year two following TAVI also 
decreased from 0.28 to 0.10. This decrease is owing to the reduction in hospitalisations, 
vascular complications, bleedings and pacemaker insertions observed compared to year 
one.  
As per previous iterations of the model, the uncertainty surrounding each of the parameters 
was incorporated into the model through the assignment of probability distributions. 
Combining results from PARTNER A with Moat et al. (2011) and Kodali et al. (2012) 
identified the total number of patients and the number for whom events occurred (Table 
7.8). All of the transition probabilities provided on Table 7.8 represent absolute risk for 
each arm of the model, AVR and TAVI. 
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Cost Parameters 
For the cost analysis the value of the following resources were estimated: AVR and TAVI 
devices, procedures, length of stay, hospitalisations and other costs incurred with PREs. 
Neither Moat et al. (2011) nor Kodali et al. (2012) provided additional information on the 
cost of the procedures, length of stay or unit costs of PREs. Therefore, the annual state 
costs and the procedural costs from Chapter 6 were maintained. The PRE costs are 
estimated as previously with a weight assigned to each event multiplied by the unit cost. 
The unit costs from Chapter 6 were maintained but the weights are updated with the 
revised probabilities. The PREs cost associated with AVR were estimated as follows. The 
cost of early minor PREs was £781 and early major PREs were £1,055. The cost of minor 
PREs were £2,341 and major PREs were £2,707 in year one. In year two onwards, the cost 
of minor PREs were £2,559 and major PREs were £3,164.  The PRE cost associated with 
TAVI were estimated as follows. The costs of early minor PREs were £440 and early 
major PREs were £1,766. The cost of minor PREs were £2,594 and major PREs were 
£2,700 in year one. In year two onwards the cost of minor PREs was £2,412 and major 
PREs were £2,160. Normal distributions were applied to the cost of treating PREs. The 
costs are discounted at the recommended 3.5%. 
Quality of Life Parameters 
As per the original model presented in Chapter 4, QALYs were also derived for each 
health state adjusting for the condition, the procedure and PREs. As with the costs, the 
impact on utility associated with the PREs were adjusted to account for the revised 
probabilities of events occurring. The utility from minor early, 1 year and 2 year PREs 
following AVR was 0.02. While the utility associated with major early, 1 year and 2 year 
PREs following AVR was 0.04. The utility associated with minor early, 1 year and 2 year 
PREs following TAVI were 0.03, 0.02 and 0.02 respectively. While the utility associated 
with major early, 1 year and 2 year PREs following TAVI was 0.04.   Moat et al. (2011) 
and Kodali et al. (2012) provided no additional information on NYHA classification of 
patients in each state either, so the utility of functioning valve replacement and failed valve 
replacement as per Chapter 6 were maintained. Normal distributions were applied to the 
utility hits associated with the PREs, while Dirichlet distributions were applied to the 
disutility associated with each NYHA classification. The QALYs are discounted at the 
recommended 3.5%.  
 266 
 
7.5.2 Analysis – Operable Patients 
An analysis similar to that employed in Chapter 4 and 6 is applied here for operable 
patients, with a UK NHS perspective. A Monte Carlo simulation with 10,000 iterations is 
used to propagate the uncertainty in the individual model parameters, reflected by the 
probability distributions assigned, through the model. This produces a distribution of 
expected costs and expected QALYs associated with each procedure. The mean values of 
these distributions are used to calculate the incremental cost effectiveness ratio (ICER) in 
terms of the expected incremental costs associated with TAVI compared to AVR per 
incremental QALY gained. The uncertainty associated with the incremental costs and 
incremental QALYs are presented through incremental cost effectiveness (ICE) planes. 
The uncertainty associated with the cost effectiveness of TAVI compared to AVR is 
presented in terms of a cost effectiveness acceptability curve (CEAC). Following this a 
number of scenario analyses were performed. After which a Bayesian VOI analysis is 
performed to estimate the value of collecting further evidence (using expected value of 
perfect information (EVPI)) and optimal data collection strategy using expected value of 
perfect information about parameters (EVPPI) and expected value of sample information 
(EVSI).  
 
7.6 COST EFFECTIVENESS RE-ANALYSIS OPERABLE 
PATIENTS  
The cost effectiveness of TAVI compared with AVR was estimated for operable patients 
based on a mix of early and late evidence from Cohort A of the PARTNER trial (Smith et 
al., 2011, Kodali et al., 2012) and the UK TAVI registry (Moat et al., 2011). The results 
indicate a 3% reduction in absolute risk in terms of all-cause mortality at the end of year 
one between TAVI and AVR which increases to 5% at the end of year two. This is 
illustrated on Figure 7.9. These mortality estimates correspond to the average mortality 
rates reported in the literature (Smith et al., 2011, Moat et al., 2011, Kodali et al., 2012). 
TAVI also offers significantly greater quality of life than AVR, with a 2% increase in 
quality of life compared to AVR in year 1 (Figure 7.10). 
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7.6.1 Deterministic Cost Effectiveness Results 
The deterministic cost effectiveness results (Table 7.9) were estimated using the point 
estimates for the transition probabilities, costs and utilities presented in the previous 
section. The results illustrate that for operable patients TAVI is both more costly (£9,836) 
and more effective (0.02 QALYs) than AVR. The ICER is estimated as £472,903 per 
QALY gained, which is above the level usually considered cost effective (£20,000-£30,000 
per QALY) (Rawlins et al., 2009). 
 
Table 7.9 Cost Effectiveness Results: Operable Patients – TAVI versus AVR 
  LYs Costs (£) ∆ Costs QALYs ∆ 
QALYs 
ICER £/ 
QALY 
  (95% CI) (95% CI) (95% CI) (95% 
CI) 
(95% CI) (95% CI) 
Deterministic Results 
AVR  4.88 34,037  2.99   
TAVI 5.04 43,873 9,836 3.01 0.02 472,903 
       
Probabilistic Results 
AVR  4.91 34,147  3.02   
(4.43-5.45) (29,920-38,540) (2.75-3.29) 
TAVI 5.08 44,069 9,922 3.03 0.02 605,756 
(4.67-5.61) (40,412-48,212) (6,099-13,361) (2.81-3.28) (-0.25-0.28)  
       
 
7.6.2 Probabilistic Cost Effectiveness Results 
Using the probability distributions assigned, a Monte Carlo simulation with 10,000 
iterations produced the mean costs and QALYs (Table 7.9). Here it is illustrated that for 
operable patients TAVI is both more costly (£9,922) and more effective (0.01 QALYs) 
than AVR. The incremental costs from the Monte Carlo simulation ranged from £1,320 to 
£17,285. While the incremental benefit ranged from -0.60 to 0.50 QALYs (95% 
confidence intervals reported in Table 7.9). The probabilistic ICER is estimated as 
£605,756 per QALY gained, which is well above the level usually considered cost 
effective (£20,000-£30,000 per QALY (Rawlins et al., 2009)). Thus, given the developed 
evidence base TAVI still cannot be considered cost effective compared to AVR for 
operable patients. 
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Figure 7.9 Survival Estimates for TAVI and AVR 
 
 
Figure 7.10 Quality of Life Estimates for TAVI and AVR  
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The ICE plane (Figure 7.11) illustrates the existence and extent of the uncertainty 
surrounding the incremental effect and incremental cost (these are the blue points plotted 
on Figure 7.11). There is considerable uncertainty surrounding the existence and extent of 
benefit for TAVI over AVR. However, there is little uncertainty surrounding the extent of 
differences in costs, TAVI is more expensive than AVR.  Furthermore, there is 
considerable uncertainty with respect to the extent of differences in costs, between TAVI 
and AVR. This is driven by uncertainties surrounding the probability of PREs.   
The CEAC (Figure 7.12) represents the decision uncertainty surrounding the cost 
effectiveness of each treatment. The uncertainty identified in the incremental costs and 
incremental effects individually does not translate into decision uncertainty regarding the 
cost effectiveness of TAVI over the range usually considered cost effective. At a ceiling 
ratio of £30,000 per QALY the probability that AVR is cost effective is 99% while the 
probability that TAVI is cost effective is 1%.  Indicating there is little decision uncertainty.   
 
Figure 7.11 Incremental Cost Effectiveness Plane: Operable Patients – TAVI 
versus AVR 
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Figure 7.12 Cost Effectiveness Acceptability Curve: Operable Patients – 
TAVI versus AVR 
 
 
7.6.3 Value of Information Analysis 
The potential value of undertaking further research is estimated by determining the value 
of eliminating all the uncertainties within the model (i.e. the EVPI). The per patient EVPI 
when deciding between TAVI and AVR, over the range usually considered cost effective 
(£20,000 - £30,000 per QALY)  (Rawlins et al., 2009), ranges from £0 to £11 per operable 
patient, for one year. A one year lifetime is chosen to reflect the evolving evidence base 
and early life cycle stage of the technology, as beyond one year evidence may no long 
represent the best evidence available. These estimates provide a maximum value for the 
return on further research, indicating there is very little value in collecting further 
information here. 
Given the public good characteristics of information the EVPI for the population (pEVPI) 
can be estimated also. Over a one year lifetime for the technology, the pEVPI for the 
operable population in the UK (2,250 (SHTG, 2009)) ranges from £563 to £24,375, over 
the range usually considered cost effective (Figure 7.13).  
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Figure 7.13 Expected Value of Perfect Information: UK Operable Population   
 
 
7.6.4 Comparison of Original and PARTNER A Model with Revised 
Model Incorporating Longer-Term Outcomes for Operable 
Patients 
Model Inputs 
As outlined above, the additional evidence from the UK TAVI Registry (Moat et al., 2011) 
and late outcomes from PARTNER Cohort A (Kodali et al., 2012) provided the 
opportunity to update the early PARTNER Cohort A trial evidence on operable patients, 
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this patient group. The updating resulted in no structural changes to the model but did 
provided revised estimates for mortality within 30 days from all causes; early stroke; early 
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stroke within 30 days remained constant at 0.05. The probability of early major PREs 
following TAVI was reduced by 0.01, while the probability of early minor PREs following 
TAVI decreased from 0.45 to 0.33. This was owing to the increase in pacemaker 
insertions. While late PREs in year one remained unchanged, late PREs beyond one year 
were updated for AVR and TAVI. The probability of late major PREs following AVR 
decreased by 0.01 the probability of late minor PREs decreased by 0.10. This was owing to 
the decrease in hospitalisations, vascular complications and bleedings observed. 
Meanwhile, the probability of major PREs in year two following TAVI was reduced by 
0.02 owing to the reduction in strokes. While the probability of minor PREs beyond one 
year following TAVI also decreased by 0.18. This was explained by the reduction in major 
bleeding, vascular events and pacemakers insertions observed in the updated evidence (See 
Appendix VII). 
Cost Effectiveness Results 
When the model is populated with the revised estimates and the cost effectiveness is re-
examined, TAVI was found to extend life and improve quality of life. The average life 
years gained in the updated PARTNER A model for patients receiving TAVI was 5.08. 
This is a significant increase on the PARTNER A model (3.44) and the original model 
(4.75). This increase was owing to the longer term mortality evidence provided by Kodali 
et al. (2012) which suggested an increased 30 day mortality rate and decreased mortality 
rates for 1 year and 2 year. For patients receiving AVR the updated PARTNER A model 
reveals 4.91 life years gained. This is also greater than the PARTNER A model (3.49) and 
the original model (4.63).   
In the re-analysis of the model, for operable patients, the costs associated with TAVI were 
estimated to be greater (£7,256; 20%) than suggested by the PARTNER A model. The 
QALYs produced in the re-analysis were also greater (0.94; 45%) than those from the 
PARTNER A model. These differences can be explained by the revised probability of 
PREs and stroke associated with TAVI and the greater life expectancy for TAVI patients. 
Meanwhile, the costs associated with AVR were estimated to be greater than suggested by 
the PARTNER A model (£4,452; 15%) as were the QALYs produced (0.82; 37%). These 
differences can be explained by the revised probability of PREs and stroke associated with 
TAVI and the greater life expectancy for AVR patients. 
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Results from the original, PARTNER A and updated PARTNER A models indicated that 
TAVI is more costly than AVR. The original model and updated PARTNER A models 
found that TAVI was marginally more effective compared with AVR for operable patients. 
However, the PARTNER A model found that TAVI was less effective than AVR for 
operable patients. The incremental costs in the updated PARTNER A model were 39% 
greater and the incremental QALYs were 109% greater than the PARTNER A model. In 
the PARTNER A model TAVI was dominated by AVR, but in the updated PARTNER A 
model TAVI is not dominated but the ICER is above the range usually considered 
acceptable (£605,756). Table 7.10 presents a comparison of the results from the three 
versions of the model.  
Thus, the original model employing data from published literature and the updated 
PARTNER A Model (with longer term evidence from the PARTNER trial), suggest that 
TAVI is more costly and slightly more effective compared with AVR in treating operable, 
high risk AS patients. However, the incremental benefit is not enough to offset the 
additional costs, so TAVI cannot be considered cost effective, given current evidence. 
The ICE plane compares the additional costs and benefits of TAVI over AVR. As 
discussed in Section 7.6.2, there is considerable uncertainty surrounding the existence and 
extent of differences in QALYs for TAVI over AVR in the updated PARTNER A model. 
Meanwhile, there is no uncertainty surrounding the difference in costs, with TAVI being 
more expensive, there is some uncertainty surrounding the extent of this uncertainty. 
Comparing the ICE planes, Figure 7.14a represents the incremental costs and QALYs for 
the original model; Figure 7.14b the PARTNER A model, and Figure 7.14c the updated 
PARTNER A model. Here it is illustrated that the uncertainty surrounding the extent of 
differences in QALYs and costs particularly has decreased when the evidence is updated. 
Comparing the updated PARTNER A model to the PARTNER A model it is evident that 
with the developed evidence base uncertainty surrounding the costs and effects persist but 
it has reduced. In the PARTNER A model the average incremental costs were £6,277 
(range: -£5,126 to £20,560) and average incremental QALYs were -0.11 (range: -0.89 to 
0.66). In the updated PARTNER A model the average incremental costs are £9,922 (range: 
£1,320 to £17,285) and average incremental QALYs are 0.02 (range: -0.60 to 0.50). This 
shift and reduction in uncertainty is explained by the updated evidence employed in the 
model which demonstrated a mortality advantage for TAVI and revised the incidence of 
PREs. 
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Comparing the CEAC from the updated PARTNER A model with the PARTNER A and 
original models demonstrates that there is little decision uncertainty. The probability that 
TAVI is cost effective compared with AVR (at a ceiling ratio of £30,000 per QALY) was 
2% in the original model; this decreased significantly when the evidence was replaced to 
0.2% in the PARTNER A model and increased to 1% in the updated PARTNER A model. 
Figure 7.15a-c presents the three CEACs side by side, to illustrate the changes in decision 
uncertainty as the cost effectiveness of TAVI for operable patients is re-examined. 
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Table 7.10 Cost Effectiveness Results Comparison Updated PARTNER A, PARTNER A and Original Model: Operable Patients 
 
 
AVR 
  
TAVI 
   
ICER 
 Costs (£) QALYs LYs Costs (£) QALYs LYs ∆ Costs ∆ QALYs £/QALY 
ORIGINAL* 26,698 2.84 4.65 31,854 2.90 4.73 5,157 0.06 85,982 
PARTNER A‡ 29,695 2.20 3.49 36,813 2.09 3.44 7,118 -0.11 TAVI Dominated 
Updated PARTNER A 34,147 3.02 4.91 44,069 3.03 5.08 9,922 0.02 605,756 
          
*Presented in Chapter     ‡ Presented in Chapter 6 † Presented in Section 7.6.2 
Figure 7.14 Incremental Cost Effectiveness Plane Comparison: Operable Patients: Original, PARTNER A and Updated PARTNER 
A Model 
(a)Original Model      (b) PARTNER A Model     (c) Updated PARTNER A Model  
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Figure 7.15 Cost Effectiveness Acceptability Curve Comparison: Operable Patients: Original, PARTNER A and Updated PARTNER A 
Model 
(a) Original Model*      (b) PARTNER A Model*   (c) Updated PARTNER A Model   
 
 
 
* Figures 7.15a and b differ to Figures 4.9, 6.6 and 6.10 as Medical Management is excluded from the analysis in Chapter 7. 
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Value of Information Analysis 
The VOI analysis estimated that the pEVPI between TAVI and AVR for operable patients 
(2,250 (SHTG, 2009)), in the updated PARTNER A model, over the range usually 
considered cost-effective ranged from £0 to £23,433 over one year. This was lower than 
that estimated in the PARTNER A model which ranged from £37,948 to £651,917 for the 
same population. Which was lower than that originally estimated using data from the 
literature which ranged from £5,252 to £501,513 for the same population
13
.  Figure 7.16 
presents the pEVPI for the original, PARTNER A and updated PARTNER A models side 
by side for comparative purposes. As illustrated here, the additional evidence reduced the 
pEVPI. While some uncertainty remains there is little value in collecting further evidence 
on the costs and effects of TAVI compared with AVR at the national accepted ceiling ratio 
levels. 
Figure 7.16 Expected Value of Perfect Information Comparison: Inoperable 
Patients - Original, PARTNER A and Updated PARTNER A Models 13 
  
                                                 
13
 Here EVPI is considered for the decision between TAVI and AVR only. Previous EVPI analyses 
presented in Figures 4.16 and 6.12, considered TAVI, AVR and Medical Management 
simultaneously. 
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7.7 WHERE NOW FOR TAVI WITH OPERABLE 
PATIENTS? 
When longer-term results for TAVI and AVR are incorporated into the model for operable 
patients, TAVI cannot be considered cost effective compared with AVR. There is little 
decision uncertainty and little value in collecting further evidence. A limitation of the re-
analysis lies in the source of the additional evidence. Firstly, Moat et al. (2011) only 
provided evidence on PREs following TAVI in the short run from the UK TAVI Registry. 
Secondly, the longer term evidence presented in Kodali et al. (2012) is from the 
PARTNER Cohort A trial. As outlined previously (Chapter 6), commentators, such as 
Schaff (2011), on the advances in TAVI have indicated that results such as those produced 
by the PARTNER trial and earlier registries, may not be as conclusive in considering the 
future for TAVI as anticipated. These trials used early generations of the device and were 
conducted in centres with early experience in delivering the procedure (Smith et al., 2011). 
Over time the devices are being modified and enhanced, which should reduce risk of injury 
and complications (Smith et al., 2011, Webb and Cribier, 2011). Simultaneously, centres 
are becoming more proficient and efficient at delivering TAVI (Smith et al., 2011). Thus, 
the rate of complications, including stroke and other PREs, are expected to fall. These are 
because of incremental innovations and movements along the learning curve, which are 
common with medical device technologies (explained Section 1.2.1). In addition, there has 
been speculation that the current price of TAVI may be revised downwards as newer 
generations of device become available; more competitors enter the market; research and 
development costs are recouped or alternatively some cost-sharing scheme is established 
(Drummond et al., 2009, Sorenson et al., 2011). 
To examine the potential impact of these changes on the cost effectiveness of TAVI a 
number of scenario analyses were performed and are presented here concerning the cost of 
the TAVI device, risk of stroke and PREs. 
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7.7.1 Scenario Analysis 1: Cost of TAVI 
The current cost of TAVI is very high (six times the cost of the AVR device) and is 
expected to decline. To investigate these claims two scenario analyses (SA) were 
performed here (results summarised in Table 7.11). 
Firstly, a scenario is considered whereby the initial cost of TAVI (including device, 
procedure and length of stay costs) is set equivalent to the initial cost of AVR (£18,988). 
This represents the possibility of the cost of the TAVI device being offset by the other 
procedure costs (Scenario 1.1). The analysis revealed that even with this reduction in the 
initial cost of TAVI it remains more expensive (£7,166; 20%) and marginally more 
effective (0.01; <1%) compared with AVR. This is owing to the high incidence of PREs 
with TAVI. The ICER is calculated as £551,323/QALY which is significantly above the 
acceptable ceiling ratio so TAVI cannot be considered cost effective compared to AVR. 
The probabilistic sensitivity analysis (PSA) revealed that at a ceiling ratio of 
£30,000/QALY the probability that TAVI is cost effective is only 5%, while the 
probability that AVR is cost effective is 95% (Figure 7.17). Here the pEVPI for the 
operable UK population (2,250 (SHTG, 2009)) at £30,000/QALY is estimated at £163,103 
for one year (Figure 7.18). This indicates in such a scenario, there is only some value in 
collecting additional information. 
Secondly, a threshold analysis was performed to identify the price that the TAVI device 
would have to be for the ICER to be equal to £30,000/QALY in a deterministic model 
(Scenario 1.2). The threshold analysis revealed that holding all else constant, the price of 
the TAVI device would have to be lowered by 75% to £3,050, for it to be considered cost 
effective compared to AVR (i.e. ICER = £30,000). A PSA revealed that at this price at a 
ceiling ratio of £30,000/QALY the probability that TAVI is cost effective in this scenario 
would be 48% while the probability that AVR is cost effective is 52% (Figure 7.17). Here 
the pEVPI for the operable UK population (2,250 (SHTG, 2009)) at £30,000/QALY is 
estimated at £3,357,524 for one year (Figure 7.18). This suggests that if such a scenario 
were to happen, there would be value in collecting additional information. 
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Table 7.11 Cost Effectiveness Results: Operable Patients – Scenario 
Analysis 
Scenario AVR TAVI ICER 
 
Costs £ QALYs Costs £ QALYs £/QALY 
1.1 Equivalent Procedure Costs 34,140 3.02 41,306 3.03 551,323 
1.2 Goal Seek: £30,000* 34,010 2.99 34,634 3.01 30,000 
      
2.1 Equivalent Stroke Rates 34,171 3.02 43,561 3.02 456,867 
2.2 33% Reduction in Early Major PREs 
TAVI 
34,180 3.02 41,994 3.09 111,021 
2.3 Equivalent Early, 1& 2 Year Major 
PREs 
34,168 3.02 39,366 3.14 42,985 
*Deterministic Result 
 
 
Figure 7.17 Scenario Analyses 1 Cost of TAVI: Cost Effectiveness 
Acceptability Curve: Operable Patients – TAVI vs. AVR  
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Figure 7.18 Scenario Analyses 1 Cost of TAVI: Expected Value of Perfect 
Information: UK Operable Population -  
 
 
7.7.2 Scenario Analysis 2: Stroke Rate and Procedure Related 
Events 
Using sensitivity analyses, the cost effectiveness analysis of TAVI produced here examines 
what if the stroke rate and early major PREs were reduced for these patients upon 
receiving TAVI through three different scenarios (results summarised in Table 7.11), 
compared to the baseline results employing best, currently available data. 
Firstly, a scenario analysis was performed whereby early major stroke (within 30 days) 
following TAVI was set equivalent to the stroke rate following AVR (0.03) (Scenario 2.1). 
The probabilistic sensitivity analysis (PSA) revealed for this scenario TAVI is more 
expensive (£9,390; 22%) and generates 0.02 additional QALYs compared with AVR. The 
ICER is calculated as £456,867, which is significantly greater than the range usually 
considered cost effective, so TAVI cannot be considered cost effective compared to AVR. 
At a ceiling ratio of £30,000/QALY the probability that TAVI is cost effective is only 2% 
while the probability that AVR is cost effective is 98% (Figure 7.19). The pEVPI for the 
operable UK population (2,250 (SHTG, 2009)) at £30,000/QALY is estimated at £77,694 
0.0
2.0
4.0
6.0
8.0
10.0
12.0
0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 100,000
Ex
p
e
ct
e
d
 V
al
u
e
 o
f 
P
e
rf
e
ct
 In
fo
rm
at
io
n
, £
 M
ill
io
n
s 
Ceiling Ratio, £ 
75% Reduction in Price
TAVI Device
Equal Cost AVR & TAVI
Updated PARTNER A
 282 
 
for one year (Figure 7.20). This indicates that at such scenarios, there would be little value 
in collecting additional information. 
Figure 7.19 Scenario Analysis 2 Stroke & Procedure Related Events: Cost 
Effectiveness Acceptability Curve: Operable Patients - TAVI versus AVR  
 
 
Figure 7.20 Scenario Analysis 2 Stroke & Procedure Related Events: 
Expected Value of Perfect Information: UK Operable Population -  
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Secondly, a scenario analysis was performed whereby all early major PREs following 
TAVI were reduced to a third of those reported (in Section 7.6) (Scenario 2.2). (A 
reduction of a third was selected based on expert opinion (Toff, 2011).) The PSA revealed 
for this scenario TAVI is more expensive (£7,814; 23%) and generates more QALYs 
(0.07; 2%) than AVR. Here the ICER is estimated to be £111,021/QALY which is outside 
the range usually considered cost effective. At a ceiling ratio of £30,000/QALY the 
probability that TAVI is cost effective is only 9% while the probability that AVR is cost 
effective is 91% (Figure 7.19). Here the pEVPI for the operable UK population (2,250 
(SHTG, 2009)) at £30,000/QALY is estimated at £340,447 for one year (Figure 7.20). 
Indicating that in this scenario there is some value in collecting further information.  
Thirdly, a scenario analysis was performed whereby the early, 1 year and 2 year major 
PREs following TAVI were reduced and set equivalent to those associated with the AVR 
procedure (Scenario 2.3). In this analysis, TAVI remained more expensive (£5,198; 15%) 
owing to the cost of the TAVI procedure etc. but generated more QALYs (0.12; 4%) than 
AVR. The ICER associated with TAVI is estimated at £42,985, which is marginally above 
the level generally considered cost effective in the UK. Thus, even with equivalent PREs to 
AVR, TAVI is still not cost effective amongst these patients, suggesting that the TAVI 
device is too expensive. If the price of the TAVI device fell and PREs improved then it 
may be considered cost effective. 
The ICE plane (Figure 7.21) shows that in this scenario, uncertainty remains in both the 
existence and extent of the differences in costs and QALYs. This translates to an increase 
in the decision uncertainty (compared to the updated PARTNER A model). At a ceiling 
ratio of £30,000/QALY, the probability that TAVI is cost effective is 36% while the 
probability that AVR is cost effective is 64% (Figure 7.19).  
This increase in the decision uncertainty leads to an increase in the maximum potential 
worth of further evidence concerning the relative effectiveness and associated costs of 
TAVI. The pEVPI is estimated to be £2.5 million for the UK operative population at a 
£30,000/QALY ceiling ratio (Figure 7.20). Given the substantial pEVPI here it was 
considered appropriate to undertake further calculations of VOI on parameters and sample 
information for this scenario analysis.  
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Figure 7.21 Scenario Analysis 2.3: Incremental Cost Effectiveness Plane: 
Operable Patients – TAVI versus AVR 
 
 
 
7.8 COLLECTING FURTHER EVIDENCE – BAYESIAN 
VALUE OF INFORMATION ANALYSIS FOR OPERABLE 
PATIENTS 
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patients (SHTG, 2009)). However, given current evidence TAVI cannot be considered cost 
effective for operable patients compared to AVR. It is worth noticing that the iterative cost 
effectiveness analyses performed in this thesis are heavily reliant on the PARTNER A trial 
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in the context of research (NICE, 2012). This recommendation is owing to inadequate 
evidence, which is a signal that the TAVI evidence base is still evolving and further 
evidence is required to demonstrate TAVI’s cost effectiveness. However, the EVPI 
estimates on the updated PARTNER A model (pEVPI is £24,375 at £30,000/QALY, 
Section 7.6) demonstrate there is little value in collecting further information based on 
currently, available data. It is anticipated however, that if new evidence (non-PARTNER) 
were to become available it may demonstrate improved TAVI outcomes amongst operable 
patients. The effect of such improvements was analysed in the previous section through 
scenario analyses which indicated that with improved TAVI outcomes the likelihood of 
TAVI being considered cost effective improves and there would be value in collecting 
further information. In which case, a sensible strategy may be to wait for additional 
evidence to emerge from other jurisdictions.  
Alternatively, primary data could be collected using a specific UK clinical trial or utilising 
and expanding the existing UK TAVI Registry. Using the expected net benefits estimated 
in the scenario analysis (2.3 in Section 7.7), where the probability of major PREs following 
30 days, one year and two year were set equivalent to those following AVR, a further 
Bayesian VOI analysis is performed and presented here.  This examines on which 
parameters future evidence is most valuable, using Expected Value of Partial Perfect 
Information (EVPPI) and how this future evidence should be collected, using Expected 
Value of Sample Information (EVSI), in the context of the scenario analysis.  
The EVPPI analysis indicates the maximum potential value associated with further data 
collection for specific parameters and/or groups of parameters. It estimates the value of 
eliminating the uncertainty surrounding those parameters under consideration, providing a 
maximum value that society would be willing to invest in further research concerning 
those parameters. While the EVSI estimates the value of a reduction in uncertainty 
associated with the collection of specific information based on a particular research design. 
(These techniques were described in detail in Chapter 2.) 
As outlined above, additional evidence can be collected via trials or registries. It is 
anticipated that both of these methods would have the power to collect additional 
information short term transition probabilities; long term transition probabilities; resources 
consumed and quality of life/utility information for patients. Whereby, the trial would 
collect this evidence for both procedures and the registry would only collect this for TAVI. 
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This expectation is informed by what is currently collected in the UK TAVI registry (as 
per Ludmann (2010)) and what was collected in the PARTNER trial (see Appendix VI). 
These parameters are grouped into eight groups as shown in Table 7.12. 
Table 7.12 Parameter Groups for a  Potential Clinical Trial and Registry for 
Operable Patients 
1 Short Term 
Outcomes 
Major PRE AVR 
Major PRE TAVI 
Minor PRE AVR 
Minor PRE TAVI 
Converting to AVR 
Converting to MM 
Converting to TAVI 
Repeat TAVI 
Major stroke AVR 
Major stroke TAVI 
Death 30 days AVR 
Death 30 days TAVI 
2 Short & Long Term 
Outcomes 
Major PRE AVR 
Major PRE TAVI 
Minor PRE AVR 
Minor PRE TAVI 
Converting to AVR 
Converting to MM 
Converting to TAVI 
Repeat TAVI 
Major stroke AVR 
Major stroke TAVI 
Death 30 days AVR 
Death 30 days TAVI 
late pre TAVI fatal yr 1 
late pre AVR fatal yr 2 
Late PRE TAVI 
Late PRE AVR 
Late minor PRE TAVI 
Late minor PRE AVR 
Late PRE TAVI yr 2 
Late PRE AVR yr 2 
Late minor PRE TAVI yr 2 
Late minor PRE AVR y2 
Late fatal PRE AVR y2 
Late fatal PRE TAVI yr2 
Relative risk of mortality AS 
Death AS – TAVI 
Death AS – post 1 year 
 
3 Quality of 
Life 
Utility Fn 
TAVI 
Utility 
persistent AS 
TAVI 
Utility Fn 
AVR 
Utility 
persistent AS 
AVR 
4 Resources 
Total LOS AVR 
Total LOS TAVI 
Post discharge AVR 
Post discharge TAVI 
Cost functioning 
AVR 
Cost functioning 
TAVI 
Cost persistent AS 
AVR 
Cost persistent AS 
TAVI 
5 Short Term 
Outcomes – TAVI 
Only 
Major PRE TAVI 
Minor PRE TAVI 
Converting to AVR 
Converting to MM 
Repeat TAVI 
Major stroke TAVI 
Death 30 days TAVI 
6 Short & Long Term 
Outcomes – TAVI Only 
Major PRE TAVI 
Minor PRE TAVI 
Converting to MM 
Repeat TAVI 
Major stroke TAVI 
Death 30 days TAVI 
Late pre TAVI fatal yr 1 
Late PRE TAVI 
Late minor PRE TAVI 
Late PRE TAVI yr 2 
Late minor PRE TAVI yr 2 
Late fatal PRE TAVI yr2 
Relative risk of mortality 
AS 
Death AS – TAVI 
Death AS – post 1 year 
7 Quality of 
Life – TAVI 
Only 
Utility Fn TAVI 
Utility persistent 
AS TAVI 
8 Resources– 
TAVI Only 
Total LOS TAVI 
Post discharge 
TAVI 
Cost functioning 
TAVI 
Cost persistent AS 
TAVI 
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7.8.1 Clinical Trial 
An application for a funded UK TAVI clinical trial was made  to the NHS HTA committee 
and subsequently appealed and reapplied for in 2011 (NIHR, 2010) and was accepted in 
spring 2012 (NICE, 2012). The application was for a prospective, multi-centre, pragmatic, 
randomised control trial comparing TAVI with AVR amongst operable patients with 
severe symptomatic aortic stenosis. Data would be collected in specialist hospitals deemed 
to have an active cardiac surgical and TAVI programme which had performed at least 30 
prior TAVI procedures. At the time of the proposal this included 20 centres around the 
UK. The target patient population was those with severe, symptomatic AS who have been 
referred for surgery. Patients would be 80 years or over, with one or more factors 
indicating high operable risk. The suggested sample size (as set out in the 2011 
application) was 808 patients. The estimated fixed costs were £2,250,000 and variable 
costs were estimated to be £15,000 per patient
14
 (Toff, 2012). The proposal identified that 
data would be collected over nine years, with five year minimum follow up. Examining the 
trial application it was apparent that the data collected would provide additional 
information on short and long term probabilities, utilities, resources and long term 
mortality. A list of the parameters such a clinical trial could provide information on is 
provided in Appendix VI. 
Expected Value of Perfect Parameter Information 
If a clinical trial, such as that described above was to be used to collect additional 
information it could potentially collect information on short and long term transition 
probabilities; mortality rates; resources and utilities for TAVI and AVR respectively. Thus, 
four groups of parameters (groups 1-4, Table 7.12) were considered individually and 
simultaneously in estimating the EVPPI, to indicate the maximum potential value 
associated with further data collection on those parameters.  
Figure 7.22 illustrates the population EVPPI for these groupings at a ceiling ratio of 
£30,000/QALY. The results of the EVPPI analysis indicates that if further data collection 
was to provide evidence on group 2 individually, the short and long term events and 
mortality parameters following TAVI and AVR, would be worth a maximum of £2.21 
                                                 
14
 Cost estimates are based on consultation with experts from the proposed UK TAVI trial (Toff, 
2012) 
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million for the UK population, at a ceiling ratio of £30,000/QALY. At this ceiling ratio 
there is no value in collecting evidence on short term probability, resource or quality of life 
parameters in isolation. While collecting additional evidence on the four groups 
simultaneously, would be worth a maximum of £2.36 million for the UK population, at 
£30,000/QALY. The population EVPI at £30,000/QALY is shown here also for 
comparison.  
 
Figure 7.22 Expected Value of Perfect Parameter Information: UK Population 
– at Ceiling Ratio of £30,000/QALY (Clinical Trial) 
 
Expected Value of Sample Information  
EVSI is calculated for groups 1-4 individually and simultaneously (illustrated as the blue 
line, series five on Figure 2.23), representing the clinical trial, for a variety of sample sizes: 
250; 500; 1000 and 2000 (summarised in Table 7.13). The results indicate that with a 
sample size of 250 patients the EVSI for the trial is £1.40 million (at a ceiling ratio of 
£30,000/QALY) for the UK population for one year. If the sample size increases to 500 
patients, the EVSI increases to £1.78 million for the UK population for one year at 
£30,000/QALY. Increasing the sample size to 1,000 patients increases the EVSI for the 
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trial to £2.05 million for the UK population for one year at £30,000/QALY. Finally, with a 
sample size of 2,000 patients the EVSI for the trial is £2.23 million for the UK population 
for one year at £30,000/QALY.  
 
Figure 7.23 Expected Value of Sample Information: Operable Patients 
 
Expected Net Benefit of Sampling 
 
As discussed in Chapter 5, in the context of Figure 5.10, the EVSI analysis employed here 
(Figure 7.23) is also subject to limitations. It was not computationally feasible to increase 
the number of iterations employed, owing to computing constraints. Methodological 
developments in meta-models etc. over time should reduce the practical challenges 
associated with implementing EVSI.  
The expected costs for a UK TAVI trial for operable patients were estimated using the 
same estimates considered in Chapter 5 (Toff, 2012).  Fixed costs are estimated to be £2.25 
million and variable costs are estimated to be £15,000 per patient. These expected costs 
can be compared to the expected benefit of the trial (measured by EVSI) to estimate the 
expected net benefit of sampling (ENBS).  
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For example, the expected value (EVSI) for a trial with 2,000 patients is £2.2 million (at 
£30,000/QALY). The expected cost of this trial is £32.5 million (estimated using fixed cost 
of £2.25 million and variable costs £30 million (£15,000 * 2,000 patients)). As the 
expected costs are greater than the EVSI, the ENBS is negative, indicating that a trial of 
this size and magnitude cannot be considered cost effective. This is repeated for different 
sample sizes. The ENBS results indicate that at a ceiling ratio of £30,000/QALY, across 
the four sample sizes, the ENBS for the trial is negative. Thus, the trial cannot be 
considered cost effective at the £30,000/QALY ceiling ratio (used to estimate EVSI). 
However, if the nationally accepted ceiling ratio was increased to £70,000 per QALY, the 
ENBS across the sample sizes is positive, indicating the trial would be viable, as 
demonstrated on Figure 7.24. 
 
Figure 7.24 Expected Net Benefit of Sampling: Clinical Trial - Operable 
Patients 
 
 
Using the expected costs estimated above, an approximation for how long the information 
from the trial would have to be relevant for to recoup the costs can be estimated. This is 
calculated by dividing the expected trial cost by the EVSI. For example, a trial with sample 
size of 250 patients is estimated to cost £6.25 million (based on the fixed and variable costs 
from above). A trial capable of collecting information on all parameters in groups 1-4 with 
this sample size has an EVSI of £1.4 million. Thus, to recoup the costs of the trial, the 
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information collected from it would need to be relevant for approximately four and a half 
years. Similarly for a trial with 2,000 patients, the expected costs are £32.5 million 
(including NHS service cost) and the EVSI is £2.2 million. Thus, to recoup the costs of the 
trial the information collected from it would need to be relevant for 14.5 years. These 
results are summarised in Table 7.13. Given the nature of novel medical devices like 
TAVI, information from trials like that proposed here are unlikely to yield information 
relevant for such long periods. 
Table 7.13 Expected Value of Sample Information: Clinical Trial - Operable 
Patients  
Sample 
Size 
EVSI @ £30,000/QALY Cost of Trial* £ Millions 
Groups 1-5 6.25 
(n=250) 
10.0 
(n=500) 
17.5 
(n=1,000) 
32.5 
(n=2,000) 
  Years to Recoup Costs 
250 1,401,705 4.46    
500 1,777,388  5.63   
1,000 2,046,758   8.55  
2,000 2,234,948    14.54 
*Costs are based on fixed costs £2.25 million and variable costs of £15,000 per patient as per 
expert opinion (Jones, 1995).  
 
 
Given the disincentives which persist for collecting additional evidence for medical 
devices and the attention TAVI has attracted, it is possible that such a trial may receive 
sponsorship from one or more device manufactures (as was the case previously for the 
PARTNER trial which was funded by Edwards LifeSciences). This could reduce the 
variable costs of the trial by up to £12,000 (assuming the sponsor covers the cost of the 
TAVI device). ENBS of the TAVI trial with fixed costs remaining at £2.25 million and 
variable costs reducing to £3,000 per patient revised the ENBS as follows (the sample 
design remains the same as above). 
At a ceiling ratio of £30,000/QALY, across the four sample sizes the ENBS remains 
negative, even for the sponsored trial. However, if the nationally accepted ceiling ratio was 
increased to £70,000/QALY, a trial with sample size of 2,000 would have the highest net 
benefit, with an ENBS of £11.2 million. These ENBS results are presented on Figure 7.25. 
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This indicates that at the current range of nationally accepted ceiling ratio, i.e. what society 
is willing to pay for an extra QALY, even sponsorship trial there a clinical trial of this 
magnitude at the current expected costs is not economically viable. 
 
Figure 7.25 Expected Net Benefit of Sample Information: Sponsored Clinical 
Trial - Operable Patients 
 
 
7.8.2 Registry 
An alternative to an expensive clinical trial would be to expand the existing UK TAVI 
Registry (Ludmann, 2010) to collect additional evidence. As per NICE guidelines, details 
on all TAVI procedures performed in the UK are recorded through the Central Cardiac 
Audit Database (CCAD) (Ludmann, 2010).  From this database the UK TAVI Registry has 
developed through collaboration between the BSCIS and STCTS
15
, Department of Health 
and Special Commissioners and Health Technology Assessment and NICE. Appendix VI 
shows the evidence currently being collected in the UK TAVI Registry and what additional 
evidence could be collected through a registry. It is anticipated that an extension of the UK 
TAVI Registry could collect additional evidence on the following types of parameters 
associated with the TAVI procedure: (1) short term probabilities, (2) short and long term 
                                                 
15
 British Cardiovascular Intervention Society (BCIS), Society of Cardiothoracic Surgeons (SCTS) 
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probabilities (including long term mortality), (3) utility and, (4) resources consumed. These 
correspond to parameter groups (5-8) listed in Table 7.12.  
Expected Value of Perfect Parameter Information 
An EVPPI analysis illustrates the maximum potential worth of collecting data on TAVI for 
each of the groupings through an expanded UK TAVI Registry. Data collected on group 6 
individually, short and long term probabilities parameters for TAVI, would be worth a 
maximum of £1.31 million for the UK population, at a £30,000/QALY. At this threshold 
there is little value in collecting evidence on any of the remaining groups of parameters (5, 
7 or 8) in isolation.   However, if further data was collected on all the parameters contained 
in groups 5-8 simultaneously, it would be worth a maximum of £1.39 million for the UK 
population, at a ceiling ratio of £30,000/QALY. Figure 7.26 illustrates the population 
EVPPI for each grouping for a range of values of cost effectiveness thresholds. The 
population EVPI is also shown here for comparison at £30,000/QALY. 
 
Figure 7.26 Expected Value of Perfect Parameter Information: UK Operable 
Population – at Ceiling Ratio of £30,000/QALY (Registry) 
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Expected Value of Sample Information  
Using the same groups of parameters as per the EVPPI calculations the EVSI was 
estimated for a variety of sample sizes: 250, 500, 1,000 and 2,000. Firstly, with a sample 
size of 250 patients the EVSI analysis revealed that collecting data on all parameters within 
groups 5-8 simultaneously was worth £1.86 million (at a ceiling ratio of £30,000/QALY) 
for the UK population for one year. Secondly, with a sample size of 500 patients the EVSI, 
when collecting data on all parameters in groups 5-8 simultaneously, was worth £1.98 
million for the UK population for one year at £30,000/QALY. Thirdly, with a sample size 
of 1,000 patients the EVSI, when collecting data on all parameters in groups 5-8 
simultaneously, was £1.67 million for the UK population for one year at £30,000/QALY. 
Finally, with a sample size of 2,000 patients the EVSI, when collecting data on all 
parameters within groups 5-8 simultaneously, was £1.49 million for the UK population for 
one year at £30,000/QALY. These are illustrated as the orange line on Figure 7.23.  
Expected Net Benefit of Sampling  
Following consultation with experts (Cunningham, 2012) the fixed costs of a registry were 
estimated at £100,000 and variable costs were estimated as £50 per patient for operable 
patients. These expected costs were compared to the expected benefit of the trial (measured 
by EVSI) to estimate the expected net benefit of sampling (ENBS). The ENBS is estimated 
for four sample sizes, ranging from 250 to 2,000 (Figure 7.27).  
For example, the expected value (EVSI) for a trial with 2,000 patients is £1.49 million. The 
expected cost of this trial is £200,000 (estimated using fixed cost of £100,000 and variable 
costs £100,000 (£50 * 2,000 patients)). As the expected costs are less than the EVSI (at 
£30,000/QALY ceiling ratio), the ENBS is positive, indicating that a registry of this size 
and magnitude can be considered cost effective.  
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Figure 7.27 Expected Net Benefit of Sampling: Registry - Operable Patients 
 
 
7.8.3 The Future for TAVI for Operable Patients 
This thesis applied an iterative approach to using a decision analytical model to handle the 
developing and evolving nature of TAVI’s evidence base, in assessing the cost 
effectiveness of TAVI for operable patients. From the analysis it is evident that the 
challenges associated with medical devices persist for this patient group. These include 
evolving evidence owing to incremental innovations, movements along the learning curve 
etc. Also, as this group is lower risk than inoperable patients, the benefits to be gained 
from TAVI are less than those for inoperable patients. This can discourage evidence 
generation amongst this patient group.  In addition, given that approval has been granted 
for TAVI amongst inoperable patients, there is a risk that the disincentives for further 
research in this patient group will remain.  
The Bayesian Value of Information (VOI) analysis performed here using the results of the 
scenario analysis demonstrated there would be value in collecting further evidence on short 
and long term transition probabilities, resources and quality of life parameters for TAVI 
and AVR in the context of Scenario 2.3, Section 7.7. As for how this evidence should be 
collected, the EVPPI demonstrates that at a ceiling ratio of £30,000/QALY, there is value 
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in collecting this information on AVR and TAVI via a clinical trial or on TAVI only via a 
registry,  in the context of Scenario 2.3 from Section 7.7. 
However, evidence collection is not cheap. Using the estimates of expected costs (based on 
expert opinion (Cunningham, 2012, Toff, 2012)) and the EVSI estimates, the expected net 
benefit of sampling (ENBS) for a clinical trial (sponsored and unsponsored) and registry 
were calculated. The results indicated that for a clinical trial (even with sponsorship) the 
costs exceed the benefits at a ceiling ratio for £30,000/QALY, so it cannot be considered 
cost effective. Meanwhile, at a ceiling ratio of £30,000/QALY, a registry could be 
considered cost effective.  
Nevertheless, uncertainties persist for this patient group and the UK TAVI Trial is going 
ahead as indicated in the most recent NICE guidance (Number 421, 2012) (NICE, 2012). 
This recommends that TAVI is only performed on operable patients in the context of 
research (“only in research”). Whereby, they encourage clinicians to report all procedures 
in the forthcoming UK TAVI Trial and the UK Central Cardiac Audit Database (i.e. the 
UK TAVI Registry). Thus, a form of Access with Evidence Development is being 
initiated. 
The analysis presented in Section 7.6 suggested there was no value in collecting further 
information and the analysis based on the scenario analysis. Also, a clinical trial could not 
be supported, owing to the negative ENBS, Nevertheless, a chief shortcoming of the 
evidence surrounding novel medical devices, like TAVI, is the lack of evidence on their 
long term performance. One reason for this is the lack of requirements for evidence, which 
in turns creates disincentives for research. In particular, there are disincentives for research 
on medium to low risk patients where the gains are less than those for high risk patients.  
A publically funded trial, like the UK TAVI Trial, endeavours to overcome these 
disincentives and to ensure evidence is collected before the device becomes part of routine 
clinical practice. It also avoids genericization by considering all devices and given the 
lengthy timeframe for the trial (approximately nine years) incremental innovations and 
movements along the learning curve should be captured. Also, it is anticipated that the trial 
will overcome some of the persistent challenges facing TAVI, owing to its medical device 
characteristics, the current evidence base and the stage it is at in its lifecycle. Thus, the UK 
TAVI Trial provides an opportunity to capture the advances in the evidence base since 
PARTNER. Another advantage of the proposed trial lies in its positioning within the NICE 
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guidance. Recommending “only in research” provides a means of collecting evidence in a 
pragmatic trial setting which should align the trial findings more closely to those expected 
in clinical practice.  Such a recommendation is in line with Access with Evidence 
Development strategies which aim to grant coverage (albeit on a limited basis) while 
collecting additional evidence in a clinical practice setting. The additional evidence 
generated can be used to inform future adoption and research priority setting decisions, in 
line with the continuous iterative framework conceptualised in Chapter 2.  
 
7.9 WHERE NOW WITH TAVI FOR ALL PATIENTS? 
In this Chapter a third iteration of the TAVI model for operable and inoperable patients 
was performed to re-address the adoption and research priority setting decisions. Using 
evidence of late outcomes from the PARTNER trial and subsequent outcomes from 
European registries, the decision analytical model was updated and the cost effectiveness 
and VOI analyses were re-assessed for inoperable and operable patients respectively.  
The results revealed that TAVI can be considered cost effective for treating inoperable 
patients compared to medical management. This supports the latest NICE guidance which 
recommends the use of TAVI for inoperable patients. The additional NICE 
recommendation that all details of the aforementioned procedures are entered into the UK 
Central Cardiac Audit Database for the UK TAVI Registry is welcomed, despite the low 
pEVPI at a ceiling ratio of £30,000/QALY, it has low collection costs. The continual 
collection of evidence ensures that up to date evidence on TAVI for inoperable patients is 
available to inform any future decisions regarding TAVI in the patient group, as per the 
continuous iterative framework.  
In contrast, , the results of the analysis presented here suggest that TAVI still cannot be 
considered cost effective for treating operable patients compared to AVR and there is no 
value in collecting further information. It is suspected that in this patient group 
uncertainties and immature evidence remain. One explanation is owing to the persisting 
reliance on PARTNER outcomes. Despite the findings of this study, the latest NICE 
guidance advocates the collection of additional information via the forthcoming UK TAVI 
Trial and the UK TAVI Registry. While not cost effective this formal evidence collection 
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will add to the evidence base and its deployment via clinical practice is in line with Access 
with Evidence Development which is noteworthy. However, the expected costs of 
collecting information via a trial, even if sponsored, are high. Even under the scenario 
analysis presented here an expanded registry is more cost effective than a trial and  the 
results of this analysis suggest such additional information will have little impact on the 
cost effectiveness results of analysis. 
Having conducted an iterative economic evaluation of TAVI, focus now turns to the 
lessons learned from the case study and the recommendations for future economic 
evaluations of expensive novel medical devices with evolving evidence, presented  in 
Chapter 8.  
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CHAPTER 8 CHALLENGES, LESSONS AND 
RECOMMENDATIONS FOR ECONOMIC 
EVALUATIONS OF HEALTH TECHNOLOGIES WITH 
AN EVOLVING EVIDENCE BASE 
 
8.1 INTRODUCTION  
While the methods for economic evaluations (described in Chapter 2) are well established 
for all types of health technologies, most international guidelines for conducting them are 
developed in the context of drugs (Drummond et al., 2009, Drummond et al., 2008). The 
National Institute of Clinical Excellence’s (NICE) appraisal programme, which is 
explicitly for medical devices, is one of the first of its kind (Sorenson et al., 2011). There is 
also considerable variability between how drugs and devices are regulated. These factors, 
along with some unique characteristics of medical devices (presented in Chapter 1), 
present challenges for conducting economic evaluations of them (Drummond et al., 2009, 
Taylor and Iglesias, 2009). Such challenges include the lack of formal processes for 
adoption, difficulties with conducting randomised control trials (RCTs), the learning curve 
and innovative nature of devices which result in evolving evidence, the suitability of 
genericization and changes in prices (explained in Section 1.2.1). While previous studies 
(for example, Sorenson (2011)) identified these challenges retrospectively, this case study 
of TAVI is the first to investigate the challenges and identify potential solutions while 
conducting an economic evaluation. These challenges do not mean that cost effective 
studies are impossible; rather that the full range of methods for conducting an economic 
evaluation (Chapter 2) should be utilised to overcome the challenges. In particular, the 
continuous iterative framework proposed in Chapter 2 can be implemented to handle these 
challenges.  
TAVI is employed in this thesis as a case study to investigate how economic evaluations of 
expensive, novel medical devices can be performed efficiently and informatively to advise 
adoption and research priority setting decisions as evidence develops using the continuous 
iterative framework proposed in Chapter 2. To investigate this, a decision analytical model 
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(DAM) is constructed and three iterations are performed for both operable and inoperable 
patients. While others have considered the cost effectiveness of TAVI for operable or 
inoperable patients amongst AS patients using PARTNER evidence (Neyt et al., 2011, 
Orlando, 2011, Reynolds et al., 2012, Watt et al., 2011) this is the first time an iterative 
framework is applied for both operable and inoperable patients. Also, the consideration of 
the Value of Information (VOI) for operable and inoperable patients is an important 
contribution of the thesis, as other studies only highlighted the need for further evidence 
qualitatively but did not formally quantify its value using Bayesian VOI. The results of the 
iterative economic evaluation and VOI are summarised below. Also, in conducting the 
evaluation characteristics of novel technologies like TAVI became apparent which 
provided challenges for the evaluation. These challenges are identified and reflected upon 
here, proposals for overcoming the challenges are considered and recommendations are 
made.  
 
8.2 COST EFFECTIVENESS ANALYSIS AND VALUE OF 
INFORMATION ANALYSIS – TAVI 
To investigate the cost effectiveness of TAVI in treating severe AS, the thesis considered 
two subgroups patients with severe AS: operable and inoperable patients (defined by risk). 
Operable patients were defined as those eligible to receive AVR, so the choice of treatment 
was between AVR, TAVI and medical management (depending on risk level). Inoperable 
patients were those considered unsuitable for AVR owing to high risk of operative 
mortality so the treatment choice was between TAVI and medical management. A DAM 
consisting of a decision tree and Markov model was constructed and populated for each 
group. To account for uncertainty, probability distributions were assigned to parameters 
and a Monte Carlo simulation was run for a probabilistic sensitivity analysis (PSA). Three 
iterations of the model were performed for both operable and inoperable patients 
(summarised on Figure 8.1). These iterations corresponded to evolutions in the evidence 
base: pre-trial evidence, evidence from the first randomised control trial (early outcomes), 
late trial and registry outcomes. The results for each subgroup are summarised below. 
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Figure 8.1 Evolutions in TAVI Evidence Base – Iterative Approach  
 
 
8.2.1 Operable Patients 
Low Risk Operable Patients 
At the outset of the thesis two subgroups of operable patients were considered – high and 
low risk. Low risk operable patients were considered suitable for AVR or TAVI. In the 
original model (populated with published evidence from case series and early registries) 
they were assumed to have an operable mortality of 5%. The PSA produced mean costs 
and benefits (measured as quality adjusted life years (QALYs)) which demonstrated that 
TAVI was more expensive and more effective than AVR with uncertainty surrounding the 
extent of the incremental differences.  The incremental cost effectiveness ratio (ICER) was 
estimated to be £147,617/QALY, which is outside the range usually considered cost 
effective (£20,000-£30,000/QALY). The cost effectiveness acceptability curve (CEAC) 
demonstrated that at a ceiling ratio of £30,000/QALY the probability that TAVI is cost 
effective was only 15%. Thus, TAVI could not be considered cost effective for this patient 
group. The expected value of perfect information for the population (pEVPI) at 
£30,000/QALY was £1.08 million indicating there is value in collecting further 
information for this patient group. However, neither cohort in the PARTNER Trial or 
subsequent published evidence considered low risk operable patients so the cost 
effectiveness of TAVI compared to AVR for these patients was not revisited explicitly 
within the thesis. Since 2007 all TAVI procedures performed in the UK are recorded in the 
UK TAVI Registry. Overtime, this may present some additional data for this patient group, 
facilitating a re-analysis.  
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High Risk Operable Patients  
For high risk operable patients the treatment decision was between TAVI, AVR and 
medical management. The “original model” (populated with published evidence from case 
series and early registries) assumed an operative mortality of 15% and demonstrated that 
TAVI was more expensive and only marginally more effective than AVR, which was in 
turn more expensive and more effective than medical management. The ICER from the 
PSA comparing TAVI and AVR was £85,982/QALY which is outside the range usually 
considered cost effective. Meanwhile, the ICER comparing AVR and medical management 
was £9,721/QALY which is inside the range usually considered cost effective. Thus, 
comparing TAVI to AVR, TAVI cannot be considered cost effective and comparing AVR 
and medical management, AVR can be considered cost effective for this patient group. The 
CEAC demonstrated that at a ceiling ratio of £30,000/QALY the probability that AVR is 
cost effective was 98%, the probability that TAVI is cost effective is only 2% and the 
probability that medical management is cost effective was 0%. The pEVPI at 
£30,000/QALY was £23,433/QALY indicating there is very little value in commissioning 
additional research on this patient group. 
Subsequent to the original analysis, the first TAVI randomised control trial (PARTNER), 
published results for high risk operable AVR versus TAVI (Cohort A). The results from 
Cohort A were employed to populate the TAVI and AVR arms of the DAM (replacing 
published literature employed in the original model) and evidence from Cohort B was used 
to populate the medical management arm (replacing published literature used in the 
original model) to reflect the best available data for a second iteration of the model 
(“PARTNER A”). This resulted in some structural changes to the model (described in 
Chapter 6). The results of the PSA indicated that TAVI was more costly and less effective 
than AVR. Thus, TAVI was dominated by AVR.  The ICER for AVR compared to medical 
management was £16,276/QALY which is within the range usually considered cost 
effective. Thus, AVR could be considered cost effective compared to medical management 
for these patients. The CEAC demonstrated that at a ceiling ratio of £30,000/QALY the 
probability that AVR is cost effective is 98.7%, the probability TAVI is cost effective is 
0.2% and the probability medical management is cost effective is 1.1%. The pEVPI at a 
ceiling ratio of £30,000/QALY was £651,917, indicating there was some value in 
commissioning further research for these patients.  
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After the initial publication of the PARTNER trial results, further external evidence 
became available for high risk operable patients (late results from PARTNER Cohort A 
and early results from the UK TAVI Registry). These were used to update the PARTNER 
Cohort A evidence from the second iteration and the cost effectiveness of TAVI compared 
to AVR was considered for a third time (“Updated PARTNER A”). The results from the 
original model and the model populated using PARTNER, both indicated that medical 
management was consistently outperformed by AVR. So where AVR was available it 
would be unethical to randomise patients to medical management. Thus, only AVR and 
TAVI were considered in this iteration. The PSA results, from updating the model with this 
evolved evidence and re-running the model, indicated that TAVI was more expensive and 
marginally more effective than AVR and the ICER was £605,756/QALY. So TAVI still 
cannot be considered cost effective compared to AVR. The CEAC demonstrated the 
probability of AVR being cost effective was 99% and TAVI was 1%. The pEVPI at a 
ceiling ratio of £30,000/QALY was £24,375, indicated there was very little value in 
commissioning further research.  
However, owing to the nature of medical device technologies like TAVI there was much 
speculation that the TAVI outcomes would improve and/or the cost of TAVI would 
decrease over time. Scenario analyses were used to investigate these hypotheses. One 
scenario considered the impact on the ICER if the probability of early, year 1 and 2 major 
procedure related events (PREs) following TAVI were equivalent to those following AVR 
(informed by expert opinion (Toff, 2011)). Here the PSA produced an ICER of 
£42,985/QALY, which is marginally outside the range considered cost effective. The 
CEAC demonstrated the probability that TAVI was cost effective was 36% and the pEVPI 
was £2.5 million at a ceiling ratio of £30,000/QALY. Further VOI analyses demonstrated 
that further research should collect evidence on short and long term probability, resource 
and quality of life parameters. However, given the expected costs associated with 
collecting this evidence via a clinical trial for TAVI and AVR, a registry only collecting 
this evidence on TAVI is more suitable. Thus, should future research indicate improved 
TAVI outcomes, the cost effectiveness and value of collecting further information 
improves. Alternatively, the additional evidence simulated here using the scenario analysis, 
may be generated and collected externally from another jurisdiction for example.  
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8.2.2 Inoperable Patients 
Inoperable patients with Aortic Stenosis are considered unsuitable for AVR owing to high 
operative mortality risk and co-morbidities. The treatment options available to these 
patients were TAVI and medical management. The first iteration of the model was 
populated using published literature on early case series, registries, expert opinion and 
experience with AVR (“Original”), owing to scarce evidence on TAVI. The operative 
mortality risk assumed for this patient group was 20%. The PSA estimates revealed an 
ICER of £23,603/QALY which was within the range usually considered cost effective. The 
CEAC demonstrated the probability that TAVI is cost effective was 86% and medical 
management was 17%. The pEVPI was £1.3 million at a ceiling ratio of £30,000/QALY. 
These results indicated that TAVI could be considered cost effective and there was value in 
collecting further information.  
While the original analysis did indicate value in collecting additional evidence, the results 
from PARTNER trial for Cohort B were published a short time later. This additional 
evidence was used to replace the original point estimates in the TAVI and medical 
management arm where available for a second iteration of the model (“PARTNER B”). 
The PSA results indicated an ICER of £37,390/QALY which is outside the range 
considered cost effective. The CEAC demonstrated the probability of TAVI being cost 
effective as 18%. The pEVPI was £756,649/QALY, indicating there is still some value in 
collecting further information. The expected value of perfect information around 
parameters (EVPPI) and the expected value of sample information (EVSI) demonstrated 
the optimal research design for collecting this additional information should include the 
collection of evidence on short and long term probability, resources and quality of life 
parameters via a registry. 
Sometime later (2012) further external evidence was published (late outcomes from 
PARTNER and early and late outcomes from European registries). The PARTNER Cohort 
B data employed in the previous iteration was updated with this new evidence facilitating a 
third iteration of the model (“Updated PARTNER B”). The PSA results indicated an ICER 
£19,078/QALY, so TAVI could now be considered cost effective. The CEAC 
demonstrated there was no decision uncertainty surrounding the cost effectiveness results 
(probability that TAVI was cost effective was 100%). The pEVPI at £30,000/QALY was 
just £10,065, indicating there was little value in commissioning research. However, given 
the low marginal costs, continued collection of evidence via the UK TAVI Registry (as per 
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NICE guidelines) is recommended and is in line with the continuous iterative framework 
proposed in Chapter 2.  
 
8.3 OVERCOMING THE CHALLENGES FOR ECONOMIC 
EVALUATIONS FOR HEALTH TECHNOLOGIES WITH 
EVOLVING EVIDENCE  
8.3.1 Evidence Requirements, Licensing Procedures, Diffusion & 
the Learning Curve 
The evidence requirements for licensing medical devices is less demanding that that for 
drug technologies. In addition, as licensing occurs close to the point of market entry there 
is rapid clinical uptake as soon as a device is available and so it quickly becomes part of 
clinical practice, which can even happen prior to RCTs reporting.   For example, the 
PARTNER trial only reported 30 day and one year outcomes in November 2010 and 
March 2011 respectively. However, the first TAVI device achieved a CE Mark in 2007 
(Edwards SAPIEN valve) and by 2009 4,498 procedures had been performed worldwide. 
In March 2010, the next generation device, the Edwards SAPIEN XT valve and its two 
delivery systems, received a CE Mark (Eggebrecht and Thielmann, 2010) and in December 
of that year Medtronic’s CoreValve system received the CE Mark (Medtronic, 2010). 
During 2010, the number of TAVI procedures performed in the UK increased to 14,599. 
This increased further to 18,372 in 2011 (Wood, 2012).  
Also, when medical devices are diffused and become part of clinical practice there is 
interaction between the device and practitioners which influences the learning curve and 
increases uncertainty around the parameters. These evolutions can be captured in the 
evolutions of the evidence base, which are incorporated in the various iterations by 
updating and re-analysing the model.  
An advantage of this rapid approval process however is the resulting increase in 
competition, which may reduce prices. The effects of such price reductions are captured 
using scenario analyses performed in Chapters 4, 5 and 7.  
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8.3.2 Difficulties with Randomised Control Trials (RCT) 
Despite TAVI being available since 2002 when this evaluation began in 2009 only short 
term evidence on TAVI from small case series and early registries were available. The 
studies that were available had small sample sizes ranging from 1 to 86, were mainly single 
centre studies and were not randomised. Thus, in populating the initial model no “gold 
standard”, i.e. randomised evidence, was available and immature evidence had to be 
employed along with AVR experience and expert opinion. To address this challenge 
Bayesian decision analytical modelling (DAM) was employed, as recommended by Taylor 
and Iglesias (2009). Such a framework facilitated evidence synthesis and extrapolation 
across patient groups and time frames. So for example, where evidence is provided for up 
to one year but a twenty year lifecycle is assumed, the estimates for year one were 
employed over twenty years. To account for uncertainty in parameters, owing to the source 
of the initial estimates and the extrapolation, probability distributions were assigned. A 
probabilistic sensitivity analysis (PSA) (described in Chapter 2) was used to propagate this 
uncertainty through the model using a Monte Carlo simulation, which provided 
distributions of expected outcomes (costs and QALYs). The mean values of these 
distributions provided estimates of the expected cost effectiveness of the device, given the 
uncertainty. These were used to estimate the ICER, incremental costs and effects and to 
estimate decision uncertainty.  
Also, an analysis of the distributions from the PSA provided estimates of the potential 
worth of collecting further evidence. This Bayesian VOI analysis provided a means of 
determining what additional information would be necessary to reduce or eliminate 
uncertainty in the model, by estimating the population Expected Value of Perfect 
Information (pEVPI). This was useful in determining if further research was required and 
what the optimal research design was, in the absence of formal evidence requirements. 
Optimal research design was initially informed by the expected value of perfect 
information about parameters (EVPPI), which indicates on which parameters additional 
information would be most valuable and the expected value of sample information (EVSI). 
The latter was compared to the expected costs of sampling, to determine the expected net 
benefit of different study designs.  
In addition, there is a tendency for early studies to focus on higher risk patients as the 
chance of demonstrating benefits are greatest amongst those patients. These data are often 
then used as “generic” and are “genericized” or applied to the other patient groups in the 
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initial model. In the case study presented here, evidence was limited in the original model. 
So by varying assumptions and structural parameters in the model the differing operative 
mortality risks and treatment options for each group could be considered. For example, an 
operative mortality risk of 5% was assumed for low risk operable patients, while 20% was 
assumed for high risk inoperable patients. Also, only the TAVI and medical management 
arms were considered suitable for high risk inoperable patients, while all three were 
suitable for high risk operable patients. As the evidence base evolved, evidence specific to 
patient groups became available so different point estimates could be incorporated to 
account for heterogeneity between patient groups reflecting the best available data for that 
time. Also, to account for heterogeneity between different patient groups, in this thesis 
individual analysis of sub-groups were considered. The DAM was populated with evidence 
associated with each particular risk group and a PSA was undertaken per sub group to 
estimate cost effectiveness and the value of collecting further information for each group.  
 
8.3.3 Incremental Innovation 
As illustrated in the summary of results above, the cost effectiveness of TAVI was 
examined three times in response to evolving evidence. This evolving evidence was linked 
to incremental changes or innovations in the TAVI device over time. Unlike drugs, where 
phase III trials are undertaken when clinical results are robust, devices undergo frequent 
modifications which impact efficiency and end points overtime. These evolutions are in 
response to clinical evidence and practice and may result in reduced procedure length, 
reduction in the number failures etc. Consequently, there is rarely a “steady-state” period 
where RCTs for devices could be undertaken without being obsolete upon reporting 
(Drummond et al., 2009, Taylor and Iglesias, 2009) as was suggested to be case with 
PARTNER by Schaff  (2011) and Webb and Criber et al. (2011) . 
To address the challenge of incremental innovations in this thesis, an iterative framework 
for the economic evaluation and DAM was applied. This provided a means of re-assessing 
the cost effectiveness or adoption decision for the technology as the evidence base evolved. 
Whereby, as there was an innovation, which updated the evidence, the transition 
probabilities and probabilistic distributions were revised, updating the evidence base and 
the decision uncertainty was re-assessed. The PSA was then re-run and the results were re-
examined.  In the TAVI case study, employed in this thesis, three iterations were 
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performed in line with significant evolutions in the evidence base (Figure 8.1).  The first 
iteration included pre-trial evidence. The second iteration was performed upon publication 
of results from the first RCT for TAVI, PARTNER trial. The third iteration was performed 
upon publication of the first late outcomes on TAVI and publication of more recent 
European Registries. This was done for both operable and inoperable patient groups. For 
each iteration, the model structure was examined to ensure it reflected understanding of the 
procedure and disease at that time, in line with the continuous iterative framework. The 
second iteration, incorporating PARTNER evidence, resulted in some structure changes to 
the model, so as to reflect practice at that time. Also, scenario analyses were employed to 
forecast the effect of future evolutions in the evidence base. Then all newly available 
evidence was incorporated, the adoption and research priority setting decisions were re-
considered.  
 
8.3.4 Genericization and Class Affect 
As outlined above, owing to lenient evidence requirements for the approval of devices, 
there is a disincentive for manufacturers to produce evidence of effectiveness after 
introduction to the market. Consequently, there may be unequal evidence available 
between device brands. This can result in evidence only being available for one brand and 
modellers having little choice but to genericize or extrapolate across brands. In the TAVI 
case study, as the Edwards devices received CE Marks before Medtronic devices (2007 
and March 2010 (Eggebrecht and Thielmann, 2010) versus December 2010 (Medtronic, 
2010)) there was less evidence available on the Medtronic devices, preventing a Medtronic 
only analysis. Thus, the results were genericized across brands. That is to say, all evidence 
available, irrespective of the brand was included. Thus, the model included all devices, and 
any additional uncertainty presented by this was handled when accounting for uncertainty 
through the PSA.  
 
8.3.5 Pricing 
The incremental innovations, undemanding evidence requirements and procurement 
procedures for medical devices can influence prices also; owing to increased competition 
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etc. To consider changes in device prices, different pricing scenarios were considered 
through sensitivity analyses in Chapters 4, 5 and 7. 
Thus, employing an iterative Bayesian framework for economic evaluations, including 
decision analytical modelling, PSA and VOI analysis permits the modeller to capture the 
uncertainties resulting from the challenges discussed above.  This enabled this economic 
evaluation of a novel expensive medical device with evolving evidence, to be just as useful 
as those for drugs in informing adoption and research priority setting decisions. A further 
means of addressing the challenges and utilising economic evaluations of devices to their 
full capacity is to consider implementing Access with Evidence Development schemes. 
This can facilitate balancing access demands and ensuring further evidence is collected 
promptly.  
 
8.4 ACCESS WITH EVIDENCE DEVELOPMENT SCHEMES 
FOR HEALTH TECHNOLOGIES WITH EVOLVING 
EVIDENCE  
8.4.1 Access with Evidence Development Schemes 
As described in Chapter 2, Access with Evidence Development (AED) schemes are 
considered as a way to balance tensions between evidence requirements/standards and 
providing access to emerging innovative technologies. Such schemes grant limited or 
temporary coverage for a specific period during which additional evidence on risks, costs 
and effectiveness can be collected for a sample of the population. As indicated to be 
worthwhile using results of the VOI analysis (Pearson et al., 2006, Tunis and Chalkidou, 
2007, Tunis and Pearson, 2006, Turner et al., 2010). As discussed in Chapter 2, there are 
different ways of organising AED schemes. For example, in the US they tend to be 
implemented via Medicare, whereby reimbursement for new technologies is only granted if 
patients enrol in relevant randomised control trials (RCTs) (Taylor and Iglesias, 2009). 
However, in the UK they tend to operate like a real-world RCTs or RCTs in practice 
whereby coverage is granted “only in research”. Regardless of implementation type, AED 
schemes provide a means of considering the issues and resulting challenges associated with 
novel technologies, such as the learning curve and incremental innovations, while 
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simultaneously considering clinical and cost effectiveness of the device (Taylor and 
Iglesias, 2009). 
Trueman et al. (2010) propose criteria to identify when AED schemes are most useful and 
valuable. Firstly, according to the authors, where a technology is meeting a high clinical 
need (previously unmet) and delivering improvements in outcomes, AED schemes are 
appropriate. Secondly, promising health technologies often have the potential to deliver 
clinical improvements compared to standard practice and have logical and theoretically 
valid value propositions. While some demonstration of efficacy and safety are necessary 
for CE Marks and equivalent, evidence of these improvements and justification for the 
value proposition may be outstanding. Thirdly, these ambiguities can suggest there is 
uncertainty surrounding clinical and cost effectiveness which are resolvable via the 
collection of additional data. Bayesian VOI analysis can be used to determine the value of 
generating this additional information. If it is demonstrated that additional data will reduce 
these uncertainties, then further information should be collected, provided it can be done at 
a reasonable cost. AED schemes can overcome the lack of motivation often present when it 
comes to collecting this additional information and incentivise it.  However, care needs to 
be taken that AED schemes do not become an op out for earlier evidence generation, for 
which incentives are already low. 
Fourthly, data collection via an AED scheme may be more appropriate than traditional 
coverage tools where there is uncertainty remaining around clinical and cost effectiveness. 
Traditionally, coverage was considered a dichotomous decision: yes or no. However, if 
coverage is granted (“yes”) there is little incentive to continue research. Fifthly, as outlined 
above, coverage may be awarded to medical devices with persistent uncertainty owing to 
the characteristics of devices. In particular, there may be little or no evidence on long term 
effectiveness. Granting coverage therefore based on small, non-randomised 
trials/observational data which is extrapolated between patient groups and device brands 
can impact patient safety. This can occur if evidence informing decisions (adoption and 
research priority setting) is not being updated as there are movements along the learning 
curve, incremental innovations and long term patient experiences are not followed up and 
reported on. Alternatively, if coverage is not awarded device manufacturers can wait for 
others to conduct the research and be free-riders. Or if the decision is never revisited 
patients are denied access to potentially lifesaving technologies. Finally, AED is a more 
dynamic means of coverage compared with conventional tools, whereby coverage is 
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granted to sub-groups for a pre-specified period, agreed by stakeholders, during which time 
the agreed evidence is collected. As mentioned above, AED can incentivise the collection 
of further evidence, without which there may be little motivation to collect the additional 
evidence. This facilitates an iterative re-assessment of the coverage decision using relevant 
evidence as it becomes available. These six criteria are summarised in Box 8.1. 
 
Box 8.1 Criteria for Access with Evidence Development Schemes 
 
1. High unmet clinical need; significant improvements in outcomes outstanding. 
2. Value proposition for the technology is logical and theoretically valid, but evidence to 
support this is lacking. 
3. Data collection is the best solution to resolve the uncertainty. 
4. Traditional coverage tools are inappropriate to resolve the clinical or cost effectiveness 
uncertainty. 
5. The primary concern is uncertainty surrounding clinical or cost-effectiveness outcomes 
(not just financial/budgetary impact). 
6. Stakeholders agree that the evidence development is achievable in a timely manner. 
 
 
8.4.2 Access with Evidence Development– Suitable for TAVI? 
Using the criteria above (summarised in Box 8.1), the feasibility and suitability of AED 
schemes for expensive novel health technologies, characterised by uncertainty and 
evolving evidence, can be examined. The TAVI case study presented here can be used to 
investigate this. Firstly, given the nature of the device and initial evidence used to gain CE 
Marks and equivalents, it was demonstrated that TAVI has the potential to improve clinical 
outcomes relative to AVR and is theoretically valid. Traditionally, AVR was the standard 
treatment for severe AS, where the aortic valve was replaced with invasive surgery. Those 
with very high operative risk were considered inoperable and they received medical 
management. This provides transient relief and does not prolong survival. TAVI offers an 
alternative for these inoperable patients providing them with a valve replacement while 
avoiding the risks associated with surgery. TAVI also provides an alternative for operable 
patients wishing to avoid the invasive procedure and longer recovery times. 
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Secondly, using a Bayesian framework for investigating cost effectiveness, including the 
DAM and PSA, persistent uncertainty surrounding the cost effectiveness of TAVI was 
investigated and shown to be constant in the first iteration, the original model. Here there 
was considerable uncertainty surrounding the cost effectiveness of TAVI compared to 
AVR for operable patients. This uncertainty persisted in the second and third iterations 
when the model was updated to incorporate trial and registry evidence.  
Thirdly, when the short term trial evidence was updated, with longer term trial outcomes 
and registry evidence for operable and inoperable patients for the third iteration, decision 
uncertainty and uncertainty surrounding the incremental costs and effects was reduced. For 
example, with inoperable patients the probability that TAVI is cost effective at 
£30,000/QALY ceiling ratio was 18% in iteration two and this increased to 100% in 
iteration three. This demonstrates how incorporating additional evidence into the DAM via 
an iterative framework can reduce uncertainties. For the other patient group, operable 
patients, uncertainty persists. Updating the PARTNER A model only increased the 
likelihood of TAVI being cost effective from 0.2% to 1%. 
Fourthly, Bayesian VOI techniques such as EVPI, EVPPI and EVSI were employed to 
determine the value of collecting further evidence to reduce the persistent uncertainty. In 
the second iteration for inoperable patients it was shown that there was value in collecting 
additional information. Here the EVPPI illustrated that further evidence on short and long 
term probability, resource and quality of life parameters are most valuable. When further 
evidence became available, from an external source, the model was updated forming the 
third iteration. Similarly, for operable patients the EVPI demonstrated there was potential 
value in collecting further information, particularly if outcomes improved. For medical 
devices, like TAVI, after CE marks etc. are granted and the devices become part of 
practice in some areas the demands for access increase, even if there outstanding 
information requirements. In such cases, AED schemes are superior to tradition coverage 
rules as they offer a means of balancing access and demand, while generating further 
evidence.  
Fifthly, despite the lack of influence on what additional evidence was generated, the cost 
effectiveness analysis here demonstrated that after the third iteration TAVI could be 
considered cost effective compared to medical management for inoperable patients. 
Meanwhile, even after three iterations decision uncertainty persists and TAVI cannot be 
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considered cost effective compared to AVR for operable patients. In this instance, 
conventional coverage tools (dichotomous yes or no) are not suitable. Given the persisting 
uncertainties a “yes” is highly unlikely, while an outright “no” has significant opportunity 
losses for those who could benefit from TAVI. Had an AED scheme for TAVI been 
developed earlier there could have been more control over the parameters informed by the 
evolving evidence. This may have reduced decision uncertainty and uncertainties 
surrounding costs and effects, particularly for operable patients, even further. As outlined 
previously, PARTNER is still heavily relied upon, as it is the only published RCT, despite 
being for one brand of the device and including early experiences of the device.  
Finally, for TAVI there has been considerable stakeholder involvement in generating 
further evidence, peripheral to this thesis. The first RCT, the PARTNER Trial, was 
initiated and funded by one of the TAVI manufacturers, Edwards LifeSciences. This 
demonstrated the manufactures commitment to research and generating further evidence. 
Also, clinicians and the health service in the UK demonstrated their commitment to 
generating further research with the establishment and continuation of the UK TAVI 
Registry and the forthcoming UK TAVI Trial.  
In the past, there has been a varied success rate for AED schemes, as discussed in Chapter 
2. This variation is due to the scheme characteristics, for example the type of data to be 
collected; the timeframe identified; the population chosen; who is funding the scheme etc. 
So when designing AED schemes access delays, which may produce disincentives for 
further innovations, and dichotomous outcomes, need to be avoided. In addition, good use 
should be made of patient sub-groups. For example, opportunities for exchangeability of 
evidence between patient sub-groups, as well as between jurisdictions, should be sought 
(Trueman et al., 2010).  
Examining the case study presented here using the proposed criteria for AED, it appears 
that TAVI is in theory a suitable candidate. Had an AED scheme been formally considered 
upon CE approval in 2007 or 2010, the current RCT (PARTNER) may have been designed 
more efficiently, informed by VOI analysis. This may have reduced the costs associated 
with further research, avoiding the costs of additional trials like the upcoming UK TAVI 
Trial which this analysis could not consider to be cost effective). It also could have reduced 
the time taken for NICE and other decision makers to decide on the suitability of TAVI for 
 314 
 
treating AS, or it would have at least formalised a time line for the re-assessment of the 
decision. Both of these may have reduced decision uncertainty and reduced access delays. 
Nevertheless, an AED scheme was not employed and ad hoc and uncoordinated evidence 
has been generated to date. One could argue therefore that the costs of collecting additional 
evidence have been higher than would have been the case if an AED scheme has been 
employed earlier. Also, uncertainties persist so more evidence is still required and further 
collection is due to commence, for example the UK TAVI Trial. Such trials increase costs 
and time spent on generating evidence by first movers, which further incentivises free 
riders given the current regulatory environment.  
Nevertheless, it is not too late, given the persisting uncertainties and expected incremental 
innovations further evidence is due to be collected on operable patients. The decision by 
NICE to only recommend the use of TAVI amongst operable patients with special 
arrangements for clinical governance, consent and data collection or research via the UK 
TAVI trial is welcomed (NICE, 2012). This form of AED attempts to balances access and 
data collection. Whereby, access is only granted for research or data collection purposes. 
This guarantees further evidence is collected and should ensure that the cost effectiveness 
of TAVI for these patients will be re-assessed.  Furthermore, as access is conditional on 
evidence collection, it can be removed more easily if the need arises, than if full coverage 
had been granted.  
 
8.5 LESSONS & RECOMMENDATIONS FOR HEALTH 
TECHNOLOGIES WITH EVOLVING EVIDENCE  
8.5.1 Access with Evidence Development? 
As mentioned above, it is not too late to implement an Access with Evidence Development 
scheme for TAVI, particularly amongst the operable patient population.  Uncertainties, the 
incremental nature of medical devices and movements along the learning curve persist 
indicating that that further information is useful. The VOI analysis presented in Chapter 7 
illustrated that a registry is more cost effective than a UK trial for generating additional 
evidence. Specifically, an expansion of the current UK TAVI Registry to collect 
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information on short and long term probability of events and mortality, resource 
consumption and quality of life of operable AS would be valuable. The VOI analysis in the 
scenario analysis (Section 7.8) indicates that a registry with 500 patients is optimal (yields 
highest ENBS) (Figure 7.27). This would mean that access would be limited to just over 
20% of the population (total operable population in the UK is 2,250 per annum). Once this 
detailed evidence on TAVI outcomes are collected the decision analytical model could be 
re-examined to consider the cost effectiveness of TAVI. Patient selection could be 
informed by the existing measures in the NICE Guidance document (Number 421, 2012). 
Employing the continuous iterative framework, conceptualised in Chapter 2, ensures that 
AED (and other Performance Based Risk Sharing Agreements) are considered each time 
there is a model iteration after the adoption and research priority setting decisions have 
been considered.  
 
8.5.2 Alternatives to UK Trials and Registries 
Despite the indication that clinical trials may not be cost effective from the analysis 
presented here, there is an apparent preference for clinical trials over registries, as 
demonstrated in the case of TAVI in the UK. Given this preference, a feasible and 
potentially cost effective option may be to use global trials (Eckermann and Willan, 2009). 
As illustrated in this thesis, employing results from the PARTNER trial, using transferable 
evidence from trials conducted in other jurisdictions is beneficial and feasible in the 
continuous iterative framework conceptualised in Chapter 2. Considering external evidence 
is useful as new technologies, like TAVI, are generally released simultaneously across 
jurisdictions. For example, CE marks are applicable across Europe. Thus, provision and 
evidence collection decisions regarding such technologies are not unique to one health care 
system. Each health system generating its own economic evaluation, decision analytical 
model and evidence can be inefficient and impossible in some cases, owing to lack of 
resources, infrastructure and experience. In addition, data collection is time consuming and 
expensive and all too often results are released in an untimely fashion (Claxton et al., 
2005). Therefore, a common evidence base could be useful to inform such coverage and 
research priority setting decisions. 
In light of these concerns, organisations such as the European Network for Health 
Technology Assessments (EUnetHTA) promote international collaboration such as global 
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trials/ registries and information exchange. This can improve resource allocation; co-
ordination of data collection and provision decisions; reduce duplication and thus improve 
the integration of HTA into policy decisions across Europe (EUnetHTA, 2011).  
Collaboration is feasible owing to the nature of information as a public good (ISPOR, 
2011, Garrison, 2010).  As indicated in Chapter 2, information is considered a public good 
as it displays the two necessary principles: non-rivalry and non-excludability (Stiglitz, 
1999). Non-rivalrous consumption means that consumption of a good by one individual 
does not detract from another. Non-excludability suggests it is impossible to exclude 
anyone from consuming a good, again for information this would mean it cannot be 
provided privately (Stiglitz, 1999).  The public good nature of information therefore 
suggests that information should not be provided on a private basis. This has important 
implications for the generation of further research on novel technologies like TAVI, where 
multi-location projects are beginning to emerge with European clinical trials and registries 
like SURTAVI
16
 from Medtronic and registries such as the European Advanced Registry
17
 
and the Source Sapien Registry
18
 (Simmonds, 2011, Piazza et al., 2010, Kappetein, 2011, 
Thomas, 2010, Thomas et al., 2011). This should maximise the quantity and quality of 
timely data available and promote the efficient use of resources.  
However, efforts must be taken to ensure “free rider” issues do not result which may cause 
market failure (Eckermann and Willan, 2009).  “Free rider” issues in this situation, refer to 
where decision makers in a jurisdiction wait for others to bear the costs of commissioning 
a trial which is used to inform decisions in the former. Market failure in this situation can 
occur when all jurisdictions wait for another to conduct the research and the research never 
gets completed. 
An optimal solution is to have global trials, where patients are selected across jurisdictions 
and fixed costs are shared amongst participating bodies. Such global trials aim to overcome 
issues faced by local decision makers, such as reducing the need for meta-analysis and 
associated problems of differences in protocols and treatments. Global trials endeavour to 
avoid delaying adoption decisions, whereby evidence is being generated in a timely 
                                                 
16
 SURTAVI Trial European Medtronic sponsored randomised controlled trial. Data collection was 
due to being in 2010/11 employing 1,000-2,000 patients (Simmonds, 2011, Kappetein, 2011). 
17
 The European Advanced Registry employs approx. 1,000 patients across 50 sites in Europe and 
expects to release results in 2016 (Piazza et al., 2010, Thomas, 2010). 
18
 SOURCE Sapien Registry has 1,038 patients enrolled and collects data from 32 sites (Thomas et 
al. 2011). 
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fashion. However, it needs to be the case that the new technology is only available through 
the trial in each jurisdiction. Overall, global trials can improve the expected net benefit of 
sampling (ENBS) relative to local trials when evidence is freely transferrable, as single 
trials underestimate the global value of trial information. Also, having more than one trial 
spreads costs and increases the homogeneity of evidence (Eckermann and Willan, 2009).  
 
8.5.3 Future for Economic Evaluations of Medical Devices 
This thesis demonstrates that employing economic evaluation methods such as decision 
modelling, PSA and VOI analysis in a continuous iterative manner for medical devices is 
feasible, despite their challenging characteristics. Just one case study was employed in this 
thesis examining the suitability of the continuous iterative framework for novel expensive 
medical devices characterised by evolving evidence and uncertainty. To test its suitability 
further, more case studies should be considered. 
These future case studies should formally consider the employment of Access with 
Evidence Development schemes earlier and more formally in the iterative framework. 
However, for that to work decision makers and the environment in which they operate 
need to adapt to the characteristics of medical devices when considering them. The current 
lenient evidence requirements for licensing and market access discourage research and 
create incentives for manufacturers to be “free-riders”. It also means that medical devices 
become part of clinical practice soon after licenses are granted, even those with persisting 
uncertainties.  The aforementioned criteria need to be revised in the interest of patient 
safety, equity in access and to maintain standards in decision making, which economic 
evaluations inform. In addition, decision makers should formally recognise the unique 
characteristics of medical devices and promote the use of iterative economic evaluations 
when assessing them.  
Also, these future case studies could examine the hypothesis that global trials are optimal 
for collecting additional evidence for novel expensive technologies compared to single 
country trials. 
 
 318 
 
8.6 LIMITATIONS 
8.6.1 Limitations of Proposed Framework 
Despite the merits of using flexible Bayesian methods within the continuous iterative 
framework for economic evaluations to overcome the challenges posed by novel 
technologies and the promise of AED schemes there are some limitations.  
Firstly, implementing a truly continuous iterative approach is challenging. It is highly 
resource intensive owing to the frequent updates and re-analyses required. Also, such 
methods warrant significant stakeholder involvement to inform the interval between 
iterations. This involvement however may be difficult to maintain over the course of the 
iterations. Iterative approaches to economic evaluations are also not conducive to academic 
publication. Owing to long lead and review times. For example, by the time a journal 
submission is returned with comments the iteration can be obsolete owing to movements 
along the learning curve and incremental innovations which lead to an evolution in the 
evidence base. This was experienced with this case study. When the original iteration was 
finalised the RCT data became available. These iterations for inoperable patients were 
written up as one paper and submitted to a leading health economics journal in April 2011. 
Comments from the editor and reviewers were received in September 2011 and the paper 
was returned in December 2011. After which a “revise and resubmit” decision was 
received in March 2012. The suggested revisions were made and in addition the results of 
the third iteration had to be included to ensure the paper was current as of submission in 
April 2012. Owing to these amendments the paper had to be considered for another review 
and notice of acceptance was only granted in August 2012. This lengthy process can 
provide a disincentive for iterative evaluations.  
Secondly, the VOI employed in the analysis are promising but given their dependence on 
PSA uptake of them is slow and they are not yet routine in informing policy decisions. 
Thus, their potential is underestimated owing to inexperience and lack of understanding in 
decision making arenas.  
Thirdly, in conducting this case study the non-rivalry of information and information as a 
public good come into question. Access to the UK TAVI registry was limited to what was 
published in late 2011 by Moat et al. (2011). Unfortunately, that publication only provided 
early outcomes aggregated for all patient risk groups. Had this registry data been available 
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earlier and in a more detailed form, it could have informed the analysis further. This brings 
into question the public nature of information and thus the usefulness of publically funded 
research for informing iterative economic evaluations such as that considered in this thesis.  
8.6.2 Limitations of Thesis 
It is acknowledged that more formal Bayesian techniques (described in Chapter 2) could 
have been employed in the model when updating the evidence between iterations. For 
example, in iteration two the early evidence from published case series and expert opinions 
could have been used as priors and updated with the PARTNER evidence. However, as 
discussed in Chapter 5 it was assumed in the model that the accumulated empirical 
evidence from the PARTNER trial dominated this early evidence and expert opinion. 
However, given that experience with TAVI from the experts was minimal and restricted to 
published case series etc. evidence from the PARTNER trial superseded experts opinion. 
This is in line with the view that expert opinion can become irrelevant in the presence of 
large RCTs; where it is considered that the accumulated empirical evidence dominates the 
expert opinion (NICE, 2004).  In future iterations of the model, more formal Bayesian 
methods could be employed, as employed for relevant parameters in iteration three. It is 
also recognised that more formal elicitation methods could have been employed for 
eliciting expert opinion. However, given that results from the PARTENR trial were 
imminent, the additional cost of formally eliciting the information was considered to 
outweigh the additional benefit. This was especially true for variables on which there was 
no existing evidence at the time of eliciting expert opinion.  
The original iteration of the model included several relative risk parameters which were 
used to model the difference between TAVI and AVR (see Table 4.4). As indicated in 
Chapter 4, these relative risk parameters were informed by expert opinion (who had little 
experience with the technology at the time), which became obsolete upon the publication 
of the first RCT. These relative risks were then replaced with absolute risks for the 
parameters considered (the rationale for the replacement strategy is discussed in Chapter 
5). Alternatively,  the relative risks between treatment options could have be estimated and 
then superimposed onto baseline probabilities (based on population  characteristics 
etc.)(Philips et al., 2006). This is considered to be particularly useful where results are not 
generalizable to the population under investigation (Palmer et al., 2002). In the case of 
TAVI however, differences in expected health outcomes between the trial region and the 
UK were unknown. In addition, PARTNER A and B represent two different patient risk 
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groups (operable versus inoperable), this baseline risk impacted on procedure related 
events, quality of life and mortality. If further information were available on differences 
between patient risk groups and between jurisdictions then relative risks could have been 
employed. However, in the absence of this information the impact of using relative instead 
of absolute risk was minimal.   
As described in Chapter 2, EVSI is a useful measure for informing the research priority 
setting decision. However, the analysis here demonstrated that employing EVSI has 
practical challenges,  owing to its high computational costs. It is anticipated that in the 
future meta methods and other Bayesian methods which are currently being developed to 
reduce the computational expenses associated with EVSI will be accessible to health 
economists. These should reduce the practical challenges associated with estimating EVSI.  
Finally, to assess uncertainty surrounding the model assumptions, a sensitivity analysis 
was employed in Chapter 7 to consider various scenarios, as is commonly done in HTAs. 
While sensitivity analyses are a straightforward means of assessing the implications of 
different assumptions they only give a partial expression of uncertainty. Conducting a 
complete analysis would require consideration of parameter uncertainty for each possible 
combination of structural assumptions in principle, however in practice this is a complex 
process. An alternative method is model averaging. Here, the results from different models 
are combined to provide a single set of averaged results. Each set of results are given a 
weight, reflecting their appropriateness (Jackson et al., 2010, Briggs et al., 2012, Jackson et 
al., 2011).  While this method does incorporate information from various models it is 
computationally burdensome.   
 
8.7 CONCLUSIONS 
Using Transcatheter Aortic Valve Implantation (TAVI) as a case study this thesis has 
demonstrated how informative and efficient economic evaluations of novel expensive 
medical device technologies, with evolving evidence, can be conducted. This is the first 
such evaluation where a formal iterative framework is applied to an economic evaluation 
of a medical device using decision analytical modelling, probabilistic sensitivity analysis 
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with Monte Carlo simulations and a Bayesian VOI analysis for patient subgroups 
simultaneously.  
Using these methods the iterative evaluation concluded that TAVI can be considered cost 
effective for inoperable patients compared with medical management. While there is little 
value in commissioning new research for continued data collection for this group, the 
continued collection of evidence via the UK TAVI trial as indicated in the NICE guidelines 
is welcomed.  This continual collection of evidence ensures that up to date evidence is 
available to inform any future decisions regarding TAVI in this patient group (in an AED 
type fashion) as advocated in the continuous iterative framework. For inoperable patients, 
the iterative model could not conclude that TAVI is cost effective compared to AVR. 
However, should further evidence demonstrate improved outcomes, it would improve the 
cost effective position of TAVI for these patients. The Bayesian VOI, in the scenario 
analysis, indicates that further information on short and long term probability, resource and 
quality of life parameters is most valuable and a cost effective research design of collecting 
such information is a registry. 
Applying the TAVI case study afforded the opportunity to examine the challenges of under 
taking a cost effectiveness analysis for such complex medical device technologies. These 
challenges were identified and overcome by employing the continuous iterative 
framework, as discussed above. This demonstrates that economic evaluations do not have 
to be static one-off activities. In fact, owing to the characteristics of medical devices 
(learning curve, incremental innovations etc.) economic evaluations of this kind should be 
continuous. Their evolving evidence should be incorporated into the decision making 
process so as to re-address their cost effectiveness on an iterative basis. Using these 
methods this thesis also demonstrates how optimal study designs can be created for such 
technologies. Further to this, the thesis examined how the economic evaluation results and 
study designs can be incorporated into emerging policies for generating further information 
like Access with Evidence Development schemes through the proposed continuous 
iterative framework.   
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I TAVI STEERING GROUP MEMBERS 
Table I.a TAVI Steering Group Members 
Name Role 
Prof Colin Berry Professor of Cardiology and Imaging 
Ms Pascale Brasseur Medtronic 
Prof Andrew Briggs  Health Economist 
Ms Carole Cohen Edwards LifeSciences 
Mr Hussein El-Shafei  Cardiac Surgeon 
Dr Elisabeth Fenwick  Health Economist 
Ms Fiona MacDonald Cardiac Services – Service Improvement Manager 
Ms Clare McGrath Senior Director HTA Policy,  Europe/ROWD 
Dr Malcolm John Metcalfe  Cardiologist 
Ms Aileen Murphy Health Economist 
Dr Keith Olroyd Cardiologist 
Mr Renzo Pessotto  Cardiac Surgeon 
Dr Karen Richie Lead Health Services Researcher, Quality Improvement Scotland 
Mr Fraser Sutherland Cardiac and Transplant Surgeon  
Dr Neil Uren Cardiologist 
Mr Derek Yuille Director of Finance, NHS Ayrshire & Arran  
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II LITERATURE REVIEW 
Table II.a Literature Review: Clinical Effectiveness of TAVI 
The literature search for evidence on TAVI began with the published review conducted 
by Vahanian et al (2008). Each of the publications reported by Vahanian et al (2008) were 
sourced and reviewed by the author. After which a literature search was conducted 
between April and May 2009 using PubMed and Google Scholar. 
 
Search Terms: 
1. percutaneous heart valve implantation 
2. percutaneous 
3. Aortic stenosis 
4. percutaneous aortic valve implantation 
5. transapical 
6. aortic valve replacement 
7. minimally invasive 
8. aortic bioprosthesis 
9. novel 
10. severe aortic stenosis 
11. older patients 
12. implant 
13. elderly 
14. management 
15. Transcatheter 
16. insertion 
Exclusion criteria:   
- pre- 2002 
Date of Search:   
- April – May 2009 
RESULTS  
Search Strategy Included/ Reason for Excluding 
1: Google Scholar  
(Cribier et al., 2004)  
(Cribier et al., 2006)  
(Cribier et al., 2002b) Included in (Cribier et al., 2004) 
(Bauer et al., 2004) Mismatch/insufficient evidence provided for model 
(Webb et al., 2006)  
(Lichtenstein et al., 2006)  
(Grube et al., 2006)  
(Webb et al., 2007)  
(Walther et al., 2007)  
2 + 6: Google Scholar  
(Grube et al., 2007)  
(Cribier et al., 2002b) Included in (Cribier et al., 2004) 
(Webb et al., 2007)  
(Grube et al., 2008) Results included in (Grube et al., 2006) & (Grube et al., 
2007) 
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Table II.a Continued 
Search Strategy Included/ Reason for Excluding 
2 + 6: Google Scholar (continued)  
(Grube et al., 2006)  
(Moss et al., 2008) Mismatch/insufficient evidence provided for model 
(Lichtenstein et al., 2006)  
2 + 3: Google Scholar  
(Cribier et al., 2002b) Included in (Cribier et al., 2004) 
(Grube et al., 2007)  
(Webb et al., 2007)  
(Webb et al., 2006)  
(Cribier et al., 2004)  
(Cribier et al., 2006)  
(Grube et al., 2006)  
(Lichtenstein et al., 2006)  
(Hanzel et al., 2005)  
(Bauer et al., 2004) Mismatch/insufficient evidence provided for model 
4: Google Scholar  
(Cribier et al., 2002b) Included in (Cribier et al., 2004) 
(Grube et al., 2008) Results included in (Grube et al., 2006) and (Grube et al., 
2007) 
(Webb et al., 2006)  
(Grube et al., 2006)  
(Wenaweser et al., 2007) Mismatch/insufficient evidence provided for model 
(Lutter et al., 2002) Reports results for animals not humans 
2+6: Pubmed  
(Sack et al., 2005)  
5+6+7: Google Scholar  
(Walther et al., 2007)  
(Walther et al., 2008)  
(Lichtenstein et al., 2006)  
(Ye et al., 2007) Included in (Ye et al., 2009) 
(Ye et al., 2009)  
4+9: Pubmed  
(Berry et al., 2007)  
8+2+12: Google Scholar  
(Grube et al., 2006)  
(Lichtenstein et al., 2006)  
(Cribier et al., 2004)  
(Lutter et al., 2002) Reports results for animals not humans 
10+13+2: Google Scholar  
(Grube et al., 2007)  
(Webb et al., 2007)  
(Cribier et al., 2006)  
(Grube et al., 2006)  
(Webb et al., 2006)  
(Grube et al., 2008) Results included in (Grube et al., 2006) and (Grube et al., 
2007) 
10+11+8: Google Scholar  
(Piazza et al., 2008a) Mismatch/insufficient evidence provided for model 
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Table II.a Continued 
Search Strategy Included/ Reason for Excluding 
(Grube et al., 2007)  
(Marcheix et al., 2007)  
(Wenaweser et al., 2007) Mismatch/insufficient evidence provided for model 
(Cribier et al., 2004)  
10+13+2+14: Google 
Scholar 
 
(Webb et al., 2007)  
(Descoutures et al., 2008)  
(Cribier et al., 2006)  
(Webb et al., 2006)  
15: Google Scholar  
(Cribier et al., 2002b) Included in (Cribier et al., 2004) 
(Piazza et al., 2008a) Mismatch/insufficient evidence provided for model 
(Ye et al., 2007) Included in (Ye et al., 2009) 
(Webb et al., 2007)  
(Lichtenstein et al., 2006)  
15 + 16: Google Scholar  
(Cribier et al., 2002b) Included in (Cribier et al., 2004) 
(Svensson et al., 2008)  
(Webb et al., 2007)  
(Piazza et al., 2008a) Mismatch/insufficient evidence provided for model 
(Walther et al., 2007)  
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Table II.b Literature Review: Clinical Effectiveness of AVR 
Search Terms: 
1. aortic stenosis 
2. bioprosthesis 
3. aortic valve replacement 
4. older 
5. early and long term results 
6. surgery 
7. severely symptomatic 
8. UK 
9. valve-related complications 
10. elderly 
11. aortic valves 
Exclusion criteria:   
- studies published pre 1990 
- balloon valvuloplasty 
- Single sex studies 
- studies with < 50 patients 
- stented/stents 
- allograft 
- full text not available 
Date of Search:   
- April – May 2009 
RESULTS  
Search Strategy Included/ Reason for Excluding 
1+2: Google Scholar  
(Rosenhek et al., 2000) 
(Pereira et al., 2002) 
(Tasca et al., 2003) 
(Aupart et al., 2006) 
Mismatch/insufficient evidence provided for model 
Mismatch/insufficient evidence provided for model 
Mismatch/insufficient evidence provided for model 
 
3+4+5: Google Scholar  
(Gehlot et al., 1996) 
(Asimakopoulos et al., 1997) 
(Melby et al., 2007)  
 
Mismatch/insufficient evidence provided for model 
 
1+6+7+8: Google Scholar  
(Gilbert et al., 1999) 
(Collinson et al., 1999) 
(Urso et al., 2007) 
(Kojodjojo et al., 2008) 
 
Sample size insufficient 
Mismatch/insufficient evidence provided for model 
Mismatch/insufficient evidence provided for model 
9+10+11: Google Scholar  
(Sidhu et al., 2001) 
(Milano et al., 1998) 
(Otto et al., 1999) 
Mismatch/insufficient evidence provided for model 
 
Mismatch/insufficient evidence provided for model 
2+12+13: Google Scholar  
(Eichinger et al., 2008) 
(Poirier et al., 1998) 
(Corbineau et al., 2001) 
(Conrad Pelletier et al., 1995) 
 
Mismatch/insufficient evidence provided for model 
Mismatch/insufficient evidence provided for model 
Mismatch/insufficient evidence provided for model 
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Table II.c Literature Review: Economic Evaluation/Cost Effectiveness TAVI 
Search Terms: 
1. Economic evaluation  
2. Cost effectiveness analysis 
3. Economic analysis  
4. cost analysis  
5. TAVI  
6. PAVR 
7. Transcatheter aortic valve implantation 
8. Percutaneous heart valve implantation 
9. Percutaneous aortic valve implantation 
10. Percutaneous aortic valve replacement 
Exclusion criteria:   
- None 
Date of Search:   
- April – May 2009 
Search Strategy: 
- 1+5; 1+6; 1+7; 1+8; 1+9; 1+10.     
- 2+5; 2+6; 2+7; 2+8; 2+9; 2+10.   Google Scholar 
- 3+5; 3+6; 3+7; 3+8; 3+9; 3+10.   Google 
- 4+5; 4+6; 4+7; 4+8; 4+9; 4+10.   PubMed 
RESULTS 
- (Van Brabandt and Neyt, 2008)  
- (Bazian, 2008) 
  
 329 
 
III PROCEDURE RELATED EVENTS 
Table III.a Definition of Procedure Related Events 
Event Definition Source 
Stroke Sudden diminution or loss of consciousness, 
sensation, and voluntary motion caused by rupture 
or obstruction (as by a clot) of a blood vessel of 
the brain.  
 
(MedlinePlus, 
2011) 
Thromboembolism The blocking of a blood vessel by a particle that 
has broken away from a blood clot at its site of 
formation. 
 
(MedlinePlus, 
2011) 
Paravalvular Leak Paravalvular leak refers to blood flowing through 
a channel between the structure of the implanted 
valve and cardiac tissue as a result of a lack of 
appropriate sealing. The majority of paravavular 
leaks are crescent, oval or roundish-shaped and 
their track can be parallel, perpendicular or 
serpiginous.  
 
(Smolka, 2010) 
 
Endocarditis Endocarditis is inflammation of the inside lining 
of the heart chambers and heart valves 
(endocardium). 
 
(Levy, 2010) 
Cardiac tamponade Cardiac tamponade is compression of the heart. It 
can occur when blood or fluid builds up in the 
space between the myocardium (heart muscle) and 
the pericardium (outer covering sac of the heart). 
 
(Health, 2010a) 
Myocardial 
infarction 
A myocardial infarction is when blood vessels 
that supply blood to the heart are blocked, 
preventing enough oxygen from getting to the 
heart. The heart muscle dies or becomes 
permanently damaged.  
 
(Health, 2010b) 
Pacemaker  A pacemaker is a device that sends small 
electrical impulses to the heart muscle to maintain 
a suitable heart rate or to stimulate the lower 
chambers of the heart (ventricles). A pacemaker 
may also be used to treat fainting spells (syncope), 
congestive heart failure and hypertrophic 
cardiomyopathy. 
(Clinic, 2011) 
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IV MODEL INVESTIGATIONS 
Table IV.a Descriptive Statistics for Input Parameters  
PARAMETERS LARGE N SMALL N* MID-POINT 
Mean Probability Mean Probability 
Major disabling stroke 0.031 0.031 0.031 
Probability of Converting to AVR 0.038 0.057 0.048 
    
Major valve related complications – TAVI 
Valve thromboembolism 0.000 0.000 0.000 
Major paravavular leak 0.038 0.063 0.050 
Endocarditis 0.000 0.000 0.000 
Cardiac tamponade 0.020 0.057 0.039 
Myocardial infarction 0.029 0.046 0.038 
    
Major valve related complications –AVR 
Valve thromboembolism 0.010 0.010 0.010 
Major paravavular leak 0.003 0.006 0.005 
Endocarditis 0.005 0.005 0.005 
Cardiac tamponade 0.000 0.000 0.000 
Myocardial infarction 0.000 0.000 0.000 
    
Minor valve related complications – TAVI 
Access site events 0.011 0.059 0.035 
Vascular Events 0.047 0.138 0.093 
Pacemaker implantation 0.062 0.062 0.062 
    
Minor valve related complications –AVR 
Access site events 0.009 0.037 0.023 
Vascular Events 0.012 0.027 0.020 
Pacemaker implantation 0.052 0.059 0.056 
    
Probability late procedure related event    
Hospitalisations  0.056 0.056 0.056 
Valve thromboembolism 0.065 0.068 0.067 
Major paravavular leak 0.006 0.016 0.011 
Endocarditis 0.024 0.024 0.024 
Cardiac tamponade 0.000 0.000 0.000 
    
Fatal Procedure related event 0.218 0.223 0.221 
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Table IV.b Descriptive Statistics from Probabilistic Sensitivity Analysis Large 
v’s Small Sample Size, 1,000 Simulations 
 
 Small 
v's Large (1) 
Difference Small v's 
Large (2) 
Difference 
rmajor_vre > -0.06 > -0.05 
rminor_vre_CVR > -0.18 > -0.17 
rminor_vre_TAVI > -0.23 > -0.22 
pconverting_to_CVR > -0.02 > -0.02 
Pmajorstroke < 0.00 < 0.00 
RRomTAVI > -0.10 > -0.09 
Rrmajorcomplications_TAVI > -0.01 > -0.01 
Excess_Stroke_Risk > 0.00 < 0.02 
Platevre > -0.01 > -0.01 
Rrvre_TAVI < 0.20 < 0.12 
Platefatalvre > 0.00 > 0.00 
rrsmrAS < 0.01 < 0.05 
pdeath_AS > -0.01 > 0.00 
Cmajorstroke < 15.52 < 7.53 
TAVIprocedure < 88.64 < 24.91 
LOSTAVI > -105.34 > -53.41 
PostdischargeTAVI < 8.42 > 8.99 
CVRprocedure < 16.77 > 22.03 
LOSCVR > -110.10 < -119.68 
PostdischargeTAVI < 30.40 > -76.85 
cminorvreCVR < -502.02 < -455.82 
cminorvreTAVI < 1462.56 < 1547.56 
Costlatevre > 156.90 < 157.73 
cfv_AS < 1.54 > -17.99 
Cfn > 1.74 < -5.91 
Relative cost of procedure < 0.02 < 0.00 
Relative cost of hospital stay < 0.00 < 0.00 
Relative cost of post-discharge 
care 
> 0.00 < 0.00 
uAS < 0.00 > 0.00 
Umajorvre > 0.00 > 0.00 
uminorvreCVR > -0.01 > -0.01 
uminorvreTAVI < 0.01 < 0.01 
Ufv_AS < 0.00 > 0.00 
uFnVR < 0.00 < 0.00 
distuility_late_vre > 0.00 < 0.00 
     
Difference refers to the difference in the ranges between the NL model and the NS model. Those 
highlighted in red indicate the unexpected. 
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Table IV.c Descriptive Statistics from Probabilistic Sensitivity Analysis Large 
v’s Small Sample Size, 10,000 Simulations 
 
 Small 
v's Large 
(1) 
Difference Small 
v's Large (2) 
% 
Difference 
rmajor_vre > 0.07 > -0.19 
rminor_vre_CVR > 0.05 > -0.17 
rminor_vre_TAVI > 0.11 > -0.37 
pconverting_to_CVR > 0.04 > -0.09 
Pmajorstroke > 0.01 > -0.07 
RRomTAVI > 0.16 > -1.35 
Rrmajorcomplications_TAVI > 0.17 > -1.51 
Excess_Stroke_Risk > 0.18 > -1.50 
Platevre > 0.02 > -0.21 
Rrvre_TAVI > 0.57 > -2.57 
Platefatalvre > 0.04 > -0.33 
rrsmrAS > 0.60 < -3.20 
pdeath_AS > 0.08 < -0.57 
Cmajorstroke > 163.98 > -806.68 
TAVIprocedure > 602.85 < -4324.63 
LOSTAVI > 905.37 > -5639.95 
PostdischargeTAVI > 152.07 < -940.32 
CVRprocedure > 483.53 < -5067.48 
LOSCVR > 1415.13 > -9992.57 
PostdischargeTAVI > 745.98 < -5344.16 
cminorvreCVR > 679.639 < -4265.245 
cminorvreTAVI > 163.058 < -2850.144 
Costlatevre > 341.761 < -3240.710 
cfv_AS > 347.456 < -8551.169 
Cfn > 218.034 < -2157.136 
Relative cost of procedure > 0.129 < -1.100 
Relative cost of hospital stay > 0.089 < -0.770 
Relative cost of post-discharge care > 0.027 < -0.240 
uAS > 0.012 < -0.571 
Umajorvre > 0.008 > -0.053 
uminorvreCVR > 0.006 > -0.046 
uminorvreTAVI > 0.002 < -0.034 
Ufv_AS > 0.012 < -0.571 
uFnVR > 0.023 > -0.839 
distuility_late_vre > 0.006 < -0.048 
     
% Difference refers to the difference in the ranges between the NL model and the NS model. Those 
highlighted in red indicate where the percentage difference is greater than 10%. 
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Table IV.d Summary of ANOVA Results (High Risk Operable Patient Group) 
 Summary of Proportion Sum of 
Squares 
Large N 1 Large N  2 Small N 1  Small N  2 
Incremental QALYs AVR vs. TAVI rrvreTAVI rrvreTAVI rrvreTAVI rrvreTAVI 
       
Incremental Costs AVR vs. TAVI rrvreTAVI rrvreTAVI rrvreTAVI rrvreTAVI 
 -------------- --------------- --------------- Pdeath_AS 
       
Incremental QALYs TAVI vs.  rrvre_TAVI rrvre_TAVI rrvre_TAVI rrvreTAVI 
Medical Management rrsmras rrsmras rrsmras -------------- 
  pdeath_as pdeath_as pdeath_as Pdeath_as 
       
Incremental Costs TAVI vs. Medical 
Management  
rrvre_TAVI rrvre_TAVI rrvre_TAVI rrvre_TAVI 
pdeath_as pdeath_as pdeath_as pdeath_as 
  --------------- --------------- --------------- Rrsmras 
      
Incremental QALYs AVR vs. 
Medical Management  
rrsmras rrsmras rrsmras Rrsmras 
pdeath_as pdeath_as pdeath_as pdeath_as 
       
Incremental Costs AVR vs. Medical 
Management 
rrsmras rrsmras rrsmras Rrsmras 
pdeath_as pdeath_as pdeath_as pdeath_as 
     
Parameters listed are those who representation > or = to 10% 
N = sample size 
 
Table IV.e Correlation Coefficients: Costs and Effects 
  
AVR:  
Costs & Effects 
TAVI:  
Costs & Effects 
Medical Management: 
 Costs & Effects 
Low Risk 
Operable 
Large N 1 0.579 0.851 0.985 
Large N 2 0.582 0.847 0.985 
 Small N 1 0.594 0.849 0.985 
 Small N2 0.601 0.853 0.985 
     
High Risk 
Operable 
Large N 1 0.628 0.824 0.985 
Large N 2 0.627 0.822 0.985 
 Small N 1 0.632 0.829 0.985 
 Small N2 0.627 0.822 0.985 
     
High Risk 
Inoperable 
Large N 1 0.667 0.806 0.985 
Large N 2 0.671 0.804 0.985 
 Small N 1 0.667 0.806 0.985 
 Small N2 0.662 0.812 0.985 
N = sample size 
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Table IV.f ANOVA Costs, QALYS and Life Years Gained per Patient Group 
and Model: Summary of Proportion Sum of Squares   
 
 Large N 
1 
Prop. 
SS 
Large N 
2 
Prop. 
SS 
Small N 
1  
Prop. 
SS 
Small N 
2 
Prop. 
SS 
AVR 
Costs 
platefata
lvre 
0.025 platefata
lvre 
0.025 platefata
lvre 
0.023 platefata
lvre 
0.023 
 RrsmrA
S 
0.193 rrsmrAS 0.196 rrsmrAS 0.149 rrsmrAS 0.149 
 pdeath_
AS 
0.679 pdeath_
AS 
0.676 pdeath_
AS 
0.733 pdeath_
AS 
0.733 
 cfv_AS 0.028 cfv_AS 0.029 cfv_AS 0.027 cfv_AS 0.029 
 Cfn 0.038 cfn 0.039 cfn 0.031 cfn 0.030 
 Residual 0.026 residual 0.025 residual 0.028 residual 0.028 
AVR 
QALYs 
    rfailed 0.066 rfailed 0.068 
 Platevre 0.091 platevre 0.093 platevre 0.096 platevre 0.094 
 rrsmrAS 0.595 rrsmrAS 0.599 rrsmrAS 0.491 rrsmrAS 0.488 
 pdeath_
AS 
0.215 pdeath_
AS 
0.210 pdeath_
AS 
0.260 pdeath_
AS 
0.261 
 uFnVR 0.061 uFnVR 0.058 uFnVR 0.054 uFnVR 0.052 
 residual 0.015 residual 0.016 residual 0.017 residual 0.020 
TAVI 
Costs 
Rrvre_T
AVI 
0.728 Rrvre_T
AVI 
0.738 Rrvre_T
AVI 
0.712 Rrvre_T
AVI 
0.706 
 pdeath_
AS 
0.172 pdeath_
AS 
0.162 pdeath_
AS 
0.195 pdeath_
AS 
0.199 
 rrsmrAS 0.049 rrsmrAS 0.048 rrsmrAS 0.039   
 residual 0.019 residual 0.020 residual 0.021 residual 0.022 
 
Prop. SS = Proportion Sum of Squares 
Parameters listed are those who represent > or = to 10% 
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V PARTNER TRIAL 
Table V.a PARTNER Inclusion and Exclusion Criteria 
Inclusion Criteria 
1. Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient 
>40 mm Hg or jet velocity > 4.0 m/s or an aortic valve area (AVA) of < 0.8 cm
2
 (or AVA index< 
0.5 cm
2
/m
2
). 
2. Symptomatic due to aortic valve stenosis as demonstrated by NYHA Functional Class ≥ II. 
 . The subject or the subject’s legal representative was informed of the nature of the study, agreed 
to its provisions and provided written informed consent as approved by the Institutional Review 
Board of the respective clinical site. 
4. The subject and the treating physician agreed that the subject would return for all required post 
procedure follow-up visits. 
5. The subject, after formal consults by a cardiologist and two cardiovascular surgeons agreed that 
medical factors precluding operation, based on a conclusion that the probability of death or 
serious, irreversible morbidity exceeded the probability of meaningful improvement. Specifically, 
the probability of death or serious, irreversible morbidity exceeded 50%. The surgeons' consult 
notes should specify medical or anatomic factors leading to that conclusion and included should 
be a printout of the STS score calculation to further identify the risks in these patients. 
 
Exclusion Criteria 
1. Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment (defined as 
Q wave MI, or non-Q wave MI with total CK elevation ≥ twice normal in the presence of CK-MB 
elevation and/or troponin level elevation (WHO definition). 
2. Aortic valve was a congenital unicuspid or congenital bicuspid valve, or was non-calcified. 
3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic 
regurgitation >3+). 
4. Any therapeutic invasive cardiac procedure performed within 30 days of the index procedure, (or 
6 months if the procedure was a drug eluting coronary stent implantation). 
5. Pre-existing prosthetic heart valve in any position, prosthetic ring, severe mitral annular 
calcification, or severe (greater than 3+) mitral regurgitation 
6. Blood dyscrasias as defined: leukopenia (WBC < 3000 mm
3
), acute anemia (Hb < 9 mg%), 
thrombocytopenia (platelet count < 50,000 cells/mm³), history of bleeding diathesis or 
coagulopathy. 
7. Untreated clinically significant coronary artery disease requiring revascularization. 
8. Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support 
devices. 
9. Need for emergency surgery for any reason. 
10. Hypertrophic cardiomyopathy with or without obstruction. 
11. Severe ventricular dysfunction with LVEF < 20%. 
12. Echocardiographic evidence of intracardiac mass, thrombus or vegetation. 
13. Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months. 
14. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or 
clopidogrel (Plavix), or sensitivity to contrast media, which cannot be adequately pre-medicated. 
15. Native aortic annulus size < 18mm or > 25mm as measured by echocardiogram. 
16. Recent (within 6 months) cerebrovascular accident or transient ischemic attack. 
17. Renal insufficiency (creatinine > 3.0mg/dL) and/or end stage renal disease requiring chronic 
dialysis. 
18. Life expectancy < 12 months due to non-cardiac co-morbid conditions. 
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Table V.a Continued 
19. Significant abdominal or thoracic aorta disease, including aneurysm (defined as maximal 
luminal diameter 5cm or greater), marked tortuosity (hyperacute bend), aortic arch atheroma 
(especially if thick [> 5 mm], protruding or ulcerated), narrowing of the abdominal aorta 
(especially with calcification and surface irregularities), or severe “unfolding” and tortuosity of 
the thoracic aorta 
20. Iliofemoral vessel characteristics that would preclude safe placement of 22F or 24F introducer 
sheath such as severe calcification, severe tortuosity or vessels size diameter < 7 mm for 22F 
sheath or < 8mm for 24F sheath          
21. Currently participating in an investigational drug or another device study. 
22. Active bacterial endocarditis or other active infections. 
23. Bulky calcified aortic valve leaflets in close proximity to coronary ostia.   
     
Source: Table 1, Leon et al. (2010) 
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Table V.b PARTNER Cohort B Clinical Outcomes at 30 day days and 1 year 
Source: Table 2, Leon et al. (2010)* NA denotes not applicable, TAVI transcatheter aortic-valve implantation, and TIA transient ischemic attack.   † P values are for between-group comparisons of the frequency of the event at each time 
point.    ‡ Deaths from unknown causes were assumed to be deaths from cardiovascular causes. § Repeat hospitalizations were included if they were due to aortic stenosis or complications of the valve procedure (e.g., TAVI). ¶ Patients 
who received renal-replacement therapy were not included.‖ │Patients who received renal-replacement therapy after randomization were included. ** One patient in the TAVI group did not receive TAVI (because of failed access) and 
subsequently underwent balloon aortic valvuloplasty, followed by aortic-valve replacement. †† A total of  0 patients underwent a repeat balloon aortic valvuloplasty after the index balloon aortic valvuloplasty procedure that had been 
performed in the first 30 days after randomization, and 36 patients underwent a first balloon aortic valvuloplasty more than  0 days after randomization. ‡‡ Three patients underwent a repeat TAVI within 2  hours after the index TAVI 
procedure; four patients in the standard-therapy group who underwent TAVI at a non-participating site outside the United States are not. 
  
Outcome TAVI  Standard Therapy  P Value TAVI  Standard Therapy  P Value 
 n % N %  n % N %  
Death                 From any cause 9 5 5 2.8 0.41 55 30.7 89 49.7 <0.001 
From cardiovascular cause 8 4.5 3 1.7 0.22 35 19.6 75 41.9 <0.001 
Repeat Hospitalisation§ 10 5.6 18 10.1 0.17 40 22.3 79 44.1 <0.001 
Death from any cause or repeat hospitalisation§ 19 10.6 22 12.3 0.74 76 42.5 126 70.4 <0.001 
Stroke or TIA       All 12 6.7 3 1.7 0.03 19 10.6 8 4.5 0.04 
TIA  0 0 0 0 - 1 0.6 0 0 1 
Stroke                  Minor 3 1.7 1 0.6 0.62 4 2.2 1 0.6 0.37 
Major 0 5 2 1.1 0.06 14 7.8 7 3.9 0.18 
Death from any cause or major stroke 15 8.4 7 3.9 0.12 59 33 90 50.3 0.001 
           Myocardial infarction      All 0 
 
0 
 
- 1 0.6 1 0.6 1 
Peripreocedural 0 
 
0 
 
- 0 
 
0 
 
- 
Vascular Complications      All 55 30.7 9 5 <0.001 58 32.4 13 7.3 <0.001 
Major 29 16.2 2 1.1 <0.001 30 16.8 4 2.2 <0.001 
Acute kidney injury 
          Creatinine !  mg/dl (265 γmol/litre) ¶ 0 
 
1 0.6 1 2 1.1 5 2.8 0.45 
Renal-replacement therapy │ 2 1.1 3 1.7 1 3 1.7 6 3.4 0.5 
Major Bleeding 30 16.8 7 3.9 <0.001 40 22.3 20 11.2 0.007 
Cardiac re-intervention 
          Balloon aortic valvuloplasty 1 0.6** 2 1.1 1 1 0.6 66 6.9†† <0.001 
Repeat TAVI‡‡ 3 1.7 NA 
 
- 3 1.7 
 
NA - 
Aortic-valve replacement 0 
 
3 1.7 0.25 2 1.1** 17 9.5 <0.001 
Endocarditis 0 
 
0 
 
- 2 1.1 1 0.6 0.31 
New atrial fibrillation 1 0.6 2 1.1 1 1 0.6 3 1.7 0.62 
New pacemaker 6 3.4 9 5 0.6 8 4.5 14 7.8 0.27 
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Table V.c PARTNER Cohort A Clinical Outcomes at 30 days and 1 year  
Outcome 30 days  1 Year 
 TAVI AVR p-value   TAVI AVR p-value  
(N = 348)  (N = 351)   (N = 348)  (N = 351)  
All mortality – no. (%)  12 (3.4) 22 (6.5) 0.07  84 (24.2) 89 (26.8) 0.44 
Cardiac mortality – no. (%)  11 (3.2) 10 (3.0) 0.9  47 (14.3) 40 (13.0) 0.63 
Rehospitalisation – no. (%)  15 (4.4) 12 (3.7) 0.64  58 (18.2) 45 (15.5) 0.38 
Death or rehosp – no. (%)  25 (7.2) 33 (9.7) 0.24  120 (34.6) 119 (35.9) 0.73 
MI – no. (%)  0 2 (0.6) 0.16  1 (0.4) 2 (0.6) 0.69 
Acute kidney inj* – no. (%)  10 (2.9) 10 (3.0) 0.95  18 (5.4) 20 (6.5) 0.56 
Vascular complications         
All – no. (%)  59 (17.0) 13 (3.8) <0.01  62 (18.0) 16 (4.8) <0.01 
Major – no. (%)  38 (11.0) 11 (3.2) <0.01  39 (11.3) 12 (3.5) <0.01 
Major bleeding – no. (%)  32 (9.3) 67 (19.5) <0.01  49 (14.7) 85 (25.7) <0.01 
Endocarditis – no. (%)  0 (0.0) 1 (0.3) 0.32  2 (0.6) 3 (1.0) 0.63 
New AF – no. (%)  30 (8.6) 56 (16.0) < 0.01  42 (12.1) 60 (17.1) 0.07 
New PM – no. (%)  13 (3.8) 12 (3.6) 0.89  19 (5.7) 16 (5.0) 0.68 
All Stroke or TIA – no. (%)  19 (5.5)  8 (2.4)  0.04  27 (8.3)  13 (4.3)  0.04 
TIA – no. (%)  3 (0.9)  1 (0.3)  0.33  7 (2.3)        4 (1.5)  0.47 
All Stroke – no. (%)  16 (4.6)       8 (2.4)  0.12  20 (6.0)  10 (3.2)  0.08 
Major Stroke – no. (%)  13 (3.8)  7 (2.1)  0.2  17 (5.1)  8 (2.4)  0.07 
Minor Stroke – no. (%)  3 (0.9)  1 (0.3)  0.34  3 (0.9)  2 (0.7)  0.84 
Death/maj stroke – no. (%)  24 (6.9)  28 (8.2)  0.52  92 (26.5)  93 (28.0)  0.68 
Source: (Smith et al., 2011) 
  
 
 
VI PARAMETERS FOR FURTHER EVIDENCE 
GENERATION  
Table VI.a Proposed Parameters for Further Evidence Generation 
Parameters Potentially 
Provided in 
trial 
Provided in 
Current 
Registry 
Could be 
provided in a 
future 
registry 
Events  
   Probability of major procedure related events AVR  
  Probability of major procedure related events TAVI    
Probability of minor procedure related events AVR  
  Probability of minor procedure related events TAVI    
Probability of converting to_AVR    
Probability of converting to_noavr    
Probability of converting TAVI  
  Probability of repeat_TAVI    
Probability of major stroke_AVR  ¥ 
 Probability of major stroke_TAVI  
 
 
Probability of death within 30 days_avr  
  Probability of death with 30days_Tavi    
Early Major PRE : TAVI 
   Valve thromboembolism    
Major paravavular leak    
Endocarditis    
Cardiac tamponade  
 
 
Myocardial infarction    
Early Minor PRE : TAVI 
   Access site events  
 
 
Vascular Events  
 
 
Pacemaker implantation    
Major Vascular Event  
 
 
Major Bleeding    
Late Major PRE : TAVI 
   Valve thromboembolism  
 
 
Major paravavular leak  
 
 
Endocarditis  
 
 
Cardiac tamponade  
 
 
stroke   
 
 
MI 
   Late Minor PRE : TAVI 
   repeat hospitalisations >30 days < 1 year  
 
 
major vascular complications >30days < 1 year  
 
 
minor vascular complications > 30 days < 1 year  
 
 
major bleeding > 30 days < 1 year  
 
 
new pacemaker > 30 days < 1 year  
 
 
Early Major PRE : AVR 
   Valve thromboembolism  
  Major paravavular leak  
  Endocarditis  
  Cardiac tamponade  
  Myocardial infarction  
  Early Minor PRE : AVR 
   Access site events  
  Vascular Events  
  Pacemaker implantation  
  Major Vascular Event  
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Table VI.a Continued     
Parameters 
Trial 
Provided in 
trial? 
Current 
Registry 
Future 
Registry 
Major Bleeding  
  Late Major PRE : AVR 
   Valve thromboembolism  
  Major paravavular leak  
  Endocarditis  
  Cardiac tamponade  
  stroke   
  MI 
   Late Minor PRE : AVR 
   repeat hospitalisations >30 days < 1 year  
  major vascular complications >30days < 1 year  
  minor vascular complications > 30 days < 1 year  
  major bleeding > 30 days < 1 year  
  new pacemaker > 30 days < 1 year  
  Probability of fatal pre AVR  
  Probability of fatal pre TAVI  
 
 
Probability of death natural causes AVR  
  Probability of death natural causes TAVI  
 
 
Probability of death persistent AS AVR   
  Probability of death persistent AS TAVI  
 
 
    Resource Use 
   Intensive Care Unit - LOS initial  
 
 
High Dependency Unit - LOS initial  
 
 
General Ward - LOS initial  
 
 
probability of hospitalisations initial   
 
 
Probability of cardiac rehab   initial  
 
 
 Temporary Nursing home LOS initial  
 
 
Annual probability of Hospitalisations - Functioning 
TAVI 
 
 
 
Probability permanent nursing home care functioning 
TAVI 
 
 
 
Routine Drug Therapy  functioning TAVI  
 
 
Annual probability of Hospitalisations - persistent AS 
TAVI 
 
 
 
Probability permanent nursing home care - persistent 
AS TAVI 
 
 
 
Routine Drug Therapy - persistent AS TAVI  
 
 
Probability of  late balloon TAVI  
 
 
Annual probability of Hospitalisations - Functioning 
AVR 
 
  Probability permanent nursing home care functioning 
AVR 
 
  Routine Drug Therapy  functioning AVR  
  Annual probability of Hospitalisations - persistent AS 
AVR 
 
  Probability permanent nursing home care - persistent 
AS AVR 
 
  Routine Drug Therapy - persistent AS AVR  
  Probability of  late balloon TAVI  
  Quality of Life 
   Utility of Aortic Stenosis - Baseline TAVI *    
Utility Functioning VR TAVI*    
Utility of Persistent AS TAVI*    
Utility of Aortic Stenosis - Baseline AVR*  
  Utility Functioning VR AVR*  
  Utility of Persistent AS AVR*  
  
    Utility of Aortic Stenosis - Baseline TAVI+  
 
 
Utility Functioning VR TAVI+  
 
 
Utility of Persistent AS TAVI+  
 
 
Utility of Aortic Stenosis - Baseline AVR+  
  Utility Functioning VR AVR+  
  Utility of Persistent AS AVR+  
  * Proportion NYHA  + EQ-5D  ¥ doesn't distinguish between major and minor  
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VII TRANSITION PROBABILITIES COMPARISION 
Table VII.a Transition Probabilities for the Five Versions of the Model 
TRANSITION 
PROBABILITIES 
All Patient 
Groups 
Inoperable Operable 
 Original 
Model 
PARTNER 
B 
Updated 
PARTNER B 
PARTNER A Updated 
PARTNER A 
Short term - 0-30 days      
Converting TAVI to AVR 0.06                   
(0.03-0.09) 
0.01                                 
(0 - 0.02) 
As per 
PARTNER B 
0.03                    
(0.01-0.04) 
0.01                    
(0.01-0.02) 
Converting TAVI to  medical 
management  
- 0.02                                 
(0.01-0.05) 
As per 
PARTNER B 
0.01                    
(0.00-0.03) 
As per 
PARTNER A 
Converting from AVR to 
TAVI 
- - - 0.003                    
(0.00-0.12) 
As per 
PARTNER A 
Repeat TAVI procedure - 0.02                                 
(0-0.04) 
0.02                                 
(0-0.04) 
0.02                    
(0.01-0.04) 
0.01                    
(0.01-0.02) 
Major stroke AVR 0.03                   
(0.02-0.05) 
- - 0.03                    
(0.01-0.05) 
As per 
PARTNER A 
Major stroke TAVI 0.03                   
(0.02-0.05) 
0.05                           
(0.03-0.09) 
0.05                    
(0.03-0.09) 
0.06                    
(0.03-0.08) 
0.05                    
(0.04-0.06) 
Major PREs AVR 0.12                    
(0.09-0.17) 
- - 0.05                    
(0.02-0.07) 
As per 
PARTNER A 
Major PREs TAVI 0.12                    
(0.09-0.17) 
0.18                    
(0.12-0.24) 
0.16                    
(0.12-0.21) 
0.16                    
(0.12-0.21) 
0.17                    
(0.13-0.22) 
Minor PREs AVR 0.19               
(0.15-0.23) 
- - 0.33                    
(0.29-0.40) 
As per 
PARTNER A 
Minor PREs TAVI 0.24                    
(0.17-0.32) 
0.58                    
(0.48-0.69) 
0.54                    
(0.43-0.63) 
0.38                    
(0.31-0.44) 
0.45                    
(0.40-0.51) 
Death 30 days all causes 
AVR 
+ - - 0.07                    
(0.04-0.10) 
As per 
PARTNER A 
Death 30 days all causes 
TAVI 
+ 0.07                      
(0.03-0.11) 
0.09                    
(0.07-0.11) 
0.04                    
(0.02-0.06) 
0.07                    
(0.06-0.09) 
AS persisting medical 
management  
1 0.96                            
(0.93-0.99) 
As per 
PARTNER B 
As per 
PARTNER B 
As per 
PARTNER B 
Death medical management  - 0.04                         
(0.01-0.07) 
As per 
PARTNER B 
As per 
PARTNER B 
As per 
PARTNER B 
Balloon valvuloplasty (MM) - 0.83                     
(0.76-0.88) 
As per 
PARTNER B 
As per 
PARTNER B 
As per 
PARTNER B 
Long term - post 30 days      
Fatal PRE AVR Year 1 0.22                    
(0.18-0.27) 
- - 0.10                    
(0.06-0.14) 
As per 
PARTNER A 
Fatal PRE TAVI Year 1 0.22                    
(0.18-0.27) 
0.23                         
(0.15-0.31) 
0.22                    
(0.17-0.27) 
0.12                    
(0.08-0.17) 
As per 
PARTNER A 
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Table VII.a Continued    
TRANSITION 
PROBABILITIES 
All Patient 
Groups 
Inoperable Operable 
 Original 
Model 
PARTNER 
B 
Updated 
PARTNER B 
PARTNER A Updated 
PARTNER A 
Fatal PRE AVR Year 2     0.07                    
(0.04-010) 
Fatal PRE TAVI Year 2 - - - - 0.08                    
(0.05-0.11) 
Major PRE AVR Year 1 0.17                    
(0.13-0.18) 
- - 0.11                    
(0.08-0.16) 
As per 
PARTNER A 
Major PRE TAVI Year 1 0.17                    
(0.13-0.18) 
0.20  
(0.13 -0.29) 
0.16                    
(0.11-0.22) 
0.18                    
(0.13-0.24) 
As per 
PARTNER A 
Major PRE TAVI Year 2 - - 0.21                    
(0.15-0.28) 
- 0.16                    
(0.12-0.21) 
Major PRE AVR Year 2 - - - - 0.10                    
(0.06-0.14) 
Minor PRE TAVI Year 1 - 0.19                    
(0.12-0.27) 
0.24                    
(0.17-0.31) 
0.28                    
(0.22-0.35) 
As per 
PARTNER A 
Minor PRE AVR Year 1 - - - 0.22                    
(0.17-0.27) 
As per 
PARTNER A 
Minor PRE TAVI Year 2 - - 0.29                    
(0.23 - 0.38) 
- 0.10                    
(0.06-0.14) 
Minor PRE AVR Year 2  - - - 0.08                    
(0.05-0.12) 
Death from AS state AVR
¶
 0.33                    
(0.23-0.43) 
- - 0.18                                  
(0.05-0.36) 
As per
PARTNER A 
Death from AS state TAVI
¶
 0.33                    
(0.23-0.43) 
0.60                          
(0.44-0.74) 
As per 
PARTNER A 
0.08                                  
(0.03-0.15) 
As per
PARTNER A 
Death from AS state - 
Medical Management
¶
 
0.33                    
(0.23-0.43) 
0.57                          
(0.49-0.65) 
As per 
PARTNER A 
0.33                          
(0.25-0.41) 
As per Original 
Model 
Death from AS state – post 1 
year 
¶
 
- 0.33                    
(0.24-0.42) 
As per 
PARTNER A 
0.33  
(0.24-0.42) 
As per Original 
Model 
Mortality from natural causes 
(mr) 
† As per 
Original 
Model 
As per Original 
Model 
As per Original 
Model 
As per Original 
Model 
Morality from natural causes 
- AVR 
- - - 0.14                    
(0.10-0.18) 
As per 
PARTNER A 
Mortality from natural causes 
- TAVI 
- - - 0.15                    
(0.10-0.19) 
As per 
PARTNER A 
Relative risk of death due to 
AS (rrsmrAS) 
1.50                   
(0.95-2.24) 
As per 
Original 
Model 
As per Original 
Model 
As per Original 
Model 
As per Original 
Model 
Mortality from persistent AS/ 
failed valve replacement  
mr * smrAS - - - - 
Balloon valvuloplasty - 0.50                            
(0.41-0.58) 
As per 
PARTNER A 
As per 
PARTNER B 
As per 
PARTNER B 
 343 
 
Table VII.a Continued    
TRANSITION 
PROBABILITIES 
All Patient 
Groups 
Inoperable Operable 
 Original 
Model 
PARTNER 
B 
Updated 
PARTNER B 
PARTNER A Updated 
PARTNER A 
Mortality from natural causes 
– TAVI (year 1) 
- 0.14                    
(0.09-0.21) 
As per 
PARTNER A 
- - 
Source: Tables 4.4, 5.1, 6.1, 7.2 and 7.8 
+ Low risk 5%; medium risk 15% and high risk 20%.   † Standard life tables ¶(Legrand et al., 
1991)  - indicates not applicable 
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